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Abstract  
This thesis aims to investigate the health of HIV-infected childbearing women living in resource-
rich and resource-constrained settings in Europe, and to examine their treatment and care in the 
context of contemporary policies. HIV prevalence is increasing among childbearing women in 
Europe and particularly in the Eastern region. Highly effective interventions for the prevention of 
mother-to-child transmission (PMTCT) have resulted in very low transmission rates in Western 
Europe, but are less available in Ukraine. This thesis uses data from the European Collaborative 
Study, an on-going prospective cohort study of HIV-infected pregnant women and their infants 
(9500 mother-child pairs in Western Europe in 1986-2012, and 9600 in Ukraine in 2000-2012), to 
examine missed opportunities for PMTCT. Results highlight a decline in mother-to-child 
transmission rates in Ukraine to 4.1% (95% CI 3.4-4.9) in 2008-2010 (vs. 1.7% (95% CI 1.1-2.5) in 
the Western Europe sites in 2000-2009), and the importance of maternal marginalisation to 
continued transmissions in both settings. In Western Europe, a substantial proportion of HIV-
positive pregnant women are now conceiving on antiretroviral therapy (ART); factors associated 
with treatment failure during pregnancy among this group are explored.  
Prevalence of HIV co-infections is high in Ukraine, and this thesis uses data from a nested 
postnatal cohort (n=2066) to explore testing coverage and factors associated with hepatitis C virus 
and chlamydia co-infections. Detection and prevalence of cervical abnormalities (an important 
potential cause of morbidity in HIV-infected women) are also explored. An additional survey in 
Ukraine provides data on ART adherence during pregnancy and postnatally (n=418) and highlights 
gaps in information provision and support.  
Against a backdrop of overall improvements in HIV care, this thesis identifies groups at heightened 
risk of mother-to-child transmission and/or poor maternal outcomes, and informs policy for their 
treatment and care. 
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Chapter 1 Introduction 
1.1 Global epidemiology of HIV 
In 2010, thirty years after the first cases of acquired immune deficiency syndrome (AIDS) were 
reported (Gottlieb et al. 1981), around 30 million people had died of AIDS-related causes 
worldwide (WHO Global Health Observatory 2012) and an estimated 34 million (31.6-35.2 million) 
people were living with human immunodeficiency virus (HIV) (UNAIDS 2011b). HIV is 
transmitted via contact with infective bodily fluids (including genital secretions and blood). 
Transmission primarily occurs through sexual intercourse, sharing of injecting equipment among 
injecting drug users (IDUs),,iatrogenic exposure, and from mother to child (described in detail in 
section 1.4) (De Cock et al. 2012). Heterosexual transmission has been particularly important in the 
spread of the epidemic in sub-Saharan Africa, where an estimated 68% of HIV-positive people live 
(UNAIDS 2011b), while in other regions the epidemic has been focused among men who have sex 
with men (MSM) and IDUs (Sullivan et al. 2009; Wolfe et al. 2010). Women account for half of all 
people living with HIV (UNAIDS 2011b); 3.4 million (3-3.8 million) children were living with HIV 
in 2010 (WHO et al. 2011b), the majority of whom became infected via mother-to-child 
transmission (MTCT). 
The annual number of new HIV infections has declined worldwide from a peak of 3.4 million in 
1997 to 2.7 million in 2010, and the number of AIDS-related deaths has also declined from a peak 
of 2.2 million in 2005 to an estimated 1.8 million in 2010 (WHO et al. 2011b). These declines have 
been a result of a combination of factors, including the successful adoption of prevention measures 
(such as behaviour change programmes, voluntary medical male circumcision and condom 
promotion/distribution) and massive scale-up of access to treatment in low and middle-income 
settings (UNAIDS 2011b). 
1.2 Epidemiology of HIV in Europe 
Europe is a heterogeneous and predominantly resource-rich region, with a number of low and 
lower-middle-income countries in the Eastern region including Armenia, Georgia, Moldova, 
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Ukraine, Uzbekistan and Tajikistan1 (The World Bank 2013). Two distinct HIV epidemics have 
affected the Western and Eastern regions. The epidemic in the West began around fifteen years 
earlier than the epidemic in the East and had affected IDU and MSM communities throughout the 
region by the early 1980s (Hamers et al. 2003; Hamers et al. 2004). Ukraine was the epicentre of the 
HIV epidemic in Eastern Europe and had just 40-80 new infections per year prior to 1995 (Hamers 
et al. 2003). In 1995, HIV began to spread explosively among IDUs in the Black Sea port cities of 
Odessa and Mykolaiv and by 1997 there were 25,000 cases reported nationwide (Dehne et al. 1999; 
Hamers et al. 2003). 
Despite the more recent epidemic in Eastern Europe, it is there that the majority of Europe’s 
burden of HIV infection is now concentrated, with an estimated 1.5 million people living with HIV 
compared with 840,000 in Western and Central Europe (UNAIDS 2011b). Of the 118,335 new 
cases of HIV diagnosed in Europe in 2010, 76% were in Eastern Europe (ECDC / WHO Regional 
Office for Europe 2010) and around 90% of these were accounted for by two countries, Russia and 
Ukraine (WHO et al. 2011b). The proportion of people living with HIV who are undiagnosed is 
estimate to be 60% in Eastern Europe vs. 30% in Western Europe (Hamers et al. 2008), and so the 
difference in HIV burden between these two regions is likely to be even greater than the number of 
diagnosed cases suggests. Importantly, the spread of the HIV epidemic in Eastern Europe shows 
little sign of stabilising, in contrast with worldwide trends (UNAIDS 2011b). Figure 1.1 summarises 
some key differences between the Western and Eastern European epidemics. 
Information on pregnant HIV-infected women and their children is available through the 
European Collaborative Study (ECS), a large multi-site prospective cohort study which, along with 
related studies (described under ‘data sources’, section 2.3 page 55), forms the basis for this thesis. 
The ECS has enrolled women in Western Europe since 1986 and Ukraine since 2000 (European 
Collaborative Study 2006), and background to the HIV epidemics in these two settings is described 
in more detail in the section that follows. The HIV epidemic in Ukraine is the most severe in 
Europe (Kruglov et al. 2008), and a major focus of this thesis.
                                                     
1 Europe is defined as the WHO European region throughout. 
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Figure 1.1: HIV infections per 100,000 population in Europe in 2010 and key estimates for the epidemics in the Eastern and Western regions 
Map from: (ECDC / WHO Regional Office for Europe 2010). References: (Hamers et al. 2008; ECDC / WHO Regional Office for Europe 2010; UNAIDS 2011b) 
All data presented here are from 2010, as the 2011 surveillance report from the European Centre for Disease Prevention and Control did not include data from Russia 
(ECDC / WHO Regional Office for Europe 2012).  
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Western Europe 
Although IDUs were initially one of the groups most affected by the HIV epidemic in Western 
Europe, the widespread adoption of harm reduction measures (including needle and syringe 
exchange programmes and opiate substitution therapy) led to a fall in HIV prevalence in this group 
during the 1990s (Hamers et al. 2004; ECDC / WHO Regional Office for Europe 2010).  By 2010, 
the proportion of newly diagnosed cases attributed to IDU in the region overall was 4% (ECDC / 
WHO Regional Office for Europe 2010), but with high HIV prevalence among IDUs in Spain, 
estimated at 39.7%(Strathdee et al. 2010). MSM continue to be an important risk group for new 
infections in Western Europe and some countries of Central Europe (Likatavicius et al. 2008; 
Bozicevic et al. 2010), accounting for 39% and 29% of newly diagnosed infections in 2010 in these 
two regions respectively (ECDC / WHO Regional Office for Europe 2010). 
The proportion of new infections which are heterosexually acquired has increased over time, partly 
due to migration patterns from countries with generalised epidemics (Hamers et al. 2004). In 2010, a 
total of 40% of newly diagnosed infections were heterosexually acquired, of which 60% were in 
people originating in Western Europe (mainly in specific populations at high risk) and 40% were 
among people originating in countries with generalised heterosexually-driven HIV epidemics, 
predominantly of Eastern and Southern Africa (ECDC / WHO Regional Office for Europe 2010). 
As the proportion of heterosexually acquired infections has increased, so too has the proportion of 
new infections among women, reaching around a quarter of new cases in 2010 (ECDC / WHO 
Regional Office for Europe 2010).  
The majority of HIV-positive women are of childbearing age (Thorne et al. 2003; WHO et al. 
2011b), and surveillance of HIV infection among pregnant women provides a means of estimating 
the HIV prevalence in this age group on a population level (Nicoll et al. 2000). However, these 
estimates may require adjustment due to differential fertility rates by HIV status (Boisson et al. 
1996; Nicoll et al. 1998). Figure 1.2 illustrates the increasing proportion of HIV-positive pregnant 
women in the Western Europe ECS who are of sub-Saharan African origin, and the decreasing 
proportion with a history of IDU. In the UK and Ireland, 79% of HIV-positive women delivering 
between 2000 and 2009 were from Africa (French et al. 2012), with an increase over time 
(Townsend et al. 2008b). 
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Figure 1.2: Time trends in characteristics of HIV-positive pregnant women enrolled in 
Western European sites of the ECS (unpublished data) 
 
Ukraine 
Ukraine is a lower-middle-income country with poor public health infrastructure (DeBell et al. 2005; 
Lekhan et al. 2010; The World Bank 2011). The HIV epidemic was fuelled by a huge rise in IDU 
following the collapse of the Soviet Union – a transition accompanied by severe economic crisis, 
unemployment, declining living standards, and increased local drug production as well as drug 
trafficking (Dehne et al. 1999; Atlani et al. 2000; Poznyak et al. 2002; Hurley 2010; Lekhan et al. 
2010). Ukraine has amongst the highest prevalence of IDU in the world at 1.16% (International 
Harm Reduction Association 2010) and the number of IDUs is estimated at 375,000 (Wolfe et al. 
2010). The most commonly injected drugs are homemade opiates and amphetamine-type 
stimulants, often used in combination (Booth et al. 2003; Booth et al. 2006; Booth et al. 2008; 
Chintalova-Dallas et al. 2009). 
Drug dependence was criminalised and treated by abstinence under the Soviet psychiatric speciality 
of narcology, and harm reduction measures have been historically opposed in Ukraine (Barcal et al. 
2005; Donoghoe et al. 2005; Hurley 2010). Needle and syringe exchange programmes have 
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expanded in recent years but coverage remains low: in 2011, 75 syringes were distributed per IDU, 
short of international targets of at least 200 syringes per IDU per year (WHO et al. 2009; Ministry 
of Health of Ukraine 2012). Buprenorphine became available for opioid substitution therapy in 
2004 and methadone in 2008 (Schaub et al. 2010), but by the end of 2011 only 6632 of an estimated 
250,000 people injecting opiates in Ukraine were on opioid substitution therapy (Ministry of Health 
of Ukraine 2012). Criminalisation of IDU remains an important barrier to uptake of harm reduction 
services (Spicer et al. 2011). Specific injecting practices which are common in Ukraine, including 
filling of IDUs’ syringes from a dealer’s syringe or common containers (Dehne et al. 1999; Booth et 
al. 2003), result in extremely high risk of transmission of bloodborne infections. The prevalence of 
HIV among IDUs is estimated at between 39% and 50% in Ukraine (Kruglov et al. 2008). 
High-risk sexual behaviours associated with IDU have contributed to the spread of sexually 
transmitted infections (STIs) in Ukraine, as have other factors associated with political transition 
including increases in commercial sex work, income inequalities and population mobility (Rhodes et 
al. 1999; Barnett et al. 2000; Rhodes et al. 2005; Booth et al. 2007). In the years following the collapse 
of the Soviet Union there were epidemics of a number of STIs, most notably syphilis with a ten-
fold increase in notification rates between 1990 and 1996 (Mavrov et al. 2002). Heterosexual 
transmission of HIV has become increasingly important over time, accounting for over half of new 
cases since 2008 (UNAIDS 2009; Ministry of Health of Ukraine 2010). These transmissions remain 
strongly linked with IDU, for example sexual partners of IDUs and other bridging populations, and 
have resulted in a rise in new cases among women: in 2011, women accounted for 46% of new 
HIV cases among people aged 25 to 49 years  in Ukraine (Ministry of Health of Ukraine 2012). 
Ukraine has the highest adult HIV prevalence in Europe estimated at 1.6% (Kruglov et al. 2008); 
antenatal HIV prevalence was 0.47% overall in 2011 (Ministry of Health of Ukraine 2012) and >3% 
in some regions (Personal Communication, Natalya Nizova, Ministry of Health of Ukraine, 2012).  
Public information provision about HIV and school-based sex education were completely lacking 
in Ukraine as late as 2005 (DeBell et al. 2005). Access to information about HIV prevention has 
now improved, with programmes targeted to specific groups including school children and high-
risk groups, but quality and coverage remains low (UNAIDS 2009). Some programmes have been 
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described as exacerbating fear of HIV infection rather than focusing on constructive prevention 
messages (Spicer et al. 2011).  
1.3 Biology, natural history and treatment of HIV 
This thesis focuses on HIV-1, the predominant of the two HIV types worldwide. HIV-2 is largely 
confined to West Africa and is less transmissible and less pathogenic, resulting in slower disease 
progression than HIV-1 (Reeves et al. 2002). There are four groups of HIV-1 (M, N, O and P), of 
which the M group is by far the most common and is the cause of the worldwide AIDS pandemic 
(Ndung'u et al. 2012). The M group can be further divided into at least nine genetically distinct 
subtypes or clades, of which subtype A is found most commonly in Eastern Europe and subtype B 
in Western Europe (Thomson et al. 2001; Thomson et al. 2007).  
A retrovirus, HIV targets cells of the human immune system by attaching to CD4  and chemokine  
receptors (CCR5 or CXCR4) on macrophages, monocytes, dendrites and T cells (LaBranche et al. 
2001). Once it has gained entry into a cell, the single-stranded viral RNA is reverse transcribed into 
double-stranded DNA which is then integrated into the host genome; subsequent transcription of 
these viral genes produces the necessary components for new viral particles and thus viral 
replication (Smith et al. 2006). Infected cells of the human immune system are killed directly by 
replication of the virus and also by apoptosis. With the gradual loss of CD4+ T cells (or T helper 
cells), the human host suffers a loss of cell-mediated immunity and increased susceptibility to 
opportunistic infections, eventually manifesting as AIDS. The natural history of HIV disease is 
characterised by a period of clinical latency between infection and the onset of AIDS of around 10 
years duration (Bacchetti et al. 1989; Moss et al. 1989; Munoz et al. 1989). Disease stage can be 
assessed by measuring levels of circulating CD4+ T cells (the ‘CD4 count’), with progressive 
damage to the immune system marked by a fall in CD4 counts and a rise in HIV RNA (‘viral load’) 
(see Figure 1.3).  
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Figure 1.3: Natural history of HIV infection: CD4 count and viral load  
Figure from (Martin 2009). The black line indicates CD4 T-lymphocyte count and the grey line 
HIV RNA load. After HIV acquisition (point A), there is a period of rapid viral replication which is 
curtailed by the cellular immune response (point B). The CD4 T-lymphocyte cell count recovers to 
a degree (point C) and a period of clinical latency ensues (point D). CD4 T-lymphocyte cell counts 
eventually fall to a level at which opportunistic infections manifest as symptomatic AIDS (point E), 
leading to death. 
 
Antiretroviral therapy 
The first antiretroviral drug that became available to treat HIV infection was zidovudine (ZDV), a 
nucleoside reverse transcriptase inhibitor (NRTI), found to reduce mortality over 24 weeks in 
patients with AIDS (Fischl et al. 1987). Several other NRTIs became available soon after, including 
didanosine, stavudine and lamivudine, but the success of treatment with these drugs was limited by 
the rapid development of resistance to antiretroviral drugs administered as monotherapy, and the 
toxicity associated with these agents (Vella et al. 2012).  
Major breakthroughs occurred with the development of two new classes of antiretroviral agents –
non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) – in the 
mid-1990s. Triple combination antiretroviral therapy (ART), consisting of two NRTIs plus either 
an NNRTI or a PI (known as highly active antiretroviral therapy (HAART) or combination ART 
(cART)), was shown to durably suppress viral load to very low levels and prevent disease 
progression (Hammer et al. 1997; Montaner et al. 1998) and was adopted as the standard of care in 
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resource-rich settings in 1997 (Kirk et al. 1998; US Centers for Disease Control and Prevention 
1998). Substantial declines in AIDS-related morbidity and mortality followed (Mocroft et al. 1998; 
Palella et al. 1998). 
Since the advent of the cART era, there has been an expansion of treatment options with 
fusion/entry and integrase inhibitors becoming available in 2003 and 2007 respectively (Table 1.1 
summarises the five current antiretroviral drug classes). The increase in treatment options together 
with improved safety of agents and the introduction of fixed-dose once-daily combination 
preparations has improved the quality of life and clinical outcomes of HIV-positive patients (Vella 
et al. 2012). Although poorer outcomes are seen in some patient groups, low-risk patients diagnosed 
at an early stage of infection and with access to cART may now have a life expectancy approaching 
that of their HIV-negative contemporaries (Sterne et al. 2005; The Antiretroviral Therapy Cohort 
Collaboration 2008; van Sighem et al. 2010). 
 
Table 1.1: The five current antiretroviral drug classes with examples 
NRTIs NNRTIs PIs Entry/fusion 
inhibitors 
Integrase 
inhibitors 
Zidovudine (ZDV) 
Didanosine (ddI) 
Zalcitabine (ddC) 
Stavudine (d4T) 
Lamivudine (3TC) 
Abacavir (ABC) 
Emtricitabine (FTC) 
Tenofovir (TDF)† 
Efavirenz (EFV) 
Nevirapine (NVP) 
Etravirine (ETR) 
 
Saquinavir (SQV) 
Lopinavir (LOP) 
Indinavir (IDV) 
Nelfinavir (NFV) 
Fosamprenavir (FPV) 
Atazanavir (ATZ) 
Darunavir (DRV) 
Ritonavir‡ (RTV) 
Maraviroc 
(MVC) 
Enfuvirtide 
(ENF) 
 
 
Raltegravir 
(RAL) 
†Tenofovir is a nucleotide reverse transcriptase inhibitor  
‡Low-dose ritonavir is used in combination with other PIs to pharmacologically ‘boost’ blood levels 
 
In 2010, World Health Organisation (WHO) guidelines were updated to recommend cART 
initiation in asymptomatic individuals at CD4 counts of ≤350 cells/mm3 (rather than ≤200 
cells/mm3) (WHO 2010b), reflecting evidence that clinical outcomes are better when cART is 
initiated at an earlier disease stage (Kitahata et al. 2009; Sterne et al. 2009). In the absence of AIDS-
defining illness or other indications for treatment, UK guidelines currently recommend cART 
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initiation at CD4 counts of ≤350 cells/mm3, while US guidelines recommend initiation for all HIV-
positive individuals and particularly those with a CD4 count ≤500 cells/mm3   or ≤350 cells/mm3 
(Panel on Antiretroviral Guidelines for Adults and Adolescents 2012; Williams et al. 2012). The 
effectiveness of ART in preventing onward transmissions to sexual partners has resulted in a recent 
focus on the use of early treatment as part of a combination prevention approach (Montaner et al. 
2010; Cohen et al. 2011; WHO et al. 2011a; WHO 2012c). 
Since 1995, the use of cART has averted an estimated 2.5 million AIDS deaths in low- and middle-
income countries (WHO et al. 2011b). The number of people on ART recently increased 
substantially, by 1.4 million in the year to December 2010, to reach 6.65 million overall (WHO et al. 
2011b). However, the estimated coverage of eligible people in low and middle-income settings with 
ART is still only around 47% (WHO et al. 2011b), leading to continued substantial AIDS-related 
morbidity and mortality worldwide and a focus on the need to improve the effectiveness and 
efficiency of the HIV/AIDS response (UNAIDS 2010; Schwartlander et al. 2011; WHO et al. 
2011a; WHO 2012c). Even where services are available, optimal treatment is often hindered by the 
late diagnosis of infected individuals at advanced stages of disease, poor adherence to cART 
regimens (described in section 1.5), and marginalisation of HIV-positive and at-risk populations 
(Lima et al. 2009; Moreno et al. 2010; WHO et al. 2011b). Some of these factors contribute to the 
continued AIDS cases seen in Western Europe, which have declined steadily to reach 1.0 per 
100,000 population in 2010 (ECDC / WHO Regional Office for Europe 2010). 
Access to HIV treatment and care in Ukraine 
In Ukraine, expansion of access to ART began in 2004, but scale-up has been slow and outstripped 
by the increasing number of HIV-positive people requiring treatment (Ministry of Health of 
Ukraine 2012). In 2011, 70% of individuals eligible for treatment and in HIV care were receiving 
cART; true coverage (i.e. including those with undiagnosed infections or not in contact with care) is 
estimated at 25% (Ministry of Health of Ukraine 2012). There were 20.1 AIDS cases reported per 
100,000 population in 2011 (Ministry of Health of Ukraine 2012), which is probably an under-
estimate due to under-reporting (ECDC / WHO Regional Office for Europe 2010).  
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Problems persist regarding both the level of government expenditure on HIV programmes and the 
efficiency with which resources are spent; ART procurement is sometimes highly inefficient, and 
local management of budgets has led to regional disparities in access (UNAIDS 2009). The shortfall 
in government funding has been partly bridged by other agencies, most notably the Global Fund to 
Fight AIDS, Tuberculosis and Malaria (‘the Global Fund’) which currently funds ART for 13% of 
patients on treatment in Ukraine and supports over 50 non-governmental organisations (NGOs) to 
deliver HIV-related services (Ministry of Health of Ukraine 2012). However, projects funded by 
external agencies are limited by a lack of long-term sustainability and problems with coverage, 
equitability of access and prioritisation of essential services (UNAIDS 2009). Illegal user fees are 
widespread in the healthcare system in Ukraine; although HIV-related services are usually free of 
charge, out-of-pocket payments are sometimes charged for diagnostic services (including client-
initiated HIV tests) and for treatment of opportunistic infections (UNAIDS 2009). The highly 
verticalised organisation of medical services (with treatment for HIV, TB and IDU delivered at 
separate specialist regional or city centres) hinders a multi-sectoral response to tackle any one of 
these issues (Atun et al. 2008; Lekhan et al. 2010).  
1.4 Mother-to-child transmission and its prevention 
Fertility intentions of HIV-positive women 
In the early years of the epidemic, before effective treatment and interventions for the prevention 
of mother-to-child transmission (PMTCT) became available, women diagnosed as HIV-positive 
had fewer live births due to both reduced incidence of conception and higher rates of pregnancy 
termination (Stephenson et al. 1996; De Vincenzi et al. 1997; van Benthem et al. 2000a; Blair et al. 
2004). Since the beginning of the cART era, the incidence of live births among HIV-positive 
women has been increasing, and the childbearing desires of HIV-positive women have become 
similar to those of uninfected women (van Benthem et al. 2000a; Stanwood et al. 2007; Fiore et al. 
2008; Huntington et al. 2012). Surveillance data from the UK and Ireland show that HIV-positive 
women are increasingly having more than one pregnancy following their HIV diagnosis (French et 
al. 2012). 
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Rates and modes of transmission 
Rates of MTCT of HIV in the absence of intervention range from 15 to 32% in industrialised 
countries and 25 to 48% in resource-limited settings, where safe and acceptable alternatives to 
breastfeeding are not widely available (Dabis et al. 1993; Thorne et al. 2003). Plasma HIV RNA is 
the foremost risk factor for MTCT (Sperling et al. 1996; Mayaux et al. 1997; Mofenson et al. 1999). 
Other risk factors include cervico-vaginal viral load, vaginal delivery, preterm delivery, prolonged 
duration of ruptured membranes, low CD4 count and maternal co-infections (Thorne et al. 2003). 
In non-breastfeeding populations, the majority of vertical transmissions occur around delivery, 
when the baby is exposed to infected maternal genital secretions and blood in the birth canal 
(Thorne et al. 2003; Lehman et al. 2007). Other potential mechanisms of intrapartum transmission 
include placental microtransfusions and ascending infection following membrane rupture (Lehman 
et al. 2007). Breastfeeding has been associated with a 16% rate of transmission in the first two years 
of life in a randomised controlled trial (RCT), accounting for 44% of vertical infections among 
infants exposed to breast milk (Nduati et al. 2000). The risk of transmission via breastfeeding is 
increased when this is not the exclusive mode of feeding (Coutsoudis et al. 2001). MTCT can also 
occur in utero, possibly due to placental disruption or exposure of the foetus to HIV in the 
amniotic fluid (Thorne et al. 2005; Lehman et al. 2007).  
Preventing HIV infection in infants 
PMTCT depends on individual-level interventions for HIV-positive women and their exposed 
infants. On a population level however, the prevention of HIV infection in infants depends on a 
much broader approach which takes into account determinants of the number of HIV-exposed 
pregnancies – HIV prevalence among adults of childbearing age and access to family planning 
services – while respecting the reproductive choices of HIV-positive women and addressing stigma-
related barriers to care. The WHO describes four components which make up a strategic 
framework for the prevention of HIV infections in infants, described in Table 1.2 (WHO 2003b). 
Knowledge of HIV among women of childbearing age is essential for primary prevention of 
infections in this group, and therefore prevention of infant infections. Among pregnant women, 
knowledge of antenatal HIV screening and of the existence of effective PMTCT interventions is 
also crucial for the timely diagnosis of infections and opportunities for appropriate management. 
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Women’s agency to protect themselves from HIV infection or to care for themselves and their 
families once infected is influenced by their experience of HIV-related stigma, itself contingent on 
HIV knowledge and attitudes in their community. Therefore the HIV knowledge and attitudes of 
women of childbearing age are of direct importance not only to their own health but to 
components 1, 3 and 4 of a comprehensive approach for PMTCT (Table 1.2, (WHO 2003b)).  
 
Table 1.2: The four components of a comprehensive approach to prevent HIV infection in 
infants 
 Some examples 
1. Primary prevention of HIV 
infection among women of 
childbearing age and their 
partners 
Promoting use of dual contraception; counselling women 
testing negative in antenatal settings on strategies to remain 
uninfected; facilitating partner testing; prevention services 
tailored to high-risk groups (IDUs, sex workers). 
2. Preventing unintended 
pregnancies in HIV-
positive women 
Meeting unmet need for family planning services (including 
postnatally); ensuring availability of HIV counselling and 
testing facilities within family planning settings; supporting 
reproductive choices of HIV-positive women. 
3. Preventing HIV 
transmission from HIV-
positive women to their 
infants 
Routine offer of antenatal screening; ART for all HIV-positive 
pregnant women for their own health and/or PMTCT; safe 
delivery practices; counselling and support for infant feeding.  
4. Care and support for HIV-
positive mothers, their 
infants and families 
Continuation of ART postnatally for women with treatment 
indications; treatment for HIV-positive infants and care for 
HIV-exposed but uninfected infants; tackling of HIV-
associated stigma. 
(WHO 2003b) 
Antenatal screening 
Interventions for PMTCT depend on the timely identification of pregnant women with previously 
undiagnosed HIV infections. ‘Opt out’ provider-initiated HIV testing and counselling early in 
antenatal care is recommended by WHO and US guidelines (US Centers for Disease Control and 
Prevention 2006; WHO et al. 2007). In Europe, routine antenatal HIV screening for all pregnant 
women (i.e. regardless of perceived risk) has been widely adopted, with national policies advocating 
a mixture of ‘opt-in’ and ‘opt-out’ strategies (Deblonde et al. 2007; Mounier-Jack et al. 2008). An 
‘opt-out’ approach, where an HIV test is conducted along with other antenatal tests unless 
specifically declined, is associated with increased coverage and detection of HIV infections among 
pregnant women (The UK Collaborative Group for HIV and STI Surveillance 2005) and has 
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become more common in Europe over time. Almost two-thirds of 21 European countries surveyed 
in 2012 had an ‘opt-out’ antenatal HIV screening policy (Aebi-Popp et al. 2013). 
In countries with generalised epidemics, the WHO recommends that pregnant women testing 
negative in the first or second trimesters are re-tested between 28 and 36 weeks gestation or during 
labour/delivery, to identify those who may have seroconverted during pregnancy (WHO 2010c). 
Repeat antenatal screening is not recommended routinely in low prevalence settings such as those 
in Western Europe, although it remains indicated for women at on-going risk of HIV acquisition 
during pregnancy - for example, current IDUs and those in discordant partnerships or with sexual 
risk behaviours (WHO 2010c). In Ukraine, a setting with a concentrated epidemic which is 
increasingly affecting women (Kruglov et al. 2008), national guidelines recommend ‘opt-out’ 
screening at initiation of antenatal care and, if negative, repeat testing during the third trimester 
(Ministry of Health of Ukraine 2010). 
In all settings, rapid HIV testing for women presenting in labour with an unknown status is 
recommended, as a maternal diagnosis even at this late stage allows for MTCT risk to be reduced 
with intrapartum and postpartum PMTCT interventions (WHO 2010a). 
PMTCT interventions 
The risk of MTCT of HIV can be lowered by reducing the infant’s exposure to infective body 
fluids (through delivery by elective caesarean section (CS) and avoidance of breastfeeding), and by 
reducing the mother’s level of replicating virus with ART given during pregnancy and intrapartum; 
in addition, ART given to the neonate after delivery provides post-exposure prophylaxis (Lehman et 
al. 2007). Breastfeeding is not considered further here, as in both Western Europe and Ukraine 
there are safe, acceptable and affordable alternatives to breast feeding available, and most infants 
born to HIV-positive women are formula fed (European Collaborative Study 2006). 
The efficacy of ART for PMTCT was first shown in 1994 in the AIDS Clinical Trials Group 076 
RCT, which demonstrated that a three-part ZDV regimen (administered during pregnancy for a 
median of 11 weeks, intrapartum and as neonatal prophylaxis) reduced MTCT by 68% (Connor et 
al. 1994). Following these results, antenatal ZDV monotherapy (ZDVm) and then antenatal cART 
were rapidly adopted as PMTCT interventions in Western Europe and the US (European 
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Collaborative Study 2001; Cooper et al. 2002). At the same time as scale-up of antenatal ART, 
delivery by elective CS became more common as a PMTCT strategy in Western Europe following 
observational findings that this mode of delivery reduced MTCT risk by around 50% (European 
Collaborative Study 1994; European Collaborative Study et al. 2010). By 1999, MTCT rates had 
fallen to <3% among non-breastfeeding women in Western Europe and the US (European 
Collaborative Study 2001; Cooper et al. 2002; Dorenbaum et al. 2002). An RCT and a meta-analysis 
were published in 1999 confirming that delivery by elective CS reduced MTCT risk, by 80% and 
57% respectively, among women with no antenatal ART or only ZDVm (The European Mode of 
Delivery Collaboration 1999; The International Perinatal HIV Group 1999). Vertical transmission 
occurred in only one of 119 women who received antenatal ZDVm and were allocated to deliver by 
elective CS in the RCT (an MTCT rate of 0.8%) (The European Mode of Delivery Collaboration 
1999). 
Antenatal cART had become the standard of care for PMTCT across Western Europe by the early 
2000s, and was associated with very low MTCT rates of 1% or less in observational studies 
(European Collaborative Study 2005; Naver et al. 2006; Townsend et al. 2008a; von Linstow et al. 
2010; Chiappini et al. 2011; Jasseron et al. 2011). In resource-limited, high prevalence settings, the 
efficacy of shorter and simpler regimens for PMTCT have been the subject of investigation. An 
RCT in Thailand demonstrated that a shortened antenatal ZDVm regimen taken for a median of 
3.6 weeks prior to delivery had an estimated efficacy in the prevention of intrapartum transmissions 
of 61% (Shaffer et al. 1999). Meanwhile, the HIVNET 012 trial in Uganda demonstrated an MTCT 
rate at birth of 10% and 8% respectively among infants born to women who received intrapartum 
ZDV or NVP (Guay et al. 1999). More recently in the Kesho Bora study,  the transmission rate at 
birth among 412 women who received ZDVm and single-dose NVP (sdNVP) (all of whom had 
CD4 counts between 200 and 500 cells/mm3, and 12% of whom delivered by CS) was 2.5%, not 
significantly higher than the 1.8% among women who received antenatal cART (de Vincenzi 2011).  
An important consideration for the use of ART for PMTCT is the risk of the development of ART 
resistance. Although monotherapy is normally avoided outside of the context of pregnancy, 
zidovudine has a moderate genetic barrier to resistance (Gardner et al. 2009) and the short term use 
of ZDVm during pregnancy is not generally associated with problems; no new zidovudine-
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associated resistance mutations were found among 53 women who received a median of 11 weeks 
of ZDVm during pregnancy in one UK study (Read et al. 2008). Nevirapine has a lower genetic 
barrier to resistance than the NRTIs and a longer half-life, which results in ‘functional 
monotherapy’ if it is given as one component of a cART regimen which is stopped abruptly 
(Gardner et al. 2009). The use of sdNVP is associated with a significant increase in the subsequent 
risk of virologic failure on a NVP-containing cART regimen, but this risk declines with longer 
intervals between sdNVP exposure and cART initiation (Lockman et al. 2010) and can be mitigated 
by the use of an NRTI ‘tail’, recommended for 7 days following sdNVP exposure (WHO 2010a). 
In the UK, ZDVm remains an option for women with a plasma viral load <10,000 copies/ml and 
willing to deliver by elective CS (de Ruiter et al. 2012), but was received by <5% of HIV-positive 
pregnant women delivering in the UK in 2007-2011, with most women eligible for ZDVm instead 
opting for cART (Personal Communication, Pat Tookey, NSHPC, 2013). In the US, guidelines take 
a more conservative approach and recommend ZDVm as an option only for women with viral 
loads <1000 copies/ml (Panel on Treatment of HIV-infected Pregnant Women and Prevention of 
Perinatal Transmission 2012). For women with treatment indications and therefore the highest risk 
of transmission, antenatal cART continued lifelong is of crucial importance in reducing morbidity 
and MTCT risk (de Ruiter et al. 2012; Panel on Treatment of HIV-infected Pregnant Women and 
Prevention of Perinatal Transmission 2012). 
Among women virologically suppressed on cART, who already have a very low risk of MTCT, the 
additional benefit of CS is uncertain (Read et al. 2005) and the conduct of sufficiently powered trials 
is challenging. This uncertainty, along with concerns around infective complications of CS among 
HIV-positive women (Ferrero et al. 2003; Fiore et al. 2004), has led to vaginal deliveries becoming 
increasingly common in Western Europe over time, but delivery practices remain heterogeneous 
(Read et al. 2005; European Collaborative Study et al. 2010). Most European national policies now 
recommend that a vaginal delivery should be an option for women with a viral load below a stated 
threshold at 36 weeks gestation; this threshold is <50 copies/ml for the majority of countries in 
Western Europe, <400 copies/ml for France and Ireland, and <1000 copies/ml for Denmark, 
Lithuania, Moldova, Russia and Ukraine (Aebi-Popp et al. 2013). Delivery by elective CS was not 
part of the original national PMTCT strategy in Ukraine due to concerns around complications 
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(Malyuta et al. 2006), but is currently recommended as national policy for women with a viral load 
>1000 copies/ml during the third trimester (Personal communication, Ruslan Malyuta, Perinatal 
Prevention of AIDS Initiative, 2011). 
The scale-up of PMTCT interventions has been slow overall in resource-limited settings, and in 
2009 only an estimated 45% of HIV-positive pregnant women worldwide were receiving any ART 
for PMTCT (WHO 2009b). In 2010, the WHO published recommendations to support the scale-
up of effective interventions for PMTCT in low- and middle-income settings, to address continued 
inequities in MTCT (McIntyre et al. 2008; WHO 2010a). These guidelines recommend initiation of 
lifelong cART for all HIV-positive pregnant women with treatment indications (defined as a CD4 
count ≤350 cells/mm3 and/or WHO stage 3-4 disease), and either antenatal ZDVm plus sdNVP or 
antenatal cART (Options A and B respectively) for those requiring ART for PMTCT only (WHO 
2010a). Use of these regimens along with infant antiretroviral prophylaxis should reduce the MTCT 
rate to <2% in non-breastfeeding populations, in accordance with goals for the virtual elimination 
of MTCT in the European region by 2015 (WHO Regional Office for Europe 2011), and in line 
with the very low rates of MTCT already achieved in Western Europe (Townsend et al. 2008a). 
Option B+, whereby lifelong cART is initiated in all HIV-positive pregnant women, was the subject 
of a recent WHO programmatic update (WHO 2012b). This strategy has potential benefits for 
maternal health, MTCT risk in subsequent pregnancies and the harmonisation of treatment 
programmes, but many questions regarding implementation are as yet unanswered, particularly 
concerning equitability and sustainability of access to ART, adherence and retention in care 
(Schouten et al. 2011a; WHO 2012b). 
In Ukraine, the coverage of PMTCT services has been an important success of the national 
response to the epidemic: over eight years to 2008, 93% of HIV-infected pregnant women received 
ART (antenatal or intrapartum) for PMTCT (Thorne et al. 2009). Table 1.3 summarises the 
timescale of PMTCT intervention scale-up in Ukraine compared with Western Europe. From 2001 
to 2007, the national Ukrainian PMTCT strategy was based on abbreviated regimens of ZDVm and 
sdNVP, and antenatal cART was available to only some women with treatment indications; the 
MTCT rate in 2006 was 7% overall (Thorne et al. 2009). At the end of 2007, national PMTCT 
policy was updated to recommend antenatal cART for all HIV-positive pregnant women (i.e. WHO 
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Option B) (Ministry of Health of Ukraine 2010). The scale-up of antenatal cART subsequent to the 
policy change and associated MTCT rates are explored in Chapter 3 of this thesis. 
Lack of antenatal ART is a major reason for continued vertical transmissions in the resource-rich 
setting of Western Europe (Mayaux et al. 2003; Peters et al. 2003; European Collaborative Study 
2005; Townsend et al. 2008a). Other factors include seroconversion during pregnancy or 
breastfeeding, use of non-suppressive antenatal ART and adverse social circumstances (for example 
insecure housing, poverty, poor social support) which preclude optimal antenatal care (National 
Study of HIV in Pregnancy and Childhood et al. 2007). In Ukraine, women with an IDU history 
continue to account for a disproportionate number of vertical transmissions due to multiple 
barriers to care; from 2000 to 2010, IDUs had an unadjusted MTCT rate of 11% compared with 
6% for non-IDUs (Thorne et al. 2012). 
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Table 1.3: Timescale of the adoption of PMTCT interventions in Western Europe and 
Ukraine 
 Ukraine Western Europe 
Pre-1994 No ART for PMTCT.  
  Isolated cases of heterosexually 
acquired HIV reported. 
 MTCT rate ~15%. 
1994 ACTG 076 trial demonstrated the efficacy of ZDV (antenatal, intrapartum and as 
neonatal prophylaxis) in reducing MTCT risk by 68%. 
Findings from observational studies showed that delivery by CS reduced MTCT risk 
by around half. 
1995  HIV begins to spread 
explosively among IDUs in 
Odessa and Mykolaiv, and then 
nationwide 
 Antenatal ZDV rapidly adopted as a 
PMTCT intervention. 
 Elective CS accounted for an increasing 
proportion of deliveries between 1995 
and 1999. 
1997 cART becomes the standard of care for treatment of HIV in resource-rich settings. 
1999 Elective CS shown to reduce MTCT risk by 50% in an RCT and a meta-analysis, 
among women receiving no ART or ZDVm. 
   Use of antenatal cART increasing 
(received by 44% of women enrolled in 
the European Collaborative Study in 
1999). 
 Delivery by elective CS peaked. 
 MTCT rate <3% overall. 
2001  National PMTCT programme 
starts, based on short course 
ZDVm from 36 weeks gestation 
and/or sdNVP.  
 MTCT rate 15%. 
 Widespread adoption of antenatal cART 
for use as a PMTCT intervention, and 
reduction in MTCT rates to <1-2%. 
 Increasing proportion of HIV-positive 
women delivering vaginally, in reflection 
of uncertainties around the additional 
benefit of CS for MTCT risk where viral 
load is suppressed. 
 HIV-positive women increasingly 
conceiving on cART. 
 Shift in focus to identification of women 
with suboptimal PMTCT interventions, 
and prevention of ‘residual’ 
transmissions among women with 
adequate virological suppression. 
 
2003  PMTCT strategy updated to 
included longer duration of 
antenatal ZDVm (from 28 
weeks) and neonatal ZDV, plus 
sdNVP if duration of maternal 
ART <4 weeks by delivery. 
 
2007  MTCT rate 7%. 
 PMTCT strategy updated to 
include cART for all pregnant 
women, including those 
requiring PMTCT only (cART 
previously available to only some 
pregnant women with treatment 
indications). 
(Connor et al. 1994; The European Mode of Delivery Collaboration 1999; The International 
Perinatal HIV Group 1999; European Collaborative Study 2001; Malyuta et al. 2006; Townsend et 
al. 2008a; Warszawski et al. 2008; Thorne et al. 2009; UNAIDS 2010; WHO 2010a; WHO Regional 
Office for Europe 2011) 
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Safety of ART in pregnancy and when to start 
Longer duration of antenatal ART is associated with lower MTCT risk, due to both an increased 
probability of virological suppression by delivery and a greater duration of protection against in-
utero transmissions (Cooper et al. 2002; European Collaborative Study 2005; Jasseron et al. 2008; 
Townsend et al. 2008a; Warszawski et al. 2008). In the UK and Ireland, the MTCT rate from 2000 
to 2006 was 0.8% among women who had received at least 14 days of ART prior to delivery (vs. 
1.2% overall), and each additional week was associated with a 10% decreased transmission risk 
(Townsend et al. 2008a). Mothers in the French Perinatal Cohort whose pregnancy resulted in 
transmission had received on average six weeks less antenatal ART than non-transmitters 
(Warszawski et al. 2008), and in the European Collaborative Study, the MTCT rate among women 
who began cART before pregnancy was 0.25%, vs. 1.92% among those starting cART antenatally 
and 11.5% among those with no ART (European Collaborative Study 2005). In the Swiss Cohort 
Study, 93% of women starting ART antenatally reached a viral load of <400 copies/ml around 
delivery, and treatment was late or suboptimal in all three pregnancies that resulted in MTCT 
(Keiser et al. 2008). 
For women not on ART at conception and requiring it for PMTCT only, European guidelines on 
when to initiate antenatal ART are heterogeneous, with recommendations to initiate at 12-14 weeks 
gestation in Italy, Portugal, Greece and Poland, and at 28-32 weeks gestation in Germany and 
Lithuania (Aebi-Popp et al. 2013). Other countries fall between these two extremes; UK and 
Ukrainian guidelines recommend ART initiation at 14-24 weeks and 24-26 weeks respectively (de 
Ruiter et al. 2012; UNICEF 2012).  
Initiation of ART during the first trimester is generally not recommended due to the theoretical 
heightened risk of teratogenic effects during this period. There have been particular concerns 
around the first-trimester use of EFV, which has been associated with teratogenicity in animal 
studies, accompanied by isolated case reports (De Santis et al. 2002; Fundaro et al. 2002; Panel on 
Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission 2012). 
However, the evidence-base for its safe use in pregnancy has been expanding over recent years, and 
a systematic review and meta-analysis updated in 2011 found no increased risk of birth defects 
among women with first-trimester exposure to EFV (Ford et al. 2011). The combination of ddI and 
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d4T is contraindicated during pregnancy due to the risk of lactic acidosis, and this is one exception 
to the general guidance that women conceiving on cART (including EFV) should continue with 
their current regimen throughout pregnancy provided that it is well-tolerated and effective (de 
Ruiter et al. 2012; Panel on Treatment of HIV-infected Pregnant Women and Prevention of 
Perinatal Transmission 2012). A substantial proportion of HIV-positive pregnant women in 
Western Europe have been on cART from before conception in recent years; national surveillance 
data from the UK and Ireland show that around 40% of HIV-positive women delivering in 2010 
conceived on cART, up from around 20% in 2005 (National Study of HIV in Pregnancy and 
Childhood). In Denmark, 57% of HIV-positive women delivering in 2000-08 conceived on ART, 
up from 11% in 1994-1999 (von Linstow et al. 2010). When HIV-positive women of childbearing 
age need to initiate cART for their own health, consideration should be given to the possibility of a 
future pregnancy, and the opportunity to optimise virological control prior to conception 
(Huntington et al. 2011). 
In addition to congenital abnormalities, other potential adverse effects of antenatal cART include 
preterm delivery and anaemia in the infant (European Collaborative Study 2003; Thorne et al. 2004; 
Thorne et al. 2007; Townsend et al. 2007). These must be balanced on an individual level with 
factors which will impact on the duration of ART required to achieve a fully suppressed viral load 
by delivery, including baseline viral load, cART regimen and treatment history, drug resistance, co-
infections and ethnicity (Patel et al. 2007; Landes et al. 2008). A UK cohort study demonstrated that 
the probability of achieving an undetectable viral load by delivery among women with a high viral 
load at baseline (>10,000 or >100,000 copies/ml) was compromised where ART was initiated after 
20.4 weeks gestation (Read et al. 2012), and although MTCT rates are very low among women who 
are virologically suppressed at delivery, residual transmissions have been shown to be associated 
with poorer virological control early in pregnancy (Tubiana et al. 2010). 
1.5 Adherence to ART 
Adherence to medication (i.e. taking prescribed doses at the prescribed intervals) is a significant 
challenge in chronic disease, and likely to be particularly problematic where a condition is 
asymptomatic and treatment is associated with significant side effects, as is often the case with HIV 
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infection and ART (Ammassari et al. 2001; WHO 2003a). When ART is taken erratically, exposure 
to antiretroviral agents may be insufficient to fully inhibit viral replication (Walsh et al. 2002). Other 
factors which can reduce exposure to antiretroviral agents and thus compromise its effectiveness 
include co-morbidities (e.g. affecting drug absorption), the physiological changes of pregnancy (e.g. 
the increase in plasma volume) and interactions between ART and other drugs (e.g. anti-
tuberculosis agents) (Chesney et al. 1999; Best et al. 2008; Jimenez-Nacher et al. 2011). Virological 
response to treatment will also be compromised if there is transmitted resistance to the 
antiretroviral agents being used (Chesney et al. 1999). 
Non-suppressive treatment is associated with HIV disease progression, mortality and development 
of de novo resistance to antiretroviral drugs (Ledergerber et al. 1999; Mocroft et al. 2004; Phillips et 
al. 2007), as is poor adherence to therapy (Gross et al. 2006; Lima et al. 2008b; Lima et al. 2009). 
Poor adherence is also associated with a smaller increase in CD4 count following initiation of ART, 
an increased risk of a discordant immunologic and virologic response to treatment and increased 
genital shedding of HIV RNA (Wood et al. 2004; Moore et al. 2005; Graham et al. 2010). During 
pregnancy, suboptimal ART adherence increases the risk of vertical HIV transmission, including 
transmission of drug resistant virus (Desai et al. 2003). After nine years of cART receipt an 
estimated 8.6% of patients will progress to extensive virologic triple class failure (Pursuing Later 
Treatment Options II (Plato II) project team for COHERE et al. 2010), highlighting the importance 
of optimising ART adherence and virological control as part of on-going HIV care. 
Incomplete adherence to ART is extremely common, can occur from the very start of treatment 
and is chronic in nature (Lopez-Suarez et al. 1998; Haynes et al. 2008). Comparisons of adherence 
levels across studies are difficult to make due to the range of methods used to measure adherence 
(Paterson et al. 2002), but average adherence levels according to objective measures (for example 
dispensing records and pill counts) have been found to be around 65-75% (Bangsberg et al. 2000; 
Bangsberg et al. 2001; Golin et al. 2002; Lima et al. 2009). Adherence levels >95% (expressed as the 
percentage of prescribed doses taken) may be required for optimal virological response (Gross et al. 
2006; Weinberg et al. 2009). The relationship between ART adherence and drug resistance is 
complex, and depends on the potency of the antiretroviral regimen, the genetic barrier to 
antiretroviral resistance, and the change in viral fitness caused by mutations conferring drug 
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resistance (Bangsberg et al. 2004; Gardner et al. 2009). Adherence to non-boosted PI-based 
regimens must exceed 95% to minimise the risk of resistance (Paterson et al. 2000), while NNRTI 
and boosted PI regimens are more potent and resistance is most likely to develop at adherence 
levels of 0-48% and 75-95% respectively (Bangsberg et al. 2006; Maggiolo et al. 2007; Gardner et al. 
2009).  
ART adherence during pregnancy and postnatally 
There is some evidence that ART adherence among pregnant women may be more complete than 
among non-pregnant or postpartum women (Ickovics et al. 2002; Vaz et al. 2007; Bardeguez et al. 
2008; Cohn et al. 2008; Mellins et al. 2008). Possible reasons for this include more regular contact 
with healthcare providers during pregnancy, enhanced support, lower chance of treatment fatigue 
(especially if ART is initiated for the first time during pregnancy for PMTCT), and higher levels of 
motivation inspired by concern for the health of the infant – cited as the greatest motivator for 
antenatal adherence by women in a Nigerian study (Ekama et al. 2012). One US study of 87 women 
followed during pregnancy and postnatally found that 57% reported no missed ART doses over a 
three-month period during pregnancy falling to 45% postnatally (p=0.03) (Cohn et al. 2008), while 
another in the US and Puerto Rico found that 61% of 309 women surveyed during the third 
trimester had missed no doses in the last month, compared with 44% of 220 women surveyed 
postpartum (p<0.01) (Mellins et al. 2008). A study in Brazil which used pill counts to measure 
adherence (i.e. by counting the number of pills remaining from a prescribed quantity) found that 
43% of 72 pregnant women had taken ≥95% of their ART on two occasions, significantly more 
than the 18% of 79 non-pregnant women assessed (p<0.01) and the 21% of 34  women followed 
postnatally (p<0.01) (Vaz et al. 2007). 
A recent meta-analysis of 51 studies estimated that 72% of HIV-positive women had adequate 
(>80%) adherence to ART during pregnancy (Nachega et al. 2012). Only two of these studies were 
from Western Europe, both of which were conducted in the UK and reported adherence as 
assessed by a clinician to be good or excellent in 75% and 84% of cases (assessment criteria not 
given) (Kingston et al. 2007; Caswell et al. 2011). In Eastern Europe, no published data are available 
on ART adherence in the perinatal period and very little data are available on ART adherence in the 
general population. One study from Estonia – a middle-income country with an IDU-driven HIV 
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epidemic similar to that in Ukraine – found that 88% of 144 participants (almost half of whom 
were female) reported perfect adherence to ART over the last three days (Uuskula et al. 2012), but 
there are no data specific to Ukraine. The generalizability of adherence data from the USA and 
Africa to Eastern Europe may be limited by differences in characteristics of HIV-positive women 
in these regions (for example, the proportion with an IDU history), and in the quality, organisation 
and financing of healthcare systems.  
Barriers to adherence and interventions 
Concerns around the public health implications of poor adherence to ART, given the 
transmissibility of resistant strains, may fuel inequalities in access to treatment for particular patient 
groups (Altice et al. 1998; Wainberg et al. 1998; Wolfe 2007). Barriers to ART adherence can be 
described as fitting into five areas: characteristics of the patient (e.g. IDU), drug regimen (e.g. 
complexity, side effects), patient-provider relationship (e.g. quality of communication), clinical 
setting (e.g. scheduling of appointments, childcare and confidentiality), and disease stage (Ickovics et 
al. 1997). Although much attention has been paid to indicators of social deprivation in relation to 
poor ART adherence, there is not a consistent association between the two (Chesney et al. 1999; 
Bangsberg et al. 2000). Among antenatal populations, the association between illicit drug use and 
adherence is also inconsistent (Laine et al. 2000; Turner et al. 2000; Cohn et al. 2008), and probably 
depends on the availability and uptake of supportive services for pregnant drug users (including 
opioid substitution therapy, shown to improve compliance with antenatal care among opiate users 
(Minozzi et al. 2008)). IDUs in Ukraine face specific barriers to adherence in the form of 
harassment and discrimination by the police, and the confiscation of ART (Mimiaga et al. 2010).  
Regimen complexity and pill burden have also been associated with ART adherence problems 
although not consistently (Chesney 2000; Turner et al. 2000; Fogarty et al. 2002; Glass et al. 2006; 
Molina et al. 2007). There is some evidence that patients are more likely to adhere if they have a 
positive relationship with their healthcare provider and feel able to trust them (Mostashari et al. 
1998; Johnston Roberts et al. 1999; Golin et al. 2002) or, in pregnancy, if they receive HIV focused 
or specialist care (Laine et al. 2000).  
Specific barriers to ART adherence exist for childbearing women, who may have little time to make  
a decision about disclosure to a partner before initiating ART for PMTCT, and may fear that 
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disclosure could result in violence or rejection (Mucheto et al.). Lack of disclosure during pregnancy 
is associated with poorer antenatal adherence and other missed opportunities for PMTCT (Jasseron 
et al. 2011; Ekama et al. 2012). Women are at greater risk of adverse reactions to ART than men 
(Ofotokun et al. 2003), and these may be exacerbated by the physical symptoms of pregnancy 
(Cohn et al. 2008). HIV-positive women also undertake substantial practical and emotional work 
during pregnancy and postnatally, including weighing up risks and benefits of interventions, 
redefining maternal identity and preparing strategies to avoid unintentional disclosure to family and 
friends when taking ART or avoiding breastfeeding (Giles et al. 2009). Qualitative findings have 
shown that women beginning ART during pregnancy for PMTCT focus more on the risk of the 
medication to their infant, whereas women receiving ART for their own health may focus more on 
its benefits (Giles et al. 2009). Poor adherence to neonatal prophylaxis has been associated with 
multiparity, low maternal social support and poor antenatal ART adherence (Turner et al. 2000; 
Demas et al. 2002; Mayaux et al. 2003; Kingston et al. 2007). In addition to general childcare 
responsibilities, the considerable anxiety around establishing the HIV status of the newborn may 
also contribute to poor maternal ART adherence postnatally (Vaz et al. 2007; Giles et al. 2009). 
Another factor that may impact on adherence is depression, itself associated with HIV diagnosis, 
female gender and low socioeconomic status (Psaros et al. 2009). The risk of depressive symptoms 
is heightened during pregnancy and the postnatal period (Bennett et al. 2004; Oates et al. 2004), and 
may be compounded by a new HIV diagnosis; a US study found a prevalence of postnatal 
depression among HIV-positive women of over 30% (Kapetanovic et al. 2009). Swiss, Spanish, 
Italian and US studies among predominantly male participants have found poorer or worsening 
ART adherence among those with depressive symptoms (Gordillo et al. 1999; Safren et al. 2001; 
Ammassari et al. 2004; Glass et al. 2009; Kacanek et al. 2010), as has a study in Botswana which 
included mainly women (Do et al. 2010). A study among pregnant and postpartum women in the 
US found that those who felt happy all or most of the time were significantly more likely to report 
perfect ART adherence (Bardeguez et al. 2008). In resource-limited settings, links between mental 
health services and HIV care provision may be particularly lacking (Collins et al. 2006). One study 
of HIV-positive people in Russia found that 39% had probable depression and an additional 28% 
had possible depression (Amirkhanian et al. 2011).  
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A wide range of complex interventions have been used to improve ART adherence, employing a 
variety of approaches (e.g. motivational interviewing, therapy focusing on managing HIV-related 
stigma, educational sessions on the importance of adherence) and have generally been found to be 
efficacious in trial settings (Simoni et al. 2006b). In a modelling study, directly observed 
administration of antenatal cART in the third trimester (among women initiating cART by 28 
weeks gestation) was associated with a relative MTCT risk of 0.39 compared with self-administered 
cART, and was cost-saving where average viral load at baseline was >1000 copies/ml (McCabe et al. 
2010). However, interventions are often highly context-dependent, and the impact of an 
intervention is strongly influenced by the normal standard of clinical care (de Bruin et al. 2010). In 
addition, it is common for interventions to involve multiple components and be tailored to 
individual patients, which decreases their fidelity and complicates comparisons and the 
generalizability of findings (Leeman et al. 2010).  
1.6 HIV co-infections and comorbidities 
Sexually transmitted infections 
STIs other than HIV are an important public health issue in Eastern Europe, where rates of 
bacterial STIs remain much more prevalent than in Western Europe (Landes et al. 2007; Uuskula et 
al. 2010; WHO Regional Office for Europe 2010). Availability and use of modern methods of 
contraception have been historically low in the former Soviet Union, and pregnancy terminations 
remain a common method of birth control (Mogilevkina et al. 2001; Ukrainian Center for Social 
Reforms et al. 2008; Gabhainn et al. 2009; Perlman et al. 2009; Lekhan et al. 2010). Although HIV-
positive individuals are entitled to free supplies of condoms, provision is patchy and lack of 
affordability remains an important barrier to their use (Saxton et al. 2010). HIV-positive individuals 
are particularly likely to be exposed to other STIs due to shared risk behaviours, and co-infection 
with other STIs increases the risk of HIV acquisition and transmission due to mucosal damage (e.g. 
genital ulcer disease) and modulatory effects on the immune system (Ward et al. 2010). For example, 
herpes simplex virus (HSV)-2 seropositivity has been associated with a two- to four-fold increased 
risk of HIV acquisition, and mucosal shedding of HIV RNA is increased among HIV/HSV-2 co-
infected people during subclinical HSV-2 reactivations (Corey et al. 2004). These biological 
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synergies have led to the investigation in several trials of treatment for STIs as a strategy to decrease 
HIV incidence, although with limited success (Hayes et al. 2010).  
Co-infection with other STIs can have particularly negative effects on the health of HIV-positive 
individuals. For example, HSV-2 co-infection is associated with increased plasma HIV viral load 
and more rapid HIV disease progression (Duffus et al. 2005; Roxby et al. 2011), and complications 
of bacterial STIs (e.g. pelvic inflammatory disease) may be more severe in HIV-positive individuals 
(Moodley et al. 2002). For HIV-positive women, co-infection with another STI has implications not 
only for their own health and for onward transmission of both infections to a sexual partner, but 
also for MTCT of HIV. Genital ulcer disease has been associated with a five-fold increased risk of 
MTCT of HIV among HIV-positive women in Kenya with very high prevalence of HSV-2 co-
infection, on adjusting for HIV RNA levels (Drake et al. 2007). A Thai study found over a two-fold 
increased risk of MTCT of HIV among women seropositive for HSV-2, independent of both 
cervicovaginal and plasma HIV RNA (Bollen et al. 2008), and a study in Zimbabwe from 1997 to 
2000 of women who had not received ART during pregnancy concluded that 28% of intrapartum 
transmissions were potentially attributable to prevalent HSV-2 co-infection (Cowan et al. 2008). 
Maternal syphilis infection has also been associated with an increased risk of MTCT of HIV, with a 
two-fold and four-fold increased risk found in studies conducted in Malawi and Ukraine 
respectively (Mwapasa et al. 2006; Thorne et al. 2008). 
Hepatitis C virus and liver fibrosis 
An estimated 160 million people are chronically infected with hepatitis C virus (HCV) worldwide (a 
prevalence of 2.4%) (Lavanchy 2011). Among HIV-positive people, the prevalence of HCV is 
around ten-fold higher than the worldwide population at 20-30%, reflecting shared modes of HIV 
and HCV acquisition (Hernandez et al. 2011): HCV is predominantly transmitted via IDU or, in 
resource-limited settings, exposure to unsterilised medical instruments or unscreened blood 
transfusions (Alter 2007). Among IDUs, the prevalence of HCV antibodies (indicating acute, 
chronic or resolved HCV infection) varies geographically but is between 60-80% in many countries 
worldwide, including Ukraine and Russia (Nelson et al. 2011). Transmission of HCV also occurs 
sexually, particularly among HIV-positive MSM who are at a four to five-fold increased risk of 
sexual HCV acquisition than HIV-negative MSM (Tohme et al. 2010). The risk of heterosexual 
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HCV transmission in low-risk discordant monogamous partnerships is as low as 1 in 10 million sex 
acts, but heterosexual transmission also seems to be substantially increased in the presence of HIV 
co-infection (Tohme et al. 2010). HCV can also be transmitted from mother to child; transmission 
rates are around 5%, but higher among women with HIV (Ohto et al. 1994; Gibb et al. 2000; Polis et 
al. 2007).  
Data on HCV prevalence in the general population in Ukraine are scarce. A report by two 
Ukrainian NGOs estimated that around one million people in Ukraine may be infected with HCV 
(i.e. 2% of the population), while seroprevalence among healthcare workers and people living with 
HIV is estimated at 3% and 53% respectively (Open Society Institute 2010). Ukrainian guidelines 
specify that donor blood should be screened for HCV RNA, but some facilities currently only 
screen for HCV antibodies (Personal communication, Michael Krone, Movement for Health, 
2012), introducing the possibility that infectious blood may enter the supply if a donor is in the 
‘window period’ of 8-12 weeks between infection and seroconversion (Rehermann 2009). NGOs in 
Ukraine have reported low levels of knowledge about HCV among clinicians, and widespread non-
compliance with measures to prevent iatrogenic transmissions ((Open Society Institute 2010), 
Personal Communication, Michael Krone, Movement for Health, 2012). 
Around 70% of people infected with HCV will develop chronic infection, with an increased risk of 
chronicity among HIV-positive people (Hernandez et al. 2011). Chronic HCV infection can cause 
liver fibrosis and eventually cirrhosis and hepatocellular carcinoma (de Torres et al. 2003); 
worldwide, around a quarter of cases of liver fibrosis and hepatocellular carcinoma are attributable 
to HCV infection (Alter 2007). In HIV-negative people chronically infected with HCV, the median 
time to development of liver cirrhosis in the absence of HCV treatment is around 30 years, but 
both HIV infection and immunosuppression are associated with more rapid disease progression 
(Massard et al. 2006). HIV infection is also itself associated with liver disease, and liver disease is a 
leading cause of morbidity and mortality among HIV-positive people (de Torres et al. 2003; Weber 
et al. 2006). 
Quantification of liver fibrosis on a population level is important in order to assess the burden of 
liver disease caused by viral hepatitis and other factors, including alcohol use, IDU and HIV 
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infection. Liver biopsy is the gold standard used to quantify the degree of liver fibrosis but has 
recognised limitations, including that results are limited by sample variability and that taking a 
biopsy is an invasive procedure associated with complications (de Torres et al. 2003). In recent 
years, there has therefore been increasing interest in the development of non-invasive measures of 
liver fibrosis which could be used more frequently than liver biopsy and rule out the need for 
biopsy in some patients (Carey et al. 2010). Hepatic fibrosis can be measured non-invasively via 
hepatic elastography, direct serologic markers such as procollagen type III amino-terminal peptide, 
or by algorithms such as FibroIndex and Fibrometer which allow for a score indicating degree of 
fibrosis to be calculated from the levels of a number of biomarkers (e.g. prothrombin, gamma 
glutamyl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) (Carey et al. 2010). 
Hepatic elastography and direct serologic markers of fibrosis are not routinely available in Ukraine, 
and so the degree of liver fibrosis among HIV/HCV co-infected women is assessed in this thesis 
using two algorithms: the FIB-4 index, and the aspartate transaminase (AST) to platelet ratio or 
‘APRI’. The FIB-4 index was developed for and validated in HIV/HCV co-infected patients 
(Sterling et al. 2006), important as HIV mono-infected individuals have elevated liver enzymes (and 
FIB-4 index scores) even in the absence of HCV co-infection (Blackard et al. 2011). The APRI 
score, derived and validated in individuals with chronic HCV mono-infection, may have less 
specificity in an HIV-positive population (Wai et al. 2003). These algorithms are described in more 
detail in Chapter 5.  
HPV infection and cervical abnormalities 
HIV-positive women are at increased risk of acquisition and/or persistence or reactivation of 
cervical infection with Human Papillomavirus (HPV) (Sun et al. 1997; Minkoff et al. 1998; Phelan et 
al. 2009), due to shared risk factors for acquisition (e.g. multiple sexual partners) and 
immunosuppression (Kojic et al. 2007; Franceschi et al. 2010). Cervical infection with HPV affects 
around 29% of women in Eastern Europe at any one time, compared with 6% in Western Europe, 
and age-standardised mortality rates for cervical cancer are two-fold higher (7.1 per 100,000 in 
Eastern vs. 3.4 per 100,000 in Western Europe (Castellsague et al. 2007)). Cervical abnormalities in 
HIV-positive women are more likely to be severe, aggressive and resistant to treatment than among 
HIV-negative women (Petry et al. 1994; Maiman 1998), and HIV-positive women are at a 5 to 8-
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fold increased risk of invasive cervical cancer compared with the general population (Frisch et al. 
2000; Clifford et al. 2005). Invasive cervical cancer has been included in the US Centers for Disease 
Control and Prevention (CDC) list of AIDS-defining illnesses since 1993, but although ART is 
associated with a reduced risk of many AIDS-defining cancers (e.g. Kaposi’s sarcoma), its role in 
the prevention of HPV-related cervical lesions or promotion of their regression is unclear (Uberti-
Foppa et al. 2003; Ahdieh-Grant et al. 2004; Del et al. 2004; Heard 2009; Minkoff et al. 2010). 
Regular cytologic screening can reduce the incidence of invasive cervical cancer by up to 80% on a 
population level (Gustafsson et al. 1997; Peto et al. 2004), and is also effective for the identification 
of cervical cell abnormalities among HIV positive women (Kitchener et al. 2007). Two or three-
yearly cytologic screening intervals are recommended in British and US guidelines for HIV negative 
women of childbearing age (Sawaya 2009; NHS Cancer Screening Programmes 2010), with more 
frequent (at least annual) tests for HIV positive women, given their increased risk of morbidity 
(Fakoya et al. 2008; US Centers for Disease Control and Prevention 2009). In the US Women’s 
Interagency HIV Study, HIV positive women receiving six-monthly cytologic screening with 
follow-up colposcopy and treatment where necessary had an incidence of invasive cervical cancer 
no higher than HIV negative women (Massad et al. 2004). Cytologic cervical screening is not 
recommended during pregnancy in UK guidelines (NHS Cancer Screening Programmes 2010), 
because invasive cervical cancer is uncommon among pregnant women in the UK, and treatment 
of all other cervical abnormalities is not considered acceptable during pregnancy due to the risk of 
complications (Wright et al. 2007; NHS Cancer Screening Programmes 2010). However, the much 
higher incidence of invasive cervical cancer among HIV-positive women may justify antenatal 
screening in this group, particularly if a woman is newly diagnosed as HIV-positive and has no 
previous cervical screening test. Perinatal care is also an opportunity to engage with women who 
are unlikely to attend for screening at another time (NHS Cancer Screening Programmes 2010), 
although samples taken during pregnancy or less than 12 weeks after delivery (when healing of the 
cervix is not complete) or if infection or discharge are present are harder to interpret (Flannelly 
2010). 
Ukrainian policy specifies that all women of childbearing age should receive six-monthly cervical 
screening (Ministry of Health of Ukraine 2002) but there are no guidelines specific to HIV positive 
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women. Screening is available free of charge at public health clinics (including family planning 
clinics, women’s health clinics, and some HIV/AIDS centres), and is predominantly opportunistic. 
There are no national figures on coverage (WHO ICO Information Centre on HPV Cervical 
Cancer 2010). World Health Survey data suggest that coverage with at least three-yearly screening in 
Ukraine, at 66%, is similar to many other European countries (Gakidou et al. 2008), but it is unclear 
whether this is the case among HIV positive women, who are more likely to be socially excluded 
(Kruglov et al. 2008).  
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1.7 Key points 
 The majority of HIV-positive women in Europe live in the Eastern region and particularly in 
Ukraine and Russia, where the HIV epidemic is driven by IDU and is amongst the most rapidly 
accelerating worldwide. Ukraine has the most severe HIV epidemic in Europe. 
 In Western Europe, migration patterns have had a large impact on the epidemiology of the 
HIV epidemic over the last ten years and this is especially the case among women, with the 
majority of pregnant HIV-positive women enrolling in Western European cohorts being from 
sub-Saharan Africa. 
 Very effective interventions for PMTCT (most notably antenatal cART) have been in 
widespread use for over a decade in the West, and have resulted in MTCT rates of <1-2%.  
 Meanwhile, in the resource-limited setting of Ukraine the MTCT rate has been slower to 
decline and was 7% in 2007. Access to antenatal cART was poor prior to 2007 but has been 
scaled up over the last few years with the adoption of a WHO ‘Option B’ policy. 
 Unanswered questions regarding the health, treatment and care of HIV-positive childbearing 
women in Western Europe include a focus on identifying the causes of vertical transmissions 
which continue to occur, and optimising the health of women who are increasingly 
accumulating treatment experience in repeat pregnancies. 
 In Ukraine, the focus is on meeting WHO goals for the virtual elimination of MTCT (a rate of 
<2%) by 2015, thus reducing inequalities with the West. As the epidemic continues to 
accelerate and the number of new infections outpaces the number of people newly started on 
cART, primary prevention is also a key priority for the epidemic response. 
 ART adherence is crucial to the success of cART for PMTCT and to improving maternal 
health outcomes. Barriers to adherence which may be particularly relevant for childbearing 
women include poor social support and perinatal depression. 
 HIV-positive women in Ukraine are particularly vulnerable to a number of co-infections and 
co-morbidities due to the IDU-driven nature of the HIV epidemic, the high prevalence of 
other STIs in this region and the lack of public health infrastructure. 
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Chapter 2 Aims and Methods 
2.1 Rationale for this work 
In an era with the necessary tools to virtually eliminate MTCT and with pressing goals for this to be 
achieved in Europe (WHO Regional Office for Europe 2011) and worldwide (UNAIDS 2011a), the 
exploration of circumstances around the suboptimal use of PMTCT interventions is a priority. This 
thesis focuses on a number of groups at heightened risk of MTCT and/or of poor maternal health 
outcomes. In chapter 3, missed opportunities for PMTCT are explored both in Ukraine, a setting 
where cART access is currently being scaled up, and in Western Europe, where overall transmission 
rates are very low (European Collaborative Study 2006; Townsend et al. 2008a) though some 
transmissions still occur (National Study of HIV in Pregnancy and Childhood et al. 2007; 
Warszawski et al. 2008). 
With the widespread availability of ART in Western Europe and increasing number of repeat 
pregnancies among HIV-positive women (French et al. 2012), the effective management of 
treatment experienced women is an issue of growing importance. In the UK, an increasing 
proportion of HIV-positive women are conceiving with a prior history of treatment (mostly short-
course ART for PMTCT) or while currently taking cART (National Study of HIV in Pregnancy and 
Childhood ; French et al. 2013). Treatment failure is associated with a heightened risk of emergence 
of drug resistance and HIV disease progression (Ledergerber et al. 1999; Mocroft et al. 2004; Phillips 
et al. 2007) and also has implications for MTCT, including transmission of resistant virus. In chapter 
4, factors associated with treatment failure during pregnancy are explored among women 
conceiving on cART in Western Europe. 
The expansion of the ECS to Ukraine in 2000 has made it possible to describe this country’s rapidly 
growing epidemic among pregnant women. Little is known about the epidemiology of HIV co-
infections and associated comorbidities among women in Ukraine, despite evidence that other STIs 
and viral hepatitis affect a significant proportion (Landes et al. 2007; Landes et al. 2008). In chapter 
5, data from the Ukraine Cohort of HIV-infected Childbearing Women are used to estimate testing 
coverage and prevalence of co-infections, and to characterize women co-infected with chlamydia 
and with hepatitis C virus (including, for the latter group, extent of liver fibrosis). As cervical cancer 
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is an important cause of morbidity among HIV-positive women (Frisch et al. 2000; Clifford et al. 
2005) but organised screening programmes are lacking in Ukraine, cervical screening coverage and 
factors associated with cervical abnormalities are also investigated with the aim of informing 
prevention programmes. 
The success of expanding access to cART in Ukraine for PMTCT and maternal health outcomes 
depends on adherence to treatment. Lower levels of antenatal adherence have been associated with 
illicit drug use and alcohol and tobacco use (Kingston et al. 2007; Cohn et al. 2008; Mellins et al. 
2008), but there are no data specific to Ukraine, where women have high levels of exposure to 
substance abuse and often poor access to psychosocial support. Information on levels and 
predictors of adherence to ART during pregnancy and postnatally are needed to strengthen 
treatment programmes and inform guidelines. In chapter 6, self-reported adherence behaviours of a 
sample of HIV-positive women during pregnancy and postpartum are described. The feasibility and 
utility of a short self-report adherence measure is investigated in this setting, and factors associated 
with poorer self-reported adherence are explored.  
  
 52 
 
2.2 Aims and Objectives 
Aim 
To investigate the health of HIV-infected childbearing women living in resource-rich and resource-
constrained settings in Europe, and to examine their treatment and care in the context of 
contemporary policies. 
Objectives 
In Western Europe and Ukraine 
1. To quantify and investigate circumstances around missed opportunities for PMTCT, 
specifically focusing on the use of antiretroviral prophylaxis and treatment in pregnancy. 
In Western Europe 
2. To explore trends in the proportion of HIV-positive pregnant women who are on cART from 
conception and, among these women, to explore the prevalence of and risk factors for 
virological failure during pregnancy. 
In Ukraine 
3. To explore testing coverage and prevalence of HIV co-infections and associated comorbidities 
in a postnatal HIV-positive cohort, with a particular focus on chlamydia, hepatitis C virus, and 
cervical abnormalities. 
4. To assess levels and predictors of adherence to maternal ART during pregnancy and in the year 
following delivery, and to neonatal prophylaxis. 
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Hypotheses and research questions for the thesis 
This thesis explores circumstances around the vertical HIV transmissions which continue to occur 
in Western Europe and Ukraine, with the hypothesis that some maternal characteristics are 
associated with an increased risk of missed opportunities for PMTCT (particularly an HIV 
diagnosis late in pregnancy and/or lack of antenatal ART). In Ukraine, poor ART coverage of 
eligible individuals in the general population suggests potential challenges to the scale-up of cART 
for pregnant women, and this hypothesis is explored through an investigation of coverage achieved 
with antenatal cART since adoption of an Option B policy. Overlaps exist between groups of 
women at increased risk of MTCT and those at increased risk of poor maternal health; women with 
virological failure on treatment are an important example. This thesis explores the hypothesis that 
in Western Europe, where a large proportion of HIV-positive pregnant women are now conceiving 
on cART, some groups are at increased risk of conceiving on a non-suppressive regimen (indicating 
poor ART adherence or antiretroviral drug resistance), with implications for pre-conceptual and 
antenatal management.  
In Ukraine, the high prevalence of HIV co-infections, poor public health provision and verticalised 
organisation of healthcare services (Atun et al. 2008; Lekhan et al. 2010) provide a basis for 
hypotheses that childbearing HIV-positive women have high levels of unmet need for services to 
diagnose, treat and prevent HIV co-infections and associated morbidity, and that some groups such 
as IDUs may be at particularly high risk. These hypotheses are explored using the examples of 
bacterial and viral co-infections (chlamydia and HCV) and cervical screening coverage and results. 
Modes of HCV acquisition among non-IDUs are explored in hypothesis-generating analyses.  
Finally, this thesis explores hypotheses that ART adherence can be effectively measured in a 
childbearing population in Ukraine using a self-report measure, that some women in Ukraine 
experience challenges adhering to ART during pregnancy and in the first year postpartum, and that 
factors associated with poor ART adherence in this population may include depressive symptoms, 
low self-efficacy and anxiety around the use of ART, as well as socio-demographic characteristics. 
The main research questions addressed by the individual studies are listed by chapter, as follows. 
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Chapter 3 Missed opportunities for the prevention of mother-to-child transmission 
 Section 3.2: In Ukraine, what maternal characteristics are associated with late antenatal HIV 
diagnosis and lack of antenatal ART, and how many vertical transmissions occur among 
women with these missed opportunities for PMTCT? What coverage has been achieved with 
antenatal cART (WHO Option B) since this became policy in 2007, and what impact has this 
policy change had on the overall MTCT rate? What are the main barriers which remain to the 
virtual elimination of MTCT in Ukraine? 
 Section 3.3: In Western Europe, to what extent does insufficient ART (a short duration or a 
complete lack of ART in pregnancy) contribute to the continuing transmissions seen in this 
region? What are the maternal and pregnancy characteristics associated with receiving no 
antenatal ART, or <14 days by delivery? 
 
Chapter 4 Virological failure in pregnancy among women conceiving on cART 
 In the Western Europe ECS, what proportion of women conceiving on cART over the last 
decade have had a non-suppressed viral load during pregnancy?  
 What maternal and treatment factors are associated with virological failure in this population? 
 
Chapter 5 HIV co-infections and associated morbidity in Ukraine 
 What is the prevalence of genital infections in a postnatal cohort of HIV-positive women in 
Ukraine? With a focus on chlamydia, what is the coverage of testing within HIV care, and what 
are the maternal characteristics associated with a recent chlamydia diagnosis? 
 What is the prevalence of HCV co-infection in this population? What are the risk factors for 
HCV co-infection? Among HIV/HCV co-infected women, what is the prevalence of advanced 
or significant liver fibrosis? 
 What is the coverage of cervical screening as part of HIV care in this population? What 
maternal factors are associated with having a screening test? How common are cervical 
abnormalities, and what factors are associated with this?  
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Chapter 6 Adherence to ART during pregnancy and postnatally in Ukraine 
 How does the CASE adherence index (a self-report ART adherence measure) perform in 
identifying poor adherence among childbearing women in Ukraine? Is CASE score associated 
with viral load? If so, which score cut-off is most useful for identifying women with a poorer 
virological response? 
 Overall, how well do women in Ukraine adhere to ART during pregnancy and the first year 
postpartum? What maternal factors are associated with poor adherence to ART at these two 
time points (to include exploration of perinatal depression, self-efficacy and anxiety around the 
use of ART)? What were the most common reasons for having missed a dose of ART? 
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2.3 Data sources 
This thesis uses data from three sources, summarised in Table 2.1. Each source is described in 
detail in the following sections. 
Table 2.1: Data sources 
 Study period Description 
European Collaborative 
Study (ECS) 
Enrolments on-going 
since 1986 
Observational birth cohort study of HIV-
positive women and their infants enrolled 
at clinic sites in ten European countries 
(including Ukraine) (linked anonymised 
data). 
 
Ukrainian Postnatal 
Cohort of HIV-infected 
Childbearing Women 
(“the Women’s Study”) 
Enrolments from 
December 2007 to May 
2012, with follow-up 
on-going 
Observational clinic-based cohort study of 
postpartum HIV-positive women nested 
within the European Collaborative Study in 
Ukraine (linked anonymised data). 
 
Adherence Study 
 
From June 2011 to 
April 2012 
 
Self-completed anonymised survey on ART 
adherence, nested within the European 
Collaborative Study in Ukraine (linked 
anonymised data). 
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The European Collaborative Study 
The ECS is an observational birth cohort study of HIV-positive pregnant women and their infants, 
established in 1986 in Western Europe to elucidate risk factors for MTCT and the natural history of 
vertically-acquired HIV infection (European Collaborative Study 1988). In 2000, the ECS expanded 
to sites in Ukraine, allowing documentation of the emerging epidemic in Eastern Europe 
(European Collaborative Study 2006). The ECS includes data from 25 clinical sites in ten countries: 
Spain, Italy, the UK, Germany, Belgium, Sweden, the Netherlands, Denmark, Poland and Ukraine. 
Enrolments in Poland are grouped with those in Western Europe for the purposes of all analyses in 
this thesis. 
As of February 2012, there were around 9500 mother-child pairs enrolled in the Western Europe 
ECS and around 9600 mother-child pairs enrolled in the Ukraine ECS. There have been declining 
enrolments in the Western ECS over recent years due to some countries setting up their own 
national cohorts, some sites ceasing enrolments and some seeing fewer deliveries to HIV-positive 
women. 
Data collected 
Women are enrolled and their infants prospectively followed according to a standard protocol. Any 
woman diagnosed with HIV before or during pregnancy, including intrapartum, is eligible for 
enrolment following her informed consent. Data are collected on maternal characteristics including 
socio-demographic factors, obstetric history, history of drug use and other HIV acquisition risk 
factors where known, date of first positive HIV test, clinical variables including antenatal CD4 
count and viral load, and antenatal ART receipt. Information is collected on mode of delivery and 
on birth outcomes including gestational age at delivery, birthweight and perinatal problems. Infants 
are prospectively followed and details collected of any clinical signs and symptoms of disease and 
results of laboratory tests, including HIV RNA, HIV DNA, HIV ELISA and CD4 count 
tests/measures. Uninfected infants are followed up to 18-24 months of age, with continued follow-
up of HIV-positive children. Maternal and perinatal data collection forms are reproduced in 
Appendix B, page 316. 
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All data collected are anonymised, with each woman assigned a unique study identifier which allows 
maternal data to be linked to infant follow-up data. In all sites except those in Ukraine, this unique 
number also allows for the identification of repeat pregnancies reported in the same woman. A 
survey carried out in 2005 found that the rate of non-participation in the ECS among eligible 
women at 11 Western Europe centres was <5% (Patel 2007). However, because of differences 
between Western European countries in HIV epidemiology and clinical practice (including policies 
for antenatal screening (Deblonde et al. 2007), Europe-wide findings may not be generalizable to 
specific countries. The Ukraine ECS began enrolment in Odessa, Mykolaiv and Simferopol in 2000, 
expanding to Kiev, Donetsk and Mariupol in 2006 and Krivoy Rog in 2008. In 2009, 33% of HIV-
positive pregnant women nationwide were enrolled in the Ukraine ECS (1291 of 3857), making 
findings broadly generalizable despite some regional differences.  
Data management 
The main co-ordinating centre of the ECS is in London at the UCL Institute of Child Health. 
There is also an Eastern Europe co-ordinating centre at the Perinatal Prevention of AIDS Initiative 
(PPAI), a non-governmental organisation in Odessa, Ukraine. Data are entered into MS Access 
2003 databases at each site or onto paper forms, and internal quality checks are conducted by key 
ECS collaborators at each site. The paper forms or electronic copies of the database are regularly 
transferred to the co-ordinating centre in London. Data consistency and logic checks are conducted 
prior to each analysis, and discrepancies resolved with local ECS coordinators. 
Research ethics approval 
The ECS has on-going research ethics approval from the Great Ormond Street Hospital for 
Children NHS Trust / Institute of Child Health Research Ethics Committee. Local ethics approval 
is also obtained at each participating site. There is no formal research ethics review process in 
Ukraine for studies conducted within the public healthcare system, so local institutional review 
board approval was granted by clinic directors on an individual clinic basis at each site participating 
in the Ukraine ECS. 
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Categories and definitions 
Definition and categories common to several chapters of the thesis are described here. Definitions 
specific to a chapter are described in the methods section of that chapter. 
History of IDU rather than current IDU was used as the exposure of interest in analyses 
throughout this thesis, in reflection of the fact that drug use is often a chronic and relapsing 
condition (Hepburn 2004) and a marker of social deprivation. In the ECS, IDU history was 
ascertained by any one of: self-report by the woman, clinical assessment, or neonatal abstinence 
syndrome in the infant. Women with no history of IDU reported in the studies are referred to as 
‘non-IDUs’ throughout the thesis for brevity. Under-ascertainment of IDU history is explored in 
section 5.3.2 (page 168). 
Marital status was categorised as married, cohabiting or single (including separated, divorced or 
widowed). Age at leaving full-time education was categorised as ≤16 years, 17-18 years and ≥19 
years. For work on the Western Europe ECS, maternal region of origin was categorised as sub-
Saharan Africa and other; this categorisation reflected differences in mode of HIV acquisition and 
immigrant status, of potential importance for access to care. Race was categorised as white, black 
and other. 
European guidelines state that infants born to HIV-infected women should receive RNA or DNA 
polymerase chain reaction (PCR) tests to detect transmission of the virus with diagnosis confirmed 
on a repeat test, and that a confirmatory antibody test is carried out at 15-18 months (PENTA 
Steering Committee 2009). PCR testing is widely available in resource-rich settings, and became 
available in Ukraine in 2006, although coverage was initially variable (Thorne et al. 2009). As of 
August 2011, 69% (2427/3535) of infants delivered from 2008 to 2010 in the Ukraine sites of the 
ECS had ≥1 RNA PCR test result available. In the absence of PCR testing, HIV-infected infants 
are diagnosed based on the persistence of HIV antibody beyond 18 months of age, since a positive 
antibody test prior to 18 months does not distinguish between a primary HIV infection in the 
newborn and passive transfer of anti-HIV antibody from the mother. For the purpose of analyses, 
infants with persistence of antibody beyond 18 months of age and/or a positive virological marker 
of infection regardless of age were categorised as infected. Infants with a negative PCR test result 
and/or a negative HIV antibody test were classified as uninfected, regardless of age (excluding 
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negative PCR test results on the day of delivery). The remaining infants and those with conflicting 
test results were categorised as having indeterminate HIV status. 
Gestational age is reported to the nearest completed week based on ultrasound or, in absence of 
ultrasound, last menstrual period; preterm delivery is classified as occurring before 37 gestational 
weeks. The first trimester is defined as 1 to 12 completed weeks of gestation, the second trimester 
as 13 to 26 weeks and the third trimester as 27 weeks of gestation onwards (Royal College of 
Obstetricians and Gynaecologists 2010). Elective CS was defined as before rupture of membranes 
and onset of labour. Parity was defined as previous live and still births. 
HIV disease staging in Western and Central European ECS sites was reported according to the US 
Centers for Disease Control and Prevention classification (severe symptomatic HIV disease 
corresponding to CDC stage C (US Centers for Disease Control and Prevention 1993)) and in 
Ukrainian sites was reported according to the World Health Organization clinical staging criteria 
(advanced and severe symptoms corresponding to WHO stages 3 and 4 respectively (WHO 2006)). 
Antenatal CD4 counts were categorised as ≤350 and >350 cells/mm3, or as <200, 200-349 and 
≥350 cells/mm3 – categories relevant for determining treatment eligibility (WHO 2006; WHO 
2010b). The quantification detection limits of viral load assays used varied over the years of the 
ECS and across Western and Eastern European sites. The limit below which a viral load was 
categorised as undetectable is defined for each analysis. Monotherapy was defined as one ARV 
drug, dual therapy as two ARV drugs and cART as ≥3 ARV drugs taken simultaneously. cART 
regimens were categorised as: PI-based, NNRTI-based, PI and NNRTI-containing, or a triple 
NRTI regimen. 
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The Ukrainian Postnatal Cohort of HIV-infected Childbearing Women 
The Ukrainian Postnatal Cohort of HIV-infected Childbearing Women (“the Women’s Study”) was 
established in December 2007 as a nested sub-study of the Ukraine ECS, to investigate clinical and 
HIV disease progression markers and socio-demographic characteristics of women after delivery 
(Saxton et al. 2010). Postpartum women who are not already enrolled in the ECS are also eligible for 
Women’s Study enrolment, if diagnosed as HIV-positive before or during a recent pregnancy 
including intrapartum. Enrolment usually takes place within 12 months of delivery. Five regional 
HIV/AIDS centres in Ukraine participate (situated in Odessa, Kiev, Mykolaiv, Donetsk and Krivoy 
Rog – see Figure 2.1). There is no specific protocol for timing of follow-up, which takes place 
whenever a woman returns to the HIV/AIDS centre for care. 
 
Figure 2.1: Study sites of the Ukrainian Postnatal Cohort of HIV-infected Childbearing 
Women  
(Mariupol and Simferopol in blue are study sites for the Ukraine ECS only). 
Data collected 
Data collected are anonymised, with clinicians providing ECS serial numbers to enable data linkage; 
over 80% of women enrolled in the Women’s Study are also enrolled in the ECS, allowing for 
investigations spanning pregnancy and the postnatal period. For women not in the ECS, 
background information on socio-demographic characteristics, timing of HIV diagnosis, receipt of 
antenatal ART in most recent pregnancy and clinical status is collected. 
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At enrolment into the Women’s Study, baseline data are collected on two standardised 
questionnaires, one completed by the clinician and one by the woman. These forms are included in 
Appendix C, page 320. In brief, the clinician provides information on HIV disease status (CD4 
count, HIV RNA viral load, current WHO stage and history of AIDS-defining illnesses) and ART 
received for the woman’s own health (including toxicities and treatment modifications). Detailed 
information is collected on co-infections including viral hepatitis and STIs diagnosed during the 
most recent pregnancy or postnatally, and on cervical screening received as part of HIV care. 
Biochemical measurements collected include haemoglobin, platelet count and liver enzyme tests.  
The woman’s baseline form includes questions on the most recent pregnancy, the woman’s living 
situation, the HIV status of her partner and whom she has disclosed her own status to. Questions 
on health behaviours cover smoking and use of alcohol and illicit drugs (including her own and her 
partner’s injecting behaviours, sharing of injecting equipment, age at initiating illicit drug use and 
injecting, contact with harm reduction programmes and use of opioid substitution therapy). The 
woman is also asked to report use of contraception including affordability and availability, use of 
HIV psychosocial support services and, if continuing ART postnatally, experience of ART side 
effects and ART adherence (frequency of missed doses in last four weeks, whether she has had a 
period of >24 hours with no ART in the last four weeks). 
At follow-up, the clinician provides updated information on HIV disease status and biochemical 
parameters, ART received (including toxicities, treatment modifications and adherence), and co-
infections diagnosed and cervical screening received since last follow-up. The clinician is also asked 
to provide updated information on the woman’s living situation, her current use of HIV 
psychosocial services, current use of contraception and incident pregnancies including miscarriages 
and terminations.  
Participation rates in the Women’s Study among women enrolled in the ECS vary substantially by 
site, from 24% in Donetsk to 87% in Kiev; these participation rates and the representativeness of 
the postnatal cohort are explored in section 5.2.1 (page 146).   
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Data management 
Data collection is co-ordinated by PPAI in Odessa. Data are entered into an MS Access 2003 
database with periodic electronic transfer to the UCL Institute of Child Health, every 4 to 6 weeks. 
Consistency and missing data checks are conducted prior to every analysis, and discrepancies 
resolved as far as possible with collaborators and by comparison of data from all sources - for 
example, woman’s date of birth is collected in the ECS and on both the clinician and woman’s 
baseline forms. 
Research ethics approval 
The Women's Study is nested within the Ukraine European Collaborative Study and covered by its 
on-going ethical approval from the Great Ormond Street Hospital for Children NHS Trust / 
Institute of Child Health Research Ethics Committee. Local institutional review board approval has 
also been granted by clinic directors at each participating site. Informed consent is obtained verbally 
and taken as implied by the woman's return of a completed questionnaire at enrolment. 
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Adherence Study 
The aim of this sub-study was to investigate levels and determinants of ART adherence among 
HIV-positive women in Ukraine both during pregnancy and postpartum. Two surveys were 
conducted – one among women delivering at three maternity hospitals in Odessa, Kiev and 
Simferopol on their adherence behaviour during pregnancy, and one among women attending six 
participating HIV/AIDS centres (in Odessa, Donetsk, Kiev, Krivoy Rog, Mykolaiv or Simferopol) 
on adherence behaviours postpartum. The Antenatal Survey was conducted at around the time of 
delivery, and the Postnatal Survey at between 4 weeks and 12 months postpartum (see Figure 2.2). 
The surveys are reproduced in Appendix D, page 332. The Postnatal Survey included questions on 
adherence to neonatal prophylaxis, as well as to maternal ART. The main survey period was from 
July to December 2011, with extension until April 2012 at sites experiencing operational problems 
(including one site which was closed to patients for a period). 
Survey participation was voluntary and involved completion of a paper-based questionnaire, which 
was designed for this study and drew on a number of previously validated tools (see Data Collected). 
Surveys were anonymously coded and code keys were held by clinicians for the purpose of referring 
women who reported adherence problems or symptoms of depression for additional support. 
Enrolment in either of the two on-going cohorts (the Ukraine ECS and the Women’s Study) was 
not a pre-requisite for participation.  
Data collected 
Data were collected on mother’s date of birth and her infant’s date of birth and sex, to allow for 
linkage of adherence study data with information on the same participants in the ECS and 
Women’s Study. This allowed for validation of self-reported adherence with viral load measures.  
As participation in the on-going cohorts was not a pre-requisite for participation in the Adherence 
Study, the adherence surveys also included some basic questions on socio-demographics and health 
behaviours (including drug use) taken from the ECS and Women’s Study questionnaires. Questions 
specific to the adherence survey on adherence, ART-related self-efficacy and perinatal depression, 
are described in the pages that follow.  
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Adherence was measured using the self-report Case Adherence Support Evaluation (CASE) index 
tool, which consists of three questions (as follows). Together, the answers to these questions give a 
composite score of between 3 and 16, with higher scores indicating better adherence.  
  Score 
How often do you have difficulty taking 
your HIV medications on time? 
 
All of the time 1 
Most of the time 2 
Rarely 3 
Never 4 
On average, how many days per week 
would you say that you missed at least one 
dose of your HIV medications? 
Every day 1 
4-6 days per week 2 
2-3 days per week 3 
Once a week 4 
Less than once a week 5 
Never 6 
When was the last time you missed at least 
one dose of your HIV medications? 
In the last week 1 
1-2 weeks ago 2 
3-4 weeks ago 3 
Between 1-3 months ago 4 
More than 3 months ago 5 
Never 6 
 
The first evaluation of this tool was conducted between 2000-02 at 12 sites in the US among 524 
patients (mostly male African Americans), and included a comparison of the CASE adherence 
index with the Adult AIDS Clinical Trial Group (AACTG) three-day recall adherence measure (a 
self-report measure of doses prescribed and missed in the previous three days) (Mannheimer et al. 
2006). A CASE adherence index score cut-off of 10, with scores >10 indicating good adherence 
and scores ≤10 indicating poor adherence, was found to have the greatest sensitivity and specificity 
in identifying patients with 95% adherence according to the AACTG measure. Scores of >10 were 
significantly associated with a 1 log reduction in HIV RNA level, achievement of an HIV RNA 
level of <400 copies/ml and increase in CD4 count over 12 months of treatment. Self-reported 
adherence may more accurately reflect pill-taking behaviour if the self-report period is longer (e.g. 
weeks or months rather than the last 7 days or less (Lu et al. 2008)) – the AACTG 3-day measure 
may therefore lack sensitivity to identify poor adherence. A study conducted in Thailand in 2007-08 
found a CASE adherence index cut-off of ≤12 to be more sensitive in identifying treatment failure 
than a cut-off of 10; all patients with a CASE adherence index score >12 had a viral load <400 
copies/ml at 6 months (n=199) and <50 copies/ml at 12 months and 18 months follow-up (n=198 
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and n=196 respectively) (Apisarnthanarak et al. 2010). A more recent study, also from Thailand, 
found that a CASE adherence index score of ≤11 was associated with the largest probability of 
predicting virologic response to ART at three different thresholds (>50 copies/ml, >1000 
copies/ml and >5000 copies/ml (Kerr et al. 2012)). In Chapter 6, CASE scores dichotomised at 
different values were validated against viral load in a subgroup of women with linked data available, 
in order to identify the best outcome measure.  
Self-reported adherence levels are generally inflated compared with more objective measures of 
adherence (Bangsberg et al. 2000; Liu et al. 2001; Kimmerling et al. 2003), due to a range of factors 
including recall and social desirability bias, poor cognitive functioning and difficulties understanding 
self-report questionnaires (Kimmerling et al. 2003; Wagner et al. 2004; Johnson et al. 2005). One 
potentially valid approach to analysing self-report adherence data is to dichotomise responses 
according to whether any missed doses are reported (Simoni et al. 2006a). As a sensitivity analysis, 
and for comparison with the outcome of poor adherence as defined by CASE score, an outcome of 
‘any reported missed dose’ was constructed and its relation with associated factors explored 
(Chapter 6). For the Antenatal Survey, ‘any reported missed dose’ referred to the whole of 
pregnancy; women in the ‘ever missed a dose’ group were those who provided a timing of their last 
missed dose (CASE question 3) and/or ≥1 reason for a missed dose on a later question  (AIDS 
Clinical Trials Group 2010a), and/or who reported missing at least one dose a week (CASE 
question 2). If a woman reported missing a dose less than once a week (CASE question 2) and gave 
no other indication of having missed a dose, she was categorised with the ‘never missed a dose’ 
group. For adherence to maternal ART postnatally, the outcome of ‘any missed dose’ was 
constructed in the same way but limited to the four weeks preceding survey completion; most of 
the women completed the survey several months after delivery (Table 6.2, page 203).  
Adherence to ART has been associated with knowledge of or familiarity with the prescribed 
regimen - for example, the ability to correctly identify pills from a selection (Parienti et al. 2001) and 
to name antiretroviral drugs currently taken (Osborn et al. 2010). In order to explore this, the 
Adherence Survey included a question on the name(s) of HIV medications currently being taken. 
Those reporting ≥3 drug names or, in the Antenatal Survey, one drug (if they were on ZDV), were 
considered to have complete knowledge of their regimen. For the 15 women who reported having 
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taken ZDVm, this was verified against self-reported pill burden (i.e. to check that they had not 
reported ZDV only from a cART regimen). Women reporting two drug names or one drug name if 
this was not ZDV were considered to have incomplete knowledge, while those reporting no names 
or only words unrecognisable as the name of an antiretroviral drug were considered to have no 
knowledge. Linked drug data from the ECS were used to give an indication of the accuracy of the 
drug names reported by the women. Lack of knowledge of regimen was investigated as a factor 
associated with adherence. 
In addition to measures of ART adherence, the Adherence Survey also included measures of 
depression and ART-related self-efficacy – factors potentially relevant to adherence behaviours. 
Depression was measured using Patient Health Questionnaire (PHQ)-2 Screening Questions from 
the Primary Care Evaluation of Mental Disorders: “During the past month, have you often been 
bothered by feeling down, depressed or hopeless?” (low mood) and “During the past month, have you 
often been bothered by little interest or pleasure in doing things?” (anhedonia). A positive response to 
either of these two questions has an estimated sensitivity of 96% and specificity of 57% for the 
detection of depression in primary care settings (Whooley et al. 1997). The tool’s specificity can be 
increased to 89% with the additional criteria of a “yes” response to “Is this something with which you 
would like help?”(Arroll et al. 2005). Patients responding positively to both of the first two questions 
are at high risk of depression irrespective of their response to the “help” question (Arroll et al. 
2005). For this study, a positive depression screening test result was therefore defined as a ‘yes’ 
response to at least two of the three screening questions (summarised in Figure 6.1). Adherence 
Study questionnaires were anonymous to researchers but not to clinicians, to allow for referrals for 
mental health or adherence support where necessary. 
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Figure 6.1: Algorithm for interpretation of PHQ-2 depression screening questions 
 
ART-related self-efficacy was measured using questions from the HIV Treatment Adherence Self-
Efficacy Scale (HIV-ASES) (AIDS Clinical Trials Group 2010b), adapted for use in the Adherence 
Surveys. The HIV-ASES tool asks respondents to rate their confidence in their own ability to adopt 
various behaviours related to HIV care. Because the Adherence Survey respondents did not 
generally have long ART treatment histories (particularly the Antenatal Survey respondents, most 
of whom would have initiated ART in pregnancy for PMTCT only), the HIV-ASES questions that 
were selected for inclusion in the survey focused on integration of pill-taking into daily life rather 
than long-term perseverance with treatment in the face of disease progression.  
The original HIV-ASES tool asks respondents to rate their confidence in various areas on a scale 
from 0 to 10, (where 0 indicates ‘cannot do’ and 10 indicates ‘confident I could do’). However, this 
layout caused confusion among respondents in the pilot Adherence Survey, and the question layout 
was therefore simplified to three options (‘could not do’ [0 points], ‘fairly confident I could do’ [1 
point] and ‘confident I could do’ [2 points]). For women answering all five of the HIV-ASES 
integration questions, their total score was investigated as a continuous variable and also as a 
categorical variable dichotomised as <5 vs. ≥5 (respondents with a score of <5 having reported 
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that they ‘could not do’ at least one of the items). Two questions on the woman’s confidence in her 
ability to ask for information and support were also included and followed the same format. 
In order to give context to self-reported ART adherence problems, the Adherence Study surveys 
included a question on reasons for missed doses from the AIDS Clinical Trials Group adherence 
tool (AIDS Clinical Trials Group 2010a). In the postnatal survey, women were also asked whether 
their adherence had improved, deteriorated or remained unchanged following delivery (question 
adapted from (Mellins et al. 2008)). This question was important in assessing changes in adherence 
behaviours over the perinatal period, which could not be measured directly due to the cross-
sectional nature of the antenatal and postnatal surveys. Women’s attitudes towards the risks and 
benefits of ART for PMTCT were explored using two questions from the NIAIDS Adult AIDS 
Clinical Trials Group supplemental antepartum adherence questionnaire (NIAID Adult AIDS 
Clinical Trials Group 2001), which focused on the degree to which women felt that antiretroviral 
drugs were effective for PMTCT or were worried about adverse effects of ART.  
Pilot study and sample size 
Twenty women at both Odessa Regional Hospital and Odessa HIV/AIDS centre completed pilot 
surveys in May and June 2011. Feedback from participants and clinicians enabled the identification 
of problems with comprehensibility and layout of the questionnaires and study logistics (including 
referral pathways for adherence and mental health support). Both surveys were continued until 100-
200 women had consented to take part and returned a completed form (200-400 forms in total). 
The participation rate was estimated at around 35-44% in the antenatal survey and 35% in the 
postnatal survey (75% among women on ART postnatally); these participation rates and the 
representativeness of the study population are described in detail in section 6.3, page 198. 
Data management 
Data collection was co-ordinated by PPAI and data entered by the data manager in Odessa into a 
Research Electronic Data Capture (REDCap) database (Harris et al. 2009), held securely on a server 
at the UCL Institute of Child Health. Linkage with ECS data allowed for checks to be conducted 
(e.g. on the eligibility of participants and the accuracy of self-reported ART regimens). 
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Research ethics approval 
Research ethics approval was granted by the UCL Research Ethics Committee for this project 
(application 3061/001, May 2011). Local institutional review board approval was granted by all 
participating clinics and maternity hospitals in Ukraine. 
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Figure 2.2: Timescale of the two Adherence Surveys, and data collected
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2.4 Data analysis 
Database management and data entry for all studies were conducted using MS Access 2003 
(Microsoft Corp., Redmond, Washington, USA) and REDCap electronic data capture tools hosted 
at the UCL Institute of Child Health (Harris et al. 2009). All data cleaning, manipulation and 
analyses were carried out in Stata versions 10.0 and 11.0 for Windows (StataCorp LP, College 
Station, Texas, USA). For the two on-going cohort studies, extraction of data from the most up-to-
date copy of the database was conducted prior to each analysis. Table 2.2 summarises the data 
source, time period and subjects (mother-child pairs or pregnancies) included in each analysis. 
 73 
 
Table 2.2: Data available for each analysis 
 
Chapter Analysis Dataset and centres Time period Subjects 
3 Insufficient antenatal ART ECS - Western and Central European 
sites 
Jan 2000 – Jul 2009 2148 mother-child pairs 
3 Use and trends of PMTCT 
interventions in Ukraine 
ECS - Ukraine sites Jan 2000 – Dec 2010 
Jan 2008 - Dec 2010 for  
missed opportunities for 
PMTCT analyses 
7346 mother-child pairs 
3535 mother-child pairs  
4 Virologic failure in 
pregnancy among women 
conceiving on cART 
ECS - Western and Central European 
sites 
Jan 2000 – Dec 2011 396 mother-child pairs 
5 Factors associated with 
chlamydia diagnosis 
Ukraine postnatal women’s study - Kiev, 
Odessa, Donetsk, Mykolaiv HIV/AIDS 
centres 
Dec 2007 – Sep 2011 2066 women 
5 HCV co-infection Ukraine postnatal women’s study - Kiev, 
Odessa, Donetsk, Mykolaiv HIV/AIDS 
centres 
Dec 2007 – Sep 2011 2066 women 
5 Cervical screening within 
HIV care 
Ukraine postnatal women’s study - Kiev, 
Odessa, Donetsk HIV/AIDS centres 
Dec 2007 – Mar 2011 1120 women 
6 ART Adherence Adherence study - Kiev, Odessa and 
Simferopol maternity hospitals; Kiev, 
Odessa, Donetsk, Mykolaiv, Krivoy Rog 
and Simferopol HIV/AIDS centres 
May 2011- April 2012 
 
185 women in antenatal 
survey, 233 in postnatal 
survey 
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2.5 Statistical methods 
Univariable comparisons of categorical variables were assessed using the 2 test or Fisher’s exact 
test where numbers were small. Sample means of normally distributed variables were compared 
using the t-test, and sample medians of skewed continuous variables were compared using the 
Wilcoxon-Mann-Whitney test or the Kruskal-Wallis test (Kirkwood et al. 2008). Trends over time 
were assessed fitting logistic or linear regression models, with year of delivery specified as a 
continuous explanatory variable.  
Univariable and multivariable logistic regression models were fitted to obtain odds ratios (OR) and 
adjusted ORs (AOR) and their 95% confidence intervals (CI). The contribution of each variable to 
a model’s goodness-of-fit was assessed by comparing nested models using the Likelihood Ratio 
Test (LRT). Akaike’s information criterion (AIC) and Bayesian information criterion (BIC) were 
also used to compare non-nested models (Kuha 2004). 
Poisson regression models with robust variance estimators were fitted in preference to logistic 
regression models where the prevalence of a binary outcome was high (>10%). Odds ratios 
obtained from logistic regression models only approximate prevalence ratios where the prevalence 
of an outcome is uncommon, and so the use of logistic regression for these analyses would have 
resulted in odds ratios not directly interpretable as a measure of association. An outcome with high 
prevalence may produce under-dispersion which can be controlled by introducing a scale parameter 
in the models; this takes the value of 1 in ordinary Poisson regression. This extra parameter models 
the changes in the variance of the response variable and is estimated using a robust procedure 
(Barros et al. 2003).  Univariable and multivariable Poisson regression models with robust variance 
estimators can be used to directly estimate prevalence ratios (PR), adjusted PRs (APR) and 95% CI 
when analysing cross-sectional binary data, and furthermore this approach results in more adequate 
controlling for confounding (which depends on measure of effect) when outcomes are common 
(Barros et al. 2003). Wald’s test was used to compare the goodness-of-fit of Poisson regression 
models with robust variance estimators, as part of the model selection procedure. 
Methods specific to each analysis are described in the corresponding chapters. 
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2.6 Role of researcher 
As this work was conducted in the context of two on-going cohort studies, I take this opportunity 
to clarify my role. Data collection was the responsibility of clinicians at each participating centre 
and I had limited involvement with data verification and entry (in some cases this was done at the 
UCL Institute of Child Health and in some cases by local partners). I conducted data checks prior 
to each analysis and had close contact with collaborators in Ukraine to resolve data queries. 
For the Adherence Study I led on the development of the protocol, questionnaires and patient 
information leaflets, which were translated by PPAI. I also designed the database and took 
responsibility for the application to the UCL Research Ethics Committee. 
I performed all analyses presented in this thesis, with guidance from my supervisors Dr Claire 
Thorne, Dr Mario Cortina-Borja and Dr Claire Townsend. To date this work has led to three 
papers and one research letter accepted for publication with another paper in preparation, as well as 
a number of conference abstracts (Appendix F, page 345). 
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Chapter 3 Missed opportunities for the prevention of mother-to-child 
transmission 
3.1 Introduction 
Worldwide, the great majority of vertical transmissions occur in low- and middle-income settings, 
where the HIV burden is the highest and where less effective PMTCT interventions (including 
sdNVP) continue to be used. In Ukraine, the national PMTCT strategy was based on antenatal 
ZDVm and sdNVP until the end of 2007, when policy changed to recommend antenatal cART for 
all HIV-positive pregnant women. In the first part of this chapter, trends in socio-demographic and 
clinical characteristics, use of PMTCT interventions and MTCT rates in the Ukraine ECS from 
2000 to 2010 are described. Factors associated with MTCT in 2008-10 are investigated as are 
missed opportunities for PMTCT, focusing on ART use and timing of maternal HIV diagnosis. 
The second part of this chapter focuses on the resource-rich setting of Western Europe, where 
some vertical transmissions continue to occur despite wide availability of the full combination of 
measures to reduce MTCT risk (National Study of HIV in Pregnancy and Childhood et al. 2007). 
Longer durations of antenatal ART are associated with greater reductions in viral load and therefore 
vertical HIV transmission risk (European Collaborative Study 2005; Keiser et al. 2008; Townsend et 
al. 2008a; Warszawski et al. 2008); the role of short ART duration as a risk factor for preventable 
vertical transmissions is explored in the Western European sites of the ECS from 2000 to 2009. 
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3.2 PMTCT in Ukraine: trends and missed opportunities 
3.2.1 Methods 
This section uses data available by August 2011 on deliveries reported from January 2000 to 
December 2010 in the Ukraine ECS. Odessa, Mykolaiv and Simferopol HIV/AIDS centres 
contributed data from January 2000 onwards, Kiev, Donetsk and Mariupol HIV/AIDS centres 
from September 2006 and Krivoy Rog HIV/AIDS centre from October 2008.  
Where a pregnancy resulted in twins or triplets, the second- and subsequent-born infants of the 
multiple birth were excluded. This approach ensured that data from a single pregnancy did not 
appear in duplicate in the analyses; this work focuses on use of PMTCT interventions, making 
pregnancies the denominator of interest. Where vertical transmission had occurred to the second- 
or subsequent-born infant in a multiple birth but not to the firstborn (n=2), the infected infant was 
retained (and firstborn excluded) to allow for the analysis of factors associated with any MTCT.  
Information on whether a pregnancy was a second or subsequent delivery to a woman previously 
enrolled in the study was not available. The proportion of pregnancies in the ECS which were 
repeat pregnancies was estimated by identifying, for each set of records with matching centre and 
maternal date of birth, any second or subsequent pregnancy where: maternal HIV diagnosis 
occurred prior to conception, estimated date of conception was after previous date of delivery, and 
parity (previous live or stillbirth) increased by one compared with the previous pregnancy. This 
estimation was based on 81% (5922/7346) of pregnancies with exact maternal date of birth and all 
other required variables available. Mother-child pairs with maternal HIV diagnosis date after the 
date of delivery, and no other information to indicate that this was an error (ART receipt during 
pregnancy or intrapartum), were excluded (n=49).  
Viral load assays with detection limits of 75 copies/ml were in use at some regional labs until 2010, 
when highly sensitive assays with detection limits of 40 copies/ml were adopted at all laboratories. 
In this work, a viral load of ≤75 copies/ml was defined as “undetectable”. Dual therapy was 
received in a small number of pregnancies (described on page 84); these pregnancies were 
considered with the ZDVm group for all analyses, as were the small number of pregnancies in 
which a drug other than zidovudine was received as monotherapy. Women who received only 
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sdNVP intrapartum were classified with the ‘no antenatal ART’ group. Treatment indication was 
defined as CD4 count of ≤350 cells/mm3 and/or WHO stage 3-4 disease (WHO 2010b). A late 
maternal HIV diagnosis was defined as one occurring during the third trimester or intrapartum. 
Risk factor analyses were conducted for three scenarios in 2008-10: i) late HIV diagnosis among 
women undiagnosed at conception, ii) non-receipt of antenatal ART among women not on ART at 
conception and diagnosed prior to delivery; iii) initiation of ZDVm rather than cART during 
pregnancy. Poisson regression models with robust variance estimators were fitted to investigate 
factors associated with these outcomes. Each covariate was tested for its significant contribution to 
the model’s goodness-of-fit using Wald’s test (significance level of <0.10). Educational status was 
available for only 44% (1545/3535) of women overall and so was excluded from main analyses to 
avoid bias, but was investigated in sub-analyses. 
In the logistic regression model fitted to investigate factors associated with MTCT from 2008 to 
2010, all factors found previously to be associated with MTCT risk in this cohort  were included a 
priori (Thorne et al. 2009) (preterm delivery, mode of delivery, receipt of antenatal and intrapartum 
ART, IDU history) with the exception of breast feeding, excluded as almost all women formula fed. 
Neonatal prophylaxis and maternal WHO stage and CD4 count were considered for inclusion at 
significance level of <0.10 on LRT.  
In order to investigate individual-level factors associated with missed opportunities for PMTCT or 
MTCT in a context where relevant policy varied over time and practice varied by centre, all models 
in this section were adjusted a priori for year of delivery and centre of enrolment. For Poisson 
regression models, centre was included as a covariate to allow for the inclusion of a robust 
estimates term. Accounting for under-dispersion in highly prevalent outcomes in this way was 
considered more important than the retention of five additional degrees of freedom (which could 
have been achieved by accounting for within-centre variation with a random effects term).  
The analyses on initiation of ZDVm rather than cART during pregnancy were limited to 2840 
pregnancies with WHO stage and/or antenatal CD4 count available (93% (2840/3068) of those 
where ART was initiated antenatally), since maternal treatment indication was so important in 
determining cART receipt.  
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3.2.2 Cohort characteristics and time trends  
Maternal characteristics 
There were a total of 7346 deliveries reported in 2000-10. Table 3.1 (page 83) shows trends over 
time in maternal and delivery characteristics. A gradual increase in maternal age was seen over time, 
from a median of 25.4 years (IQR 22.3, 29.6) in 2000 to 27.8 years (IQR 24.2, 31.6) in 2010, with 
women increasingly likely to have had a previous live birth at enrolment. There was also a 
consistent increase in the proportion of women with known HIV infection at conception. Repeat 
ECS pregnancies were estimated to account for 4% (268/5922) overall (most (258/268) were 2nd 
pregnancies, and 10 were 3rd pregnancies), increasing from 2% to 3% of pregnancies in the period 
from 2003 to 2007 to 4% of pregnancies (47/1118) in 2008, 5% (60/1162) in 2009 and 11% 
(97/846) in 2010 (trend p<0.01 for 2008 to 2010). The length of time between HIV diagnosis and 
delivery increased significantly from a median of 18 weeks in 2000 to 29 weeks in 2010, with a 
concomitant increase in the proportion of women with WHO stage 3-4 disease or a CD4 count 
≤350 cells/mm3 (reaching 16% and 36% respectively in 2010, Table 3.1). Of 364 women diagnosed 
before pregnancy, not on cART at conception and delivering in 2010, 41% (n=150) had WHO 
stage 3-4 disease and/or a CD4 count ≤350 cells/mm3 during pregnancy (i.e. treatment indications 
for their own health). Among those diagnosed during pregnancy in the same year, 8% (36/474) had 
WHO stage 3-4 disease and 32% (162/512) had WHO stage 3-4 disease and/or a CD4 count ≤350 
cells/mm3 during pregnancy. 
Overall, 82% (6017/7306) of women were married or cohabiting at the time of enrolment, with no 
change over time (trend p=0.14). The proportion of women who had stayed in full-time education 
until at least the age of 17 years was 61% (576/948) in 2000-05 and 83% (1651/1990) in 2006-10 
(trend p<0.01), although there was a dip to 70% (366/523) in 2010. IDU history was associated 
with lower level of education (see ‘Characteristics of women with an IDU history’), and levels of 
education increased concomitant with a decline in the proportion of women with a personal history 
of IDU or IDU partner (50% prior to 2006 declining to a third in 2006-10). The proportion of 
women with a history of IDU varied by centre in 2008-10 (the years when all centres contributed 
data) from 9% (33/355) in Mariupol to 32% (180/554) in Kiev (seven centres, 2=177.91, p<0.01). 
Almost all women were white (99%, 7214/7312) and born in Ukraine (99.7%, 7312/7333). 
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Characteristics of women with an IDU history, 2008-10 
Women with an IDU history were different in several important respects to non-IDUs, and are 
characterised here to aid interpretation of later analyses focusing on the years 2008-10. In these 
three years, women with an IDU history were significantly more likely to be unmarried (63% 
(324/513) vs. 54% (1618/2986) with no IDU history, 2=14.27 p<0.01), to have had at least one 
previous live birth (51% (254/496) vs. 46% (1367/2953) of non-IDUs, 2=4.12 p=0.04) and to 
have left full-time education at ≤16 years (33% (96/295) vs. 14% (243/1683) of non-IDUs, 
2=61.31 p<0.01). They were also more likely to have WHO stage 3-4 disease (30% (132/446) vs. 
11% (276/2529) of non-IDUs, 2=111.84 p<0.01) and to have been diagnosed prior to conception 
(60% (275/461) vs. 36% (1038/2908) of non-IDUs, 2=100.24 p<0.01), reflecting higher coverage 
of HIV testing in high-risk groups and temporal shifts in modes of HIV acquisition. Just over a 
quarter (26%, 882/3440) of women delivering in 2008-10 had an IDU partner; among IDUs, the 
proportion was 38% (182/482) vs. 24% (699/2956) of non-IDUs (2=43.31 p<0.01). 
Timing and trends in availability of laboratory tests 
Laboratory capacity for CD4 and viral load monitoring increased over time, particularly from 2008 
to 2010 (Table 3.1). In 2010, among the 75% (742/994) of women diagnosed as HIV-positive by 
the end of the 18th week of gestation, 78% (576/742) had at least one antenatal CD4 count 
available (54% (n=399) had one count at median 21 weeks gestation; 24% (n=177) had ≥2, the first 
and last at median 15 and 35 weeks gestation). Among the same group 66% (n=491) had at least 
one viral load measurement available (39% (n=291) had one measure at median 23 weeks gestation; 
27% (n=200) had ≥2, the first and last at median 17 and 35 weeks gestation). Among women 
diagnosed after the 18th week of gestation in the same year, the proportions with at least one CD4 
count or viral load measurement available were 68% (171/252) and 50% (126/252) respectively. 
Coverage of CD4 and viral load measurements was highest in Simferopol (94% (176/188) had a 
CD4 count and 93% (174/188) had a viral load measurement) and lowest in Odessa (34% (82/242) 
had a CD4 count and 24% (59/343) had a viral load measurement). The proportion of women 
diagnosed with HIV late (after the start of the third trimester) varied significantly by centre (see 
Table 3.3 page 95). In addition, there was geographical variability in funding available for test 
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reagents and lab equipment repairs, and at some labs there were periods when viral load and CD4 
measurements were not available or available only to patients on ART (Igor Semenenko, Personal 
communication, PPAI, 2011). 
Immediately following the establishment of the ECS in Ukraine in 2000, laboratory facilities for 
infant virological testing were not available in the country and so infant dried blood spots were sent 
to Amsterdam for testing (European Collaborative Study 2006). In the early years of the study, 
there were wide fluctuations in the proportion of infants receiving a PCR test by 6 months of age 
from 80% (48/60) born in 2000 to 22% (58/267) born in 2002, 65% (195/300) born in 2003 and 
36% (181/500) born in 2005. In 2006, PCR testing for HIV-exposed infants was introduced 
nationwide in Ukraine at three inter-regional laboratories (Thorne et al. 2009). Coverage has been 
consistently above 60% since, but with no increase from 2007 to 2010 (OR 0.95 for receipt of PCR 
by 6 months of age by increasing year, 95% CI 0.90-1.00, p=0.06). PCR coverage is limited by 
laboratory capacity (in a setting with a substantial increase in the number of HIV-exposed infants 
born year-on-year), technical problems and uptake (Thorne et al. 2009). 
Trends in mode of delivery 
From 2007, Ukrainian policy has recommended delivery by elective CS for HIV-positive women 
with a viral load >1000 copies/ml at 36 weeks gestation. Mode of delivery varied significantly by 
centre; in 2010, 44% (82/188) of deliveries in Simferopol were by elective CS compared with 37% 
(17/46) in Krivoy Rog, 36% (87/242) in Odessa, 14% (12/86) in Donetsk, 14% (15/104) in 
Mariupol, 12% (25/215) in Mykolaiv and 8% (12/144) in Kiev (2=108.97 p<0.01). The inter-
centre differences were not explained by availability of viral load (elective CS deliveries accounted 
for 34% (615/1833) of deliveries among women with a viral load available vs. 29% (1608/5510) of 
those among women with no viral load, 2=12.43 p<0.01). In 2007-10, 44% (197/448) of women 
with a third trimester viral load of >1000 copies/ml delivered by elective CS compared with 25% 
(185/755) of women whose viral load was <1000 copies/ml. Overall, the proportion of deliveries 
by elective CS reached a low of 24% (250/1027) in 2010 following a gradual decline from 40% 
(201/500) in 2005 (trend p<0.01). This change was accounted for by the inclusion of Kiev, 
Donetsk, Mariuopol and Krivoy Rog HIV/AIDS centres in later years of the study, rather than by a 
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change in clinical practice at any one centre over time. At Odessa, Mykolaiv and Simferopol 
HIV/AIDS centres (the three centres enrolling women from the study’s inception in 2000), there 
was no time trend in proportion of deliveries by elective CS (p=0.61). Deliveries by emergency CS 
accounted for 4% (304/7343) overall (time trend p=0.16). 
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Table 3.1: Time trends in maternal characteristics and availability of laboratory tests, 2000-10 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Time 
trend 
 n=60 n=197 n=267 n=300 n=458 n=500 n=694 n=1335 n=1217 n=1291 n=1027  
             
Maternal age, median 
(years) 
25.4 24.9  25.2  25.2  
 
25.9 25.9 25.6 26.0 26.4 26.6 27.8 p<0.01 
Parous at enrolment 40% 
21/53 
43%  
84/195  
41% 
104/255 
42% 
124/293  
 42%  
191/458 
41%  
206/500 
35% 
242/694 
38% 
504/1335 
41% 
500/1216 
46% 
588/1266 
57% 
558/981 
p<0.01 
Diagnosed HIV+ before 
conception 
23%  
11/47  
19% 
34/180  
19%  
44/233  
19% 
53/286 
27%  
123/458 
22% 
110/499 
25% 
166/656 
31% 
377/1235 
34% 
404/1184 
38% 
471/1250 
44% 
439/994 
p<0.01 
Diagnosed HIV+ in 3rd 
trimester / intrapartum 
38% 
18/47  
46% 
83/180  
44% 
103/223  
36% 
104/286  
33% 
149/458 
27% 
137/499 
16% 
106/656 
16% 
203/1235 
12% 
143/1184 
10% 
128/1250 
11% 
111/994 
p<0.01 
Median weeks before 
delivery HIV diagnosed 
18 weeks 15 weeks 17 weeks 19 weeks 22 weeks 22 weeks 24 weeks 26 weeks 27 weeks 28 weeks 29 weeks p<0.01 
IDU history 39% 
21/54  
35% 
63/182  
27% 
65/238  
29% 
84/286  
28% 
127/458 
20% 
98/500 
16% 
110/694 
18% 
236/1334 
16% 
195/1215 
14% 
180/1273 
14% 
139/1017 
p<0.01 
IDU partner 45% 
24/53  
44% 
75/172  
42% 
96/230  
44% 
124/279  
36% 
164/458 
42% 
211/500 
35% 
241/693 
24% 
326/1334 
27% 
321/1205 
23% 
288/1242 
27% 
273/993 
p<0.01 
No IDU history or IDU 
partner 
47% 
28/60 
50% 
98/197 
56% 
150/267 
52% 
156/300 
52% 
239/458 
52% 
262/500 
61% 
420/694 
65% 
871/1335 
64% 
784/1217 
68% 
884/1291 
64% 
654/1027 
p<0.01 
WHO stage 3-4 0/50 0/158 0/187 1/297  
  
0 4% 
22/499 
6% 
38/615 
10% 
107/1126 
12% 
124/1009 
13% 
144/1096 
16% 
143/885 
p<0.01 
Availability of antenatal 
CD4 count  
0/60  1/197  
 
1/267  
 
2%  
6/300 
19% 
87/458 
16% 
81/500 
33% 
228/694 
42% 
562/1335 
50% 
606/1217 
70% 
908/1291 
73% 
749/1027 
p<0.01 
(2003-10) 
CD4 count ≤350 cells/mm3 
(first antenatal measure) 
- 0/1 0/1 1/6 25% 
22/87 
36% 
29/81 
31% 
70/228 
29% 
163/562 
33% 
199/607 
33% 
302/908 
36% 
273/749  
p<0.01 
(2004-10) 
Availability of antenatal 
viral load 
0/60 1/197 0/267  0/300 0/458 0/500 0/694 3% 
36/1335 
34% 
410/1217 
60% 
769/1291 
60% 
619/1027 
p<0.01 
(2007-10) 
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Trends in use of antenatal and intrapartum ART 
Figure 3.1 illustrates the changing use of antenatal and intrapartum ART over time from January 
2000, when less than 20% of women received any antenatal ART, to 2010, when almost 90% of 
women received antenatal ART and 60% received cART. Although sdNVP was superseded in the 
national PMTCT strategy in 2003 by ZDVm from 28 weeks gestation, sdNVP continues to be used 
as the main PMTCT intervention for women diagnosed as HIV-positive during labour or 
presenting in labour without having received antenatal care, and is used in combination with 
ZDVm when this is initiated later than the 28th week gestation. 
Almost all women on monotherapy received ZDV (99.6%, 2964/2977), with one woman receiving 
TDF (enrolled in Mykolaiv in 2010) and twelve receiving ABC (enrolled across five different 
centres in 2008-09). Although ZDV continues to be the NRTI of choice for use as monotherapy in 
pregnant women (WHO 2010a), its use is associated with anaemia and Ukrainian policy specifies 
that if this is a concern then another NRTI or NtRTI can be substituted provided that a woman’s 
CD4 count is >350 cells/mm3 and viral load <10,000 copies/ml; if these conditions are not met 
then cART should be used (Ministry of Health of Ukraine 2007).  
The majority (87%, 1585/1823) of women on cART received a protease inhibitor (PI)-based 
regimen, most commonly ZDV, 3TC and ritonavir-boosted lopinavir (LPV/r) which accounted for 
two-thirds (1178/1823) of cART regimens. Among women who received cART, use of PI-based 
regimens increased from 73% (79/108) in 2007 to 80% (217/270) in 2008, 94% (669/709) in 2009 
and 91% (572/627) in 2010 (trend p<0.01). Of the 13% (236/1823) receiving an NNRTI-based 
regimen, most (200/236) received ZDV, 3TC and NVP. Dual therapy is not recommended for 
PMTCT, but was received by 22 women (delivering across all seven centres, 20 in 2008-10), most 
of whom received ZDV and 3TC. This was mainly due to drug shortages of LPV/r, and a 
reluctance to prescribe NVP (the only other alternative drug) because of concerns around 
hepatotoxic effects in pregnant women with higher CD4 counts (Lyons et al. 2006)(Personal 
communication, Igor Semenenko, PPAI, 2011).
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Figure 3.1: Time trends in antenatal and intrapartum ART receipt  
(n=7355)
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Timing of initiation and duration of antenatal ART 
Conceptions on cART increased over time, from 2% (6/377) of women diagnosed before 
conception and delivering in 2007 to 12% (52/439) in 2010 (trend p<0.01). Prior to 2005, the 
majority (97%, 722/744) of women initiating ART during pregnancy did so in the third trimester. 
Subsequently, the proportion starting ART earlier in pregnancy has increased substantially from 
12% (45/390) in 2005 to 46% (492/1078) in 2008 and 68% (577/851) in 2010 (trend p<0.01). The 
duration of ART received by delivery among those not on ART at conception increased 
accordingly, from a median of 5 weeks in 2004 to 10 weeks in 2006 and 14 weeks in 2010 (one-way 
analysis of variance (ANOVA) p<0.01). In 2008-10, duration of treatment received by women 
initiating ART during pregnancy varied by centre from a median of 10 weeks in Odessa to 13 weeks 
in in Krivoy Rog (one-way ANOVA p<0.01). 
Use of single-dose nevirapine 
The decrease in use of sdNVP over time reflects its replacement by more effective interventions for 
PMTCT, and the increased opportunity for receipt of antenatal ART where HIV diagnosis occurs 
earlier in pregnancy or prior to conception (Table 3.1, page 83). However, the proportion of 
women receiving sdNVP only (and therefore lacking antenatal care) did not decrease between 2008 
and 2010, remaining at around 5% overall (trend p=0.90). The proportion receiving no ART was 
unchanged from 2005 onwards at 5% overall (range 3% to 7%, trend p=0.51). Around 10% of 
women have therefore continued to receive no ART during pregnancy in recent years. This group is 
the focus of a later analysis (see section 3.2.2, page 79), given their comparatively very high risk of 
MTCT. 
Trends in use of neonatal prophylaxis 
Overall, neonatal prophylaxis was given to 97% (6942/7172) of infants: 11% (760/7172) received 
sdNVP only, 58% (4128/7172) ZDV only, 17% (1188/7172) ZDV plus sdNVP, 1% (69/7172) 
other regimens (including cART) and 11% (797/7172) were missing information on type of 
prophylaxis received. The duration of treatment with ZDV was one week for most (86%, 
4542/5298) and four weeks for 14% (728/5298) – according to Ukrainian policy, four weeks of 
neonatal prophylaxis are prescribed where maternal HIV diagnosis occurs after the start of the third 
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trimester, or where the mother has received <12 weeks of antenatal ART by delivery (Ministry of 
Health of Ukraine 2007). There was a shift in the type of ART used for neonatal prophylaxis, from 
sdNVP only in 2000-04 (59%, 751/1267) to ZDV only in 2005-10 (70%, 4115/5905). Of the 17% 
(1060/6064) of infants who received sdNVP in the later period, all except nine received it in 
conjunction with ZDV. 
Achieving an undetectable viral load by delivery 
Figure 3.2 shows, for the period 2008-10, the proportion of women with at least one antenatal viral 
load measurement and whether this was detectable or not, by ART receipt. Among women 
conceiving on cART, 69% (90/131) had a viral load measurement taken during pregnancy, of 
whom 86% (n=77) had an undetectable viral load at their last antenatal measure (median 97 days 
before delivery). Of women initiating cART during pregnancy, the proportion with an undetectable 
antenatal viral load was 43% (318/733) (measure taken a median of 74 days after initiating cART 
and 26 days before delivery), but substantially higher (69%, 143/207) among a sub-group who had 
been on cART for at least three months by the time of the measurement. Fifteen per cent (63/425) 
of women on ZDVm had an undetectable viral load recorded during pregnancy (measure taken a 
median of 57 days after treatment initiation and 29 days before delivery); only 12% (51/425) had a 
measurement available at least three months after ART initiation but before stopping ART at 
delivery, of whom 18% (9/51) had an undetectable viral load. The proportion of women with an 
undetectable viral load reported in pregnancy increased substantially from 17% (71/410) in 2008 to 
25% (193/769) in 2009 and 35% (219/619) in 2010 (trend p<0.01), reflecting the roll-out of cART 
for PMTCT. 
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Figure 3.2: Availability of antenatal viral load measurements and proportion with detectable 
viral load by ART receipt (2008-10) 
Where >1 measurement was available, the last before delivery was used. n=3515. 
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Trends in mother-to-child-transmission rate 
Figure 3.3 shows the decline in unadjusted MTCT rates from 2000 to 2010 (trend p<0.01). In 
addition to PMTCT policy changes summarised in this Figure, other factors which will have 
impacted on the MTCT rate reported each year include changes over time in participating centres 
and differences between centres with respect to resources, policies, clinical practice and patient 
population (socio-demographics and clinical characteristics). The MTCT rate in 2008-10, which was 
4.1% overall (95% CI 3.4-4.9), is explored in more detail in section 3.2.6 (page 106).  
 
Figure 3.3: MTCT rate over time, 2000-10 
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3.2.3 Maternal HIV diagnosis late in pregnancy, 2008 to 2010 
Overall in 2008-10, just over one in ten (382/3429) deliveries were to women diagnosed “late” 
(during the third trimester or intrapartum); as Ukrainian policy involves repeat testing in the third 
trimester for women negative at the first antenatal test, some of these women may have 
seroconverted during pregnancy. Figure 3.4 shows pregnancies in 2008-10 by timing of diagnosis 
and the number in which no antenatal ART was received. 
Although the proportion of women with a late HIV diagnosis decreased significantly over time 
from 2000 to 2008 (Table 3.1, page 83) there was no change from 2008 to 2010 (trend p=0.46). 
These trends were also true for women undiagnosed at conception: 51% (308/604) were diagnosed 
late in 2000-03 declining to 29% (595/2072) in 2004-07 (trend p<0.01), but with no change from 
2008 to 2010 (trend p=0.53). Of women undiagnosed at conception in 2008-10, significant 
differences in timing of diagnosis existed by centre of enrolment with 8% (14/165) of women in 
Krivoy Rog diagnosed late compared with 24% (44/181) in Mariupol (seven centres, 2=29.18 
p<0.01). Overall, 22% (74/331) of women diagnosed late had WHO stage 3-4 disease and/or a 
CD4 count of ≤350 cells/mm3 compared with 28% (440/1592) of women diagnosed in the first or 
second trimesters (2=3.90 p=0.05).
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Figure 3.4: Pregnancies reported in 2008-10 by timing of diagnosis and receipt of ART
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Table 3.2 shows maternal and delivery characteristics by timing of HIV diagnosis in 2008-10. 
Among those undiagnosed at conception, 18% (382/2114) were diagnosed late: 16% (334/2114) in 
the third trimester (a median of 8 weeks before delivery, IQR 6-11 weeks) and 2% (48/2114) 
intrapartum. Women with a late diagnosis were more likely to be single, to have had previous live 
birth(s) and fewer years of full-time education. The association between late diagnosis and previous 
live birth was stronger than that between late diagnosis and any previous pregnancy (including 
termination, miscarriage and stillbirth, (2=3.93 p=0.05). There was no association between 
maternal age and late diagnosis (4 categories, 2=6.44 p=0.09). Of women undiagnosed at 
conception, 28% (56/200) of IDUs were diagnosed late compared with 17% (326/1904) non-IDUs 
(Table 3.2). Among non-IDUs, women delivering preterm at <37 weeks were more likely to be 
diagnosed intrapartum (3% (7/214) vs. 1% (27/2720) of those delivering at term, 2=9.12 p<0.01), 
probably due to less opportunity for antenatal HIV testing. This association was not observed 
among IDUs (2=0.19 p<0.66) who were probably more likely to completely lack antenatal care. 
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Table 3.2: Maternal and delivery characteristics by timing of HIV diagnosis among women 
undiagnosed at conception, 2008-10 
 Timing of HIV diagnosis  
 1st or 2nd trimester 
(n=1732) 
3rd trimester or 
intrapartum 
(n=382) 
2 test for 
categorical variables 
Maternal age – median [IQR] 
(n=2111) 
26.2 [22.8, 30.2] 26.7 [22.6, 30.9]  
Marital status (n=2112)    
Married  816 (47%)  109 (29%) 2=52.39, p<0.01 
Cohabiting 683 (39%)  182 (48%)  
Single 231 (13%)  91 (24%)  
Previous live birth at enrolment 
(n=2080) 
0 
1 
≥2 
  
 
1152 (68%) 
428 (25%) 
121 (7%) 
 
 
195 (51%) 
119 (31%) 
65 (17%) 
 
 
2=52.18, p<0.01 
Age at leaving full-time 
education (n=1181) 
   
≤16 years 111 (11%)  55 (26%) 2=41.72, p<0.01 
17-18 years 272 (28%)  73 (34%)  
≥19 years 586 (60%)  84 (40%)  
History of IDU (n=2104)    
No 1578 (92%) 326 (85%) 2=14.41, p<0.01 
Yes 144 (8%) 56 (15%)  
IDU partner (n=2068)    
No 1307 (77%) 268 (72%) 2=3.45, p=0.06 
Yes 391 (23%) 102 (28%)  
WHO stage (n=1788)    
1-2 1368 (93%) 278 (90%) 2=2.91, p=0.09 
3-4 110 (7%) 32 (10%)  
Mode of delivery (n=2113)    
Vaginal / emergency CS 1213 (70%)  300 (79%) 2=11.01, p<0.01 
Elective CS 518 (30%)  82 (21%)  
Gestation at delivery (n=2109)    
≥37 weeks 1603 (93%)  348 (92%) 2=0.58, p=0.45 
<37 weeks 126 (7%)  32 (8%)  
MTCT rate (95% CI) (n=1709) 2.6% (1.8-3.5%)  8.5% (5.6-12.2%) 2=25.46, p<0.01 
 
In univariable analyses, factors significantly associated with late diagnosis among women 
undiagnosed at conception were having an IDU history, being unmarried, having fewer years of 
full-time education, having had previous live birth(s) and centre of enrolment (Wald’s test p<0.01) 
(Table 3.3, page 95), but not maternal age, WHO stage and IDU partner (p>0.5 in univariable 
analyses and p>0.1 after adjusting for centre and year). IDU history, marital status and previous live 
births remained associated with late diagnosis in adjusted analyses (Table 3.3). There was no 
heterogeneity of effect of marital status on late diagnosis by history of IDU or live births (Wald’s 
test p=0.78 and p=0.85 respectively). Women with previous live births who were diagnosed late had 
either acquired HIV since their last pregnancy or had had a previous pregnancy in which their HIV 
infection went undetected. 
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Among 1148 women with educational status available, those leaving full-time education at 17-18 
years or at ≤16 years (vs. ≥19 years) remained at significantly increased risk of late diagnosis in 
adjusted analyses (APR 1.63 95% CI 1.20-2.21 and APR 1.78 95% CI 1.26-2.51 respectively on 
adjusting for year, IDU history, marital status, previous live births and centre). The association 
between marital status and late diagnosis was reduced on adjusting for education in addition to 
other factors, but remained significant (from APR 1.94 95% CI 1.43-2.63 in model excluding 
education to APR 1.78 95% CI 1.31-2.41 in model including education for cohabiting status, and 
APR 2.45 95% CI 1.78-3.38 to APR 2.30 95% CI 1.68-3.16 respectively for single status). IDU, as 
well as being an independent risk factor for late diagnosis, was also associated with being 
unmarried, having previous live births and a lower level of education (see page 80). 
Use of PMTCT interventions 
Women diagnosed during the third trimester were significantly less likely than those diagnosed in 
the first or second trimesters to deliver by elective CS (24% (81/334) vs. 30% (518/1731), 2=4.38 
p=0.04) and were more likely to lack antenatal ART (11% (36/334) vs. 2% (33/1732) diagnosed 
earlier in pregnancy, 2=68.29 p<0.01). Sixteen women received sdNVP only despite being 
diagnosed at least a week (median 19 days) prior to delivery. Among those receiving antenatal ART, 
cART was received by 45% (135/298) of women diagnosed during the third trimester compared 
with 44% (749/1699) of those diagnosed in the first or second trimesters (2=0.15 p=0.70). 
Women on ZDVm were more likely to receive sdNVP in addition if they had been diagnosed in 
the third trimester than earlier in pregnancy (42% (66/158) vs. 11% (99/942) respectively, 
2=103.72 p<0.01), reflecting guidelines which recommend the use of sdNVP where ZDV duration 
is short.   
Infants born to women who had been diagnosed late were no more or less likely to lack neonatal 
prophylaxis than those born to women diagnosed earlier in pregnancy (3% (12/369) and 4% 
(61/1666) lacked neonatal prophylaxis respectively, 2=0.15 p=0.70). The unadjusted MTCT rate 
was over three-fold higher among women with a late diagnosis than among those diagnosed during 
the 1st / 2nd trimesters (Table 3.2). 
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Table 3.3: Factors associated with late maternal HIV diagnosis (3rd trimester or intrapartum) among women undiagnosed at conception, 2008-10 
 Proportion (n) 
diagnosed late 
Unadjusted PR (95% CI) Adjusted PR† (95% CI) (n=2069) 
Year of delivery (n=2114)    
2008 18% (143/780) 1.00 1.00 
2009 16% (128/779) 0.82 (0.65-1.03) p=0.09 0.98 (0.79-1.23) p=0.87 
2010 20% (111/555) 0.92 (0.73-1.15) p=0.44 1.02 (0.82-1.28) p=0.83 
IDU history (n=2104)    
No 17% (326/1904) 1.00 1.00 
Yes 28% (56/200) 1.64 (1.28-2.09)  p<0.01 1.55 (1.22-1.96)  p<0.01 
Marital status (n=2112)    
Married 12% (109/925) 1.00 1.00 
Cohabiting 21% (182/865) 1.79 (1.43-2.22) p<0.01 1.68 (1.34-2.10)  p<0.01 
Single 28% (91/322) 2.40 (1.87-3.07) p<0.01 2.24 (1.75-2.87)  p<0.01 
Age at leaving full-time 
education (n=1181) 
   
≥19 years  13% (84/670) 1.00 Omitted due to missing data 
17-18 years 21% (73/345) 1.69 (1.27-2.25)  p<0.01  
≤16 years 33% (55/166) 2.64 (1.97-3.55)  p<0.01  
Previous live births at 
enrolment (n=2080) 
   
0 14% (195/1347) 1.00 1.00 
1 22% (119/547) 1.50 (1.22-1.85)  p<0.01 1.45 (1.19-1.77)  p<0.01 
≥2 35% (65/186) 2.41 (1.91-3.05)  p<0.01 2.30 (1.82-2.91)  p<0.01 
Centre (n=2114)    
Odessa 17% (83/493) 1.00 1.00 
Mykolaiv 21% (82/397) 1.23 (0.93-1.62) p=0.15 1.09 (0.83-1.43) p=0.52 
Kiev 16% (57/362 0.94 (0.69-1.27) p=0.67 1.01 (0.73-1.38) p=0.97 
Donetsk 13% (26/198) 0.78 (0.52-1.17) p=0.23 0.87 (0.57-1.32) p=0.50 
Mariupol 24% (44/181) 1.44 (1.04-2.00) p=0.03 1.43 (1.05-1.95) p=0.02 
Krivoy Rog 8% (14/165) 0.50 (0.29-0.86) p=0.01 0.51 (0.30-0.87) p=0.01 
Simferopol 24% (76/318) 1.42 (1.08-1.87) p=0.01 1.26 (0.95-1.65) p=0.10 
†Adjusted a priori for year of delivery and centre of enrolment 
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3.2.4 Lack of antenatal ART 
Maternal and delivery characteristics by receipt of ART are given in Table 3.4. Overall, a tenth 
(336/3535) of women received no antenatal ART. Timing of diagnosis was available for only 71% 
(237/336) (compared with 99.7% (3191/3199) of women receiving antenatal ART), probably due 
to incomplete antenatal records among a group likely to have lacked antenatal care or been 
diagnosed late (Table 3.4). Of the 99 women who lacked antenatal ART and were missing timing of 
diagnosis, nine had an antenatal CD4 count or VL measure reported, confirming that diagnosis had 
occurred prior to delivery. The remaining 90 are excluded from the analyses in this section. Women 
diagnosed via rapid testing during labour accounted for 20% (48/246) of those without antenatal 
ART; these 48 women are also excluded from the subsequent analyses, in order to investigate 
barriers to the receipt of antenatal ART among the group with diagnosed infection. Of note, 
diagnosis occurred prior to conception in half of pregnancies with no antenatal ART where timing 
of diagnosis was available (Table 3.4). 
Among 3266 women diagnosed prior to delivery and not on cART at conception, the proportion 
lacking antenatal ART varied significantly by centre (from 19.7% (62/332) in Mariupol to 9.4% 
(70/743) in Odessa, 6.5% (38/589) in Mykolaiv, 3.7% (19/509) in Simferopol, 1.6% (4/242) in 
Krivoy Rog, 0.8% (4/506) in Kiev and 0.3% (1/345) in Donetsk, Fisher’s exact test p<0.01). The 
three centres with almost universal (>98%) antenatal ART coverage of women diagnosed prior to 
delivery (Krivoy Rog, Kiev and Donetsk) were omitted from the analyses of factors associated with 
lack of antenatal ART (Table 3.5, page 99). Maternal age was not associated with a lack of antenatal 
ART (PR 1.02 per increasing year, 95% CI 1.00-1.05, p=0.10) and neither was severity of HIV 
disease (WHO stage 1-2 vs. 3-4 2=0.23 p=0.64). 
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Table 3.4: Maternal and delivery characteristics by receipt of antenatal and intrapartum 
ART, 2008-10 
  ART initiated during pregnancy or received at delivery 
 Conceived on 
cART (n=131) 
cART initiated 
during pregnancy 
(n=1475) 
Antenatal 
ZDVm‡ +/- 
sdNVP (n=1593) 
No antenatal 
ART (n=336) 
Maternal age – median 
[IQR] (n=3523) 
30.0 years [27.2, 
32.6] 
27.3 years [23.7, 
31.1] 
26.1 years [22.9, 
30.0] 
27.5 years [24.0, 
32.0] 
Marital status (n=3523)     
Married 81 (62%)  698 (47%) 694 (44%)  90 (27%) 
Cohabiting 43 (33%)  561 (38%) 653 (41%)  147 (45%) 
Single 7 (5%)  211 (14%)  246 (15%)  92 (28%) 
Previous live births at 
enrolment (n=3463) 
    
No 34 (27%) 781 (54%) 907 (57%) 118 (37%) 
Yes 95 (74%) 654 (46%) 676 (43%) 198 (63%) 
Timing of HIV diagnosis 
(n=3428) 
    
Before pregnancy 131 (100%)  588 (40%)  476 (30%) 120 (51%) 
1st/2nd trimesters -  749 (51%) 950 (60%)  33 (14%) 
3rd trimester -  135 (9%) 163 (10%) 36 (15%) 
Delivery -  -  -  48 (20%) 
Age at leaving full-time 
education (n=1990) 
    
≤16 years 14 (19%)  104 (13%) 180 (20%) 41 (23%) 
17-18 years 24 (32%)  253 (31%) 255 (28%)  82 (46%) 
≥19 years 37 (49%) 463 (56%)  481 (53%)  56 (31%) 
History of IDU (n=3505)     
No 86 (66%) 1251 (85%) 1431 (90%) 222 (70%) 
Yes 44 (34%) 217 (15%) 158 (10%) 95 (30%) 
IDU partner (n=3440)     
No 89 (68%) 1016 (71%) 1208 (77%) 245 (81%) 
Yes 42 (32%) 415 (29%) 366 (23%) 59 (19%) 
WHO stage 3-4 (2990)     
1-2 45 (39%) 1096 (82%) 1251 (95%) 187 (86%) 
3-4 70 (61%) 240 (18%) 71 (5%) 30 (14%) 
CD4 count†  (n=2263)     
Median [IQR]  370 cells/mm3 
[260, 490] 
360 cells/mm3 
[250, 510] 
530 cells/mm3 
[410, 660] 
410 cells/mm3 
[295, 530] 
Proportion ≤350 cells/mm3 49 (48%) 577 (48%) 130 (14%) 18 (45%) 
Delivery / infant characteristics 
Mode of delivery (n=3533)     
Vaginal / emergency CS 77 (59%) 1021 (69%)  1130 (71%) 311 (93%) 
Elective CS 54 (41%)  454 (31%)  461 (29%) 25 (7%) 
Gestation at delivery 
(n=3520) 
    
≥37 weeks 113 (86%) 1336 (91%)  1482 (94%) 267 (81%) 
<37 weeks 18 (14%) 137 (9%)  103 (6%)  64 (19%) 
MTCT rate (95% CI) 
(n=2854) 
0%  
(0-3.5%) 
1.4%  
(0.8-2.2%) 
3.8%  
(2.8-5.0%) 
20.6% 
(15.6-26.3%) 
† first in pregnancy ‡ including women who received dual therapy (n=20) or a non-zidovudine monotherapy 
regimen (n=13) 
 98 
 
Factors significantly associated with lack of antenatal ART in univariable analyses were IDU 
history, being single or cohabiting (vs. married), leaving full-time education at ≤18 years, history of 
previous live birth, maternal HIV diagnosis before conception or in the third trimester (vs. 1st/2nd 
trimesters) and preterm delivery (<37 weeks gestation) (Table 3.5). Although women delivering in 
2010 were more likely to have lacked antenatal ART compared with those delivering in 2008 
(p=0.05), this was explained by an increase over time in the proportion leaving education at ≤18 
years (50% (181/363) in 2008 vs. 68% (196/290) in 2009 and 79% (244/308) in 2010, 2=64.42 
p<0.01) and an increase in the proportion who were parous at enrolment (45% (348/780) in 2008 
vs. 51% (380/744) in 2009 and 58% (427/733) in 2010, 2=28.14 p<0.01). On adjusting for these 
factors and centre of enrolment, there was no association between year of delivery and the outcome 
(Wald’s test p=0.71).  
In adjusted analyses, IDU history, marital status, previous live births, timing of maternal HIV 
diagnosis, preterm delivery and centre of enrolment remained significantly associated with a lack of 
antenatal ART (Table 3.5). Preterm delivery at <37 weeks was associated with a 70% increased risk 
of lacking antenatal ART. Women diagnosed with HIV during the first or second trimester were 
the least likely to lack antenatal ART, probably because these women were a selected group in 
timely contact with antenatal care. Compared with these women, the 3.4-fold increased risk of not 
receiving antenatal ART among women diagnosed prior to conception is an indication of 
disengagement from on-going HIV care among a group more likely to have an IDU history. The 
120 women diagnosed prior to conception who lacked antenatal ART had a MTCT rate of 22% 
(95% CI 13-33%, infection status available for 78 infants), highlighting substantial missed 
opportunities for PMTCT.  
Women with at least two previous live births were significantly more likely to lack antenatal ART 
than those with no previous children in adjusted analyses (and were also more likely to be 
diagnosed late, see page 95). Among 926 women with educational status available, those leaving 
full-time education at 17-18 years were significantly more likely to lack antenatal ART than those 
educated until ≥19 years in the multivariable model (APR 2.49 95% CI 1.07-5.80 p=0.03). There 
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was no significant change (>10%) in the other multivariable associations after adjusting for 
educational status. 
 
Table 3.5: Factors associated with lack of antenatal ART among women diagnosed with 
HIV before delivery and not on cART at conception, 2008-10 
 Proportion (n) 
with no antenatal 
ART 
Unadjusted Prevalence 
Ratio (95% CI)  
Adjusted‡ PR (95% CI) 
(n=2164) 
Year of delivery (n=2173)    
2008 7% (56/760) 1.00 1.00 
2009 8% (61/719) 1.15 (0.81-1.63) p=0.43 1.15 (0.83-1.60) p=0.40 
2010 10% (72/694) 1.41 (1.01-1.97) p=0.05 1.28 (0.93-1.78) p=0.13 
IDU history (n= 2173)    
No 7% (146/1965) 1.00 1.00 
Yes 21% (43/208) 2.78 (2.04-3.79) p<0.01 2.13 (1.59-2.87) p<0.01 
Marital status (n=2171)    
Married 6% (53/898) 1.00 1.00 
Cohabiting 9% (90/956) 1.60 (1.15-2.21) p<0.01 1.62 (1.19-2.22) p<0.01 
Single 15% (46/317) 2.46 (1.69-3.57) p<0.01 1.88 (1.30-2.71) p<0.01 
Age left full-time education (n=927)    
≥19 years 5% (17/327) 1.00 Omitted due to missing 
17-18 years 14% (49/348) 2.71 (1.59-4.61) p<0.01 data 
≤16 years 11% (28/252) 2.14 (1.20-3.82) p=0.01  
Previous live births at enrolment 
(n=2173) 
   
0 6% (63/1081) 1.00 1.00 
1 9% (70/751) 1.60 (1.15-2.22) p<0.01 1.28 (0.93-1.76) p=0.14 
≥2 16% (56/341) 2.82 (2.01-3.95) p<0.01 1.76 (1.26-2.46) p<0.01 
Timing of HIV diagnosis (n=2173)    
1st/2nd trimester 3% (33/1104) 1.00 1.00 
Before conception 14% (120/832) 4.83 (3.32-7.02) p<0.01 3.38 (2.28-5.01) p<0.01 
3rd trimester 15% (36/237) 5.08 (3.24-7.98) p<0.01 4.15 (2.66-6.46) p<0.01 
Preterm delivery <37 weeks (n=2166)    
No 8% (159/1993) 1.00 1.00 
Yes 17% (30/173) 2.17 (1.52-3.11) p<0.01 1.70 (1.19-2.42) p<0.01 
Centre of enrolment (n=2173)    
Odessa 9% (70/743) 1.00 1.00 
Mykolaiv 6% (38/589) 0.68 (0.47-1.00) p=0.05 0.61 (0.42-0.89) p=0.01 
Mariupol 19% (62/332) 1.98 (1.44-2.72) p<0.01 1.69 (1.24-2.31) p<0.01 
Simferopol 4% (19/509) 0.40 (0.24-0.65) p<0.01 0.33 (0.20-0.53) p<0.01 
‡Adjusted a priori for year of delivery and centre of enrolment 
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In order to examine factors associated with a lack of antenatal ART among women who were aware 
of their HIV diagnosis at conception, and thus should have been particularly well-placed to receive 
comprehensive ART for PMTCT, a model limited to this sub-group was fitted and explored 
separately from a model limited to women diagnosed during pregnancy (Table 3.6). The proportion 
of women lacking antenatal ART was 14% (120/832) in the group diagnosed prior to conception 
(which included women completely lacking antenatal care) and 5% (69/1341) in the group who had 
been diagnosed during pregnancy but before delivery. Of women diagnosed prior to conception, 
having an IDU history, being single (vs. married) and having ≥2 previous live births (vs. 0) were 
independent risk factors for lacking antenatal ART (Table 3.6). Educational status did not add 
significantly to the model fit (Wald’s test p=0.15).  
Of the group diagnosed antenatally, women who lacked antenatal ART were more likely to have an 
IDU history, have delivered preterm and been diagnosed in the 3rd trimester (vs. first or second 
trimesters) than those who received antenatal ART (Table 3.6). IDU history was associated with a 
three-fold independent increased risk of lacking antenatal ART in this group, but women with an 
IDU history were also more likely to have other risk factors including late diagnosis (see page 95) 
and preterm delivery (18% (90/510) of deliveries to women with an IDU history were <37 weeks 
gestation vs. 8% (227/2980) of those to non-IDUs, 2=53.05 p<0.01). Among the 547 women 
diagnosed antenatally and with educational status available, those leaving full-time education at 17-
18 years were at increased risk of lacking antenatal ART compared with those in education until 
≥19 years after adjusting for other factors in the multivariable model (APR 2.49 95% CI 1.07-5.80 
p=0.03). Among the group with educational status available, the association between preterm 
delivery and lack of antenatal ART was larger than in the cohort as a whole (APR 3.15 95% CI 
1.26-7.89) and increased to APR 3.43 (95% CI 1.46-8.04) on adjusting for education. 
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Table 3.6: Factors associated with lack of antenatal ART by timing of maternal HIV diagnosis, among women not on cART at conception, 2008-10 
 Diagnosed before conception  Diagnosed during pregnancy (before delivery) 
 Proportion (n) lacking 
antenatal ART 
Unadjusted PR (95% CI) Adjusted PR† (95% CI) 
(n=830) 
Proportion (n) lacking 
antenatal ART 
Unadjusted PR  
(95% CI) 
Adjusted PR† (95% CI) 
(n=1337) 
Year of delivery       
2008 14% (39/271) 1.00 1.00 3% (17/489) 1.00 1.00 
2009 14% (37/257) 1.00 (0.66-1.52) p=1.00 0.97 (0.65-1.46) p=0.92 5% (24/462) 1.49 (0.81-2.75) p=0.20 1.61 (0.89-2.89) p=0.11 
2010 14% (44/304) 1.01 (0.67-1.50) p=0.98 1.08 (0.73-1.60) p=0.71 7% (28/390) 2.07 (1.15-3.72) p=0.02 1.82 (1.01-3.29) p=0.05 
IDU history       
No 13% (88/701) 1.00 1.00 5% (58/1264) 1.00 1.00 
Yes 24% (32/131) 1.95 (1.36-2.79) p<0.01 1.95 (1.37-2.76) p<0.01 14% (11/77) 3.11 (1.70-5.69) p<0.01 2.50 (1.44-4.34) p<0.01 
Marital status       
Married  11% (37/352) 1.00 1.00 3% (16/546) 1.00 1.00 
Cohabiting 14% (50/348) 1.37 (0.92-2.04) p=0.12 1.42 (0.97-2.09) p=0.08 7% (40/608) 2.25 (1.27-3.96) p<0.01 1.91 (1.09-3.33) p=0.02 
Single 25% (33/130) 2.41 (1.58-3.69) p<0.01 2.09 (1.37-3.17) p<0.01 7% (13/187) 2.37 (1.16-4.84) p=0.02 1.39 (0.67-2.87) p=0.38 
Age at leaving full-time education       
≥19 years 9% (10/106) 1.00  3% (7/221) 1.00 Omitted due to missing  
17-18 years 22% (32/147) 2.31 (1.19-4.49) p=0.01  8% (17/201) 2.67 (1.13-6.31) p=0.03 data 
≤16 years 15% (19/127) 1.59 (0.77-3.26) p=0.21  7% (9/125) 2.27 (0.87-5.96) p=0.10  
Previous live births at enrolment 
0 
1 
≥2 
 
11% (27/254) 
13% (48/383) 
23% (45/195) 
 
1.00 
1.18 (0.76-1.84) p=0.47 
2.17 (1.40-3.37) p<0.01 
 
1.00 
1.33 (0.87-2.03) p=0.19 
2.20 (1.44-3.37) p<0.01 
 
4% (36/827) 
6% (22/368) 
8% (11/146) 
 
1.00 
1.37 (0.82-2.30) p=0.23 
1.73 (0.90-3.32) p=0.10 
 
Preterm delivery <37 weeks       
No 14% (104/747) 1.00  4% (55/1246) 1.00 1.00 
Yes 20% (16/82) 1.40 (0.87-2.25) p=0.16  15% (14/91) 3.49 (2.02-6.02) p<0.01 2.79 (1.57-4.96) p<0.01 
Timing of diagnosis       
1st / 2nd trimesters - -  3% (33/1104) 1.00 1.00 
3rd trimester - -  15% (36/237) 5.08 (3.24-7.98) p<0.01 4.66 (2.99-7.24) p<0.01 
Centre       
Odessa 15% (39/254) 1.00 1.00 6% (31/439) 1.00 1.00 
Mykolaiv 12% (25/208) 0.78 (0.49-1.25) p=0.31 0.74 (0.46-1.18) p=0.20 3% (13/341) 0.54 (0.29-1.01) p=0.06 0.52 (0.27-0.97) p=0.04 
Mariupol 26% (43/164) 1.71 (1.16-2.51) p<0.01 1.72 (1.18-2.52) p<0.01 11% (19/168) 0.78 (1.04-3.07) p=0.04 1.92 (1.12-3.29) p=0.02 
Simferopol 6% (13/206) 0.41 (0.23-0.75) p<0.01 0.43 (0.24-0.77) p<0.01 2% (6/303) 0.31 (0.13-0.74) p<0.01 0.23 (0.10-0.55) p<0.01 
Factors independently associated with outcome (p<0.05) in adjusted analyses are in bold. †Adjusted a priori for year of delivery and centre of enrolment
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3.2.5 Scale-up of cART, 2008-10 
Where ART was initiated during pregnancy, cART was received in 48% (1475/3068) of cases 
overall, increasing from 22% (240/1082) of deliveries in 2008 to 58% (660/1129) in 2009 and 67% 
(575/857) in 2010 (trend p=0.03). The 52% (1593/3069) of women who initiated ZDVm had a 
significantly higher CD4 count at the first measure in pregnancy than those who initiated cART 
(Table 3.4, two-sided t test p<0.01). Among women with treatment indications (WHO stage 3-4 
and/or CD4 ≤350 cells/mm3) who initiated ART during pregnancy, cART was received by 56% 
(137/244) delivering in 2008, 83% (276/332) delivering in 2009 and 91% (270/298) delivering in 
2010 (trend p<0.01), reflecting the prioritisation of this group for limited cART supplies. Where 
ART appeared to be initiated for PMTCT only (i.e. among women with WHO stage and/or CD4 
count available, but without WHO stage 3-4 and/or CD4 ≤350 cells/mm3), 12% (84/709) of 
women received cART in 2008 increasing to 49% (360/731) in 2009 and 55% (289/526) in 2010 
(trend p<0.01). 
There were significant differences by HIV/AIDS centre in the proportion of women initiating 
ZDVm (rather than cART) during pregnancy (seven centres, Table 3.7b on page 105, 2=232.70 
p<0.01). Overall, almost two-thirds of women without treatment indications initiated ZDVm rather 
than cART, compared with 22% of those with indications for treatment (Table 3.7a, page 104). In 
addition to year of delivery, centre and maternal treatment indication, other factors associated with 
initiation of ZDVm in univariable analyses included IDU history, IDU partner, marital status, 
previous live births, timing of HIV diagnosis and educational status (Tables 3.7a and 3.7b). 
Although both IDU history and IDU partner were associated with a smaller likelihood of receiving 
ZDVm (i.e. greater likelihood of receiving cART) in univariable analyses, this was accounted for by 
more severe HIV disease in these groups (see page 80).  
The probability of receiving ZDVm more than halved between 2008 and 2010, after adjusting for 
other factors (Table 3.7a). Having ≥2 previous live births (vs. none) and being cohabiting (vs. 
married) were both associated with an increased likelihood of receiving ZDVm. Women diagnosed 
with HIV during pregnancy were also more likely to receive ZDVm, partly because they were less 
likely to have indications for treatment (27% (500/1847) vs. 38% (374/987) of those diagnosed 
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before conception and initiating ART during pregnancy, 2=35.32 p<0.01). However, this 
association remained after adjusting for treatment indication and other factors (Table 3.7a). Among 
women without treatment indications, median CD4 counts were 520 cells/mm3 and 550 cells/mm3 
for women diagnosed before conception and in first or second trimesters respectively (Wilcoxon-
Mann-Whitney test p=0.28). Having an IDU partner did not contribute significantly to the 
multivariable model’s goodness-of-fit (p=0.15) and was excluded.  
In a similar multivariable model adjusting also for educational status (n=1555), women with less 
education were significantly more likely to receive ZDVm (APR 1.18, 95% CI 1.05-1.33, p<0.01 
and APR 1.43, 95% CI 1.25-1.64, p<0.01 for those leaving full-time education at 17-18 years and 
≤16 years respectively vs. those leaving education at ≥19 years). This was despite lower educational 
status being associated with lower CD4 counts among women without treatment indications 
(median CD4 count 510 cells/mm3, 530 cells/mm3and 560 cells/mm3 for women leaving education 
at ≤16, 17-18 and ≥19 years respectively, Kruskal-Wallis test p=0.05). This could be because 
clinicians perceived these women to be more likely to experience adherence problems. Women with 
≥2 previous live births were more likely to have left education <19 years (72% (170/236) vs. 52% 
(322/617) of women with one and 41% (445/1097) of women with no previous live births, 
2=83.24 p<0.01), as were cohabiting women (56% (392/705) vs. 39% (361/917) of married 
women, 2=42.24 p<0.01). After adjusting for educational status, the associations between ZDVm 
initiation and ≥2 previous live births / cohabiting status were both reduced (APR 1.14, 95% CI 
1.00-1.30, p=0.06, and APR 1.06, 95% CI 0.97-1.17, p=0.20 respectively). 
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Table 3.7a: Factors associated with initiation of ZDVm (rather than cART) during pregnancy, 2008-10 (continued in Table 3.7b) 
 
 Proportion (n) 
receiving ZDVm 
Unadjusted PR 
(95% CI) 
Unadjusted PR (95% 
CI) – limited to 2770 
women† 
Adjusted PR (95% CI) 
(n=2770) ‡ 
Year of delivery (n=3068)     
2008 78% (842/1082) 2.36 (2.14-2.62) p<0.01 2.32 (2.09-2.57) p<0.01 2.32 (2.11-2.55) p<0.01 
2009 42% (469/1129) 1.26 (1.12-1.42) p<0.01 1.21 (1.07-1.37) p<0.01 1.25 (1.12-1.39) p<0.01 
2010 33% (282/857) 1.00 1.00 1.00 
IDU history (n=3057)     
Yes 42% (158/375) 1.00 1.00 1.00 
No 53% (1431/2682) 1.27 (1.12-1.43) p<0.01 1.23 (1.08-1.40) p<0.01 1.10 (0.99-1.23) p=0.09 
IDU partner (n=3005)     
Yes 47% (366/781) 1.00   
No 54% (1208/2224) 1.16 (1.07-1.26) p<0.01   
Marital status (n=3063)     
Married 50% (694/1392) 1.00 1.00 1.00 
Cohabiting 54% (653/1214) 1.08 (1.00-1.16) p=0.05 1.09 (1.00-1.18) p=0.04 1.09 (1.02-1.16) p=0.02 
Single 54% (246/457) 1.08 (0.98-1.19) p=0.13 1.08 (0.97-1.21) p=0.16 1.01 (0.91-1.11) p=0.90 
Maternal treatment indication 
(n=3182) 
    
Yes 22% (191/874) 1.00 1.00 1.00 
No 63% (1233/1966) 2.87 (2.52-3.27) p<0.01 2.87 (2.52-3.26) p<0.01 2.53 (2.22-2.87) p<0.01 
Previous live births at enrolment 
(n=3018) 
    
0 54% (907/1688) 1.00 1.00 1.00 
1 49% (475/976) 0.91 (0.84-0.98) p=0.01 0.91 (0.84-0.99) p=0.03 1.01 (0.93-1.08) p=0.89 
≥2 57% (201/354) 1.06 (0.96-1.17) p=0.29 1.07 (0.96-1.20) p=0.20 1.22 (1.11-1.35) p<0.01 
Timing of HIV diagnosis (n=3061)     
Before conception 45% (476/1064) 1.00 1.00 1.00 
1st / 2nd trimester 56% (950/1699) 1.25 (1.15-1.35) p<0.01 1.28 (1.18-1.40) p<0.01 1.11 (1.03-1.20) p<0.01 
3rd trimester 55% (163/298) 1.22 (1.08-1.38) p<0.01 1.22 (1.07-1.39) p<0.01 1.02 (0.91-1.15) p=0.70 
†those with complete data available on all explanatory variables included in the adjusted model ‡Adjusted a priori for year of delivery and centre 
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Table 3.7b: Factors associated with initiation of ZDVm (rather than cART) during pregnancy, 2008-10 (continued from Table 3.7a) 
 
 Proportion (n) 
receiving ZDVm 
Unadjusted PR  
(95% CI) 
Unadjusted PR (95% 
CI) – limited to 2770 
women† 
Adjusted PR (95% CI) 
(n=2770) ‡ 
Age at leaving  full-time education 
(n=1736) 
    
≥19 years 51% (481/944) 1.00 Omitted due to missing Omitted due to missing  
17-18 years 50% (255/508) 0.99 (0.89-1.10) p=0.78 data data 
≤16 years 63% (180/284) 1.24 (1.12-1.39) p<0.01   
Centre of enrolment (n=3068)     
Odessa 64% (434/673) 1.00 1.00 1.00 
Mykolaiv 72% (397/551) 1.12 (1.04-1.21) p<0.01 1.11 (1.02-1.22) p=0.02 1.31 (1.21-1.42) p<0.01 
Kiev 40% (201/502) 0.62 (0.55-0.70) p<0.01 0.65 (0.58-0.74) p<0.01 0.74 (0.66-0.82) p<0.01 
Donetsk 51% (177/344) 0.80 (0.71-0.90) p<0.01 0.83 (0.74-0.94) p<0.01 0.81 (0.73-0.89) p<0.01 
Mariupol 39% (104/270) 0.60 (0.51-0.70) p<0.01 0.61 (0.52-0.72) p<0.01 0.69 (0.60-0.79) p<0.01 
Krivoy Rog 39% (92/238) 0.60 (0.51-0.71) p<0.01 0.62 (0.52-0.74) p<0.01 0.89 (0.76-1.05) p=0.17 
Simferopol 38% (188/490) 0.59 (0.52-0.67) p<0.01 0.61 (0.53-0.69) p<0.01 0.74 (0.66-0.83) p<0.01 
†those with complete data available on all explanatory variables included in the adjusted model ‡Adjusted a priori for year of delivery and centre 
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3.2.6 Mother-to-child-transmission in 2008-10 
Figure 3.5 shows unadjusted MTCT rates in 2008-10 by antenatal and intrapartum ART receipt and 
by timing of the woman’s HIV diagnosis. Among 2854 infants with infection status reported (81%) 
the MTCT rate was 4.1% (95% CI 3.4-4.9); 1.3% (95%CI 0.7-2.0) among women receiving 
antenatal cART, 3.8% (95% CI 2.8-5.0) among those receiving ZDVm, 18.6% (95% CI 12.3-26.4) 
following sdNVP only and 22.9% (95% CI 15.4-32.0) among untreated women. Overall, 42% 
(49/116) of transmissions occurred to the 8% (n=238) without antenatal ART exposure. Of 1045 
women without treatment indications who received ZDVm, MTCT occurred in 3.7% (95% CI 2.7-
5.1).
 
Figure 3.5: Unadjusted MTCT rates by antenatal / intrapartum ART receipt and timing of 
HIV diagnosis 
Capped line represents 95% CI. Of those diagnosed in the first and second trimesters, no 
transmissions occurred among the eight women who received sdNVP only (one-sided confidence 
interval). 
 
Bias and confounding in reporting of infant infection status 
Despite the roll-out of cART for PMTCT from 2008 to 2010, there was no decline in MTCT rate 
over these years (trend p=0.41, see also Figure 3.3, page 89), a time period when all seven centres 
contributed data.  At the time of the analysis, infection status was available for 65% (666/1027) of 
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infants born in 2010 vs. 84% (1086/1291) and 91% (1102/1217) born in 2009 and 2008, due to 
reporting delays and incomplete coverage with early infant PCR testing. Bias in reporting of infant’s 
HIV status according to factors influencing vertical transmission risk was investigated among 
infants born in 2010. Women who had lacked antenatal ART were slightly more likely to have an 
infant with indeterminate status (43% (51/118) vs. 34% (310/909) of women who had received 
antenatal ART, 2=3.80 p=0.05), as were women with an IDU history (44% (61/139) vs. 34% 
(296/878) of non-IDUs, 2=5.45 p=0.02). There was no difference in reporting of infant’s 
infection status by mother’s receipt of cART vs. ZDVm (35% (204/575) and 29% (83/282) of 
infants had an indeterminate HIV status respectively, 2=3.10 p=0.08), or by preterm birth (p=0.53) 
or mode of delivery (p=0.67). MTCT rates were slightly higher in all maternal ART groups in 2010 
compared with 2009 (cART: 2.8% (95% CI 1.4-4.9) vs. 0.3% (95% CI 0.2-1.6); ZDVm+/-sdNVP: 
5.1% (95% CI 2.5-9.2) vs. 1.3% (95% CI 0.4-3.1); sdNVP only or no ART: 28.4% (95% CI 18.0-
40.7) vs. 17.1% (95% CI 9.7-27.0)). When the 2010 transmission rates by maternal ART group were 
applied to the 361 infants born that year and with an indeterminate HIV status, the overall 
transmission rate increased by 0.2% to 6.4% (95% CI 5.0-8.1), indicating that the MTCT rate 
observed here for 2010 may be an underestimate. 
The proportion of women receiving no ART increased substantially from 4% (51/1217) in 2008 to 
7% (74/1027) in 2010 (trend p<0.01). This increase occurred across three centres (Odessa, Donetsk 
and Mariupol) and was explored in more detail in section 3.2.4 (page 96). Among those receiving 
cART, there was no difference in the proportion receiving less than four weeks of treatment by 
centre (2=11.14 p=0.08) and no increase in this proportion over time from 2008 to 2010 (trend 
p=0.36).  
To investigate the possibility of MTCT rate being biased by infant death, where improvements in 
neonatal and infant care over time resulted in improved case ascertainment among infants at 
highest risk of HIV infection, deaths occurring among infants at <6 months of age from 2003-10 
were explored. There was a significant decline in infant deaths at <6 months of age over this time 
period (from 2.3% (7/300) in 2003 to 1.5% (20/1335) in 2007 and 0.3% (3/1027) in 2010, trend 
p<0.01). However, when infants who died with an indeterminate infection status were assigned to 
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infected and uninfected groups according to probable cause of death (Appendix E, page 343), the 
MTCT rate in each year changed by ≤0.2% and there remained no significant decline from 2008 to 
2010.  
Factors associated with MTCT 
Table 3.8 (page 110) shows factors associated with MTCT in 2008-10. Antenatal cART was 
associated with a 70% reduction in MTCT risk compared with ZDVm +/- sdNVP, in adjusted 
analysis. Both sdNVP and no ART were associated with a four-fold increased risk of MTCT 
compared with ZDVm. Preterm delivery was associated with a two-fold increased risk of 
transmission overall (Table 3.8). Although there was no significant interaction between preterm 
delivery and ART receipt (LRT p=0.33), the overall association was driven by an increased risk of 
transmission to preterm infants born to women on ZDVm +/- sdNVP (APR 3.45, 95%CI 1.54-
7.73, p<0.01). There was no statistically significant association between preterm delivery and MTCT 
among women who received antenatal cART (APR 2.32, 95% CI 0.50-10.65, p=0.28). Maternal 
CD4 count and WHO stage were not included in the final model (LRT p=0.20 and p=0.42 
respectively). Breastfeeding, reported by only 0.5% (6/1225) of women in 2008-10, was excluded; 
three of the breastfed infants had an infection status available and were uninfected at the time of 
the test. Neonatal prophylaxis was included in the final model (LRT p=0.06) and was weakly 
associated with an increased likelihood of infant HIV infection (Table 3.8, p=0.08), probably due to 
confounding by indication; lack of neonatal prophylaxis was associated with longer duration of 
antenatal ART (14 weeks vs. 10.7 weeks for those who did receive neonatal prophylaxis, Wilcoxon-
Mann-Whitney test p=0.07).     
In the adjusted model, the vertical transmission rate was significantly lower in 2009 than in 2008, 
and increased in 2010 (Table 3.8). Over these years, there was an increase across several centres in 
the proportion of enrolments among women who had left education at ≤16 years, and this trend 
was particularly marked in Mykolaiv (where 5% (9/171) had left education at ≤16 years in 2008 
increasing to 33% (53/159) in 2009 and 51% (96/187) in 2010, trend p<0.01 vs. p=0.06 for other 
centres). Given the association between fewer years of education and missed opportunities for 
PMTCT, this shift may have increased the overall MTCT risk at a population level through factors 
not captured here (e.g. poorer adherence to ART). When Mykolaiv was omitted from the 
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multivariable model, there was no evidence of a difference in MTCT risk during 2010 compared 
with 2008 (AOR 1.50 95% CI 0.82-2.72 p=0.19). 
There was no association between transmission risk and mode of delivery in adjusted analyses 
(Table 3.8). However, elective CS deliveries were disproportionately conducted among lower risk 
pregnancies. For example, of women delivering at term (≥37 weeks gestation) and diagnosed 
before delivery, 34% (486/1449) of those receiving cART delivered by elective CS compared with 
32% (396/1255) of those receiving ZDVm, 22% (46/208) who received ZDVm plus sdNVP, 11% 
(8/74) who received sdNVP only and 9% (8/92) who received no ART (2=47.85 p=0.01). 
Statistical power may have been insufficient to detect any additional benefit of elective CS in the 
group that actually delivered in this way (i.e. the group most likely to have suppressed viral loads).  
Median duration of antenatal ZDVm was shorter than for cART (12.6 weeks, IQR 9.9-14.9 and 
13.9 weeks, IQR 10.1-16.6) respectively). Adjusting for ART duration (2-7, 8-11 or ≥12 weeks) in 
addition to other factors in Table 3.8, cART was associated with a 59% reduction in MTCT risk 
compared with ZDVm among 2504 women with ≥14 days of ART by delivery (AOR 0.41, 95%CI 
0.21-0.79, p<0.01).  
Among the subgroup of 1409 pregnancies in women receiving antenatal ART, delivering vaginally 
or by elective CS and with viral load available, preterm delivery was not significantly associated with 
MTCT risk (AOR 1.63 95%CI 0.51-5.19 p=0.41, adjusting for ART type, IDU history, mode and 
year of delivery, viral load, neonatal prophylaxis and centre). Each log10 unit increase in antenatal 
viral load (measured a median of 41 days before delivery) was associated with a 77% (AOR 1.77, 
95% CI 1.25-2.51) increased transmission risk. After adjusting for viral load in addition to the other 
factors in Table 3.8, the reduction in MTCT risk associated with cART remained similar (AOR 0.36 
95% CI 0.16-0.81 p=0.01).  
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Table 3.8: Factors associated with MTCT, 2008-10 
 MTCT rate (n) Unadjusted OR  
(95% CI) 
Adjusted OR†  
(95% CI) (n=2793) 
Antenatal / intrapartum 
ART 
   
cART 1.3% (16/1274) 0.32 (0.18-0.57) p<0.01 0.31 (0.17-0.58) p<0.01 
ZDVm 3.8% (51/1342) 1 1 
sdNVP only 18.6% (24/129) 5.79 (3.42-9.77) p<0.01 4.52 (2.45-8.29) p<0.01 
None 22.9% (25/109) 7.53 (4.45-12.76) p<0.01 5.06 (2.69-9.52) p<0.01 
Mode of delivery    
Vaginal 4.9% (94/1916) 1 1 
Elective CS 2.5% (20/800) 0.50 (0.30-0.81) p<0.01 0.73 (0.42-1.26) p=0.25 
Emergency CS 1.5% (2/137) 0.29 (0.07-1.18) p=0.08 0.26 (0.06-1.14) p=0.08 
Gestation at delivery    
≥37 weeks 3.5% (92/2597) 1 1 
<37 weeks 9.3% (23/247) 2.80 (1.74-4.50) p<0.01 2.23 (1.28-3.90) p<0.01 
IDU history    
No 3.8% (92/2416) 1 1 
Yes 5.3% (22/414) 1.42 (0.88-2.28) p=0.15 1.12 (0.64-1.97) p=0.70 
Year of delivery    
2008 4.7% (52/1102) 1 1 
2009 2.1% (23/1086) 0.44 (0.27-0.72) p<0.01 0.51 (0.28-0.90) p=0.02 
2010 6.2% (41/666) 1.32 (0.87-2.02) p=0.19 1.76 (1.05-2.93) p=0.03 
Neonatal prophylaxis    
No 5.6% (7/125) 1 1 
Yes 4.0% (109/2701) 0.71 (0.32-1.56) p=0.39 2.50 (0.90-6.92) p=0.08 
Viral load    
Per log10 increase  1.65 (1.24-2.20) p<0.01 Omitted due to lack of 
data – see text 
†AORs are estimated including a random effect to account for unobserved variables specific to each 
centre of delivery 
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3.2.7 Key points 
 In 2008-10, almost a fifth of antenatal diagnoses occurred in the third trimester or intrapartum, 
precluding optimal PMTCT interventions. Women with an IDU history, those who were 
unmarried, parous or with less education were at increased risk of a late diagnosis. 
 A tenth of women delivering from 2008 to 2010 lacked antenatal ART (received no ART or 
sdNVP only), a fifth of whom were diagnosed intrapartum. Three centres (Krivoy Rog, Kiev 
and Donetsk) had >98% coverage with antenatal ART of women diagnosed before delivery. At 
the remaining four centres, risk factors for lacking antenatal ART were having an IDU history, 
being unmarried, multiparous, delivering preterm and being diagnosed as HIV-positive before 
conception or in the third trimester (vs. in the first or second trimesters).  
 At Krivoy Rog, Kiev and Donetsk, <2% of women diagnosed prior to delivery lacked antenatal 
ART. At Mariupol, Odessa, Mykolaiv and Simferopol, women diagnosed during pregnancy 
were more likely to lack antenatal ART if diagnosed late or delivering preterm, or if they had a 
lower level of education. Among women diagnosed prior to conception at these four centres, 
6% lacked antenatal ART (indicating disengagement from HIV care), and multiparous women 
were at increased risk. Unmarried women and those with an IDU history were at increased risk 
of lacking antenatal ART regardless of timing of HIV diagnosis.  
 Of women initiating ART during pregnancy, the proportion who received cART (rather than 
ZDVm) increased to 67% in 2010, with priority given to those with most severe HIV disease. 
Women who were unmarried, multiparous and with less education were more likely to receive 
ZDVm (and less likely to receive cART) when initiating ART during pregnancy. 
 Unmarried women, those with other children and those with less education were therefore at 
risk of multiple missed opportunities for PMTCT, as were IDUs. 
 In 2008-10, the MTCT rate was 4.1% (95% CI 3.4-4.9) overall and 1.3% (95% CI 0.7-2.0) 
among those who received antenatal cART. cART was associated with a 69% reduction in 
MTCT risk compared with ZDVm +/- sdNVP, the standard of care for PMTCT prior to 2007 
in Ukraine, demonstrating its effectiveness for PMTCT in this operational, lower-middle 
income setting. 
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3.3 PMTCT in Western and Europe: Insufficient antenatal ART 
3.3.1 Methods 
This analysis was limited to births from January 2000 to July 2009 at Western European sites of the 
ECS in nine countries (Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, Sweden 
and the UK).  
The main outcome was receipt of ‘insufficient antenatal ART’, defined as receipt of no ART in 
pregnancy or short duration of ART, initiated 1-13 days before delivery. This short ART duration 
was chosen in order to focus on those with the most elevated risk of vertical transmission 
(Townsend et al. 2008a). Figure 3.6 summarises the availability of data on receipt and duration of 
antenatal ART. Pregnancies with missing information on ART receipt were excluded (n=42). 
Multiple births were excluded because of their association with preterm delivery, a factor potentially 
limiting duration of antenatal ART. Pregnancies in which ART was received but treatment duration 
was missing (n=246) were included in the “≥14 days of ART” group, as in the vast majority 
treatment was likely to have been for longer than 14 days: 84% (191/228) were diagnosed pre-
conception, 33% (48/144) had undetectable viral load at delivery, and 66% (103/155) had a CD4 
count >350 cells/mm3 at last antenatal measure. Where HIV diagnosis was recorded one day either 
side of delivery (n=6) it was categorised as intrapartum. Where HIV diagnosis occurred more than 
one day post-partum (n=3) the pregnancy was excluded. Logistic regression models were fitted to 
explore factors associated with insufficient antenatal ART in the cohort as a whole, and in stratified 
analyses of women diagnosed with HIV pre- and post-conception, as different factors might be 
important in these two groups (Mayaux et al. 2003). 
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Figure 3.6: Availability of data on receipt of insufficient (none or <14 days) antenatal ART 
 †Women with missing ART start date are included in the ≥14 days antenatal ART group in all analyses 
 
Timing of HIV diagnosis during pregnancy indicates access to and uptake of antenatal care in 
Europe, where HIV testing is offered to all pregnant women as policy in most countries (Aebi-
Popp et al. 2013). Because HIV diagnosis occurring late in pregnancy or intrapartum is a barrier to 
receipt of ART, factors associated with “late” HIV diagnosis (occurring during the third trimester 
or intrapartum) were explored among women who were not yet diagnosed with HIV at conception. 
Maternal factors were investigated (age at delivery, marital status, sub-Saharan African origin, IDU 
history, previous live births, severe symptomatic HIV disease) as were delivery details (year, country 
of delivery and gestational age). Delivery before 34 weeks gestation (precluding 14 days of antenatal 
ART if started at week 32, the latest suggested by British guidelines in this time period (Hawkins et 
al. 2005; de Ruiter et al. 2008)) was investigated as a factor associated with receiving either no ART 
2262 births 
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to July 2009
Multiple births 
excluded (n=72)
Missing data on 
antenatal ART 
receipt (n=42)
2148 singleton births
Antenatal ART 
(n=2006)
No antenatal ART 
(n=142)
Missing ART 
start date (n=246)†
Duration available 
(n=1760)
≥14 days antenatal 
ART (n=1719)
1-13 days antenatal 
ART (n=41)
Groups combined 
as denominator for 
outcome (n=1965) 
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or 1-13 days ART before delivery. Although history of IDU was considered rather than current 
IDU in multivariable analyses, current IDU was described and defined as active IDU reported 
during pregnancy or neonatal abstinence syndrome in the infant. Mode of delivery and antenatal 
CD4 count were not included as explanatory variables in the logistic regression analyses, being 
affected by and/or a consequence of insufficient antenatal ART or HIV diagnosis late in pregnancy 
(including intrapartum), rather than predisposing risk factors. During model selection, each 
covariate’s contribution to the model’s goodness-of-fit was assessed with the LRT    (significance 
level of ≤0.1).  
Random effects models were fitted in all analyses to account for underlying, unobserved variation 
in the outcome by country of delivery (Rabe-Hesketh et al. 2002). All models were adjusted a priori 
for year of delivery to account for changes in clinical practice over time (European Collaborative 
Study et al. 2010). 
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3.3.2 Cohort characteristics 
A total of 2148 deliveries between January 2000 and July 2009 were reported in 1940 women; 173 
women had two pregnancies, 16 had three and one woman had four. Of the 2148 pregnancies, 142 
(7%) were in women who received no ART, and a further 41 (2%) were in women who received 
less than two weeks of ART before delivery (Figure 3.6, page 113). Baseline maternal and 
pregnancy characteristics by receipt of antenatal ART are given in Table 3.9. Overall, in two fifths 
of mother-child pairs the mother was born in sub-Saharan Africa (ranging from 0% in Poland to 
87.4% in Belgium (2=618.4, p<0.01)), three-quarters were married or cohabiting and around a fifth 
had an IDU history (ranging from 1.3% in Belgium to 75.3% in Poland (2=481.8, p<0.01)). 
Median age at delivery was 31.5 years (IQR 27.2, 35.4 years). In at least 27% (106/390) of the 
mother-child pairs where the mother had an IDU history there was evidence of current IDU. In 
just over a tenth of pregnancies the mother had severe symptomatic HIV disease, and median CD4 
count (first recorded in pregnancy) was 410 cells/mm3 (IQR 280, 580 cells/mm3).  
In almost three-quarters of pregnancies the woman was aware of her HIV infection before 
conception. Among women with unknown HIV status at conception, 79% (471/596) were 
diagnosed by the end of the second trimester, 17% (101/596) in the third trimester and 4% 
(24/596) at delivery. The proportion with late HIV diagnosis (during the third trimester or at 
delivery) decreased over time from 24% (94/393) of those with unknown status at conception in 
2000-03, to 15% (31/203) in 2004-09 (2=6.04, p=0.014). 
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Table 3.9: Maternal and delivery characteristics by receipt of antenatal ART 
 ≥14 days of 
antenatal ART 
or missing 
duration 
(n=1965) 
1-13 days of 
antenatal ART 
(n=41) 
No antenatal 
ART (n=142) 
 
Maternal characteristics 
   
Marital status (n=1930)    
Married or cohabiting 1334 (75%) 21 (62%) 79 (69%) 
Single 447 (25%) 13 (38%) 36 (31%) 
Ethnic group (n=2101)    
White 914 (48%) 18 (45%) 87 (63%) 
Black 919 (48%) 22 (55%) 44 (32%) 
Other 90 (5%) 0  7 (5%) 
Sub-Saharan African origin (n=2089)    
No 1106 (58%) 18 (45%) 101 (73%) 
Yes 804 (42%) 22 (55%) 38 (27%) 
Previous live births at enrolment (n=2033)    
0 798 (43%) 16 (40%) 54 (41%) 
1 613 (33%) 17 (43%) 40 (30%) 
2 or more 450 (24%) 7 (18%) 38 (29%) 
History of IDU (n=2091)    
No 1581 (82%) 36 (88%) 84 (64%) 
Yes 337 (18%) 5 (12%) 48 (36%) 
Current IDU (n=2091)    
No 1838 (96%) 39 (95%) 108 (82%) 
Yes 80 (4%) 2 (5%) 24 (18%) 
Timing of HIV diagnosis (n=2069)    
Pre-conception 1388 (73%) 16 (41%) 69 (52%) 
1st / 2nd trimester 449 (24%) 4 (10%) 18 (14%) 
3rd trimester / delivery 61 (3%) 19 (49%) 45 (34%) 
HIV disease symptoms (n=1535)    
Asymptomatic / non-severe HIV symptoms 1229 (86%) 29 (88%) 72 (95%) 
Severe symptomatic HIV disease 197 (14%) 4 (12%) 4 (5%) 
CD4 count - first in pregnancy (cells/mm3) 
(n=1722) 
   
<200 214 (13%) 6 (18%) 10 (14%) 
200-349 414 (25%) 12 (36%) 21 (30%) 
≥350 1024 (62%) 15 (45%) 38 (55%) 
 
Delivery 
   
Time period (n=2148)    
2000-03 1224 (62%) 25 (61%) 106 (75%) 
2004-09 741 (38%) 16 (39%) 36 (25%) 
Mode (n=2044)    
Vaginal or emergency caesarean section 664 (35%) 19 (49%) 64 (48%) 
Elective caesarean section 1207 (65%) 20 (51%) 70 (52%) 
Gestation (weeks) (n=2109)    
<34 99 (5%) 8 (20%) 16 (12%) 
34-36 300 (16%) 7 (17%) 23 (17%) 
≥37 1531 (79%) 26 (63%) 99 (72%) 
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3.3.3 Maternal HIV diagnosis late in pregnancy 
Although a smaller proportion of African women had been diagnosed with HIV pre-conception 
compared with non-African women (64% vs. 76%, 2=39.71, p<0.01), African women diagnosed 
during pregnancy were no more likely to be diagnosed late than non-African women (OR 1.32, 
95% CI 0.83-2.12, p=0.24 adjusting for year and country of delivery and IDU).  This indicates that 
access to and uptake of antenatal care was not lower among African migrants – a group at potential 
risk of poorer healthcare utilisation and pregnancy outcomes (Hayes et al. 2011). HIV diagnosis 
occurred pre-conception in 87% (178/205) of pregnancies in women with severe symptomatic HIV 
disease vs. 69% (894/1296) of those in women with no or non-severe symptoms (2=24.68, 
p<0.01). Women with severe symptomatic HIV disease were also more likely to have been on ART 
at conception (56% (107/191) vs. 31% (350/1145) of women with no or non-severe symptoms 
2=47.12, p<0.01). Among women diagnosed during pregnancy, severe symptomatic HIV disease 
was present in only 6% (27/1429) and was not associated with probability of a late diagnosis 
(Fisher’s exact test p=1.00).  
HIV diagnosis was more likely to have occurred pre-conception where there was a maternal history 
of IDU (89% (325/365) vs. 68% (1121/1657) of pregnancies with no maternal IDU history, 
2=67.17, p<0.01). However, where HIV diagnosis occurred after conception, women with an IDU 
history were more likely to be diagnosed late (35% (14/40) vs. 20% (108/536) of pregnancies with 
no maternal IDU history, 2=4.92, p=0.027). Maternal IDU history was the only factor associated 
with late HIV diagnosis among women diagnosed during pregnancy. 
3.3.4 Receipt of insufficient ART 
The proportion of pregnancies where the mother received no antenatal ART decreased from 8% 
(106/1355) in 2000-03 to 5% (36/793) in 2004-09 (2=8.73, p<0.01), but no decline was seen in the 
proportion with 1-13 days of antenatal ART (2% (41/2006) of those with treatment) (p=0.78). 
Significant differences in non-receipt of antenatal ART existed by country of delivery, from 0% 
(0/202) of pregnancies in the Netherlands to 21% (18/87) in Poland (nine countries, 2=72.31, 
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p≤0.01), and also in the receipt of 1-13 days of antenatal ART, from 0% (0/35) of pregnancies in 
Denmark to 6% (10/156) in Germany (2=21.04, p<0.01).  
In the group with at least 14 days of ART, 5% (99/1930) of deliveries were at less than 34 weeks 
gestation compared with two and four-fold this rate among the groups who had received no ART 
and 1-13 days of ART respectively (Table 3.9).  
In half (85/171) of pregnancies with insufficient antenatal ART the woman was aware of her HIV 
status before conception. These women had a median CD4 count at the last antenatal measurement 
of 310 cells/mm3 (IQR 240, 440 cells/mm3) (median 25 days before delivery) compared with 450 
cells/mm3 (IQR 320, 630 cells/mm3) among women diagnosed pre-conception and treated for at 
least two weeks (p<0.01). In pregnancies with pre-conception HIV diagnosis, those with 
insufficient antenatal ART had a rate of severe maternal immunosuppression (CD4 count <200 
cells/mm3) twice as high as those with at least two weeks of treatment (20%, 10/49 versus 8%, 
93/1149). Overall however, women with insufficient antenatal ART were less likely to have severe 
symptomatic HIV disease than those treated for longer (7%, 8/109 and 14% respectively, 
197/1426, 2=3.67, p=0.06). 
 A late maternal HIV diagnosis was received in only 3% (61/1898) of pregnancies with “adequate” 
treatment compared with 37% (64/171) of pregnancies with no or 1-13 days of ART (2=323.47, 
p<0.01). Given the overlap between late HIV diagnosis and insufficient antenatal ART (and the fact 
that late diagnosis to some extent precluded a sufficient ART duration) timing of maternal HIV 
diagnosis was not included in multivariable models.  
Factors associated with receiving no antenatal ART and 1-13 days of ART before delivery are 
shown in Table 3.10. Preterm delivery at <34 weeks gestation was the only factor associated with 
short duration of ART, whereas IDU history, maternal clinical HIV stage and preterm delivery <34 
gestational weeks were associated with not receiving ART in both univariable and multivariable 
analyses. Of pregnancies with current maternal IDU, 23% (24/106) had no antenatal ART 
compared with 8% (24/284) of those in ex-IDUs (2=13.46, p<0.01).
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Table 3.10: Factors associated with receiving no or 1-13 days of antenatal ART – all women 
 No ART (vs. any ART) (n=2148) 1-13 days of ART (vs. ≥14 days of ART) (n=2006) 
  Proportion (n) not 
receiving ART  
Unadjusted Odds Ratio  
(95% CI) 
Adjusted Odds Ratio† 
(95% CI) 
Proportion (n) 
receiving 1-13 days 
ART 
Unadjusted Odds Ratio 
(95% CI) 
Adjusted Odds Ratio† 
(95% CI) 
History of IDU       
No 4.9% (84/1701)  1.00 1.00 2.2% (36/1617) 1.00  
Yes 12.3% (48/390) 2.70 (1.86-3.92), p<0.01 2.91 (1.55-5.44) p<0.01 1.5% (5/342) 0.65 (0.25-1.67), p=0.37  
HIV Symptoms       
Asymptomatic / non-severe 
symptoms 
 5.4% (72/1330) 1.00 1.00 2.3% (29/1258) 1.00  
Severe symptomatic HIV 
disease 
   2.0% (4/205) 0.35 (0.13-0.96) p=0.042 0.23 (0.08-0.67) p<0.01 2.0% (4/201) 0.86 (0.30-2.47) p=0.78  
Preterm delivery <34 weeks 
gestation 
      
No  6.1% (122/1986) 1.00 1.00 1.8% (33/1864) 1.00 1.00 
Yes    13.0% (16/123) 2.28 (1.31-3.99) p<0.01 2.93 (1.40-6.10) p<0.01 7.5% (8/107) 4.48 (2.02-9.96) p<0.01 4.37 (1.95-9.78) p<0.01 
Year of delivery       
2000-03  7.8% (106/1355) 1.00 1.00 2.0% (25/1249) 1.00 1.00 
2004-09    4.5% (36/793) 0.56 (0.38-0.83) p<0.01 0.69 (0.39-1.23) p=0.21 2.1% (16/757) 1.06 (0.56-2.00) p=0.86  0.98 (0.51-1.89) p=0.95 
†AORs are estimated accounting for country of delivery as a random effect
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Although univariable analysis suggested that maternal sub-Saharan African origin was associated 
with a decreased probability of non-receipt of ART (OR 0.51 for not receiving ART among African 
vs. non-African women, 95% CI 0.35-0.75, p<0.01), this association was accounted for by IDU 
history, a factor almost exclusive to white women (377 of 383 pregnancies with maternal IDU 
history were in white women). When limited to pregnancies without a maternal history of IDU, 
sub-Saharan African origin was not significantly associated with non-receipt of antenatal ART (OR 
0.74 for African non-IDUs vs. non-African non-IDUs, 95% CI 0.47-1.14, p=0.17).  
In the model limited to 1473 mother-child pairs with HIV diagnosis before conception, 6% (n=85) 
received insufficient ART. Being single and having an IDU history were associated with not 
receiving antenatal ART (Table 3.11), but these factors were not significantly associated with short 
duration of ART. Delivery at <34 weeks was associated with short duration of ART only (Table 
3.11). 
Among 596 mother-child pairs with HIV diagnosis after conception, 14% (n=86) received 
insufficient ART. History of IDU was associated with not receiving ART but not with short 
duration of ART (Table 3.12). Preterm delivery <34 weeks was associated with both no ART and 
short duration of treatment.
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Table 3.11: Factors associated with receiving no or 1-13 days of antenatal ART – women diagnosed pre-conception 
†AORs are estimated accounting for country of delivery as a random effect 
  
 No ART (vs. any ART) (n=1473) 1-13 days of ART (vs. ≥14 days of ART) (n=1404) 
 Proportion (n) 
not receiving 
ART 
Unadjusted Odds Ratio  
(95% CI) 
Adjusted Odds Ratio† 
(95% CI) 
Proportion (n) 
receiving 1-13 
days of ART 
Unadjusted Odds Ratio  
(95% CI)  
Adjusted Odds Ratio† (95% 
CI) 
Marital status       
Married / cohabiting 4.0% (41/1019) 1.00 1.00 0.7% (7/978) 1.00  
Single  7.6% (24/314) 1.97 (1.17-3.32) p=0.01 1.88 (1.06-3.33) p=0.030 1.7% (5/290) 2.43 (0.77-7.73) p=0.131  
History of IDU       
No 3.1% (35/1121) 1.00 1.00 1.2% (13/1086) 1.00  
Yes 10.2% (33/325) 3.50 (2.14-5.74) p<0.01 2.00 (1.06-3.77) p=0.033 1.0% (3/292) 0.86 (0.24-3.03) p=0.810  
Preterm delivery <34 weeks 
gestation 
      
No 4.4% (60/1377) 1.00  1.0% (13/1317) 1.00 1.00 
Yes 9.4% (9/96) 2.27 (1.09-4.73) p=0.028  3.5% (3/87) 3.58 (1.00-12.82) p=0.05 3.62 (1.01-12.98) p=0.048 
Year of delivery       
2000-03 5.9% (54/911) 1.00 1.00 1.1% (9/857) 1.00 1.00 
2004-09 2.7% (15/562) 0.44 (0.24-0.78) p<0.01 0.58 (0.31-1.09) p=0.088 1.3% (7/547) 1.22 (0.45-3.30) p=0.693 1.25 (0.46-3.40) p=0.656 
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Table 3.12: Factors associated with receiving no or 1-13 days of antenatal ART – women diagnosed after conception 
†AORs are estimated accounting for country of delivery as a random effect 
 
 
 
 No ART (vs. any ART) (n=596) 1-13 days of ART (vs. ≥14 days of ART) (n=533) 
 Proportion (n) 
not receiving 
ART 
Unadjusted Odds Ratio  
(95% CI) 
Adjusted Odds Ratio† 
(95% CI) 
Proportion (n) 
receiving 1-13 
days of ART 
Unadjusted Odds Ratio  
(95% CI)  
Adjusted Odds Ratio† (95% 
CI) 
Marital status       
Married / cohabiting 9.6% (36/374) 1.00  4.1% (14/338) 1.00  
Single  6.1% (10/163) 0.61 (0.30-1.27) p=0.188  4.6% (7/153) 1.11 (0.44-2.81) p=0.826  
History of IDU       
No 8.4% (45/536) 1.00 1.00 4.5% (22/491) 1.00  
Yes 27.5% (11/40) 4.14 (1.94-8.83) p<0.01 2.46 (1.04-5.86) p=0.041 3.5% (1/29) 0.76 (0.10-5.86) p=0.793  
Preterm delivery <34 
weeks gestation 
      
No 10.0% (57/571) 1.00 1.00 3.5% (18/514) 1.00 1.00 
Yes 24.0% (6/25) 2.85 (1.09-7.42) p=0.032 5.27 (1.74-16.03) p<0.01 26.3% (5/19) 9.84 (3.20-30.29) p<0.01 11.15 (3.31-37.55) p<0.01 
Year of delivery       
2000-03 10.9% (43/393) 1.00 1.00 4.3% (15/350) 1.00 1.00 
2004-09 9.9% (20/203) 0.89 (0.51-1.56) p=0.682 0.77 (0.39-1.51) p=0.441 4.4% (8/183) 1.02 (0.42-2.45) p=0.963 0.85 (0.33-2.18) p=0.733 
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Use of other PMTCT interventions where antenatal ART was insufficient 
Delivery by elective CS was less common in pregnancies with no vs. any antenatal ART (52% 
(70/134) vs. 64% (1227/1910) respectively, 2=7.78 p<0.01), and slightly less common in 
pregnancies with 1-13 days vs. ≥14 days ART (51% (20/39) vs. 65% (1207/1871), 2=2.91 p=0.09). 
This was due to the association between insufficient ART and preterm birth; although HIV 
infection is associated with iatrogenic preterm delivery (Lopez et al. 2012), most (83%, 1066/1280) 
elective CS were conducted at ≥37 weeks of gestation. Among deliveries at ≥37 weeks, there was 
no association between receipt of no ART or 1-13 days ART and delivery by elective CS (2=1.41 
p=0.24 and 2=0.16 p=0.69 respectively). Among women diagnosed antenatally, there was no 
difference in proportion of elective CS deliveries by timing of maternal HIV diagnosis (62% 
(286/458) of women diagnosed in the 1st/2nd trimesters delivered by elective CS vs. 56% (53/95) of 
those diagnosed in the 3rd trimester, 2=1.47 p=0.23). 
Very few infants were breastfed overall, but the rate was higher among women who received no 
ART than among those receiving any ART (3% (4/136) vs. 0.9% (17/1942) respectively) (Fisher’s 
exact test p=0.04). There was no difference in rate of breastfeeding between those receiving 1-13 
days or ≥14 days of therapy (0/40 and 0.9% (17/1902) respectively, Fisher’s exact test p=1.00). Of 
the four women who received no antenatal ART and breastfed, one was diagnosed intrapartum 
(and may therefore have been unaware of her diagnosis at the time of breastfeeding), one was 
diagnosed antenatally and two were diagnosed prior to conception. Of those with follow-up 
information available (14/21), all had stopped breastfeeding by their first follow-up appointment at 
four to six weeks after the birth. 
Information on neonatal prophylaxis receipt was available for 63% (1361/2148) of infants, 99.4% 
(1353/1361) of whom received some prophylaxis, mostly ZDVm (77%, 1040/1353). Infants born 
to women with insufficient antenatal ART more commonly received combination neonatal 
prophylaxis (i.e. ≥3 drugs) than infants born to those with ≥14 days antenatal ART (24% (27/114) 
vs. 3% (42/1233) respectively 2 =88.29, p<0.01). However, infants born to women who received 
no antenatal ART were also more likely to miss out on neonatal prophylaxis (6% (5/90) vs. 0.2% 
(3/1271) of those born to women with any ART, Fisher’s exact test p<0.01). There was no 
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association between lack of neonatal prophylaxis and short duration of antenatal ART (p=0.79). 
Median duration of post-exposure ARV prophylaxis was six weeks in both the insufficient antenatal 
ART and ≥14 days antenatal ART groups (IQR 4-6 weeks).  
Vertical transmission 
The vertical transmission rate was 1.7% (95% CI 1.1-2.5%) overall and was significantly higher in 
pregnancies with insufficient ART: 5.8% (95% CI 2.2-12.2%) among pregnancies with no ART and 
12.1% (95% CI 3.4-28.2) in those with 1-13 days of ART, compared with 1.1% (95% CI 0.6-1.9) 
among those with longer duration of ART (p<0.01 for both). Of the 25 HIV-infected infants, 25% 
(6/25) were born to the 7% of women with no antenatal ART and 16% (4/25) to the 2% of 
women with 1-13 days of ART. 
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3.3.5 Key Points 
 In 2000-09, 7% of pregnancies were in women who received no antenatal ART despite 
diagnosis before delivery in the majority of cases. The proportion of pregnancies with no 
antenatal ART declined over time from 8% of deliveries in 2000-03 to 5% in 2004-09. 
 In around 2% of pregnancies with antenatal ART, the duration of treatment received before 
delivery was less than two weeks, and this proportion stayed constant over time. 
 The 9% of pregnancies with no or <14 days of antenatal ART accounted for 40% of vertical 
transmissions occurring in this cohort, and therefore represent important missed opportunities 
both for PMTCT and for optimising the health of HIV positive women. 
 Late antenatal HIV diagnosis and preterm delivery are important practical barriers to receiving 
a sufficient duration of antenatal ART, and were associated with not receiving antenatal ART 
and particularly with short duration of ART in this cohort. 
 Women who received no antenatal ART were more likely to be single and to have an IDU 
history. In over half of all pregnancies with insufficient ART the woman was diagnosed prior to 
conception, and a significant proportion of these women required treatment for their own 
health, indicating disengagement from care and possible risk of loss to follow-up postnatally. 
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3.4 Limitations 
Data on reasons for non-receipt of ART are not routinely collected in the ECS, and so the 
proportion of women without ART who might have refused this and other PMTCT interventions 
was not known. In the Western Europe analyses, two women each had two sequential pregnancies 
with no antenatal ART, but it was not possible to conclude whether this was due to refusal of 
interventions or lack of access to or uptake of care. In Ukraine, a repeat antenatal HIV test is 
offered routinely in the third trimester to all women testing negative at the first test, and so a 
diagnosis at this time may have indicated seroconversion during pregnancy rather than a lack of 
timely antenatal care. 
Pregnancies with insufficient ART in the Western Europe ECS were significantly more likely than 
those with sufficient ART to have missing data on marital status, maternal HIV disease symptoms 
and IDU (p<0.02 for each variable), probably because these pregnancies were more likely to be 
unmonitored or in women with a late HIV diagnosis, and therefore to have less complete antenatal 
care records. Similarly in the Ukraine analyses, women lacking antenatal ART were more likely to 
have missing data on timing of HIV diagnosis, marital status and previous live births variables 
(p<0.01 for all). The associations between these variables of interest and the outcomes may 
therefore have been under-estimated. IDU history was an important risk factor for multiple missed 
opportunities for PMTCT in this chapter. No information on biomarkers of current drug use were 
available in the ECS; under-ascertainment of IDU is explored in section 5.3.2, page 168.   
The number of pregnancies with missing data on receipt of antenatal ART was low (Figure 3.4, 
page 91 and Figure 3.6, page 113) but could have led to an under-ascertainment of pregnancies with 
no or insufficient antenatal ART, as could the categorisation of pregnancies with missing ART 
duration to the “sufficient ART” group in the Western Europe analyses. The outcome measure of 
<14 days of ART used in section 3.3 was designed to capture women most at risk of vertical 
transmission but did not necessarily capture all at risk women, since there is no precise duration of 
ART considered sufficient to minimise MTCT risk.  
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Chapter 4 Virological failure in pregnancy among women conceiving 
on cART 
4.1 Introduction 
Non-suppressive treatment has implications for PMTCT and for maternal health due to its 
association with increased risk of emergence of drug resistance, treatment failure and disease 
progression (Ledergerber et al. 1999; Mocroft et al. 2004; Phillips et al. 2007). Previous findings from 
the ECS from 1998 to 2006 suggested that, of those conceiving on cART with a detectable viral 
load, only a minority achieve viral suppression by the final month of pregnancy (European 
Collaborative Study 2010). Most women conceiving on cART in this time period were taking a 
regimen based on unboosted NFV (European Collaborative Study 2010) which has been shown to 
be inferior to LPV/r in terms of virological response (Walmsley et al. 2002; King et al. 2004), and is 
no longer recommended for treatment (Williams et al. 2012). 
In this chapter, trends over time in virological failure among women conceiving on cART are 
explored, along with associated factors. An improved understanding of the characteristics of 
women conceiving on a failing regimen will aid the development of interventions to optimise their 
pre-conceptual and antenatal management, in turn improving maternal and pregnancy outcomes. 
4.2 Methods 
This study uses data available by February 2012 on deliveries reported from January 2000 to 
December 2011 at ECS sites in nine countries in Western Europe (Belgium, Denmark, Germany, 
Italy, the Netherlands, Poland, Spain, Sweden and the UK). Second and subsequent born infants of 
multiple births were excluded, as this work focuses on maternal treatment and viral suppression, 
making pregnancies the denominator of interest. 
Definition of group at risk of virological failure 
Most patients achieve viral suppression 12-24 weeks after initiating cART (Smith et al. 2004; Read et 
al. 2012). Treatment guidelines recommend that patients with an unsuppressed viral load after 24 
weeks should be assessed for adherence problems, drug resistance and other potential causes of 
treatment failure (European AIDS Clinical Society 2011; Asboe et al. 2012; Panel on Antiretroviral 
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Guidelines for Adults and Adolescents 2012). For this work, which explores virological failure in 
pregnancy among women conceiving on cART, the group at risk of the outcome were those who 
had  received ≥28 days of cART by estimated date of conception and had a viral load measure 
available ≥24 weeks after ART initiation (within 28 days prior to conception or during pregnancy). 
The 22 women who had been on cART for <28 days by estimated date of conception were 
excluded because of the possibility that ART was actually started early in pregnancy (date of 
conception was approximate). 
Ascertainment of cART duration 
Where a woman had switched cART regimen before conception, cART duration was taken as the 
duration of the most recent regimen (full information on treatment history before pregnancy was 
not routinely collected, but was provided for some women). If a woman switched regimen during 
pregnancy, before the first viral load measurement and without treatment interruption, she was 
treated as though she had not switched (i.e. the new regimen contributed towards the total cART 
duration), because these switches were assumed to be due to concerns around teratogenicity rather 
than treatment failure. Women conceiving on ART, interrupting treatment during pregnancy and 
without a viral load measure ≥24 weeks after ART initiation which pre-dated the interruption were 
excluded. Where more than one viral load measure was available at ≥24 weeks after ART initiation, 
the first was used for analyses. If a viral load measure was available at ≥24 weeks after the regimen 
was started, but this was preceded by a viral load at <24 weeks, the later viral load was included 
only if there had not been a treatment switch between the two viral load measurements (i.e. 
possibly due to early detection of problems with treatment response). Figure 4.1 (page 130) and 
Figure 4.3 (page 133) summarise data available on ART receipt and on viral load measures, and 
show the numbers of women to whom the various exclusions applied. Women diagnosed as HIV-
positive prior to conception but missing ART start dates (n=196) were excluded from the main 
analysis.  
Definition of virological failure 
The lower detection limits for viral load assays in use across the ECS sites from 2000-11 varied 
from 20 to 500 copies/ml. Although an optimal virological response to treatment is one in which 
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the viral load is below the detection limit of the assay, episodes of low level and transient detectable 
viraemia (“blips”) in otherwise successfully treated patients can occur for a range of reasons and do 
not necessarily indicate an increased risk of virological failure (Havlir et al. 2001). Because of this, a 
viral load cut-off of >200 copies/ml has been suggested as a more useful criterion for 
distinguishing treatment failure than a cut-off of >50 copies/ml (a common detection limit of 
modern assays) (Aldous et al. 2009; Panel on Antiretroviral Guidelines for Adults and Adolescents 
2012).  
For the main analyses, viral suppression was defined as a viral load of ≤200 copies/ml and 
virological failure as a viral load of >200 copies/ml. This allowed for consistency of categorisation 
for the majority of assays used across the years of the study; the small number of women (n=8) 
with an undetectable viral load reported at a sensitivity limit of >200 copies/ml were excluded (see 
Figure 4.3, page 133). A sensitivity analysis was conducted using a viral load cut-off of >1000 
copies/ml, to investigate factors associated with a ‘high’ viral load among women who conceived 
on cART. 
Statistical analyses 
Poisson regression models with robust estimates of variances were fitted to investigate factors 
associated with non-suppression of viral load among women conceiving on cART. Duration of 
current cART regimen was included a priori in multivariable analyses, along with year and country 
of delivery to account for differences in clinical practice over time and between countries. Factors 
which could feasibly be associated with treatment failure or adherence problems were considered 
for inclusion in each multivariable model if they were associated with the outcome of a non-
suppressed viral load (p<0.2) on adjusting for the three a priori factors. During model selection, 
each factor was tested for its contribution to the model’s goodness-of-fit using Wald’s test with a 
significance level of <0.1. 
All ECS sites included in these analyses identified sequential pregnancies reported in the same 
woman. Having had a previous pregnancy was considered as a possible risk factor for subsequent 
virological failure, due to its association with exposure to short course ART for PMTCT and socio-
demographic factors. Parity was investigated separately as this variable captured reproductive 
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history more fully, including pregnancies which took place before a woman’s HIV diagnosis and in 
which care was received at a non-ECS site. 
Boosted PI and non-boosted PI-based regimens were considered separately when investigating the 
association between cART regimen type and non-suppressed viral load, because these regimens 
have been associated with different virological response rates in both observational studies and 
clinical trials (Walmsley et al. 2002; King et al. 2004; Wood et al. 2007). The use of boosted PIs 
largely replaced non-boosted PIs over the years of the ECS explored here (described on page 131). 
Viral load at a second or subsequent measure among women conceiving on cART (i.e. maintenance 
of viral suppression, or achievement of this where first measure was not suppressed) are described. 
Viral load measures dated up to a week after delivery were considered with those taken at delivery, 
to allow for delays in obtaining test results. 
 
Figure 4.1: Receipt of ART and timing of initiation among women enrolled in the Western 
Europe sites of the ECS from 2000-11 
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4.3 Results 
Of 2413 pregnancies from 2000-11, almost a quarter (n=567) were among women who conceived 
on cART (Figure 4.1). An additional 196 pregnancies (8% of the total) were among women 
diagnosed as HIV-positive before pregnancy, but missing timing of ART initiation. In total, 3% 
(n=67) of women conceived on mono or dual therapy, most (n=52) of whom delivered prior to 
2004.  
The proportion of women diagnosed as HIV-positive prior to conception was 70% (478/687) in 
2000-01, increasing to 80% (68/85) in 2010-11 (trend p<0.01). The proportion conceiving on ART 
also increased over time (see Figure 4.2; for women diagnosed before pregnancy, this increase was 
from 35% (169/478) in 2000-01 to 54% (37/68) in 2010-11, trend p<0.01). 
 
Figure 4.2: Trend in the proportion of women conceiving on cART and, among this group, 
the proportion with a non-suppressed viral load at first antenatal measure 
 
The 567 women conceiving on cART had been on their current regimen for a median of 11.8 
months (IQR 5.9, 26.8) by conception. The 48% (n=274) who conceived on a PI-based regimen 
were most commonly receiving NFV (40%, n=117), LPV/r (21%, n=61) or IDV (13%, n=38). 
Boosted PIs accounted for an increasing proportion of PI regimens received over these years: 17% 
(15/89) in 2000-01, 63% (25/40) in 2004-05 and 92% (24/26) in 2010-11 (trend p<0.01). Of the 
40% (n=224) conceiving on an NNRTI-based regimen, 83% (n=187) received NVP and 17% 
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(n=37) EFV. One in ten (n=55) of the women conceiving on cART were on a triple NRTI regimen 
(for 39 of the 55 this consisted of ZDV, 3TC and ABC), and 2% (n=14) conceived on a regimen 
containing both a PI and an NNRTI. Almost half (47%, n=267) of all women conceiving on cART 
were on an NRTI backbone of ZDV and 3TC, with a further 16% (n=92) on 3TC and stavudine 
(all but four of whom delivered prior to 2005). 
The median CD4 count at first measure in pregnancy among women conceiving on cART was 445 
cells/mm3 (IQR 318, 601) (measure available for 502 women), taken at a median of 12.8 weeks 
gestation. Around a third (163/502) had a CD4 count ≤350 cells/mm3 (time trend p=0.82). The 
proportion with severe symptomatic HIV disease (i.e. CDC stage C) was 22% (108/482). 
A fifth (118/567) of women conceiving on cART switched regimens during pregnancy and a total 
of 64 had an antenatal treatment interruption. For 33 women the interruption occurred between 
switching regimens. Treatment interruptions began at a median of 6.2 weeks gestation (IQR 4.9, 
8.3) and lasted a median of 12.4 weeks (IQR 6.9, 17.0). Figure 4.3 shows the exclusions applied to 
reach the sample of 396 women included in the main analyses, all of whom initiated cART ≥28 
days before conception and had a viral load measure available ≥24 weeks later, which was not pre-
dated by a treatment interruption or the combination of a viral load measure and ART switch.  
Of the 196 women diagnosed as HIV-positive before conception but missing drug start dates (see 
Figure 4.1, page 130), 112 had a viral load available at a median of 12.8 weeks gestation, of whom 
57% (n=64) were suppressed (≤200 copies/ml). This was higher than the 24% (257/1072) 
suppressed at first viral load measure among women starting ART during pregnancy, and lower 
than the 74% (332/447) who were suppressed among those conceiving on cART before exclusion 
of women with treatment interruptions (see Figure 4.3). The 196 women without an ART start date 
were therefore likely to be heterogeneous with regards to timing of ART initiation, and were 
omitted from the main analyses. 
Overall 81% (n=322) of the 396 women in the main analysis had a suppressed viral load (≤200 
copies/ml) at their first eligible viral load measure, taken a median of 18.5 months (IQR 10.5, 31.0) 
after initiating their current regimen and at a median of 13.2 weeks of gestation (IQR 7.6, 21.3). 
Although all 396 women had been on cART for at least 24 weeks by the time of the viral load 
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measure, those in the non-suppressed group had been on cART for a slightly shorter duration - a 
median of 69.1 weeks, compared with 81.2 weeks for the suppressed group (Wilcoxon-Mann-
Whitney test, p=0.07). The virologically suppressed group had their first viral load measure taken at 
a median of 13.3 weeks gestation compared with 12.9 weeks gestation for the non-suppressed 
group (Wilcoxon-Mann-Whitney test, p=0.74) indicating similar access to and timing of antenatal 
care, and there was no change in timing of first viral load measure by calendar year (trend p=0.37). 
The proportion of women conceiving on cART who had a non-suppressed viral load at first 
measure declined substantially over time (see Figure 4.2 page 131; of 396 women meeting inclusion 
criteria for analyses, this proportion was 34% (32/93) in 2000-01, declining to 10% (7/72) in 2004-
05 and 3% (1/33) in 2010-11, time trend p<0.01). Of the 74 women with a non-suppressed viral 
load included in these analyses, 64 were enrolled prior to 2006.  
 
Figure 4.3: Inclusions and exclusions for the analyses of factors associated with a non-
suppressed viral load in pregnancy among women conceiving on cART 
Exclusions are shown in red. 
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Of the 322 women in the main outcome group who had a viral load ≤200 copies/ml (Figure 4.3), 
92% (296/322) had a viral load below the detection limit of the assay; for 282 this was <50 
copies/ml or less. The median viral load among the 74 non-suppressed women was 1370 copies/ml 
(IQR 480, 6000); 42 had a viral load in excess of 1000 copies/ml.  
The socio-demographic and clinical characteristics of the 396 women on cART at conception 
according to whether they were virologically suppressed are given in Table 4.1. Women with a non-
suppressed viral load had more severe HIV disease than the virologically suppressed group, and had 
also been diagnosed with HIV for longer, despite a shorter duration of treatment with their current 
cART regimen. Women with a viral load of >200 copies/ml were also more commonly IDUs, with 
an IDU partner and of white race than virologically suppressed women (Table 4.1). However, time 
trends in conception with a non-suppressed viral load coincided with important shifts over time in 
the characteristics of women enrolling in the study. Most notably, these years saw a decline in the 
proportion of women with an IDU history (from a fifth (53/271) of women delivering in 2000-05 
to 2% (3/123) in 2006-11, 2=20.33 p<0.01), and an increase in the proportion of sub-Saharan 
African origin (from 45% (120/269) of women delivering in 2000-05 to 79% (98/124) in 2006-11, 
2=40.72 p<0.01). Year of delivery therefore confounded associations between viral suppression 
and some factors, particularly IDU history, race and sub-Saharan African origin. There was no 
overall trend in maternal age (trend p=0.13), but women conceiving on cART in more recent years 
had been diagnosed as HIV-infected for longer (median 1.1 years by conception for 2000-01, 1.7 
years for 2004-05, 2.8 years for 2010-11, trend p<0.01). 
Women with non-suppressed viral load were more commonly taking a cART regimen based on a 
non-boosted PI, while NNRTI-based regimens were more common among the virologically 
suppressed group (Table 4.1). The proportion of women with a non-suppressed viral load among 
those conceiving on cART varied significantly by country of delivery, from 9% (2/22) in The 
Netherlands to 38% (12/32) in Italy (nine countries, 2=32.99 p<0.01). However, enrolments 
varied by country over time; country of delivery was not associated with virological suppression in a 
Poisson regression model adjusting for year of delivery (Wald’s test p=0.19).  
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Table 4.1: Characteristics of 396 women on cART at conception by virological suppression 
 Viral load ≤200 
copies/ml 
n=322 
Viral load >200 
copies/ml  
n=74 
 
Maternal age, years – median (IQR) 33.5 (30.3, 36.9) 32.9 (29.0, 36.2) p=0.24† 
Marital status    
Married 150 (48%) 34 (47%) 2=1.05 p=0.59 
Cohabiting 73 (23%) 21 (29%)  
Single, divorced, widowed or separated 89 (29%) 18 (25%)  
Race    
White 97 (31%) 46 (63%) 2=26.18 p<0.01 
Black 198 (63%) 24 (33%)  
Other 18 (6%) 3 (4%)  
Born in sub-Saharan Africa    
No 123 (39%) 52 (70%) 2=24.46 p<0.01 
Yes 196 (61%) 22 (30%)  
Age at leaving full-time education    
≤16 years 62 (51%) 9 (43%) 2=3.12 p=0.21 
17-18 years 30 (25%) 9 (43%)  
≥19 years 29 (24%) 3 (14%)  
Parity    
0 108 (35%) 23 (32%) 2=1.48 p=0.48 
1 99 (32%) 19 (27%)  
≥2 104 (33%) 29 (41%)  
Previous pregnancy enrolled in ECS    
No 231 (72%) 51 (69%) 2=1.00 p=0.61 
Yes – one 71 (22%) 16 (22%)  
Yes – two or more 20 (6%) 7 (9%)  
History of IDU    
No 285 (89%) 53 (72%) 2=14.99 p<0.01 
Yes 35 (11%) 21 (28%)  
IDU partner    
No 265 (89%) 51 (73%) 2=12.68 p<0.01 
Yes 32 (11%) 19 (27%)  
Time from HIV diagnosis to conception 
– median (IQR) 
5.2 years  
(2.8, 8.1) 
6.9 years  
(3.9, 10.2) 
p=0.02† 
Time from initiating current cART 
regimen to viral load measure – median 
(IQR) 
18.7 months 
(10.9, 31.6) 
15.9 months  
(8.5, 25.4) 
p=0.11† 
cART regimen at conception    
PI-based (non-boosted) 66 (21%) 35 (47%) 2=23.90 p<0.01 
PI-based (boosted) 83 (26%) 15 (20%)  
NNRTI-based 127 (39%) 18 (24%)  
Contained both PI and NNRTI 7 (2%) 0  
Triple NRTI / NtRTI 39 (12%) 6 (8%)  
First antenatal CD4 count    
>350 cells/mm3 227 (72%) 35 (49%) 2=14.11 p<0.01 
≤350 cells/mm3 90 (28%) 37 (51%)  
HIV disease symptoms    
Asymptomatic / non-severe symptoms 234 (80%) 41 (65%) 2=6.45 p=0.01 
Severe symptomatic HIV disease 59 (20%) 22 (35%)  
Year of delivery    
2000-05 208 (65%) 64 (86%) 2=13.41 p<0.01 
2006-11 114 (35%)  10 (14%)  
†p value from Wilcoxon-Mann-Whitney test. PI: protease inhibitor, NNRTI: non-nucleoside reverse 
transcriptase inhibitor, NRTI / NtRTI: nucleoside/nucleotide reverse transcriptase inhibitor
 136 
 
Factors associated with non-suppressed viral load 
Tables 4.2a and 4.2b (pages 138 and 139) give unadjusted PRs, PRs adjusted for the three a priori 
factors (year and country of delivery and cART duration) and PRs adjusted for all factors in the 
multivariable model. Neither marital status nor age at leaving full-time education were associated 
with non-suppressed viral load among women conceiving on cART (Wald’s test p=0.57 and p=0.20 
respectively, very small numbers for educational status) and are thus omitted from the final analysis. 
Because CD4 count and HIV disease staging were available only at the time of the pregnancy and 
not at ART initiation, these variables were also omitted from models as they were at least in part a 
consequence of (rather than risk factor for) treatment failure. 
In univariable analyses, black women and those born in sub-Saharan Africa were at reduced risk of 
a non-suppressed viral load while those with an IDU history or IDU partner were at increased risk, 
but these associations disappeared or were much reduced on adjusting for year, country and cART 
duration (Table 4.2a). Other factors significantly associated with having a non-suppressed viral load 
in univariable analyses were being on a non-boosted PI-based (vs. NNRTI-based) cART regimen 
and having a longer history of diagnosed HIV infection, with each additional year conferring a 6% 
(95% CI 1-10%)  increased risk of having a viral load >200 copies/ml. Duration of current cART 
regimen was not associated with viral suppression (all women included in the analyses had been on 
their current regimen for ≥24 weeks). 
Although not associated with the outcome in univariable analyses, having ≥2 previous ECS 
pregnancies (vs. none) was associated with an increased risk of a non-suppressed viral load after 
adjusting for year, country and cART duration (Table 4.2a). Repeat ECS pregnancies became more 
common in the cohort as a whole between 2000-01 and 2006-07 (accounting for 10% (67/704) and 
32% (77/240) of enrolments in these two time periods respectively, trend p<0.01), with no 
statistically significant change from 2006-11 (trend p=0.47). Among women conceiving on cART, 
repeat ECS pregnancies have accounted for between 31% and 38% of enrolments between 2002 
and 2011 (trend p=0.39). Repeat ECS pregnancies were more common among women of sub-
Saharan African origin (29% (308/1059) had ≥2 previous ECS pregnancies, 34% (358/1059) had 
one and 37% (393/1059) had none compared with 19% (232/1193), 33% (391/1193) and 48% 
(570/1193) respectively among women not born in sub-Saharan Africa, 2=36.84 p<0.01). 
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In multivariable analyses, women with two or more previous pregnancies enrolled in the ECS were 
three times more likely to have a non-suppressed viral load in subsequent pregnancies than women 
with no previous ECS enrolment. Of the 111 women included in the analyses and with ≥1 previous 
ECS pregnancy recorded, 98 had information available on exposure to ART in a previous 
pregnancy (information is not routinely collected on regimens received outside of the context of 
antenatal care). Of the 75 women with one previous ECS pregnancy, 73% (n=55) had previously 
received antenatal cART, 24% (n=18) mono/dual therapy and 3% (n=2) no ART. Among the 23 
women with ≥2 previous ECS pregnancies, 20 had previously received antenatal cART, two 
mono/dual therapy and one woman had no prior exposure to antenatal ART. Only two of the 98 
women had post-delivery stop dates reported for drugs received during pregnancy. However, it is 
possible that some of the remaining 96 women were not on ART continuously since their last 
delivery (which was a median of 1.8 years (IQR 0.8, 2.9) prior to their next conception), as stop 
dates for drugs that were stopped at some point after delivery may not have be captured, and data 
on treatment interruption between pregnancies are also not routinely collected. 
In the fully adjusted model, women conceiving on non-boosted PI-based cART regimens remained 
at over a two-fold increased risk of having a non-suppressed viral load compared with those on 
NNRTI-based regimens. Those on boosted PI-based regimens also tended towards an increased 
risk, but this did not reach statistical significance (p=0.07). Women with longer duration of 
diagnosed HIV infection were at increased risk of having a viral load >200 copies/ml. After 
adjusting for this and other factors, older women were at decreased risk of having non-suppressed 
viral load compared with younger women (5% decrease in risk of non-suppression per year of 
maternal age). 
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Table 4.2a: Factors associated with a non-suppressed viral load, among women who conceived on cART (continued in Table 4.2b) 
 
Proportion with viral load 
>200 copies/ml at first 
measure 
Crude PR (95% CI) 
 
 
PR adjusted for year, 
country, cART duration 
 
Adjusted PR 
(multivariable model)†, 
n=380 
Race 
    White 33.1% (46/139) 1.00 1 
 Black 11% (24/219) 0.33 (0.21-0.52) p<0.01 0.59 (0.33-1.08) p=0.09 
 Other 14.3% (3/21) 0.43 (0.15-1.27) p=0.13 0.90 (0.31-2.61) p=0.84 
 Sub-Saharan African origin 
    No 30.4% (52/171) 1.00 1 
 Yes 10.2% (22/215) 0.34 (0.21-0.53) p<0.01 0.53 (0.29-0.98) p=0.04 
 Parity at enrolment 
    0 18.1% (23/127) 1.00 1 
 1 16.4% (19/116) 0.90 (0.52-1.57) p=0.72 1.01 (0.59-1.71) p=0.98 
 ≥2 22.0% (29/132) 1.21 (0.74-1.98) p=0.44 1.57 (0.97-2.54) p=0.07 
 Previous pregnancy enrolled in ECS 
    No 18.3% (51/278) 1.00 1 1.00 
Yes - one 18.8% (16/85) 1.03 (0.62-1.70) p=0.92 1.39 (0.83-2.31) p=0.21 1.47 (0.89-2.44) p=0.13 
Yes - two or more 26.9% (7/26) 1.47 (0.74-2.90) p=0.27 2.61 (1.35-5.08) p<0.01 3.08 (1.49-6.36) p<0.01 
IDU history 
    No 15.9% (53/333) 1.00 1 
 Yes 38.9% (21/54) 2.44 (1.61-3.70) p<0.01 1.20 (0.74-1.96) p=0.46 
 †Adjusted a priori for country of delivery (not shown)   
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Table 4.2b: Factors associated with a non-suppressed viral load, among women who conceived on cART (continued from Table 4.2a) 
†Adjusted a priori for country of delivery (not shown) ‡7 women on both a PI and an NNRTI were excluded (all of whom were virologically suppressed) 
 
Proportion with viral load 
>200 copies/ml at first 
measure 
Unadjusted PR (95% CI) 
 
 
PR adjusted for year, 
country, cART duration 
 
Adjusted PR 
(multivariable model)†, 
n=380 
IDU partner 
    No 16.5% (51/310) 1.00 1 
 Yes 38% (19/50) 2.31 (1.50-3.57) p<0.01 1.10 (0.66-1.85) p=0.70 
 Type of cART‡ 
    NNRTI-based 12.4% (18/145) 1.00 1 1.00 
PI-based (non-boosted) 34.7% (35/101) 2.79 (1.68-4.65) p<0.01 2.15 (1.22-3.77) p<0.01 2.26 (1.28-4.00) p<0.01 
PI-based (boosted with ritonavir) 15.3% (15/98) 1.23 (0.65-2.33) p=0.52 1.77 (0.94-3.35) p=0.08 1.90 (0.96-3.78) p=0.07 
Triple NRTI/NtRTI 13.3% (6/45) 1.07 (0.45-2.54) p=0.87 1.13 (0.47-2.73) p=0.78 1.27 (0.52-3.12) p=0.60 
Maternal age (per increasing year) 
 
0.97 (0.93-1.01) p=0.18 0.97 (0.93-1.01) p=0.12 0.95 (0.91-0.99) p=0.02 
Per year HIV diagnosed prior to conception 
 
1.06 (1.02-1.11) p<0.01 1.05 (1.01-1.10) p=0.02 1.06 (1.01-1.10) p<0.01 
Duration current cART regimen (per increasing 
year) 
 
0.88 (0.75-1.03) p=0.11 1.01 (0.84-1.22) p=0.89 1.01 (0.83-1.23) p=0.92 
Year of delivery (per increasing year) 
 
0.81 (0.74-0.88) p<0.01 0.82 (0.74-0.92) p<0.01 0.80 (0.72-0.89) p<0.01 
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In a sensitivity analysis of factors associated with high (>1000 copies/ml) viral load among the 
same group of 396 women who conceived on cART, the results were very similar (Tables 4.3a and 
4.3b). In multivariable analyses, women with two or more previous ECS pregnancies were at 
increased risk of a high viral load, as were younger women (the risk decreasing by 7% per increasing 
year of maternal age), and women who had been diagnosed as HIV-positive for longer (Table 4.3b, 
p=0.06). Type of cART regimen was not associated with high viral load among women conceiving 
on cART after adjusting for year, country and cART duration (Wald’s test p=0.17), and was thus 
excluded from the multivariable analysis. It is reassuring that women on a PI-based rather than 
NNRTI-based regimen were not at increased risk of a ‘high’ viral load, despite their increased risk 
of being non-suppressed. Previous ECS results have shown that women initiating PI-based 
regimens during pregnancy take longer to attain an undetectable viral load than those initiating 
NNRTI-based regimens (Patel et al. 2007), but the possibility of ART resistance needs to be 
considered and assessed for all women on non-suppressive cART (de Ruiter et al. 2012). The next 
section describes ART switches and virological outcomes among women who conceived on cART 
with a non-suppressed viral load at first measure. 
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Table 4.3a: Factors associated with a high viral load (>1000 copies/ml) at first measure in pregnancy, among women who conceived on cART  (continued in 
Table 4.3b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Adjusted a priori for country of delivery (not shown) 
 
 
  
 
Proportion with viral load 
>1000 copies/ml 
Crude PR (95% CI) 
 
PR adjusted for year, 
country, cART duration 
Adjusted PR (multivariable 
model)† n=380 
Race 
    White 20.9% (29/139) 1.00 1.00 
 Black 4.6% (10/219) 0.22 (0.11-0.44) p<0.01  0.39 (0.17-0.93) p=0.03 
 Other 9.5% (2/21) 0.46 (0.12-1.78) p=0.26 0.85 (0.21-3.53) p=0.82 
 Sub-Saharan African origin 
    No 18.7% (32/171) 1.00 1.00 
 Yes -SSA 4.7% (10/215) 0.25 (0.13-0.49) p<0.01 0.43 (0.18-1.04) p=0.06 
 Parity at enrolment 
    0 9.4%(12/127) 1.00 1.00 
 1 11.2% (13/116) 1.19 (0.56-2.50) p=0.65 1.40 (0.68-2.91) p=0.36 
 ≥2 11.4% (15/132) 1.20 (0.59-2.47) p=0.62 1.69 (0.81-3.54) p=0.17 
 Previous pregnancy enrolled in the ECS 
    No 11.2% (31/278) 1.00 1.00 1.00 
Yes – one 7.1% (6/85) 0.63 (0.27-1.47) p=0.29 0.81 (0.35-1.87) p=0.63 0.84 (0.37-1.92) p=0.69 
Yes – two or more 19.2% (5/26) 1.72 (0.73-4.06) p=0.21 2.77 (1.13-6.80) p=0.03 3.20 (1.11-9.22) p=0.03 
IDU history 
    No 8.1% (27/333) 1.00 1.00 
 Yes 27.8% (15/54) 3.43 (1.95-6.01) p<0.01 1.72 (0.81-3.67) p=0.16 
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Table 4.3b: Factors associated with a high viral load (>1000 copies/ml) at first measure in pregnancy, among women who conceived on cART  (continued 
from Table 4.3a) 
 
Proportion with 
viral load >1000 
copies/ml 
Crude PR (95% CI) 
 
 
PR adjusted for year, 
country, cART duration 
Adjusted PR 
(multivariable model)† 
n=380 
IDU partner 
    No 9% (28/310) 1.00 1.00 
 Yes 24% (12/50) 2.66 (1.45-4.88) p<0.01 1.24 (0.59-2.58) p=0.57 
 Type of cART‡ 
    NNRTI-based 6.9% (10/145) 1.00 1.00 
 PI non-boosted 19.8% (20/101 2.87 (1.40-5.88) p<0.01 1.71 (0.79-3.70) p=0.18 
 PI boosted 10.2% (10/98) 1.48 (0.64-3.42) p=0.36 1.89 (0.79-4.51) p=0.15 
 triple NRTI/NtRTI 4.4% (2/45) 0.64 (0.15-2.84) p=0.56 0.60 (0.14-2.67) p=0.50 
 Maternal age (per increasing year) 
 
0.96 (0.91-1.01) p=0.14 0.95 (0.89-1.01) p=0.13 0.93 (0.87-0.99) p=0.03 
Per year HIV diagnosed prior to conception 
 
1.08 (1.02-1.14) p<0.01 1.06 (1.00-1.13) p=0.05 1.06 (1.00-1.13) p=0.06 
Duration of current cART regimen (per increasing year) 
 
0.87 (0.72-1.05) p=0.16 0.96 (0.76-1.21) p=0.74 0.92 (0.72-1.18) p=0.53 
Year of delivery (per increasing year) 
 
0.81 (0.71-0.93) p<0.01 0.88 (0.76-1.01) p=0.08 0.84 (0.74-0.96) p=0.01 
†Adjusted a priori for country of delivery (not shown) ‡7 women on both a PI and an NNRTI were excluded (all of whom were virologically suppressed) 
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Virological outcomes in pregnancy among women conceiving on a failing regimen 
Most women who conceived on cART with a viral load ≤200 copies/ml at first measure in 
pregnancy had another viral load available within four weeks of delivery (90%, 291/322); 94% 
(273/291) remained suppressed at this time. Five of the 18 women who lost viral suppression 
between their first and last viral load measures had had a treatment interruption during pregnancy, 
compared with 1% (3/273) of those who remained suppressed (2=44.96 p<0.01). 
Among the 74 women who had a viral load >200 copies/ml at first measure, 65 had at least one 
other viral load measure available later in pregnancy. Two-thirds (41/65) of this group achieved a 
viral load of ≤200 copies/ml later in pregnancy at a median of 32.8 weeks gestation, and for 51% 
(33/65) this measure was undetectable at a sensitivity limit of <50 copies/ml. The 24 women who 
remained unsuppressed throughout pregnancy had a median viral load at first measure of 1861 
copies/ml, compared with 1340 copies/ml for the 41 women who did go on to achieve viral 
suppression (Wilcoxon-Mann-Whitney test, p=0.23). Median CD4 count at first measure in 
pregnancy was 340 cells/mm3 for those whose viral load remained >200 copies/ml around delivery 
compared with 372 cells/mm3 for the women who went on to become virologically suppressed 
(Wilcoxon-Mann-Whitney test, p=0.47). 
Among women with a non-suppressed viral load at first measure, subsequent treatment 
interruption during pregnancy was uncommon, occurring in 3/41 women who were later 
virologically suppressed and 1/24 women whose viral load remained >200 copies/ml (2=0.26 
p=0.61). ART regimen modifications were frequent however, as would be expected: 43% (32/74) 
of the non-suppressed group either switched regimens (n=28) or added a drug to their current 
regimen (n=4) during pregnancy vs. 14% (45/322) of women who conceived on cART with a viral 
load of <200 copies/ml (2=32.91 p<0.01). Of the women who modified their regimen, 70% 
(21/30) became virologically suppressed compared with 57% (20/35) of the group whose regimen 
remained unchanged throughout pregnancy (2=1.15 p=0.28). In the earlier years of the study, 
women conceiving on cART with a viral load of >200 copies/ml were less likely to achieve viral 
suppression later in pregnancy than women delivering in more recent years, although numbers in 
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more recent years were small: 64% (18/28) of those delivering in 2000-01 remained non-suppressed 
vs. 43% (9/21) in 2002-03, 33% (2/6) in 2004/05 and 20% (2/10) for 2006-11, trend p<0.01.  
4.4 Limitations 
Data were not available on several factors which could have influenced treatment response. CD4 
count and viral load at time of ART initiation (i.e. prior to conception) were not known, but 
previous results from the ECS on viral load trajectories during pregnancy showed that higher 
baseline viral loads and lower CD4 counts were associated with a longer duration of time to viral 
suppression (Patel et al. 2007; European Collaborative Study 2010), as has been shown in other 
studies (Smith et al. 2004; Katz et al. 2010; Read et al. 2012). Information was also not available on 
AIDS-defining conditions diagnosed prior to cART initiation, ART adherence before and during 
pregnancy, and history of and current ART resistance (including whether a woman was already on a 
salvage regimen). One or a combination of these factors may account for the reported observations 
- for example, younger women may have been more likely to have a non-suppressed viral load due 
to poorer adherence behaviours than older women, and women in the earlier years of the study may 
have had more severe HIV disease at ART initiation. 
Exclusions from the analyses included 98 women without a viral load measure available and 41 
women who interrupted treatment before a viral load measure was taken. Women in whom viral 
load monitoring was lacking or less frequent may have had poorer HIV care in general and may 
have been more likely to be on non-suppressive treatment around the time of conception, making 
the proportion of women conceiving on non-suppressive cART reported here an underestimate. 
However, these enrolments were predominantly in the earlier years of the study (73/98 of those 
missing a viral load measure and 38/41 of those with a treatment interruption were enrolled prior 
to 2006), and so these factors will have had minimal impact on estimates in the later years. 
Data on age at leaving full-time education were available for only 35% (140/396) of the study 
population (Table 4.1, page 135), which may have precluded identification of an association 
between educational status and virological suppression (for example mediated through adherence 
behaviours). 
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4.4 Key points 
 Although the proportion of HIV-positive pregnant women already on cART at conception has 
increased over time, the proportion with virological failure has declined substantially over the 
last 12 years. Among 396 women included in these analyses, 34% had a non-suppressed viral 
load in 2000-01 declining to 3% in 2010-11. Calendar year remained significantly associated with 
likelihood of a non-suppressed viral load in adjusted analyses.  
 Among women conceiving on cART with a non-suppressed viral load, the likelihood of 
achieving a suppressed viral load later in pregnancy also increased over time. 
 In adjusted analyses which included year and country of delivery and duration of current cART 
regimen, factors associated with virological failure among women conceiving on cART were 
younger maternal age, longer duration of diagnosed HIV infection, being on a non-boosted PI-
based (vs. NNRTI-based) regimen, and having two or more previous ECS pregnancies (vs. 
none). These same factors, with the exception of cART type, were also associated with having 
high (>1000 copies/ml) viral load. 
 Non-boosted PI-based regimens have been almost entirely phased out of use in this cohort, to 
be replaced by more potent boosted PI-based regimens. However, the proportion of enrolments 
among women who have already received HIV care in at least one previous pregnancy has 
increased over the last 12 years. The association between this and non-suppressive treatment is 
of potential concern. 
 That younger women had poorer outcomes in terms of viral suppression after adjusting for 
duration of HIV diagnosis and previous pregnancy highlights the particular needs that this 
group may have for adherence support or support in accessing HIV services. 
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Chapter 5 HIV co-infections and associated morbidity in Ukraine 
5.1 Introduction 
Prevalence of HIV co-infections is high in Ukraine, fuelled by rapid increases in IDU and 
expansion of the sex industry following the collapse of the Soviet Union, and a lack of public health 
and harm reduction services. Data on HIV co-infections are collected in the Ukrainian Postnatal 
Cohort of HIV-infected Childbearing Women (“the Women’s Study”). In section 5.2, women 
enrolled in this study are characterised in terms of their health, health behaviours and socio-
demographics, and compared with women enrolled in the Ukraine ECS. Diagnosed co-infections 
are described in section 5.3 and two co-infections are investigated in more detail: chlamydia, which 
is the most prevalent bacterial STI in this population, and HCV, the most common co-infection 
among HIV-positive IDUs (Thorne et al. 2012). In the final part of this chapter (section 5.4), 
cervical screening coverage as part of HIV care is explored, along with prevalence of and risk 
factors for abnormal cervical cytology. 
 
5.2 Description of the Women’s Study 
5.2.1 Enrolments and representativeness 
By September 2011, 2066 women were enrolled into the Women’s Study, 29% (n=607) of whom 
had follow-up information available. Most (81%, 1671/2066) had previously participated in the 
ECS while 19% (n=395) were enrolled in the Women’s Study only. Enrolments by year are given in 
Table 5.1. 
Table 5.1: Enrolments and availability of follow-up in the Women’s Study by year 
 Total enrolments in 
Women’s Study 
Proportion with follow-
up by September 2011 
December 2007 - 2008 341 38% (n=128) 
2009 677 29% (n=199) 
2010 655 38% (n=249) 
2011 (January to September) 393 8% (n=31) 
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According to Ukrainian policy, clinical follow-up is indicated six-monthly for HIV-positive patients 
who do not yet require ART for their own health, and at least three-monthly for those on ART. 
The low proportion of women with follow-up available (particularly among women enrolled in the 
earlier years of the study) may partly be due to arrangements for follow-up of patients living far 
from the HIV/AIDS centre at local clinics, but also suggests substantial loss to follow-up. Systems 
to routinely invite patients back to the HIV/AIDS centres for follow-up are lacking, and outreach 
provision for patients defaulting on follow-up care is ad hoc and dependent on local resources and 
arrangements with social services. 
Table 5.2 shows, for women enrolled in the ECS, the participation rate in the Women’s Study by 
centre of enrolment; the highest participation rate was seen in Kiev, and the lowest in Donetsk. 
 
Table 5.2: Participation rate in the Women’s Study by HIV/AIDS centre, among women 
enrolled in the ECS 
 Number of ECS 
enrolments 2008-10 
Proportion also enrolled 
in the Women’s Study 
Donetsk 400 24% (n=97) 
Kiev 568 87% (n=496) 
Krivoy Rog 264 78% (n=205) 
Mykolaiv 629 54% (n=340) 
Odessa 793 29% (n=226) 
 
Overall, the MTCT rate was significantly higher among women participating only in the ECS (5.2% 
(91/1753) vs. 2.2% (25/1119) among women also enrolled in the Women’s Study, 2 =15.41, 
p<0.01). This is probably because women lacking antenatal care and PMTCT interventions were 
also more likely to be disengaged from HIV care postpartum, thus missing the opportunity to enrol 
in the Women’s Study; antenatal ART was received by 96% (1311/1364) of women enrolled in the 
ECS and Women’s Study compared with 86% (1888/2195) of those enrolled in the ECS only (2 
=94.40, p<0.01).  
There was no difference in HIV disease severity between women enrolled in the ECS only and 
those also participating in the Women’s Study (14% were at WHO stage 3-4 and median CD4 
count at first measure in pregnancy was 440 cells/mm3  in both groups). Women who received 
 148 
 
cART antenatally (associated with more severe HIV disease, see Chapter 3) were no more likely to 
be enrolled in the Women’s Study than those who received ZDVm (2=0.59, p=0.44). This may 
indicate the importance of factors other than HIV disease severity (for example marginalisation and 
health care literacy) in determining attendance for postnatal HIV care, or be explained by a lower 
likelihood of consent for participation in the Women’s Study among women with severe or 
advanced HIV disease. 
5.2.2 Characteristics of women at enrolment 
Socio-demographic characteristics 
The 2066 women enrolled by September 2011 had a median age of 27.6 years (IQR 24.4, 30.9) and 
most were married (50%, 1022/2056) or cohabiting (34%, 697/2056), with 13% single (n=261), 3% 
(n=59) divorced and 1% (n=17) widowed. The latter three categories included women with non-
cohabiting partners (single in terms of marital rather than relationship status). Overall, age at 
leaving full-time education was available for 62% (n=1284) of women. Of these, almost half 
(n=626) had remained in full-time education until at least the age of 19, 30% (n=381) until 17-18 
years and 22% (n=277) until ≤16 years. Those in full-time education until ≥19 years were more 
likely to be married (66% (409/623) vs. 40% (263/653) of those with less education, 2=82.3, 
p<0.01). As in the Ukraine ECS, almost all women were white (99%, 1723/1735) and born in 
Ukraine (1741/1743).  
At cohort enrolment (a median of 5 months (IQR 1, 11) postpartum), 98% (1985/2024) of the 
women were living with their infant. Overall, 90% (1828/2032) of women were living in a 
household with at least one other adult (57% (n=1161) with partner or husband, 12% (n=241) with 
family members and 21% (n=426) with both partner and family). Of the 10% (204/2032) who 
reported being the only adult in their household, most (75%, n=153) were single, divorced or 
widowed, 8% (n=16) were married and 17% (n=35) reported their marital status as “cohabiting”, 
possibly because, of the available options, this most adequately captured the notion of a committed 
(albeit non-cohabiting) relationship. Of these 35 women, all reported having a sex partner, as did 
40% (135/336) of women reporting their marital status as single, divorced or widowed. 
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Throughout the following analyses, the marital status category of ‘single, divorced or widowed’ 
includes women in non-cohabiting relationships. 
At enrolment into the Women’s Study, women had lived in their current accommodation for a 
median of 3 years (IQR 2, 5) and therefore for most since before their most recent pregnancy. Most 
(60%, 1221/2022) lived in their own home, 12% (248/2022) in rented accommodation and 27% 
(539/2022) in their parents’ or grandparents’ home; 1% (n=14) of women reported their housing 
situation as “other” which included living in a shelter, hostel, prison or being homeless. A history of 
ever having been in prison was self-reported by 4% (71/1942), with most recent imprisonment 
having occurred a median of 5 years prior to Women’s Study enrolment (IQR 3, 6 years). Four 
women had been in prison less than a year prior to cohort enrolment. 
HIV disease status 
At cohort enrolment, 14% (264/1836) of women had advanced or severe HIV disease (WHO stage 
3 or 4). The median CD4 count (available for 1855 women) was 452 cells/mm3 (IQR 327, 599); 9% 
(172/1855) had a CD4 count ≤200 cells/mm3 and 20% (367/1855) a CD4 count 200-350 
cells/mm3. In total, 38% (773/2052) had indications for treatment (WHO stage 3-4 and/or CD4 
count ≤350 cells/mm3 during pregnancy or postnatally).  
Postnatal ART 
In total, 23% (464/2046) of women were on ART at postnatal enrolment and 53% (408/770) of 
those with clinical or immunological indications for treatment, increasing from 34% (41/121) of 
those with treatment indications in 2008 to 72% (117/162) in 2011 (trend p<0.01) (3 women with 
treatment indications did not have information on ART available). As in pregnancy, most of the 
women on cART were on a PI-based regimen (75% (315/422) of those with ART information 
available).  
Just over a third (157/453) of the women on ART postnatally reported ART side effects. This is 
somewhat higher than the 20% (91/464) prevalence of minor side effects and 1% (6/464) 
prevalence of major side effects (steatosis, hepatotoxicity, nephrotoxicity, severe skin rash, anaemia 
or severe diarrhoea) reported by their clinicians. The discrepancy between clinician- and patient-
reported prevalence of ART side effects is likely to be due to under-reporting of minor side effects 
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by women to their clinicians, an under-documentation of these in the medical notes or a difference 
in attribution of symptoms to ART.  
Use of psychosocial support services 
Three-quarters (1553/2066) of women reported using at least one psychosocial support service; 
half (1043/2066) reported using social services, 48% (985/2066) peer counsellors, 25% (520/2066) 
support groups and 23% (468/2066) treatment adherence programmes. Of this last group, 48% 
(223/466) were not currently on ART, and so their response may have reflected past use, or 
included ART preparedness programmes. Use of social services was highest among women with 
the least education (77% (212/277) of women leaving full-time education at ≤16 years reported 
using social services vs. 50% (508/1007) among those leaving education at ≥17 years, 2 =60.02, 
p<0.01). However there was no association between educational status and use of support groups 
(2 =0.00, p=1.00) or peer counselling (2 =1.23, p=0.27), probably because these services are 
NGO-provided and available to all women, whereas eligibility for state-provided social services is 
limited to the most marginalised or vulnerable groups. Social services were also used more 
frequently by unmarried women (54% (561/1034) vs. 47% (478/1022) of married women, 2 
=11.52, p<0.01) and those with a history of IDU (67% (290/432) vs. 46% (753/1634) without an 
IDU history, 2 =60.54, p<0.01).  
Disclosure of HIV status and HIV status of partner 
Overall, 60% (1231/2066) of women had disclosed their HIV status to one or both parents, 7% 
(149/2066) to another family member (including sibling) and 3% (52/2066) to a friend. Of the 
1865 women with a current partner at enrolment, 85% (n=1577) had disclosed their HIV status to 
their partner. Around a third (586/1849) did not know their partner’s HIV status, and these women 
were significantly more likely not to have disclosed their own status to their partner (31% 
(180/586) vs. 8% (98/1263) of those who knew their partner’s HIV status (2 =165.14, p<0.01)). 
Of those who knew their partner’s status, 41% (522/1263) were in a discordant partnership and 
59% (741/1263) in a concordant partnership. Overall, 7% (153/2066) of women had not disclosed 
their status to anyone, a third (n=52) of whom had no current partner. 
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Parity and pregnancy planning 
For 34% (559/1635) of women, the pregnancy preceding study enrolment was their first (including 
terminations, miscarriages, stillbirths and live births). Overall, 44% (732/1665) of women had a 
history of pregnancy termination, 9% (142/1645) a history of miscarriage and 47% (777/1642) had 
at least one previous live birth or stillbirth (13% (210/1642) had ≥2). Parity was associated with age 
(74% (262/356) of women aged ≥31 years were multiparous at enrolment vs. 27% (81/305) of 16-
23 year-olds, 4 age groups, 2 =159.35, p<0.01) and with marital status (49% (673/1369) of 
married/cohabiting women were multiparous at enrolment vs. 38% (100/266) of single women, 2 
=11.95, p<0.01). 
In total, 71% (1442/2036) of women reported that they had planned their most recent pregnancy. 
Women planning their pregnancy were more likely to be married (62% (894/1439) vs. 20% 
(118/592) with unplanned pregnancy 2 =298.70, p<0.01) and to have been in full-time education 
until ≥19 years (58% (528/918) vs. 26% (89/344) with unplanned pregnancy (2 =100.28, p<0.01) 
and less likely to have an IDU history (17% (241/1442) vs. 30% (181/594) of those with unplanned 
pregnancies, 2 =48.47, p<0.01). Of those with an antenatal HIV diagnosis, women with a planned 
pregnancy were less likely to be diagnosed late (11% (95/843) were diagnosed during the third 
trimester or intrapartum vs. 29% (81/276) of those with an unplanned pregnancy, 2 =7.91, 
p<0.01). Overall, women who had been aware of their HIV diagnosis prior to conception were 
more likely to have an unplanned pregnancy than those diagnosed during pregnancy or at delivery 
(31% (395/573) vs. 25% (276/1119)), reflecting the higher proportion of IDUs in the previously 
diagnosed group and inadequate family planning provision for diagnosed women. There was no age 
difference by planning of pregnancy (p=0.4). 
Contraceptive use 
The 71% (1420/1996) of women who reported being sexually active at cohort enrolment were 
enrolled a median of six months postpartum (vs. three months for the non-sexually active group, 
Wilcoxon-Mann-Whitney test p<0.01). Among sexually active women, condoms were the most 
popular choice of contraception, used as the sole method by 54% (771/1417), in addition to 
withdrawal (and therefore indicating inconsistent use) by 24% (336/1417) and in conjunction with 
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another modern contraceptive method (injectable hormone, intrauterine device (IUD) or oral 
contraceptive (OC) pill) by 12% (175/1417). One in ten (135/1417) sexually active women 
reported no condom use; 2% (32/1417) were using another modern contraceptive method and 7% 
(103/1417) were using no contraception or only withdrawal. Three women had been sterilised by 
cohort enrolment; these women were categorised with the group using injectable hormone, IUD or 
OC pill.  
Overall, 21% (408/1990) of women reported not being able to afford contraception, 18% 
(310/1758) that contraception wasn’t available and accessible to them and 13% (232/1756) that 
both of these statements were true. There was no change over time in the proportion reporting that 
contraception was unaffordable (p=0.10) but the proportion reporting that contraception was not 
accessible declined from 25% (83/336) in 2007-08 to 7% (22/316) in 2011, p<0.01). Women with 
lower levels of education were significantly more likely to report that contraception was 
unaffordable (33% (86/257), 20% (75/368) and 11% (67/601) of those leaving full-time education 
at <16, 17-18 and ≥19 years of age respectively, 2 =60.32, p<0.01). This was also the case for 
women with ≥3 previous live or still births at study enrolment (41% (81/198) reported 
contraception to be unaffordable vs. 16% (220/1384) of those with ≤2 previous live or still births, 
2 =70.34, p<0.01). Overall, 31% (143/464) of women in full-time education until ≥19 years 
reported using a non-barrier contraceptive method, compared with  5% (18/381) of those with a 
lower level of education (2 =92.37, p<0.01).  
Smoking, drug and alcohol use 
Overall 21% (432/2066) of women had a history of IDU (self- and clinician-report from the 
Women’s Study and Ukraine ECS, or mothers of infants with neonatal abstinence syndrome). At 
enrolment, the proportion with an IDU history varied significantly by age group from 10% 
(43/415) of those aged 16-23 years to 16% (67/420) of women 24-26 years, 26% (149/570) of 
women 27-30 years and 33% (149/447) of those ≥31 years (2 =80.78, p<0.01).  
Of 389 women who self-reported an IDU history on enrolment into the Women’s Study, 14% 
(n=53) reported current use, the majority of whom (96%, 50/52) were injecting homemade opiates 
and 4% (n=2) heroin. Among the current injectors, 52% (25/48) reported being in contact with a 
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harm reduction programme and 14% (7/49) that they were participating in an opiate substitution 
therapy programme. Most (82%, 37/45) current injectors had an IDU partner compared with 47% 
(132/282) of ex-injectors and 12% (160/1328) of women without an IDU history.  
Almost three-quarters (1446/2045) of women had a history of cigarette smoking: 23% (464/2045) 
were ex-smokers, 22% (450/2045) current light smokers (<15 cigarettes a day) and 26% (533/2045) 
current heavy smokers (≥15 cigarettes a day). Current smokers were significantly more likely to 
have a history of IDU (38% (370/983) vs. 6% (59/1053) of ex/non-smokers, 2 =313.75, p<0.01) 
as were women reporting alcohol consumption at postnatal enrolment (46% (134/291) had an IDU 
history vs. 17% (290/1736) of non-drinkers, 2 =129.72, p<0.01) (see Figure 5.1). Current smokers 
were also of lower socioeconomic status, indicated by their increased probability of reporting 
contraception to be unaffordable (26% (251/950) compared with 15% (156/1029) of ex/non-
smokers, 2 =129.72, p<0.01). Overall, of the 14% (291/2027) who reported drinking alcohol, most 
(70%, 126/180) reported use on one day per week, 22% (39/180) on two days and 8% (15/180) on 
three days or more. 
 
 
Figure 5.1: Smoking, drug and alcohol use at Women’s Study cohort enrolment 
(n=2024) 
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HIV acquisition risk groups 
Figure 5.2 shows the reported modes of HIV acquisition using data from the Women’s Study and 
the ECS. Women with both an IDU history and an IDU partner have been assigned to the IDU 
history group, to reflect the category of highest HIV acquisition risk. Of the group with no 
reported risk factor for HIV acquisition, 14% (111/779) had no partner at Women’s Study 
enrolment, 46% (355/779) had an HIV-negative partner and 40% (313/779) had a partner whose 
HIV status was unknown to them.  
 
Figure 5.2: Mode of HIV acquisition among women enrolled in the Women’s Study 
n=2064, 2 women with occupationally-acquired HIV or exposure to blood products are omitted. 
† Other known heterosexual risk includes women reporting rape, sex work or multiple sexual 
partners and women with sexual partners at high risk of HIV acquisition (MSM and partners who 
have received blood products (including haemophiliacs), are from a high prevalence country, or 
have a history of imprisonment). 
 
 
 
  
432, 21% 
160, 8% 
553, 27% 
134, 6% 
785, 38% 
IDU history
IDU sexual partner
Non-IDU sexual partner,
known to be HIV-positive
Other known heterosexual 
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5.2.3 Characteristics of women at follow-up 
For the 607 women with follow-up available (19% (114/607) of whom had follow-up data available 
on ≥2 occasions), the first follow-up was a median of 5.9 months after study enrolment. Among 
women enrolled by the end of 2010 (eight months prior to the cut-off for analyses used here), the 
characteristics of women with follow-up were compared with those without follow-up. In this 
group, women on postnatal ART were more likely to have subsequent follow-up (42% (134/321) 
vs. 33% (435/1332) of those not on ART, 2 =9.46, p<0.01), reflecting policy for the closer 
monitoring of this group and their need to return to the HIV/AIDS centre for further ART 
supplies. However there was no difference in availability of follow-up by presence of severe / 
advanced HIV disease (p=0.2). Those with follow-up available were slightly older than those 
without (median 27.7 vs. 27.2 years, p=0.01) and more likely to be multiparous (55% (269/492) vs. 
43% (413/969) of those with no follow-up, 2 =19.05, p<0.01). They were also significantly less 
likely to have an IDU history (17% (96/576) vs. 23% (255/1097) of those with no follow-up, 2 
=9.86, p<0.01).  
Women with follow-up had been enrolled initially a median of 37 days after delivery vs. 10.5 
months for those with no follow-up (limited to those enrolled by the end of 2010, Wilcoxon-Mann-
Whitney test p<0.01). The combination of earlier presentation at the HIV/AIDS centre postnatally 
and regular attendance for follow-up reflects greater engagement with care and compliance with 
medical advice, which may extend to other health-seeking behaviours. Among women who had 
been tested for ≥2 STIs during pregnancy or postnatally, only 7% (30/450) of women with follow-
up had ≥2 positive tests, compared with 21% (161/753) of women with no follow-up (2 =45.66, 
p<0.01), possibly reflecting more consistent condom use and better prior access to testing and 
treatment services. 
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5.3 HIV co-infections 
STI definitions 
Sexually transmitted infections (STIs) were defined as: Chlamydia trachomatis (‘chlamydia’), 
gonorrhoea, syphilis, Trichomonas vaginalis (TV), HSV-2 and hepatitis B virus (HBV), which is 
highly sexually transmissible, but may also be transmitted via sharing of contaminated IDU 
equipment. Bacterial vaginosis, although positively associated with number of sexual partners and 
with acquisition of STIs (including HIV), is not itself considered to be sexually transmitted. Risk of 
heterosexual HCV transmission is thought to be low, but may be elevated among HIV-positive 
individuals (Tohme et al. 2010); this is explored further in section 5.3.2. Genital infections reported 
were any diagnosed during the most recent pregnancy or postnatally up to the time of cohort 
enrolment. Infections reported up to 28 days before estimated date of conception were included in 
all analyses.  
Testing policies and data availability on co-infections 
Data availability on each co-infection depended on local practice and testing facilities (including 
adequate supplies of consumables), national and local policies for testing and patients’ engagement 
with care. Table 5.3 gives the proportion of women with a test result reported for each co-infection.  
Ukrainian policy specifies that all patients should be screened for HCV at the time of HIV 
diagnosis, with annual screening thereafter for HCV-seronegative IDUs; screening coverage in this 
cohort was 74% (Table 5.3). Antenatal syphilis and HBV screening is routinely carried out for all 
pregnant women in Ukraine. However, tests performed as part of routine antenatal care before an 
HIV diagnosis is made (i.e. tests done at the same time as the HIV screening test, for women 
diagnosed as HIV-positive during the most recent pregnancy) may not be reported here, due to lack 
of data sharing between antenatal clinics and the HIV/AIDS centre. This may explain the fact that 
while 99% (1706/1715) of these women had an HIV test before delivery, only 75% had a syphilis 
test result reported here - syphilis screening coverage among women accessing antenatal care is 
reported to be 92% nationally (Ministry of Health of Ukraine 2012). 
Testing for other STIs and genital infections (HSV-2, chlamydia, gonorrhoea, TV, BV and vulvo-
vaginal candidiasis) varied by HIV/AIDS centre. Some HIV/AIDS centres aim to screen HIV-
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positive pregnant women routinely for all of these infections, while other centres may provide 
testing only when signs or symptoms are present (for example for vulvo-vaginal candidiasis, 
indicated by the high prevalence of positive tests among the small proportion tested, Table 5.3). 
Some HIV/AIDS centres were not resourced to test and treat HIV-positive women for genital co-
infections, and HIV-positive women could access these services through local women’s clinics or 
sexual health clinics (the same channels as HIV-negative women).  Of the six STIs on which data 
were collected, 14% (n=286) of women had no test results available, 24% (n=502) were tested for 
between 1 and 3 infections, 28% (n=588) for 4 infections, 5% (n=93) for 5 and 29% (n=597) for all 
six (median: 4 STI tests).  
Prevalence of co-infections 
Table 5.3 gives the prevalence of sexually transmitted and genital infections diagnosed during the 
most recent pregnancy or postnatally, and prevalence of HCV seropositivity (indicating past or 
chronic HCV infection). Hepatitis B surface antigen (HBsAg) positivity indicates acute or chronic 
HBV infection. 
Table 5.3: Prevalence of co-infections 
 Proportion tested             
(n=2066) 
Of those tested, proportion 
positive 
Viral   
HSV-2 seropositive 63% (n=1309) 60% (n=786) 
HCV seropositive 74% (n=1529) 32% (n=492) 
HBsAg positive 81% (n=1672) 15% (n=244) 
Bacterial   
Chlamydia trachomatis 47% (n=970) 24% (n=229) 
Syphilis 73% (n=1515) 2% (n=35) 
Gonorrhea 56% (n=1167) 0.3% (n=4) 
Other   
Trichomonas vaginalis (TV) 38% (n=784) 11% (n=88) 
Bacterial vaginosis (BV) 61% (n=1260) 13% (n=170) 
Vulvo-vaginal candidiasis 35% (n=717)    88% (n=631) 
Genital infections were diagnosed as follows: chlamydia by enzyme immunoassay on endocervical 
swab; syphilis by specific treponema test; gonorrhea by Gram stain microscopy on vaginal swab; 
TV by microscopy; BV by Gram stain microscopy in 99% and by symptoms in 1%; vulvo-vaginal 
candida by Gram stain microscopy in 67%, culture in 12% and symptoms in 21%. 
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5.3.1 Chlamydia 
Objectives of this section 
1. To describe timing and coverage of chlamydia testing as part of HIV care among this cohort of 
HIV-positive childbearing women. 
2. To investigate factors associated with a recent chlamydia diagnosis. 
Methods 
For this analysis, only enrolment data were used; women with follow-up were less likely to have a 
history of genital infection than those with no follow-up (see section 5.2.3), and were non-
representative of the cohort as a whole. Krivoy Rog HIV/AIDS centre reported no chlamydia test 
results and Mykolaiv HIV/AIDS centre reported only two; these centres were excluded from the 
analysis of factors associated with a positive chlamydia test result. 
Centre and year of enrolment were included in all models a priori, to account for differences in 
chlamydia prevalence by geographical area and over time. All variables which remained significantly 
associated with a positive chlamydia test result on adjusting for year and centre (Wald’s test 
significance level <0.1) were included in the multivariable model, and then removed one-by-one if 
they were no longer associated with the outcome on adjusting for the other factors in the model 
(Wald’s test significance level >0.1). Women enrolled in December 2007 (n=15) were grouped with 
those enrolled in 2008 for the purpose of adjusting for year of enrolment. 
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Characteristics by chlamydia test result 
Table 5.4 gives socio-demographic and clinical characteristics of the 53% (n=1096) of women with 
no recent chlamydia test reported, the 36% (n=741) testing negative and the 11% (n=229) testing 
positive; prevalence of chlamydia among those tested was 24% (229/970). Women testing positive 
more often did not know their partner’s HIV status than women testing negative, and were the 
least likely of the three groups to be using condoms as their only contraceptive method if sexually 
active at cohort enrolment (Table 5.4).  
IDU history, current smoking and postnatal alcohol use were all more common among women 
with a positive chlamydia test (Table 5.4). Among those tested, 42% (96/229) of women with an 
IDU history or an IDU partner were positive for chlamydia (vs. 26% (190/741) of those with no 
IDU history or IDU partner, 2 =22.30, p<0.01), highlighting overlapping sexual and parenteral risk 
factors for transmission of infections among IDUs. Older women were slightly more likely to test 
positive for chlamydia (trend p=0.09), but this was mediated by the older age of IDUs; among 
women with no IDU history, there was no association between age and likelihood of a chlamydia 
diagnosis among those tested (trend p=0.65). Of the 38% of women with no reported risk factor 
for HIV acquisition (see Figure 5.2, page 154), 91% (711/785) were tested for at least one other 
STI of whom 53% (375/711) were positive; the prevalence of chlamydia among this group was 
22% (84/387).  
Timing of chlamydia testing 
Among the 781 women who had timing of chlamydia test available, 81% (634/781) were tested 
during pregnancy and 19% (147/781) postnatally. The data collection form had space for one test 
date per infection; a positive postnatal test may therefore have indicated a lack of antenatal testing, 
re-infection or ineffective treatment following a prior positive test, or an incident infection.  Only 
16% (23/147) of postnatal tests were positive compared with 25% (161/634) of antenatal tests (2 
=6.30, p=0.01) (negative postnatal tests did not indicate test-of-cure for an antenatal infection, as 
positive test results were reported preferentially). Women with an IDU history were slightly more 
likely to be tested antenatally if a test was done (86% (160/186) vs. 80% (474/595) of non-IDUs, 2 
=3.75, p=0.05), indicating that antenatal testing was to some extent targeted to higher risk women.   
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Table 5.4: Socio-demographics and clinical characteristics by chlamydia diagnosis 
 No chlamydia test 
reported (n=1096) 
Negative 
chlamydia test 
(n=741) 
Positive 
chlamydia test 
(n=229) 
Median age at cohort enrolment (IQR) 
(n=1852) 
27.7  
(24.6, 30.8) 
27.3  
(24.0, 30.7) 
27.5  
(24.6, 32.0) 
Marital status (n=2056)    
Married 470 (43%) 435 (59%) 117 (51%) 
Cohabiting 415 (38%) 198 (27%) 84 (37%) 
Single / widowed / divorced 205 (19%) 105 (14%) 27 (12%) 
Previous live and still births (n=1642)    
1 435 (49%) 332 (57%) 98 (54%) 
2 310 (35%) 200 (35%) 57 (32%) 
≥3 139 (16%) 46 (8%) 25 (14%) 
History of pregnancy termination 
(n=1665) 
   
0 431 (48%) 390 (67%) 112 (62%) 
1 187 (21%) 109 (19%) 29 (16%) 
≥2 283 (31%) 85 (15%) 39 (22%) 
Age at leaving full-time education 
(n=1284) 
   
<16 years 214 (27%) 43 (12%) 20 (16%) 
17-18 years 297 (37%) 60 (17%) 24 (19%) 
≥19 years 291 (36%) 255 (71%) 80 (65%) 
Timing of HIV diagnosis in relation to 
most recent pregnancy (n=1715) 
   
Prior to conception 320 (34%) 210 (35%) 53 (29%) 
1st and 2nd trimesters 496 (53%) 336 (56%) 116 (63%) 
3rd trimester and intrapartum 114 (12%) 56 (9%) 14 (8%) 
Partner’s HIV status among 1849 
women with a partner at enrolment 
   
Negative 245 (26%) 217 (32%) 60 (27%) 
Positive 367 (39%) 289 (43%) 85 (39%) 
Don't know 340 (36%) 171 (25%) 75 (34%) 
Disclosure of HIV status to partner 
(n=1865) 
828 (86%) 569 (83%) 180 (81%) 
Most recent pregnancy planned 
(n=2036) 
672 (63%)  600 (81%) 170 (75%) 
Barrier contraceptive use among 1417 
women sexually active at cohort 
enrolment 
   
Condoms as only contraceptive method 410 (60%) 296 (52%) 65 (38%) 
Condoms and another method (injectable 
hormone,  IUD, OC pill or withdrawal) 
221 (32%) 207 (37%) 83 (49%) 
No condom use 52 (8%) 61 (11%) 22 (13%) 
Can afford family planning (self-report) 805 (77%)  599 (83%) 178 (80%) 
Can access family planning (self-report) 652 (80%) 609 (84%) 187 (85%) 
Using any support services 807 (74%)  554 (75%) 192 (84%) 
Drug and alcohol use    
History of IDU (n=2066) 213 (19%) 139 (19%) 80 (35%) 
History of smoking (n=2045) 802 (74%)  467 (63%) 177 (78%) 
Current smoker (n=2036) 529 (49%) 319 (43%) 135 (59%) 
Alcohol use postnatally (n=2027) 101 (9%)  127 (17%) 63 (28%) 
Clinical / immune status    
WHO stage 3-4 (n=1836) 98 (11%) 125 (17%) 41 (18%) 
Median CD4 count (IQR) (cells/mm3) 
(n=1855) 
453 (318, 608) 441 (334, 590) 456 (342, 586) 
Taking ART postnatally (n=2042) 236 (22%)  192 (26%) 32 (14%) 
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Chlamydia and other STIs 
Among those tested, the 24% of women who were positive for chlamydia were significantly more 
likely to be positive for a number of other STIs, with the exceptions of gonorrhoea (only 4 cases 
overall) and HBV, and to be positive for BV (Figure 5.3). Women testing positive for chlamydia 
were more likely to be HCV seropositive (46% (88/192) vs. 25% (152/598) of those negative for 
chlamydia, 2 =28.64, p<0.01), reflecting their more frequent history of IDU (Table 5.4), and 
possibly risk factors for sexual HCV acquisition (explored in section 5.3.2, page 168). Of the 229 
women testing positive for chlamydia, all except one woman had ≥1 other STI test(s) available; 
81% (184/228) had at least one other STI in addition to chlamydia and HIV (mostly HSV-2).  
 
Figure 5.3: Other STIs and genital infections by recent chlamydia diagnosis 
(n=970) 
Women with no reported chlamydia test 
The proportions of women with a chlamydia test reported by HIV/AIDS centre of enrolment were 
as follows: 91% (448/490) in Odessa, 63% (127/201) in Donetsk, 52% (393/759) in Kiev, 0.5% 
(2/409) in Mykolaiv and 0/207 in Krivoy Rog. Only 70% (247/352) of women enrolled in 
Mykolaiv or Krivoy Rog reported that they had access to family planning (compared with 85% 
(1201/1406) at Odessa, Donetsk and Kiev, 2 =45.07, p<0.01) and 74% (427/577) reported that 
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family planning was affordable (compared with 82% (1155/1413) at the other three centres, 2 
=15.05, p<0.01). Women enrolled in Mykolaiv and Krivoy Rog were also more likely to have a 
history of multiple pregnancy terminations (60% (341/564) vs. 36% (391/1101) of women at the 
other three centres, 2 =94.22, p<0.01), suggesting a particular lack of access to sexual and 
reproductive health services among women enrolled at these two centres. 
STI test results for at least one infection other than chlamydia (i.e. syphilis, gonorrhoea, TV, HSV-2 
and HBV) were available for 74% (810/1096) of the women without a chlamydia test (vs. 99% 
(965/970) of those with a chlamydia test, median number of STI tests: 4 and 6 respectively). Most 
tests for other STIs were done on the same day as the chlamydia test (82% (561/684) of 
gonorrhoea tests, 74% (646/869) of syphilis tests, 81% (546/670) of TV tests and 87% (748/862) 
of HSV-2 tests). The proportion of women positive for at least one STI other than chlamydia (and 
HIV) was 51% (410/810) in the group with no chlamydia test and 55% (535/965) in the group 
tested for chlamydia (regardless of result) (2 =4.11, p=0.04).  
Chlamydia and other STI testing may be selectively offered in response to identification of sexual 
risk factors and symptoms, both of which increase the likelihood of a positive result. However, of 
women enrolled at Odessa, Donetsk and Kiev centres, women with no chlamydia test result were 
more likely to be diagnosed with HIV late (14% (53/366) vs. 9% (70/783) of those tested for 
chlamydia, 2 =8.01, p<0.01) and to have an IDU history (31% (148/482) vs. 23% (219/968) of 
those with a chlamydia test reported, 2 =11.12, p<0.01), indicating poorer access to services 
among those without a chlamydia test result.  
Factors associated with a recent chlamydia diagnosis 
The prevalence of chlamydia among those tested differed significantly by HIV/AIDS centre, from 
33% (129/393) in Kiev to 21% (96/448) in Odessa and 3% (4/127) in Donetsk (2 =49.09, 
p<0.01). There were also significant differences by year of enrolment, with the prevalence of 
positive test results ranging from 35% (120/345) in 2009 to 10% (15/146) in 2011 (4 year groups, 
2 =50.32, p<0.01). Factors associated with a positive chlamydia test in univariable analyses or on 
adjusting for centre and year of enrolment only (Wald’s test significance level <0.1) are shown in 
Tables 5.5a and 5.5b. Timing of HIV diagnosis, educational status, having an HIV-positive partner 
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and disclosure of HIV status to partner were not associated with a chlamydia diagnosis in 
univariable analyses, or on adjusting for year and centre (Wald’s test p=0.56, p=0.20, p=0.88 and 
p=0.17 respectively). 
The adjusted model was based on complete cases (women with no missing data on any of the 
variables of interest), but included the large majority (941/968) of the 67% (968/1450) of women 
with a chlamydia test available at the three HIV/AIDS centres. Parity, history of smoking, IDU 
partner, planning of most recent pregnancy, accessibility of contraception and history of pregnancy 
termination were associated with chlamydia diagnosis on adjusting for year and centre (Tables 5.5a 
and 5.5b), and were therefore initially included in the multivariable model, but subsequently 
removed as they did not contribute significantly to the model’s final fit (Wald’s test p>0.1 for all). 
Women who knew their partner’s HIV status were more likely to have planned their most recent 
pregnancy (87% (561/646) vs. 69% (170/246) of those with unaware of their partner’s status and 
51% (33/65) with no partner at postnatal enrolment, 2 =71.40, p<0.01). Accessibility of 
contraception was associated with its affordability (retained in the model); almost all (95%, 
1347/1423) women able to afford contraception reported that it was accessible to them, vs. only 
30% (101/333) of women reporting that contraception was unaffordable (2 =772.09, p<0.01).
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Table 5.5a: Factors associated with a recent chlamydia diagnosis among those tested (continued in Table 5.5b) 
 
 
 
Proportion (n) testing 
positive for chlamydia 
Unadjusted Prevalence 
Ratio (95% CI) 
Prevalence Ratio (95% CI) 
adjusted for year and centre 
Adjusted Prevalence Ratio 
(95% CI) n=941 
Marital status     
Married 21% (117/551) 1.00 1.00 1.00 
Cohabiting 30% (84/282) 1.40 (1.1-1.78) p=0.01 1.61 (1.27-2.04) p<0.01 1.40 (1.10-1.78) p<0.01 
Single / widowed / divorced 21% (27/131) 0.97 (0.67-1.41) p=0.88 1.09 (0.77-1.55) p=0.63 0.89 (0.59-1.35) p=0.59 
Parity     
1 23% (98/429) 1.00 1.00  
2 22% (57/256) 0.97 (0.73-1.30) p=0.86 1.00 (0.76-1.32) p=1.00  
≥3 35% (25/71) 1.54 (1.07-2.21) p=0.02 1.61 (1.14-2.27) p<0.01  
History of smoking     
Yes 28% (177/643) 1.00 1.00  
No 16% (51/319) 0.58 (0.44-0.77) p<0.01 0.70 (0.54-0.92) p=0.01  
History of IDU     
No 20% (149/749) 1.00 1.00 1.00 
Yes 37% (80/219) 1.84 (1.46-2.30) p<0.01 1.70 (1.37-2.12) p<0.01 1.56 (1.24-1.96) p<0.01 
IDU sex partner     
No 20% (127/620) 1.00 1.00  
Yes 31% (48/155) 1.51 (1.14-2.00) p<0.01 1.27 (0.97-1.67) p=0.08  
Most recent pregnancy planned     
Yes 22% (170/769) 1.00 1.00  
No 29% (57/194) 1.33 (1.03-1.72) p=0.03 1.50 (1.17-1.91) p<0.01  
Affordability of contraception     
Can afford 23% (178/775) 1.00 1.00 1.00 
Can’t afford 26% (44/171) 1.12 (0.84-1.49) p=0.44 1.74 (1.34-2.27) p<0.01 1.46 (1.11-1.92) p<0.01 
Accessibility of contraception     
Can access 24% (187/795) 1.00 1.00  
Can’t access 22% (33/147) 0.95 (0.69-1.32) p=0.78 1.53 (1.14-2.06) p<0.01  
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 Table 5.5b: Factors associated with a recent chlamydia diagnosis among those tested (continued from Table 5.5a).
 
 
Proportion (n) testing 
positive for chlamydia 
Unadjusted Prevalence 
Ratio (95% CI) 
Prevalence Ratio (95% CI) 
adjusted for year and centre 
Adjusted Prevalence Ratio 
(95% CI) n=941 
Prior pregnancy termination     
None 22% (112/501) 1.00 1.00  
1 21% (29/138) 0.94 (0.65-1.35) p=0.74 0.85 (0.6-1.19) p=0.34  
≥2 32% (39/123) 1.42 (1.04-1.93) p=0.03 1.36 (1-1.85) p=0.05  
Woman’s knowledge of her current 
partner’s HIV status 
    
Known (positive or negative) 22% (145/650) 1.00 1.00 1.00 
Unknown 30% (75/246) 1.37 (1.08-1.73) p=0.01 1.48 (1.17-1.87) p<0.01 1.39 (1.09-1.77) p<0.01 
No current partner 12% (8/66) 0.55 (0.28-1.07) p=0.08 0.69 (0.36-1.32) p=0.26 0.80 (0.37-1.71)  p=0.56 
Centre     
Odessa 21% (96/448) 1.00 1.00 1.00 
Donetsk 3% (4/127) 0.15 (0.06-0.39) p<0.01 0.14 (0.05-0.36) p<0.01 0.13 (0.05-0.34) p<0.01 
Kiev 33% (129/393) 1.53 (1.22-1.92) p<0.01 1.30 (1.03-1.62) p=0.02 1.45 (1.15-1.84) p<0.01 
Year of enrolment     
2007/08 15% (44/289) 1.00 1.00 1.00 
2009 35% (120/344) 2.29 (1.68-3.12) p<0.01 2.05 (1.51-2.78) p<0.01 1.91 (1.41-2.57) p<0.01 
2010 26% (50/190) 1.73 (1.20-2.48) p<0.01 1.69 (1.18-2.41) p<0.01 1.64 (1.16-2.30) p<0.01 
2011 10% (15/145) 0.68 (0.39-1.18) p=0.17 0.64 (0.37-1.10) p=0.11 0.60 (0.35-1.03) p=0.06 
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In the multivariable model, women who were cohabiting (vs. married), had an IDU history, 
reported being unable to afford contraception and did not know their partner’s HIV status were at 
increased risk of testing positive for chlamydia after adjusting for year and centre of enrolment 
(Table 5.5a and 5.5b). Among women who knew their partner’s HIV status, there was no difference 
in likelihood of a chlamydia diagnosis by whether their partner was HIV-positive or HIV-negative 
(22% (60/277) and 23% (85/373) tested positive for chlamydia respectively, 2 =0.12, p=0.73). 
There is therefore no evidence that the reduced risk of chlamydia among women who knew their 
partner’s HIV status was driven by a greater likelihood of condom use among women in discordant 
partnerships. Knowledge of partner’s HIV status will be partly determined by the partner’s access 
to and uptake of HIV testing services (and therefore possibly testing and treatment for other STIs), 
and may also be an indicator of knowledge and skills around safer sex. Women who knew their 
partner’s HIV status or who were married (vs. cohabiting) may also have been more likely to be in 
longer-term or exclusive partnerships, reducing their likelihood of STI exposure.  
Although affordability of contraception was not associated with chlamydia diagnosis in univariable 
analysis, this was due to confounding by centre; 93% (349/377) of women enrolled in Kiev 
reported contraception to be affordable compared with 82% (366/446) in Odessa and only 49% 
(60/123) in Donetsk (2 =120.12, p<0.01). After adjusting for centre and other factors, those not 
able to afford contraception were significantly more likely to test positive for chlamydia than 
women who could afford contraception. Ukrainian policy specifies that HIV-positive women 
should have free access to condoms, but implementation varies between oblasts. These results 
support previous findings that women attending Kiev HIV/AIDS centre have better access than 
HIV-positive women elsewhere (Saxton et al. 2010). The association between affordability of 
contraception and chlamydia diagnosis may indicate direct financial barriers to use of condoms, and 
possibly also indirect mechanisms whereby women of lower socioeconomic status are at greater risk 
of STI acquisition (for example, due to lower levels of health literacy).   
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Recent chlamydia diagnosis and postnatal condom use 
Information on contraceptive use was collected at postnatal cohort enrolment (subsequent to 
chlamydia diagnoses). Among sexually active women, there was no difference in “any” condom use 
(condom use alone or with another method, including withdrawal) by chlamydia test result (87% 
(148/170) of those testing positive for chlamydia reported any postnatal condom use vs. 89% 
(503/564) of those testing negative, 2 =0.59, p=0.44). However, women who had tested positive 
for chlamydia were less likely to be using condoms exclusively (38% (65/170) vs. 52% (296/564) of 
women who had tested negative, 2 =10.61, p<0.01) and more likely to be using injectable 
hormone, IUD or OC (25% (42/170) of those positive for chlamydia vs. 16% (93/564) of those 
negative, 2 =5.88, p=0.02). Condom use may be less consistent among women using other reliable 
contraceptive methods.  
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5.3.2 Hepatitis C virus 
Objectives of this section 
1. To investigate prevalence of and risk factors for HCV acquisition in the Women’s Study. 
2. To characterise markers of liver fibrosis among HCV co-infected women. 
Methods: Risk factors for HCV acquisition 
History of IDU was ascertained by any one of: self-report by the woman, clinical assessment or 
neonatal abstinence syndrome in the infant. Two non-IDUs with occupational exposure to blood 
or blood transfusion reported did not have HCV serostatus available, and so were omitted from 
these analyses. When exploring factors associated with HCV seropositivity among non-IDUs, 
multivariable analyses were not presented due to problems with interpretation where some factors 
were markers for multiple different modes of acquisition risk. For example, previous history of 
pregnancy termination was more common among IDUs, but also a marker of unsafe sex and 
possible iatrogenic exposure to HCV. 
Methods: Non-invasive markers of liver fibrosis 
To characterise the likely prevalence of liver fibrosis among HIV/HCV co-infected women, two 
algorithms were used - the FIB-4 index and aspartate transaminase (AST) to platelet ratio (‘APRI’) 
(Wai et al. 2003; Sterling et al. 2006). These are defined below: 
FIB-4 = (age [years] X AST [U/L]) / (PLT [10
9
/L]   (ALT [U/L])1/2) 
 APRI = (AST/upper limit of normal) / PLT [10
9
/L]   100  
 ALT: alanine transaminase, AST: aspartate transaminase, PLT: platelet count.  
 Liver enzymes are measured in units per litre (U/L). 
 
Previous work to validate the FIB-4 algorithm in a population of HIV/HCV co-infected patients, 
21% of whom had advanced fibrosis, showed that a FIB-4 score of <1.45 had a negative predictive 
value of 90% for excluding advanced fibrosis and a sensitivity of 70%. A score of >3.25 had a 
positive predictive value of 65% and a specificity of 97% for detecting advanced fibrosis (Sterling et 
al. 2006). APRI cut-offs of ≤0.50 and >1.50 can be used to predict absence and presence of 
significant fibrosis respectively in patients with chronic HCV infection (negative predictive value of 
86% for ≤0.50 and positive predictive value of 88% >1.50) (Wai et al. 2003). 
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Viral hepatitis and IDU history 
Of the 2066 women enrolled by September 2011, HCV serostatus was available for 74% (n=1529): 
76% (327/432) of IDUs and 74% (1202/1634) of non-IDUs (2=0.81 p=0.37). Among women 
with an IDU history, prevalence of HCV seropositivity was 78% (256/327) vs. 20% (236/1202) 
among women with no IDU history (2 =405.23 p<0.01). Overall, 48% (222/465) of the HCV 
seropositive women had no reported history of IDU. Figure 5.4 shows the overlap in HCV 
seropositivity, Hepatitis B surface antigen (HBsAg) positivity and IDU history reported in the 
cohort. HBV vaccination had been received by 14% (169/1224) of HBsAg negative women overall: 
16% (156/977) of non-IDUs and 5% (13/247) of IDUs (2 =18.90 p<0.01). 
 
Figure 5.4: Viral hepatitis B and C and IDU history at cohort enrolment 
n=1479; Prevalence of HCV seropositivity and HBsAg positivity shown here are slightly different 
to those in Table 5.3 (page 157), due to omission from Venn diagram of women with missing data 
on at least one of the three variables. 
 
Women with no HCV serostatus available 
The proportion of women with HCV serostatus reported varied by HIV/AIDS centre from 94% 
(385/409) in Mykolaiv to 86% (655/759) in Kiev, 78% (382/490) in Odessa, 50% (101/201) in 
Donetsk and 3% (6/207) in Krivoy Rog (2 =752.79 p<0.01). HCV antibodies were detected after 
HIV diagnosis in 91% (366/402) of women with timing of both tests available, reflecting policy 
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which recommends HCV screening only for HIV-positive individuals and those with other specific 
risk factors for HCV acquisition. The women with unknown HCV serostatus at the centres with 
≥50% coverage (Mykolaiv, Kiev, Odessa and Donetsk) were more likely to be diagnosed with HIV 
late (17% (40/231) had late HIV diagnosis vs. 9% (120/1272) of those with known HCV 
serostatus, 2 =12.77 p<0.01), and thus had less opportunity to be screened for HCV following 
their HIV diagnosis and by Women’s Study enrolment. These women were also more likely to lack 
testing for all STIs (15% (39/252) vs. 0.5% (6/1196) of those with known HCV serostatus).  
Timing of first positive HCV antibody test 
Timing of first positive HCV antibody test was during most recent pregnancy for 67% (274/409), 
prior to conception for 30% (122/409) and postnatally for 3% (13/409). Among the 36 women 
who were diagnosed with HCV prior to or at the same time as HIV, 23 (64%) had a reported 
history of IDU - an indication for HCV screening independent of HIV status. None of the 
remaining 13 non-IDUs had an IDU partner reported – these women were enrolled over four 
centres, and their reason for being tested for HCV prior to their HIV diagnosis is unknown. Of 
women with an IDU history who tested positive for HCV antibodies, this occurred before 
conception in 38% (79/209) of cases (vs. 22% (43/200) among non-IDUs, 2 =14.41 p<0.01), 
reflecting IDUs’ increased likelihood of being diagnosed as HIV-positive before their most recent 
pregnancy. 
Risk factors for HCV acquisition 
The 20% prevalence of HCV antibodies among women with no reported history of IDU may 
indicate under-ascertainment of IDU history, or other routes of HCV acquisition (including sexual 
or iatrogenic). These possibilities are explored in turn. Socio-demographic and clinical 
characteristics of HCV seropositive and HCV seronegative women by reported IDU history are 
given in Tables 5.6a and 5.6b.  
 171 
 
Table 5.6a: Socio-demographics and clinical characteristics by IDU history and HCV serostatus (continued in Table 5.6b) 
 No IDU history  History of IDU  
 HCV 
seronegative, 
(n=966) 
HCV 
seropositive, 
(n=236) 
 HCV 
seronegative, 
(n=71) 
HCV 
seropositive, 
(n=256) 
 
Median age at cohort enrolment, years (IQR) 
(n=1518) 
26.4 (23.4, 30.1) 27.6 (25.0, 30.6) p=0.022 27.8 (24.8, 31.0) 28.7 (26.2, 32.3) p=0.012 
Marital status (n=1520)       
Married 519 (54%)  121 (51%)  2=2.63 p=0.27 32 (45%) 124 (49%) 2=4.94 p=0.09 
Cohabiting 318 (33%)  75 (32%)  19 (27%) 86 (34%)  
Single / divorced / widowed 124 (13%)  40 (17%)  20 (28%) 42 (17%)  
Parity (n=1232)       
1 408 (55%)  97 (46%) 2=10.82 p<0.01 33 (52%) 100 (47%) 2=0.57 p=0.75 
2 256 (34%)  72 (34%)  23 (37%) 82 (39%)  
≥3 84 (11%)  41 (20%)  7 (11%) 29 (14%)  
History of pregnancy termination (n=1246)       
0 437 (58%)  109 (52%) 2=6.88 p=0.03 36 (56%) 101 (47%) 2=2.07 p=0.36 
1 147 (19%) 35 (17%)  12 (19%) 44 (20%)  
≥2 171 (23%) 66 (31%)  16 (25%) 72 (33%)  
Sexual partner       
IDU partner (n=1261) 91 (12%) 37 (18%) 2=5.48 p=0.02 22 (35%) 120 (55%) 2=7.73 p<0.01 
HIV-positive partner ever documented (n=1529) 416 (43%) 116 (49%) 2=2.85 p=0.09 22 (31%) 133 (52%) 2=9.80 p<0.01 
Does not know current partner’s HIV status 
(n=1383 with partner) 
265 (30%) 51 (24%) 2=2.89 p=0.09 27 (44%) 52 (22%) 2=12.13 p<0.01 
Disclosed own HIV status to current partner 
(n=1396 with partner) 
760 (86%) 175 (83%) 2=1.17 p=0.28 41 (67%) 204 (85%) 2=10.68 p<0.01 
Age at leaving full-time education (n=950)       
≤16 years 106 (19%) 42 (24%) 2=2.65 p=0.27 11 (28%) 80 (47%) 2=7.90 p=0.02 
17-18 years 137 (24%) 40 (23%)  10 (25%) 45 (27%)  
≥19 years 325 (57%) 91 (53%)  19 (48%) 44 (26%)  
Smoking and alcohol use       
Current alcohol use (n=1500) 97 (10%) 18 (8%) 2=1.37 p=0.24 20 (29%) 85 (34%) 2=0.66 p=0.42 
History of smoking (n=1514) 596 (62%) 150 (64%) 2=0.23 p=0.63 63 (90%) 248 (97%) 2=7.01 p<0.01 
Current smoker (n=1504) 379 (40%) 97 (42%) 2=0.20 p=0.65 55 (79%) 229 (90%) 2=6.81 p<0.01 
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Table 5.6b: Socio-demographics and clinical characteristics by IDU history and HCV serostatus (continued from Table 5.6a) 
       
 No IDU history   History of IDU   
 HCV 
seronegative, 
(n=966) 
HCV 
seropositive, 
(n=236) 
 HCV 
seronegative, 
(n=71) 
HCV 
seropositive, 
(n=256) 
 
Currently lives alone(n=1529) 66 (7%) 20 (8%) 2=0.68 p=0.41 12 (17%) 42 (17%) 2=0.03 p=0.87 
History of being in prison (n=1439) 3 (0%)  2 (1%) 2=1.31 p=0.25 12 (17%) 35 (14%) 2=0.53 p=0.47 
Postnatal condom use among 1417 women 
sexually active at cohort enrolment 
      
Condoms as only contraceptive method 392 (52%) 86 (49%) 2=1.32 p=0.52 15 (38%) 82 (53%) 2=9.97 p<0.01 
Condoms and another method (injectable 
hormone, IUD, OC pill or withdrawal) 
292 (39%) 77 (44%)  16 (40%) 64 (41%)  
No condom use 63 (8%) 13 (7%)  9 (23%) 10 (6%)  
Can afford contraception (n=1468) 804 (87%) 182 (81%) 2=4.41 p=0.04 50 (71%) 189 (77%) 2=0.76 p=0.38 
Co-infections1       
Hepatitis B surface antigen positive (n=1479) 122 (13%) 54 (24%) 2=18.35 p<0.01 13 (19%) 41 (17%) 2=0.19 p=0.67 
Chlamydia (n=790) 91 (18%) 31 (30%) 2=7.37 p<0.01 13 (28%) 57 (42%) 2=3.00 p=0.08 
Trichomonas vaginalis (n=640) 41 (10%) 6 (8%) 2=0.30 p=0.59 2 (5%) 10 (9%) 2=1.01 p=0.32 
HSV-2 antibodies (n=1166) 404 (56%) 141 (73%)  2=19.31 p<0.01 21 (37%) 156 (83%) 2=45.31 p<0.01 
Vulvo-vaginal candida (n=607) 374 (90%) 74 (86%) 2=1.10 p=0.29 24 (89%) 61 (78%) 2=1.48 p=0.22 
Bacterial vaginosis (n=1057) 72 (10%) 19 (12%) 2=0.64 p=0.42 7 (13%) 36 (27%) 2=4.22 p=0.04 
Median years since HIV diagnosis (IQR) 
(n=1277) 
1.3 (0.7, 1.9) 1.6 (0.9, 3.1) p<0.012 2.0 (0.9, 4.4) 1.9 (1.4, 4.6) p=0.402 
Median years since first HCV antibody positive 
test (IQR) (n=454)  
- 1.1 (0.4, 1.8)  - 1.5 (1.1, 3.4)  
Clinical / immune status       
WHO clinical stage 3-4 (n=1506) 90 (9%) 48 (21%) 2=23.81 p<0.01 12 (17%) 88 (35%) 2=8.41 p<0.01 
CD4 count (cells/mm3) (n=1410)       
≤200 75 (8%) 18 (8%) 2=0.45 p=0.80 6 (10%) 34 (14%) 2=1.21 p=0.55 
201-350 162 (18%) 45 (20%)  12 (19%) 48 (20%)  
>350 651 (73%) 160 (72%)  45 (71%) 154 (65%)  
Taking ART postnatally (n=1512) 218 (23%) 61 (26%) 2=0.91 p=0.34 12 (17%) 81 (32%) 2=6.02 p=0.01 
1Syphilis and gonorrhoea omitted due to small numbers; 2t-test on log-transformed values
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Under-ascertainment of IDU 
Population level characteristics suggest that in many respects the 236 HCV-seropositive non-IDUs 
were more similar to HCV-seronegative non-IDUs than to women with a reported IDU history.  
Smoking and postnatal alcohol use are both associated with IDU in this population (see Table 5.6a 
and Figure 5.1, page 153), but there was no difference in these behaviours by HCV serostatus 
among non-IDUs (Table 5.6a). Results from the Ukraine ECS showed that women with an IDU 
history were more likely to be diagnosed with HIV late in pregnancy and to miss out on antenatal 
ART if diagnosed (see sections 3.2.3, page 90 and 3.2.4, page 96), but neither of these outcomes 
were more common among HCV-seropositive than HCV-seronegative non-IDUs (16% (21/131) 
vs. 14% (76/559) respectively for late diagnosis (2 =0.52 p=0.47), and 3% (4/158) vs. 2% (13/626) 
respectively for lack of antenatal ART (2 =0.12 p=0.73)). Adverse birth outcomes are strongly 
associated with maternal IDU history among HIV-positive women in Ukraine (Thorne et al. 2012), 
and maternal HCV infection may be associated with poor perinatal outcomes independent of IDU 
(Connell et al. 2011). However, HCV-seropositive non-IDUs were not at a greater risk of preterm 
delivery or having a low birth weight infant than HCV-seronegative non-IDUs (Table 5.7).  
Table 5.7: Birth outcomes by HCV serostatus and IDU history (among women in the ECS) 
  
 
Non-IDUs 
   
 
IDUs 
  Non-
IDUs vs. 
IDUs 
 HCV 
seronegative 
HCV 
seropositive 
 HCV 
seronegative 
HCV 
seropositive 
  
Preterm 
delivery 
6%           
(47/760) 
10%             
(20/210) 
2=2.85 
p=0.09 
14%             
(9/63) 
17% 
(39/224) 
2=0.34 
p=0.56 
2=40.40 
p<0.01 
Low 
birth 
weight 
9%            
(66/726) 
7%             
(15/201) 
2=0.52 
p=0.47 
16%            
(10/63) 
20% 
(44/217) 
2=0.61 
p=0.44 
2=36.88 
p<0.01 
 
Finally, a history of imprisonment was reported by 14% (47/327) of IDUs with HCV serostatus 
available and only 0.4% (5/1202) of non-IDUs, with no difference by HCV serostatus (Table 5.6b). 
Neonatal abstinence syndrome occurs in 60-80% of infants exposed to opiates during pregnancy 
(Bandstra et al. 2010). Of the 72 infants born with neonatal abstinence syndrome in the Ukraine 
ECS from 2008-10, only seven (10%) were born to women who had not reported an IDU history 
or had this detected by their clinician, suggesting that identification of heavy and recent opiate use 
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in pregnancy is fairly complete. It is more difficult to rule out a pre-conception history of opiate 
use, particularly among women who have only ever been infrequent injectors or experimenters. 
Ephedrine-based stimulants are sometimes injected alone as well as in combination with opiates in 
Ukraine (Booth et al. 2008), but their use during pregnancy is also associated with adverse birth 
outcomes (Minnes et al. 2011). 
The 13 non-IDUs who were diagnosed with HCV antibodies at the same time as or prior to their 
HIV diagnosis (and did not have an IDU partner reported) may have an unreported history of 
IDU, or had another indication for HCV testing (e.g. liver dysfunction).  
Among non-IDUs, those with antibodies to HCV were more likely to have been diagnosed with 
HIV prior to their most recent pregnancy (39% (83/214) vs. 29% (228/787) of HCV seronegative 
non-IDUs respectively, 2 =7.57 p<0.01) and to have WHO stage 3-4 disease (Tables 5.6a and 
5.6b), both characteristics associated with an IDU history in this population (see section 3.2.2, page 
80). However, among non-IDUs, a longer duration of diagnosed HIV infection and more advanced 
HIV disease could also be associated with an increased risk of sexual HCV acquisition (due to 
immunosuppression) and iatrogenic acquisition (due to longer history and more frequent episodes 
of hospitalisation). In addition, HBV co-infection negatively impacts on HIV disease progression 
(Chun et al. 2011) and here was associated with HCV co-infection among non-IDUs (Table 5.6b). 
HCV co-infection may itself also accelerate HIV disease progression, although the evidence for this 
is conflicting (Law et al. 2004; Potter et al. 2010). 
Among non-IDUs, HCV seropositivity was also associated with having an IDU partner (Table 
5.6a), which may indicate an increased likelihood of unreported IDU history (including 
experimenting), but also indicates sexual exposure to HCV and the possibility of household 
transmission. 
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Markers of sexual risk among HCV seropositive non-IDUs 
Risk of sexual HCV transmission is thought to be low overall, but is increased in the presence of 
mucosal damage and HIV co-infection (Tohme et al. 2010). This lends plausibility to the hypothesis 
that HIV/HCV co-infected women who acquired HIV sexually may also have acquired HCV from 
a sexual partner. No data were collected in the Women’s Study on specific risky sexual practices 
(e.g. anal sex), and only seven women reported sex work as a risk factor for HIV acquisition (five 
non-IDUs, one of whom was HCV seropositive). However, other STI diagnoses indicate risky 
sexual behaviours, and STIs may also increase the risk of sexual HCV acquisition in their own right 
– for example, by causing genital ulcer disease.  
Prevalence of other STIs by HCV serostatus was therefore explored among non-IDUs. Analyses 
were stratified by centre as there were significant centre differences in the prevalence of HCV 
among non-IDUs (see Table 5.8, 2 =40.36 p<0.01; Note: Krivoy Rog was excluded due to very 
low screening coverage). The three infections that were more common overall among HCV 
seropositive than seronegative non-IDUs (HBsAg, chlamydia and HSV-2 – see Table 5.6b, page 
172) also had varying prevalence by HIV/AIDS centre (Table 5.8). This likely reflects local 
differences in important aspects of the risk environment, for example access to STI prevention and 
treatment services and prevalence of sex work and IDU in the general population. Although only 
10% (128/1261) of non-IDUs were aware of and reported IDU in their partner (Table 5.6a, page 
171), the proportion exposed to HCV sexually will be much larger; around half of all HIV-positive 
people in Ukraine are estimated to be HCV seropositive and this figure is probably higher among 
men, who account for the majority of IDUs (Pinkham et al. 2008; Open Society Institute 2010). 
Table 5.8 summarises national and regional data available from Ukraine on prevalence of HCV 
among IDUs and HIV-positive people - important in understanding sexual HCV acquisition risk 
among HIV-positive non-IDUs. 
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Table 5.8: Indicators of sexual risk environment among non-IDUs.  
 Kiev Odessa Mykolaiv Donetsk 
Regional HIV prevalence among IDUs 
– sentinel surveillance data (Ministry of 
Health of Ukraine 2012) 
18.1% 31.6% 43.8% 28.5% 
HCV seroprevalence among IDUs:  
National estimate 
 
62% (Open Society Institute 2010) (no regional sentinel data) 
HCV seroprevalence among female 
IDUs in Women’s Study: 
Proportion tested 
 
Of tested, proportion positive 
 
 
 
85% 
(204/239) 
89% 
(182/204) 
 
 
78% 
(75/96) 
56%  
(42/75) 
 
 
86% 
(38/44) 
79%  
(30/38) 
 
 
31%  
(10/32) 
20%  
(2/10) 
Proportion of non-IDUs with IDU 
partner 
14% (60/428) 10% (26/263) 16% (51/321) 7% (9/138) 
Estimated national HCV seroprevalence 
among people living with HIV (Open 
Society Institute 2010) 
No regional data – estimated at 53% nationally 
Prevalence of HCV-seropositivity 
among non-IDUs 
25% 
(112/452) 
10%  
(30/307) 
24%  
(83/347) 
7%  
(6/91) 
Proportion reporting contraception to 
be affordable among non-IDUs 
96%  
(486/504) 
84% 
(329/392) 
76% 
(252/331) 
51%  
(82/162) 
Proportion reporting contraception to 
be accessible among non-IDUs 
98%  
(486/497) 
85% 
(334/391) 
91% 
(117/129) 
60%  
(97/162) 
Proportion using condoms (any) among 
non-IDUs sexually active at postnatal 
cohort enrolment 
95%  
(392/411) 
82% 
(272/332) 
93% 
(240/259) 
92%  
(84/91) 
Coverage and results of recent STI tests among non-IDUs 
HSV-2:  
Proportion tested 
       
Of tested, proportion positive 
 
62% 
(322/520) 
81% 
(260/322) 
 
93% 
(366/394) 
21% 
(77/366) 
 
86% 
(315/365) 
80% 
(251/315) 
 
18%  
(31/169) 
10%  
(3/31) 
Chlamydia:  
Proportion tested 
 
Of tested, proportion positive 
 
53% 
(278/520) 
27%  
(74/278) 
 
93% 
(367/394) 
20%  
(72/367) 
 
1%  
(2/365) 
0% 
(0/2) 
 
62% 
(104/169) 
3%  
(3/104) 
HBsAg:  
Proportion tested 
 
Of tested, proportion positive 
 
88% 
(459/520) 
2%  
(7/459) 
 
96% 
(377/394) 
15%  
(56/377) 
 
92% 
(337/365) 
36% 
(122/337) 
 
89% 
(151/169) 
1%  
(2/151) 
Shaded cells indicate national or regional data 
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No consistent associations were found between recent STI diagnosis and HCV seropositivity 
among non-IDUs across centres (Table 5.9), although power was limited by the small number of 
women tested for each combination of infections at some of the centres. When data from Odessa 
and Kiev centres were pooled, recent chlamydia diagnosis was associated with a 42% increased risk 
of HCV seropositivity among non-IDUs overall (APR 1.42 95% CI 0.99, 2.04 p=0.06, adjusted for 
centre), suggesting a possible association between recent risky sexual behaviour and HCV 
antibodies. Of note, a recent chlamydia diagnosis was also associated with an IDU history (see 
Table 5.5a page 164), and so this association could also be explained by under-ascertainment of 
IDU.
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Table 5.9: Association between recent STI diagnoses and HCV seropositivity among non-IDUs, by centre† 
†Donetsk is excluded from the table, as only six non-IDUs were HCV-seropositive at this centre. 
 
 
 
 
 
 Kiev  Odessa  Mykolaiv  
 Proportion (n) 
seropositive for HCV 
among those tested 
Unadjusted Prevalence 
Ratio (95% CI) 
Proportion (n) 
seropositive for HCV 
among those tested 
Unadjusted Prevalence 
Ratio (95% CI) 
Proportion (n) 
seropositive for HCV 
among those tested 
Crude Prevalence Ratio 
(95% CI) 
HSV-2 antibody test       
Negative 23% (14/61) 1.00 9% (20/234) 1.00 22% (14/63) 1.00 
Positive 30% (70/237) 1.29 (0.78, 2.12) p=0.32 14% (8/59) 1.59 (0.73, 3.43) p=0.24 25% (63/248) 1.14 (0.69, 1.90) p=0.61 
Chlamydia test       
Negative 25% (48/193) 1.00 9% (23/244) 1.00 0% (0/2) Omitted due to lack of 
data Positive 37% (25/68) 1.48 (0.99, 2.20) p=0.05 12% (6/51) 1.25 (0.53, 2.91) p=0.61 0% (0/0) 
HBsAg       
Negative 24% (104/436) 1.00 10% (26/256) 1.00 15% (33/215) 1.00 
Positive 14% (1/7) 0.60 (0.10, 3.71) p=0.58 8% (4/49) 0.80 (0.29, 2.20) p=0.67 42% (49/118) 2.71 (1.85, 3.96) p<0.01 
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Possible markers of iatrogenic risk among HCV-seropositive non-IDUs 
No data are available in the ECS or Women’s Study on receipt of tattoos, dental work or 
acupuncture, and data on receipt of blood transfusions are also not routinely collected (unless 
reported as the mode of HIV acquisition). However, parity and history of pregnancy termination 
give some indication of prior exposure to medical procedures and/or a healthcare environment. 
Table 5.10 shows the associations between these factors and HCV seropositivity among non-IDUs, 
adjusting for centre, to account as much as possible for regional variation in HCV seroprevalence 
and thus risk of acquisition in a medical setting. 
Table 5.10: Association between possible markers of iatrogenic risk and HCV seropositivity 
among non-IDUs 
 Proportion (n) 
seropositive for 
HCV among those 
tested 
Unadjusted PR (95% 
CI) 
PR adjusted for centre 
(95% CI) 
History of pregnancy 
termination (n=965) 
   
0 20% (109/546) 1.00 1.00 
1 19% (35/182) 0.96 (0.68, 1.36) p=0.83 1.01 (0.72, 1.43) p=0.94 
≥2 28% (66/237) 1.39 (1.07, 1.82) p=0.01 1.42 (1.07, 1.87) p=0.02 
Parity (n=958)    
1 19% (97/505) 1.00 1.00 
2 22% (72/328) 1.14 (0.87, 1.50) p=0.34 1.14 (0.87, 1.49) p=0.34 
≥3 33% (41/125) 1.71 (1.25, 2.32) p<0.01 1.67 (1.23, 2.26) p<0.01 
  
In this cohort of childbearing women, non-IDUs with ≥2 previous pregnancy terminations or ≥3 
previous births were significantly more likely to be HCV seropositive than those with no history of 
termination or only one birth respectively. However, both of these characteristics were also more 
common among women with a reported IDU history (31% (110/359) of IDUs had a history of 
multiple pregnancy terminations vs. 23% (297/1306) of non-IDUs, 2 =9.87 p<0.01, and 52% 
(182/348) of IDUs had ≥3 previous births vs. 46% (595/1294) of non-IDUs, 2 =4.39 p=0.04). 
Risky sexual behaviour is associated with IDU (Booth et al. 2007) and may also be independently 
associated with multiparity and a history of multiple pregnancy terminations. In the absence of 
more direct measures of iatrogenic risk, inferences cannot be made regarding the acquisition of 
HCV in medical settings in this population.  
  
 180 
 
Other methods of drug administration 
Non-injection drug use, particularly of crack, has been implicated in HCV transmission elsewhere 
(Neaigus et al. 2007; Nurutdinova et al. 2011). However, cocaine costs around €130 per gram in 
Ukraine, making it unaffordable for the vast majority of drug users (use is reported at <3% drug 
users overall (Viyevskyy et al. 2010)). In the Women’s Study, only one woman reported using 
cocaine. No data are available on other drugs and methods of administration in this study  (e.g. 
smoked opium and snorted dried poppy juice, previously reported by 8% and 4% of drug users in 
central Ukraine respectively (Dumchev et al. 2009)). It is possible that non-injection drug use 
contributes to HCV acquisition risk among non-IDUs. 
Markers of liver fibrosis among HCV co-infected women 
Only 1% (5/441) of the HCV seropositive women had received HCV treatment by enrolment, with 
an additional three women (of 33 with information available) receiving treatment at follow-up 
(median duration of follow-up of HCV seropositive women was 11 months). Pegylated interferon 
and ribavirin (PegIFN/RBV), the standard of care for HCV treatment during these years, is not 
publicly funded in Ukraine. Its cost ($16,667 for a 48 week course in 2009 (Open Society Institute 
2010)) is prohibitive to the vast majority of HCV-infected individuals. 
Median FIB-4 scores were 0.62 (IQR 0.43, 0.95) for HCV seronegative women and 0.92 (IQR 0.62, 
1.38) for HCV seropositive women (t-test p<0.01). Median APRI scores were also significantly 
higher in the presence of HCV co-infection (0.50 (IQR 0.33, 0.82) compared with 0.29 (IQR 0.19, 
0.45) among HCV seronegative women, t-test p<0.01). Among co-infected women, both scores 
were higher among women with an IDU history (Table 5.11), indicating greater likelihood of liver 
fibrosis. 
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Table 5.11: FIB-4 and APRI scores among HCV seropositive women by IDU history 
 HCV 
seronegative 
HCV 
seropositive 
  
  No IDU 
history 
(n=236) 
IDU history 
(n=256) 
t-test for 
difference by 
IDU history 
among HCV 
seropositive 
Median FIB-4 score (IQR) 
(n=430) 
0.62 
(0.43, 0.95) 
0.78  
(0.57, 1.08) 
1.11  
(0.72, 1.56) 
p<0.01 
Median APRI score (IQR) 
(n=433) 
0.29 
(0.19, 0.45) 
0.42  
(0.27, 0.60) 
0.60  
(0.38, 0.99) 
p<0.01 
 
Compared with non-IDUs, IDUs were more likely to be using alcohol postnatally and also to be on 
ART (27% (116/432) of IDUs were on ART postnatally vs. 22% (348/1614) of non-IDUs, 2 
=5.44 p=0.02) - both factors increasing the risk of liver dysfunction. IDUs may also have been 
infected with HCV for longer, both because of earlier exposure and older age at cohort enrolment, 
and thus have more advanced HCV disease. Among 41 women with information available, median 
age at initiating IDU was 17 years. Median time to HCV infection following IDU initiation is 
estimated to be 3-4 years in cohorts in Canada, the US and Australia (Hagan et al. 2004; Maher et al. 
2006; Roy et al. 2009), but may be shorter in Ukraine where coverage of harm reduction services is 
low and high-risk injection practices are commonplace. IDUs were a median of 29 years of age at 
cohort enrolment, and so many may have been infected with HCV for 10 or more years. Only ten 
women were taking ≥1 antituberculosis drugs associated with liver toxicity at cohort enrolment 
(isoniazid (n=9), pyrazinamide (n=1) and unspecified tuberculosis treatment (n=2)), five of whom 
were HCV seropositive. 
Overall, 79% (338/430) of HCV seropositive women had a FIB-4 score <1.45 indicating no 
advanced fibrosis and 1% (3/430) had a FIB-4 score >3.25 associated with advanced fibrosis. 
Using the APRI score (which is possibly less specific than FIB-4 due to validation in mono-HCV 
infected patients only), 51% (220/433) had a score of ≤0.5 which indicates the absence of 
significant fibrosis and 8% (34/433) had a score of >1.50, predicting significant fibrosis. In total, 
843 HCV seronegative women and 430 HCV seropositive women had data allowing for calculation 
of both APRI and FIB-4 scores. Table 5.12 shows the distribution of these women’s scores. 
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Table 5.12: FIB-4 and APRI scores among 843 HCV seronegative women (blue) and 430 
HCV seropositive women (red). 
 
  APRI score   
  ≤0.5  (no 
significant 
fibrosis) 
0.5-1.50 
(indeterminate) 
>1.50 
(significant 
fibrosis) 
FIB-4 score <1.45 (no 
advanced 
fibrosis) 
663 
212 
115 
120 
0 
6 
 1.45-3.25 
(indeterminate) 
2 
1 
51 
64 
4 
24 
 >3.25 (advanced 
fibrosis) 
0 
0 
3 
0 
5 
3 
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5.4 Cervical screening and factors associated with an abnormal finding 
Objectives of this section 
1. To explore coverage of cervical screening as part of HIV care. 
2. To investigate factors associated with an abnormal finding on cervical screening.  
Methods 
This analysis is limited to 1120 women enrolled at Odessa, Kiev and Donetsk HIV/AIDS centres 
by March 2011 (Krivoy Rog and Mykolaiv HIV/AIDS centres did not report any cervical screening 
results and are excluded from these analyses). Information on cervical screening tests received as 
part of HIV care was collected at enrolment and at follow-up.  
Study centre and year of enrolment (December 2007-08, 2009, 2010-11) were included a priori in 
the multivariable analysis of factors associated with having a test reported, to account for 
differences in local policy and changing clinical practice over time. Variables which remained 
significantly associated with the outcome after these adjustments (Wald’s test p<0.1) were included 
in the multivariable model. In analysis of factors associated with an abnormal finding on cervical 
screening, all variables known to be associated with invasive cervical cancer and available in the 
dataset were included a priori (use of oral hormonal contraception, smoking, parity, HSV-2 
antibodies, chlamydia infection and CD4 count) (Muñoz et al. 2006). Other variables were 
considered for inclusion in the multivariable model only if significant in univariable analyses. 
Results of cervical cytology were reported according to the 2001 Bethesda System as negative for 
intraepithelial lesion or malignancy (‘normal’), low-grade squamous intraepithelial lesion (LSIL) 
(corresponding to HPV / mild dysplasia / cervical intraepithelial neoplasia (CIN) 1) and high-grade 
squamous intraepithelial lesion (HSIL) (corresponding to moderate and severe dysplasia, carcinoma 
in situ; CIN 2 and CIN 3) (Solomon et al. 2002). A finding of LSIL or HSIL was defined as an 
abnormal result. 
Previous pregnancy (including stillbirths, live births, miscarriages and terminations) was examined 
as a measure of previous access to gynaecological or obstetric care. 
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Cervical screening test receipt 
Just under one third of women (337/1120) had a cervical screening test reported at enrolment. 
Cohort characteristics and prevalence of co-infections by cervical screening test receipt are shown 
in Tables 5.13 and 5.14 respectively. The 1120 women included in this analysis were enrolled into 
the Women’s Study at a median 10 months postpartum (83% (924/1120) at ≥12 weeks postpartum, 
beyond the period in which cervical screening may be postponed to allow for regression of 
hormonal changes and healing of the cervix (NHS Cancer Screening Programmes 2006). Women 
diagnosed as HIV-positive fewer than six months before enrolment - six months being the 
screening interval specified for all women of childbearing age by Ukrainian policy - accounted for 
7% (69/970). 
Timing of screening tests reported at enrolment  
Over half of those with date of cervical screening test reported (180/310) had received their most 
recent test postnatally (median 28 weeks after delivery, 17% (30/180) <12 weeks after delivery), 
24% (74/310) during pregnancy and 18% (56/310) pre-conception. Most (69%, 232/334) had been 
tested over six months and 34% (115/334) over one year previously (median 40 weeks prior to 
enrolment). There were differences in timing of cervical screening tests by centre: almost half 
(44/90) of tests reported in Odessa and 13/15 of those at Donetsk were conducted during 
pregnancy vs. only 17/205 at Kiev, where the majority of tests reported were performed 
postnatally. Overall, women diagnosed with HIV prior to conception were more likely than those 
diagnosed antenatally or intrapartum to have a screening test reported at enrolment (44% (136/306) 
versus 26% (176/665), 2 =31.06 p<0.01). Of the 783 women with no test at baseline, 22% 
(n=176) had follow-up data available, of whom 39% (68/176) had been screened at follow-up. 
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Table 5.13: Cohort characteristics by cervical screening test report 
 Test reported at 
enrolment  
(n=337) 
No test at 
enrolment 
(n=783) 
Median age at enrolment (IQR) 28.0  
(25.2, 31.3) 
27.0  
(23.7, 30.2) 
Marital status (n=1113)   
Married 225 (67%)  412 (53%)  
Cohabiting 73 (22%)  235 (30%)  
Single† / widowed / divorced 38 (11%)  130 (17%)  
Previous pregnancies‡ (n=903)   
1 95 (32%)  287 (47%)  
2 87 (29%)  147 (24%)  
3 or more 116 (39%)  171 (28%) 
Age at leaving full-time education (n=653)   
≤16 years 32 (14%)  71 (16%) 
17-18 years 44 (20%)  84 (19%) 
≥19 years 146 (66%)  276 (64%)  
History of injecting drug use (n=1120)   
No 247 (73%) 616 (79%) 
Yes 90 (27%) 167 (21%) 
Alcohol use postnatally (n=1104)   
No 268 (81%) 603 (78%) 
Yes 63 (19%) 170 (22%) 
History of smoking (n=1114)   
No 98 (29%) 238 (31%) 
Yes 236 (71%) 542 (69%) 
Current smoking (n=1111)   
No 153 (46%) 389 (50%) 
Yes 181 (54%) 388 (50%) 
Disclosure of HIV status to anyone (n=1120)   
No 15 (4%) 42 (5%) 
Yes 322 (96%) 741 (95%) 
Disclosure of HIV status to family / friends (n=1120)   
No 107 (32%) 293 (37%) 
Yes 230 (68%) 490 (63%) 
Disclosure of HIV status to partner (n=1120)   
No 67 (20%) 189 (24%) 
Yes 270 (80%) 594 (76%) 
WHO stage (n=1109)   
1-2 255 (76%) 657 (85%) 
3-4 82 (24%) 115 (15%) 
CD4 count (n=959)   
≤ 200 cells/mm3 22 (7%)  63 (10%)  
201-350 cells/mm3 56 (18%)  114 (18%)  
> 350 cells/mm3 234 (75%)  470 (73%)  
Median 468 cells/mm3 456 cells/mm3 
Taking ART postnatally (n=1114)   
No 262 (78%) 643 (82%) 
Yes 72 (22%) 137 (18%) 
Any OC‡ use reported postnatally (n=1120)   
No 291 (86%) 715 (91%) 
Yes 46 (14%) 68 (9%) 
Can afford family planning (self-report) (n=1089)   
No 40 (12%) 179 (24%) 
Yes 292 (88%) 578 (76%) 
†Includes non-cohabiting partnerships; ‡Previous pregnancies include still births, live births, 
miscarriages and terminations. OC, oral hormonal contraceptive. 
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Table 5.14: Co-infections by cervical screening test report at enrolment 
 Test reported at 
enrolment (n=337) 
No test at 
enrolment (n=783) 
Chlamydia (n=851) 71 (25%) 144 (25%)  
Syphilis (n=907) 13 (4%)  17 (3%)  
Trichomonas vaginalis (n=645) 19 (6%) 52 (15%)  
HSV-2 antibodies (n=806) 156 (55%)      255 (49%)  
Vulvo-vaginal candida (n=739) 134 (43%)  232 (54%)  
Bacterial vaginosis (n=731) 67 (22%) 59 (14%)  
Hepatitis C seropositive (n=872) 120 (41%)  179 (31%)  
Hepatitis B surface antigen positive (n=1002) 23 (7%) 61 (9%)  
 
Factors associated with having a cervical screening test result reported 
There was no significant change over time in the proportion of women with a screening test 
reported as part of HIV care at study enrolment (30% overall, p=0.87) but significant differences by 
centre from 11% (19/173) in Donetsk to 26% (111/419) in Odessa and 39% (207/528) in Kiev (2 
=53.46, p<0.01). In univariable analyses, age, marital status, number of previous pregnancies, IDU 
history, WHO clinical stage, timing of HIV diagnosis, affordability of contraception and centre 
were significantly associated with having a screening test at the HIV/AIDS centre (Tables 5.15a 
and 5.15b). HCV seropositivity and IDU history were both associated with report of a screening 
test in univariable analysis (2 =9.69, p<0.01 and 2 =3.85, p=0.05 respectively), but not after 
adjusting for year and centre (p=0.44 and p=0.48 respectively) and were therefore excluded from 
the multivariable model. Other factors that were not associated with having a test reported were 
smoking (current or history), current alcohol use, disclosure of HIV status to a partner, postnatal 
ART receipt and CD4 count. 
BV was more common among women with a cervical screening test result reported than among 
those without (22% (67/311) vs. 14% (59/420) respectively, 2 =7.04, p<0.01). The opposite was 
true for TV (6% (19/297) prevalence among those with a cervical screening test vs. 15% (52/348) 
among those without, 2 =11.94, p<0.01) and vulvo-vaginal candida (43% (134/309) prevalence 
among those with a cervical screening test vs. 54% (232/430) among those without, 2 =8.06, 
p<0.01). There was no difference in probability of having a screening test reported HSV-2 antibody 
status (2 =2.47, p=0.12). All of these infections are associated with genital symptoms which may 
prompt a pelvic examination and opportunistic cervical screening test. Conversely, if an incidental 
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finding of genital infection is made during pelvic examination for cervical screening and discharge 
or bleeding is present, the screening test may be postponed until the infection is treated. Due to 
these problems with interpretation, diagnosis of genital infection was not examined as an 
explanatory variable in analyses investigating factors associated with having a cervical screening test 
result reported. 
Of note, women who had not been tested for BV, TV, candida or HSV-2 antibodies were less likely 
to have a cervical screening test result reported than women who were tested and negative for these 
infections (p<0.01 for all three infections), indicating that common factors underlie access to and 
uptake of both tests for genital infections and cervical screening.  
In the multivariable model (Tables 5.15a and 5.15b), there were significant differences in reporting 
of cervical screening tests by centre (Wald’s test p<0.01), and women were twice as likely to have a 
test reported if diagnosed prior to their most recent pregnancy than during the 3rd trimester or 
intrapartum. Women with one previous pregnancy (vs. ≥2) were less likely to have a test reported 
(p=0.05).  
In order to investigate factors associated with being screened among women with the longest 
exposure to HIV care, a sub-analysis was conducted limited to the 306 women diagnosed with HIV 
before their most recent pregnancy. In this group, 44% (136/306) of whom had a cervical screening 
test result reported at enrolment, age, marital status, affordability of contraception, HIV disclosure, 
WHO stage and centre were significantly associated with reporting of a test result in univariable 
analyses (Table 5.16). In multivariable analyses adjusting for year, centre and affordability of 
contraception, women leaving full-time education at ≤16 (vs. ≥19) years of age and who were 
cohabiting (vs. married) were less likely to have a test reported, although the latter was not 
statistically significant (p=0.06). The four-category age variable did not significantly contribute to fit 
of the model when adjusting for year and centre (Wald’s test p=0.14), however women ≥27 years 
were significantly more likely to have a test reported than those <27 years when a binary variable 
was used (APR 1.57, 95% CI 1.11-2.20 adjusting for marital status, education, affordability of 
contraception, year and centre, p=0.01). 
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Table 5.15a: Factors associated with having a cervical screening test reported at study enrolment (continued in Table 5.15b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Limited to 870 women included in the multivariable model ‡Adjusted for all factors in final model: age, marital status, previous pregnancies, WHO stage, timing of HIV 
diagnosis, affordability of contraception, year and centre of enrolment
 Proportion (n) 
with test 
Unadjusted PR(95% 
CI) 
PR (95% CI) adjusted for 
year and centre 
PR (95% CI) adjusted for 
year and centre n=870† 
Adjusted PR‡ – (95% 
CI) n=870 
Age at enrolment      
16-23 years 21% (55/265) 1.00 1.00 1.00 1.00 
24-26 years 31% (78/255) 1.47 (1.09,1.99) p=0.01 1.37 (1.02,1.84) p=0.04 1.18 (0.86,1.62) p=0.32 1.07 (0.78,1.47) p=0.68 
27-30 years 33% (111/339) 1.58 (1.19,2.09) p<0.01 1.40 (1.06,1.85) p=0.02 1.33 (0.99,1.79) p=0.06 1.13 (0.84,1.51) p=0.42 
≥31 years 36% (92/257) 1.72 (1.29,2.30) p<0.01 1.64 (1.23,2.17) p<0.01 1.49 (1.10,2.10) p<0.01 1.24 (0.90,1.69) p=0.18 
Marital status      
Married 35% (225/637) 1.00 1.00 1.00 1.00 
Cohabiting 24% (73/308) 0.67 (0.54,0.84) p<0.01 0.74 (0.59,0.93) p=0.01 0.77 (0.60,0.98) p=0.04 0.81 (0.63,1.04) p=0.10 
Single / widowed/ divorced 23% (38/168) 0.64 (0.47,0.86) p<0.01 0.70 (0.52,0.94) p=0.02 0.73 (0.54,0.99) p=0.04 0.84 (0.61,1.16) p=0.29 
Previous pregnancies at 
enrolment 
     
≥2 39% (203/521) 1.00 1.00 1.00 1.00 
1 25% (95/382) 0.64 (0.52,0.78) p<0.01 0.65 (0.53,0.80) p<0.01 0.66 (0.54,0.81) p<0.01 0.80 (0.65,1.00) p=0.05 
History of IDU      
No 29% (247/863) 1.00 1.00   
Yes 35% (90/257)   1.22 (1.00,1.49) p=0.05 1.07 (0.88,1.31) p=0.48   
WHO clinical stage      
1-2 28% (255/912) 1.00 1.00 1.00 1.00 
3-4 42% (82/197) 1.49 (1.22,1.81) p<0.01 1.36 (1.11,1.65) p<0.01 1.30 (1.06,1.59) p=0.01 1.07 (0.87,1.32) p=0.51 
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Table 5.15b: Factors associated with having a cervical screening test reported at study enrolment (continued from Table 5.15a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Limited to 870 women included in the multivariable model ‡Adjusted for all factors in final model: age, marital status, previous pregnancies, WHO stage, timing of HIV 
diagnosis, affordability of contraception, year and centre of enrolment
 Proportion (n) 
with test 
Unadjusted PR(95% 
CI) 
PR (95% CI) adjusted 
for year and centre 
PR (95% CI) adjusted 
for year and centre 
n=870† 
Adjusted PR‡ – (95% 
CI) n=870 
Timing of HIV diagnosis      
Prior to conception 44% (136/306) 1.00 1.00 1.00 1.00 
1st / 2nd trimesters 28% (155/545) 0.64 (0.53,0.77) p<0.01 0.59 (0.49,0.70) p<0.01 0.57 (0.47,0.68) p<0.01 0.62 (0.51,0.75) p<0.01 
3rd trimester / intrapartum 18% (21/120) 0.39 (0.26,0.59) p<0.01 0.36 (0.24,0.53) p<0.01 0.37 (0.25,0.55) p<0.01 0.42 (0.28,0.63) p<0.01 
Affordability of contraception      
Can afford 34% (292/870) 1.00 1.00 1.00 1.00 
Can’t afford 18% (40/219) 0.54 (0.40,0.73) p<0.01 0.71 (0.52,0.95) p=0.02 0.77 (0.56,1.06) p=0.12 0.76 (0.54,1.07) p=0.12 
Year of enrolment      
2007/08 30% (101/339) 1.00 1.00 1.00 1.00 
2009 31% (135/435) 1.04 (0.84,1.29) p=0.71 0.90 (0.73,1.12) p=0.36 0.94 (0.74,1.18) p=0.59 0.96 (0.76,1.20) p=0.71 
2010/11 29% (101/344) 0.99 (0.78,1.24) p=0.90 0.93 (0.74,1.17) p=0.54 1.04 (0.81,1.32) p=0.78 0.97 (0.76,1.23) p=0.80 
Centre of enrolment      
Odessa 26% (111/419) 1.00 1.00 1.00 1.00 
Kiev 39% (207/528) 1.48 (1.22,1.79) p<0.01 1.51 (1.24,1.84) p<0.01 1.28 (1.03,1.59) p=0.03 1.32 (0.07,1.63) p<0.01 
Donetsk 11% (19/173) 0.41 (0.26,0.65) p<0.01 0.42 (0.27,0.67) p<0.01 0.43 (0.26,0.72) p<0.01 0.49 (0.29,0.82) p<0.01 
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Table 5.16: Factors associated with cervical screening test reported at study enrolment, among women diagnosed with HIV prior to most recent pregnancy 
 Proportion (n) 
with test 
Unadjusted PR(95% CI) PR (95% CI) adjusted for 
year and centre 
PR (95% CI) adjusted for 
year and centre, n=207† 
Adjusted PR‡(95% CI) 
n=207 
Age at enrolment      
16-23 years 27% (12/44) 1.00 1.00   
24-26 years 39% (24/62) 1.42 (0.80,2.53) p=0.23 1.32 (0.76,2.29) p=0.33   
27-30 years 51% (56/110) 1.87 (1.11,3.13) p=0.02 1.66 (1.00,2.75) p=0.05   
≥31 years 49% (44/89) 1.81 (1.07,3.07) p=0.03 1.66 (1.00,2.76) p=0.05    
Marital status      
Married 55% (99/180) 1.00 1.00 1.00 1.00 
Cohabiting 30% (24/80) 0.55 (0.38,0.78) p<0.01 0.63 (0.44,0.90) p=0.01 0.51 (0.29,0.90) p=0.02 0.58 (0.32,1.03) p=0.06 
Single / widowed / divorced 27% (12/44) 0.50 (0.30,0.82) p<0.01 0.58 (0.36,0.94) p=0.03 0.63 (0.36,1.09) p=0.10 0.74 (0.42,1.31) p=0.30 
Age at leaving full-time education      
≥19 years 50% (60/121) 1.00 1.00 1.00 1.00 
17-18 years 46% (21/46) 0.92 (0.64,1.32) p=0.66 0.73 (0.52,1.04) p=0.08 0.76 (0.54,1.08) p=0.13 0.79 (0.56,1.13) p=0.20 
≤16 years 36% (17/47) 0.73 (0.48,1.11) p=0.14 0.55 (0.36,0.83) p<0.01 0.56 (0.37,0.84) p=0.01 0.66 (0.44,1.01) p=0.05 
Affordability of contraception      
Can afford 51% (114/223) 1.00 1.00 1.00 1.00 
Can’t afford 25% (19/75) 0.50 (0.33,0.75) p<0.01 0.68 (0.45,1.02) p=0.06 0.57 (0.33,0.98) p=0.04 0.79 (0.44,1.43) p=0.44 
HIV status disclosure to family or 
friends 
     
Yes 51% (95/188) 1.00 1.00   
No 35% (41/118) 0.69 (0.52,0.91) p=0.01 0.89 (0.68,1.17) p=0.41   
WHO stage      
1-2 41% (82/202) 1.00 1.00   
3-4 53% (54/101) 1.32 (1.03,1.69) p=0.03 1.19 (0.94,1.51) p=0.15   
Year of enrolment      
2007/08 38% (36/95) 1.00 1.00 1.00 1.00 
2009 45% (44/98) 1.18 (0.84,1.66) p=0.33 1.13 (0.79,1.60) p=0.51 0.95 (0.63,1.45) p=0.82 0.85 (0.58,1.24) p=0.39 
2010/11 50% (56/112) 1.32 (0.96,1.81) p=0.09 1.26 (0.90,1.75) p=0.18 1.06 (0.69,1.63) p=0.78 0.91 (0.61,1.36) p=0.66 
Centre of enrolment      
Odessa 48% (49/102) 1.00 1.00 1.00 1.00 
Kiev 56% (78/139) 1.17 (0.91,1.50) p=0.22 1.10 (0.84,1.44) p=0.48 1.24 (0.79,1.94) p=0.35 1.11 (0.73,1.69) p=0.63 
Donetsk 14% (9/65) 0.29 (0.15,0.55) p<0.01 0.28 (0.15,0.55) p<0.01 0.38 (0.18,0.82) p=0.01 0.38 (0.18,0.80) p=0.01 
†Limited to 207 women included in the multivariable model ‡Adjusted for: marital status, age at leaving full-time education, affordability of contraception, year and centre 
of enrolment
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Cervical abnormalities  
At enrolment, among the 30% with a screening test result reported, prevalence of cervical 
abnormalities at the most recent test was 21% (68/325) overall (17% (n=54) LSIL and 4% (n=14) 
HSIL). Results were not available for 4% (12/337) of those tested, presumably because the sample 
was inadequate. In total, 38% (123/325) of women with a screening test result reported at 
enrolment had the test conducted on the same day as a positive sample was taken or diagnosis 
made for at least one of: chlamydia, gonorrhoea, syphilis, HSV-2, candida, TV or BV. Among the 
68 women who only had a test reported at follow-up, prevalence of cervical abnormalities was 31% 
(21/68). 
In crude analyses, women with BV infection were more likely to have a diagnosis of LSIL or HSIL, 
as were those who were HSV-2 seropositive and those with two or more previous pregnancies 
(Table 5.17). No other factors were significantly associated with abnormal findings. In the 
multivariable model, HSV-2 seropositivity was associated with an 83% increased risk of an 
abnormal finding and BV diagnosed antenatally or postnatally with over a three-fold increased risk 
(Table 5.17). Because the 30% of women with a cervical screening test result were more likely to 
have tested positive for BV, the prevalence of cervical abnormalities reported here may be an over-
estimate.
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Table 5.17: Factors associated with an abnormal finding (LSIL or HSIL) on cervical screening 
 Proportion (n) with 
abnormal result 
Unadjusted PR (95% CI) Unadjusted PR (95% CI) 
n=213† 
Adjusted PR‡ (95% CI) n=213 
Age at enrolment     
16-23 years 23% (15/65) 1.00 1.00 1.00 
24-26 years 23% (18/77) 1.02 (0.53-1.96) p=0.95 1.60 (0.55-4.68) p=0.39 1.52 (0.57-4.04) p=0.41 
27-30 years 24% (21/89) 1.04 (0.57-1.91) p=0.90 1.97 (0.72-5.40) p=0.19 1.72 (0.69-4.31) p=0.24 
≥31 years 20% (14/69) 0.93 (0.49-1.78) p=0.83 1.81 (0.65-5.05) p=0.26 1.42 (0.56-3.60) p=0.46 
Previous pregnancies at enrolment     
≥2 26% (51/195) 1.00 1.00 1.00 
1 15% (14/92) 0.58 (0.34-1.00) p=0.05 0.44 (0.21-0.93) p=0.03 0.56 (0.26-1.22) p=0.15 
CD4 count     
>350 cells/mm3 22% (50/228) 1.00 1.00 1.00 
201-350 cells/mm3 21% (11/53) 0.95 (0.53-1.69) p=0.85 1.21 (0.65-2.27) p=0.55 1.36 (0.74-2.49) p=0.33 
≤200 cells/mm3 25% (5/20) 1.14 (0.51-2.53) p=0.75 1.57 (0.65-3.77) p=0.31 2.07 (0.93-4.57) p=0.07 
Currently smoking     
No 25% (38/151) 1.00 1.00 1.00 
Yes 19% (33/171) 0.77 (0.51-1.16) p=0.21 0.99 (0.59-1.67) p=0.98 0.78 (0.49-1.26) p=0.31 
Oral contraceptive use postnatally (any)     
No 22% (61/279) 1.00 1.00 1.00 
Yes 24% (11/46) 1.09 (0.62-1.92) p=0.76 0.94 (0.46-1.93) p=0.86 0.95 (0.48-1.88) p=0.88 
HSV-2 antibodies     
No 18% (22/125) 1.00 1.00 1.00 
Yes 27% (40/150) 1.52 (0.95-2.41) p=0.08 1.73 (1.00-3.00) p=0.05 1.83 (1.07-3.11) p=0.03 
Chlamydia     
No 20% (41/205) 1.00 1.00 1.00 
Yes 25% (17/68) 1.25 (0.76-2.05) p=0.38 1.32 (0.75-2.32) p=0.33 0.79 (0.46-1.36) p=0.40 
Bacterial vaginosis     
No 17% (40/236) 1.00 1.00 1.00 
Yes 39% (25/64) 2.30 (1.52-3.50) p<0.01 3.36 (2.07-5.45) p=<0.01 3.49 (2.11-5.76) p=<0.01 
Trichomonas vaginalis     
No 19% (52/269) 1.00 1.00  
Yes 44% (8/18) 2.30 (1.30-4.07) p<0.01 1.80 (0.76-4.24) p=0.18  
†Limited to 213 women included in the multivariable model  ‡Adjusted a priori for age, previous pregnancies, CD4 count, current smoking, oral contraceptive use, HSV-2 
and chlamydia, and additionally for BV
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5.5 Limitations 
Data availability on testing for HIV co-infections in this observational study will have been affected 
by factors including local policy and resources (indicated by the almost complete lack of cervical 
screening and chlamydia test results among women enrolled at Krivoy Rog and Mykolaiv 
HIV/AIDS centres), assessment of women’s infection risk and their attendance for HIV care, and 
possibly also the provision of sexual and reproductive healthcare by other local providers. Testing 
coverage was only 80% for HCV, 67% for chlamydia and 30% for cervical screening among centres 
included in analyses. Bias in availability of test results may have led to under- or over-estimation of 
infection prevalence; IDUs were more likely to test positive for chlamydia but less likely to have 
received a test, while women with BV were more likely to have a finding of cervical abnormality 
when screened and more likely to have a screening result reported. Bias may also have influenced 
the associations found between cervical abnormalities and BV or HSV-2, if women at increased risk 
of HPV infection and other infections (e.g. those with high-risk sexual behaviours) were selectively 
tested. Results may not be generalizable to women who were not tested, who enrolled at centres 
excluded from the various analyses, and to HIV-positive women not in contact with HIV services. 
HCV analyses focusing on possible non-IDU modes of HCV acquisition were exploratory and 
hypothesis-generating in nature, and were limited by a lack of direct measures of sexual and 
iatrogenic risk. Proxies of these risks were problematic due to possible confounding by under-
ascertainment of IDU. These results are discussed in more detail in section 7.4.3, page 264. Some 
of the HCV seropositive women included in the work on non-invasive markers of liver fibrosis will 
have spontaneously resolved their infection, but could not be identified because qualitative HCV 
RNA tests are not routinely carried out in Ukraine.  
Data are not routinely shared between HIV/AIDS centres and other primary healthcare providers 
or referral hospitals, and so there was no information available on testing or investigations received 
elsewhere (including on colposcopy and histology, for women with cervical abnormalities). Rates of 
false positives or negatives on cytologic screening may have been elevated by the fact that a quarter 
of samples were taken during pregnancy, 10% at <12 weeks postpartum and 38% on the same day 
as a positive sample for a genital infection (Flannelly 2010). 
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5.6 Key points 
 Prevalence of genital infections was high among women tested in this cohort: 88% for vulvo-
vaginal candidiasis, 60% for HSV-2 antibodies, 24% for chlamydia, 15% for HBsAg, 13% for 
BV, 11% for TV, 2% for syphilis and 0.3% for gonorrhoea. Coverage with HBV vaccination of 
HBsAg negative women was very low. 
 Of those with chlamydia, 81% had at least one other STI in addition to HIV (mostly HSV-2). 
In adjusted analyses, factors associated with a positive chlamydia test were: history of IDU, 
being in a cohabiting partnership (vs. married), not knowing their partner’s HIV status and 
reporting contraception to be unaffordable. 
 The HIV/HCV co-infection rate was 32% overall; 78% among IDUs and 20% among non-
IDUs. The prevalence of HCV antibodies among non-IDUs may be partially explained by an 
under-ascertainment of IDU history in this cohort, but also by acquisition of HCV via sex, 
iatrogenic contact, or through non-injecting drug use.  
 Coverage with cervical screening as part of HIV care was low: 30% of women had been 
screened by cohort enrolment. Women with a longer duration of diagnosed HIV infection 
were more likely to have been screened as part of HIV care. Those leaving full-time education 
at ≤16 years had poorer coverage with screening than those educated beyond the age of 18. 
 The prevalence of cervical abnormalities (low or high grade squamous intraepithelial lesions) 
among those screened was 21%. HSV-2 antibodies and a recent BV diagnosis were both 
associated with an increased risk of an abnormal finding in adjusted analyses. 
 There was significant variation in the availability of test results for HIV co-infections and 
cervical screening by HIV/AIDS centre, highlighting the inconsistency of provision as part of 
HIV care in Ukraine. 
 There is substantial unmet need for sexual and reproductive healthcare among women in this 
cohort, all of whom were in contact with HIV services following delivery. 
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Chapter 6 Adherence to ART during pregnancy and postnatally in 
Ukraine 
6.1 Introduction 
 
In this chapter, ART adherence during pregnancy and postnatally among women in Ukraine is 
explored using the results of an anonymous self-report survey conducted at maternity hospitals and 
HIV/AIDS centres. Data were matched to the ECS and postnatal Women’s Study to provide 
additional clinical information. The survey included questions on a number of factors potentially 
influencing adherence behaviour including perinatal depression, self-efficacy, and self-perception of 
the risks and benefits of ART. Responses to these questions as well as characteristics of the study 
population are described in section 6.3, followed by levels of self-reported adherence to maternal 
ART during pregnancy and postnatally and to neonatal prophylaxis (sections 6.4 and 6.5). In 
section 6.6, the self-report adherence measure is validated against antenatal viral load among a small 
sub-group of women with both measures available. Factors associated with poor adherence, 
according to this measure and to the outcome of ‘any reported missed dose’, are explored in section 
6.7. Survey results on aspects of local policy and practice relevant to the results in this chapter (e.g. 
adherence and psychosocial support available at the HIV/AIDS centres) are given in Chapter 2 
(page 76). 
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6.2 Methods 
The design of the Antenatal and Postnatal Adherence Surveys is described in Chapter 2 and copies 
of the questionnaires are provided in Appendix D, page 332. Specific details of the CASE 
adherence index tool used are given starting on page 64, followed by details of the other tools used 
(e.g. to measure perinatal depression and self-efficacy). The CASE score cut-off used to define 
‘poor’ adherence was informed by the results of validation analyses exploring the associations 
between CASE scores and viral load measures (section 6.6, page 215). This definition was 
compared with the outcome of ‘any missed dose’, the most sensitive measure of poor adherence 
available using a self-report tool.  
Data analysis 
Availability of viral load measures to validate CASE adherence index scores was limited and 
particularly measures taken at least 12 weeks after initiating ART when viral suppression might be 
achieved. It was therefore not possible to calculate the sensitivity and specificity of different CASE 
score cut-offs in identifying non-suppressed patients. Instead, the frequency distribution of viral 
load suggested fitting zero-inflated negative binomial models (Ridout et al. 2001), which account for 
an excess of zeros and over-dispersion. These models were used to investigate the strength of 
association between shifted, censored HIV RNA load values (whereby a value of 0 corresponded to 
an undetectable measure) and CASE scores dichotomised at different values. These models were 
limited to women who had been on ART for at least 4 weeks by the time of the viral load measure. 
The use of the zero-inflated negative binomial model is described further in section 6.6. ART 
duration and type of cART (PI-based or not) were included in the models a priori but were 
subsequently removed if not associated with the outcome. The BIC was used to identify the model 
maximising goodness-of-fit (section 6.6). The BIC was preferred to the AIC for this work as it 
yields models more conservative against over-fitting (Kuha 2004) and the number of data points 
was small.  
For analyses of factors associated with poor adherence during pregnancy and postnatally, 
univariable comparisons were made using Fisher’s exact test. Poisson regression models with 
robust estimates of variances (Barros et al. 2003) were fitted to obtain PRs adjusted for hospital of 
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enrolment, as there was some evidence of between-hospital variation in adherence. For factors 
associated with poor adherence postnatally, the small number of enrolments at some centres and 
scarcity of the outcome precluded between-centre comparisons and PRs are presented unadjusted 
for centre. Multivariable analyses were not conducted, because many of the factors associated with 
poor adherence were correlated and statistical power was insufficient to adjust for confounding. 
The aim of this work was to broadly characterise women most likely to experience adherence 
problems, in order to identify groups of women likely to benefit most from targeted adherence 
support, rather than to establish the relative importance of independent factors. 
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6.3 Description of Adherence Survey participants 
Enrolment and study matching 
In total, 198 forms were returned in the Antenatal Survey and 185 included in analyses (exclusions 
shown in Figure 6.2). Over half (97/185) of those included in the analyses were returned by women 
already enrolled in the ECS by September 2012. Of the 274 forms returned in the Postnatal Survey, 
41 were excluded from analyses, most (n=29) because eligibility criteria were not met (see Figure 
6.3). Of the 233 postnatal surveys included in analyses, 49% (n=114) were returned by women 
enrolled in the ECS only and 41% (n=96) by women also enrolled in the postnatal Women’s Study. 
Thirteen women took part in both the Antenatal and Postnatal Adherence Surveys. 
 
Figure 6.2: Availability of matched Antenatal Survey and ECS data, and identification of 
surveys with matched viral load measures for validation of CASE adherence index scores 
Exclusions shown in red. †These six responses were excluded from all analyses, as it was not 
possible to verify that they were from unique responders. 
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Figure 6.3: Availability of matched Postnatal Survey and Women’s Study data 
Exclusions shown in red. †These four responses were excluded from all analyses, as it was not 
possible to verify that they were from unique responders. ‡Among the six woman who participated 
twice, the first completed survey (i.e. closest to delivery) was retained for analyses. 
 
Survey participation 
The 185 Antenatal Surveys included in analyses were returned by women delivering at Kiev (n=74), 
Odessa (n=83) and Simferopol (n=28) maternity hospitals. The 233 postnatal surveys were 
completed by women receiving HIV care in the year following delivery at six HIV/AIDS centres: 
Kiev (n=13), Odessa (n=75), Mykolaiv (n=38), Donetsk (n=38), Krivoy Rog (n=55) and Simferopol 
(n=14).  
Participation rates were estimated over the main six-month survey period (i.e. excluding the pilot 
period and extension period for sites with operational problems). Over this period, the 106 
respondents in the Antenatal Survey represented an estimated participation rate of 35-44% (240-
300 HIV-positive women deliver across the three participating hospitals over a six month period). 
The participation rate among eligible women (i.e. those who received antenatal ART for at least the 
last four weeks of their pregnancy) could be estimated to be in the region of 39-49%, based on the 
assumption that 10% of women did not receive ≥4 weeks of antenatal ART (see Chapter 3).  
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For the Postnatal Survey, the participation rate at the five HIV/AIDS centres enrolling into the 
Women’s Study (and therefore with denominator data available) was estimated at 35% (137/396) 
overall and 75% (63/84) among those on postnatal ART. This estimate considered only women 
attending the HIV/AIDS centre for the first time postnatally and not those returning for follow-up 
– the true participation rate may therefore have been lower.  
Representativeness of Adherence Survey participants 
Table 6.1 shows characteristics of the 97 Antenatal Adherence Survey respondents and 114 
Postnatal Adherence Survey respondents with linked ECS data available, compared with 1596 
women participating only in the ECS and enrolled at the same centres in 2010-2012. 
Postnatal Survey participants currently on ART were in substantially worse clinical and 
immunological health than the other study groups, and were more likely to have been diagnosed as 
HIV-positive before the most recent pregnancy and to have conceived on cART. They were also 
more likely to have an IDU history (associated with more advanced HIV disease, page 80). 
Among the Antenatal Adherence Survey group, prevalence of an IDU history or IDU partner, 
severity of HIV disease and timing of HIV diagnosis were all similar to the group enrolled in the 
ECS only. However, women in the Antenatal Adherence Survey group were more likely to have 
received cART (vs. ZDVm) and less likely to be single than women enrolled only in the ECS (Table 
6.1). Duration of ART by delivery was similar: 13.7 weeks (IQR 11.3, 17) for the Antenatal 
Adherence Survey group (n=93) and 14.6 weeks (IQR 11.3, 17.1) for women enrolled only in the 
ECS (n=1426) (Wilcoxon-Mann-Whitney test p=0.97). For the Postnatal Adherence Survey group, 
median duration of ART by date of survey participation was 43.7 weeks for women who continued 
on ART (IQR 26.0, 54.9, n=41). 
Educational status of women in all three adherence survey groups was higher than among women 
enrolled only in the ECS. This reflects the association between educational status and receipt of 
ART reported in Chapter 3. It is also possible that those with less education were less likely to 
consent to take part. This under-representation of women with the lowest levels of education in the 
Adherence Survey samples has implications for the generalizability of results.   
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Table 6.1: Representativeness of Adherence Survey respondents in terms of ECS 
enrolments 
  Adherence Surveys, linked ECS data available 
 ECS enrolment 
only (n=1596) 
Antenatal 
(n=97) 
Postnatal, on 
ART (n=44) 
Postnatal, not 
on ART (n=70) 
Marital status     
Married 634 (40%)  49 (51%)  24 (55%)  27 (39%) 
Cohabiting 738 (47%)  43 (44%)  13 (30%)  34 (49%) 
Single 214 (13%)  5 (5%)  7 (16%)  9 (13%) 
Age at leaving full-time 
education 
    
≤16 years 204 (26%)  1 (6%)  2 (9%)  3 (8%) 
17 years or above 595 (74%)  15 (94%)  20 (91%)  33 (92%) 
History of IDU     
No 1398 (88%)  87 (90%)  35 (80%)  69 (99%) 
Yes 191 (12%)  10 (10%)  9 (20%)  1 (1%) 
IDU partner     
No 1055 (68%)  67 (71%)  35 (85%)  56 (82%) 
Yes 491 (32%)  27 (29%)  6 (15%)  12 (18%) 
History of pregnancy 
termination 
    
0 540 (41%)  40 (45%)  14 (39%)  18 (34%) 
1 338 (26%)  27 (31%)  8 (22%)  18 (34%) 
2 or more 435 (33%)  21 (24%)  14 (39%)  17 (32%) 
Parity at ECS enrolment     
0 514 (38%)  29 (32%)  12 (34%)  19 (38%) 
1 543 (40%)  44 (48%)  16 (46%)  28 (56%) 
2 or more 296 (22%)  18 (20%)  7 (20%)  3 (6%) 
Timing of HIV diagnosis     
Before pregnancy 693 (44%)  44 (46%)  23 (52%)  23 (33%) 
1st/2nd trimesters 736 (46%)  48 (50%)  21 (48%)  42 (60%) 
3rd trimester/intrapartum 159 (10%)  4 (4%)  0 5 (7%) 
Antenatal CD4 count (first in 
pregnancy) 
    
≤350 cells/mm3 484 (39%)  19 (28%)  26 (76%)  14 (22%) 
>350 cells/mm3 773 (61%)  48 (72%)  8 (24%)  50 (78%) 
Antenatal viral load available     
No 437 (27%)  26 (27%)  8 (18%)  11 (16%) 
Yes 1159 (73%)  71 (73%)  36 (82%)  59 (84%) 
WHO stage     
1-2 1160 (81%)  67 (78%)  25 (61%)  67 (99%) 
3-4 269 (19%)  19 (22%)  16 (39%)  1 (1%) 
Timing of ART initiation     
Before conception 95 (7%)  7 (8%)  7 (17%)  0 
1st/2nd trimester 929 (65%)  61 (66%)  23 (56%)  45 (64%) 
3rd trimester 402 (28%)  25 (27%)  11 (27%)  25 (36%) 
Antenatal ART regimen     
mono/dual 314 (22%)  11 (12%)  3 (7%)  12 (17%) 
cART 1139 (78%)  83 (88%)  39 (93%)  58 (83%) 
Gestation at delivery     
≥37 weeks 1402 (88%) 88 (91%)  35 (80%)  67 (96%) 
<37 weeks 187 (12%) 9 (9%)  9 (20%)  3 (4%) 
Year of delivery     
2010 571 (36%) 0 12 (12%)  8 (6%) 
2011 774 (48%) 118 (64%)  86 (84%)  113 (86%) 
2012 251 (16%)  67 (36%)  4 (4%)  10 (8%) 
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Characteristics of Adherence Survey participants 
Table 6.2 summarises characteristics of all Adherence Survey participants (i.e. including women 
without linked ECS data available). Postnatal respondents took part a median of 5.7 months after 
delivery, and women on postnatal ART were slightly older than the other two groups. Only five 
women in the Antenatal Survey and six in the Postnatal Survey were adolescents (<20 years of age). 
Over 90% of women in each survey group had disclosed their HIV status to their partner, a family 
member or a friend at the time of survey participation. Most women were living with their husband 
or partner. Of those who were single, over half (18/33) in the Antenatal Survey and 41% (19/46) in 
the Postnatal Survey were living with their parents or other family members. 
Reporting of current illicit drug use was very low; two women reported current marijuana use in the 
Antenatal Survey and an additional two reported current use of another illicit substance (with the 
same numbers in the Postnatal Survey, although different women). With the exception of smoking, 
alcohol and marijuana use, a history of drug use was more common among Antenatal Survey 
participants and postnatal participants on ART than among women participating in the Postnatal 
Survey and not currently on ART (Table 6.2). Support groups, peer counselling and adherence 
programmes were much more commonly used by the Postnatal Survey group than by the Antenatal 
Survey group (Table 6.2), which may be explained by better engagement with services among 
women who return for postnatal follow-up, greater opportunity where a woman has been 
diagnosed as HIV-positive for longer, and specific targeting of NGO-provided support to new 
mothers. 
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Table 6.2: Characteristics of Adherence Survey participants 
 Antenatal 
Survey  
(n=185) 
Postnatal 
Survey, on 
ART (n=102) 
Postnatal 
Survey, not on 
ART    (n=131) 
Median age at participation (IQR) 27.5 years  
(25.0, 30.9) 
29.5 years 
(25.9, 33.5) 
27.3 years  
(24.2, 30.8) 
Median time since delivery (IQR) 1 day  
(1, 2) 
5.3 months 
(2.4, 7.8) 
6.0 months 
(2.0, 7.7) 
Marital status    
Married 100 (54%) 55 (54%) 47 (36%) 
Cohabiting 51 (28%) 23 (23%) 61 (47%) 
Single 34 (18%)  24 (24%) 23 (18%) 
Pregnancy unplanned 50 (28%)  26 (27%) 44 (38%) 
Living with:    
Husband/partner 132 (72%) 80 (79%) 102 (79%) 
Extended family (including parents) 60 (33%) 23 (23%) 42 (33%) 
Living as only adult in household 12 (7%) 13 (13%) 16 (12%) 
Disclosure of HIV status    
To husband/partner 135 (74%) 80 (79%) 103 (82%) 
Family or friend(s) 108 (59%) 55 (54%) 78 (62%) 
No one at all 16 (9%) 7 (7%) 5 (4%) 
Do you have someone you can rely on to 
help you care for your baby? 
   
Yes 164 (91%) 89 (88%)  112 (88%) 
No 17 (9%) 12 (12%)  15 (12%) 
Smoking, alcohol and drug use    
Current smoker 49 (27%) 28 (28%) 48 (37%) 
Current alcohol use 168 (9%) 8 (8%) 10 (8%) 
Ever used marijuana 25 (14%) 15 (15%) 14 (11%) 
Ever used illicit drugs other than marijuana 24 (13%) 17 (17%) 6 (5%) 
Severity of ART side effects    
Not bothered by side effects or only slightly  132 (75%) 76 (76%)  N/A 
Somewhat/ terribly bothered by side effects 44 (25%) 24 (24%)  N/A 
Use of support services    
Currently using support group 10 (5%) 21 (21%) 14 (11%) 
Currently using peer counselling 10 (5%) 27 (26%) 60 (46%) 
Currently using social services 40 (22%) 28 (27%) 55 (42%) 
Currently using adherence programme 4 (2%) 39 (38%) 4 (3%) † 
†These four women may have been engaged in a programme focusing on ART preparedness. 
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Perinatal depression 
About a quarter of respondents in each of the three survey groups had a positive screening test 
result for depression. Low mood was reported more frequently than anhedonia; the proportions of 
women reporting each and both of these symptoms are shown in Table 6.3.  
Table 6.3: Self-reported symptoms of depression and depression screening test results 
 Antenatal 
Survey 
(n=180) 
Postnatal Survey 
– women on 
ART (n=101) 
Postnatal Survey – 
women not currently 
on ART (n=127) 
Low mood 61 (34%) 31 (31%) 38 (30%) 
Anhedonia 28 (16%) 19 (19%) 27 (21%) 
Both low mood and anhedonia 21 (12%) 18 (18%) 19 (15%) 
Positive depression screening test 49 (27%) 27 (27%) 30 (24%) 
 
ART-related self-efficacy 
Responses to the five HIV-ASES questions on integration of HIV treatment into daily life are 
shown in Figure 6.4 (Antenatal Survey) and Figure 6.5 (Postnatal Survey – respondents currently on 
ART only). Responses to all five questions were given by 76% (141185) of Antenatal Survey 
participants and 65% (66/102) of Postnatal Survey participants on ART. When scores were applied 
to each answer to give a maximum of 10 points (see 68), the median score in both Antenatal and 
Postnatal surveys was 5 (Wilcoxon-Mann-Whitney test p=0.47, women with scores in both surveys 
were omitted from the antenatal group because this was the larger sample).  
The area in which most women lacked confidence was the ability to keep taking ART even if side 
effects began to interfere, with 15% of antenatal and 20% of postnatal respondents reporting that 
they could not do this (a quarter of respondents in both surveys reported being somewhat or 
terribly bothered by side effects, see Table 6.2). In the Antenatal Survey, a greater proportion of 
women reported not being able to keep taking ART if their routine was disrupted and not being 
able to keep medical appointments if they interfered with daily activities compared with the 
Postnatal Survey (Figures 6.4 and 6.5), but these differences were not statistically significant 
(2=3.55 p=0.06 and 2=2.41 p=0.12 respectively). As the postnatal survey only included women 
attending for care (and not those lost to follow-up postnatally), their confidence to attend 
appointments is likely to be higher than for the population overall. The Antenatal Survey group 
were more confident that they could keep taking medication when not feeling well (43% (74/172) 
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said that they could do this, 47% (80/172) were fairly sure and 10% (18/172) said that they could 
not, compared with 24% (20/85), 62% (53/85) and 14% (12/85) respectively in the Postnatal 
Survey, 2=9.32, p<0.01). Linked ECS data indicated that women on ART in the Postnatal Survey 
had more advanced HIV disease (and thus more experience of HIV-related ill health). 
In the four weeks before birth, how confident did you feel that you could…? 
 
Figure 6.4: Measures of self-efficacy related to ART adherence, Antenatal Survey 
 
 
In the last four weeks (postnatally), how confident have you been that you could…? 
 
Figure 6.5: Measures of self-efficacy related to ART adherence, Postnatal Survey 
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Overall almost 95% (238/253) of women were confident or fairly confident that they could ask 
their clinician for more information and support if they needed to, with slightly fewer reporting 
being confident that they could ask someone for support with taking their medication (Table 6.4, 
comparisons between Antenatal and Postnatal Surveys, 2 =3.64 p=0.16 and 2 =1.49 p=0.48 
respectively).   
Table 6.4: Measures of self-efficacy related to seeking support 
 Antenatal Survey Postnatal Survey – 
women currently 
on ART 
In the last four weeks, how confident did you feel 
that you could ask your clinician for more 
information if you needed to, and tell them about 
your concerns or worries? 
  
Confident I could do 37% (61/167) 48% (41/86) 
Fairly confident I could do 56% (94/167) 49% (42/86) 
Could not do 7% (12/167) 3% (3/86) 
In the last four weeks, how confident did you feel 
that you could ask someone for support with taking 
your medication if you needed it? 
  
Confident I could do 33% (54/165) 30% (26/86) 
Fairly confident I could do 47% (78/165) 43% (37/86) 
Could not do 20% (33/165) 27% (23/86) 
 
In the Postnatal Survey, women not able to ask someone for support with taking their medication 
were significantly more likely to have a positive screening test for depression (48% (11/23) vs. 22% 
(15/68) of those confident/fairly confident that they could ask for support, 2 =5.59 p=0.02), but 
there was no association between these factors in the Antenatal Survey (2 =0.14 p=0.71). Those 
screening positive for depression more commonly reported being unable to do at least one of the 
five items related to integration of HIV treatment into daily life (in the Antenatal Survey: 32% 
(12/37) vs. 16% (16/101) of those not depressed, 2 =4.61 p=0.03; in the Postnatal Survey: 26% 
(5/19) vs. 13% (6/47) of those not depressed, Fisher’s exact test p=0.17). The high prevalence of 
depression among even women with high levels of self-efficacy (who were confident that they 
could ask for help) may reflect the poor provision of mental health care in Ukraine, discussed in 
section 7.4.2. 
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Self-perception of ART risk and benefit 
The large majority of Antenatal Survey respondents were either completely or fairly sure that taking 
antenatal ART was effective for PMTCT (44% (80/180) and 51% (91/180) respectively), with only 
nine women (5%) reporting that they were not at all sure of this. Because this was a sample selected 
on the basis that they had taken ART for at least the last four weeks of pregnancy, the true 
proportion of women with doubts about the effectiveness of ART for PMTCT may be higher than 
observed here. However, most women were a little worried (39%, 70/181) or worried (44%, 
79/181) that antenatal ART might harm their baby; only 18% (32/181) reported that they weren’t 
worried about this. Women who were completely sure about the effectiveness of ART for PMTCT 
had lower levels of anxiety than those who were only fairly sure (Figure 6.6, 2 =6.65 p=0.04). 
 
Figure 6.6: Levels of worry that antenatal ART might harm the baby, by level of confidence 
that HIV medication is effective for PMTCT  
(n=180) 
In the Postnatal Survey, 72% (156/218) of women agreed that neonatal prophylaxis could help to 
prevent HIV from being passed to their baby, 27% (58/218) didn’t know/weren’t sure and four 
(2%) disagreed. Although the proportion of women worried about neonatal prophylaxis causing 
harm was the same as for antenatal ART (44%, 95/218), fewer women were a little worried (23%, 
50/218) and more women not worried at all (33% (73/218) for neonatal prophylaxis vs. 18% 
(32/181) for antenatal ART). As with antenatal ART, there was a significant association between 
confidence in the effectiveness of neonatal prophylaxis and a lower level of anxiety about the 
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possibility of it causing harm (Figure 6.7, 2 =7.46 p=0.02 for women agreeing that neonatal 
prophylaxis was effective vs. those not sure). 
 
Figure 6.7: Levels of worry that neonatal prophylaxis might harm the baby, by opinion on 
whether neonatal prophylaxis is an effective intervention for PMTCT  
(n=218) 
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6.4 Adherence to ART during pregnancy and postnatally 
Pill burden and knowledge of ART regimen 
In both Antenatal and Postnatal Surveys, over half of women were able to report the names of the 
HIV medications that they had been taking (Table 6.5, see page 66 for definition of ‘complete 
knowledge’). Matched ECS drug data were available for 47% (51/109) of Antenatal Survey 
participants categorised as having ‘complete’ knowledge of their regimen: for 86% (n=44) of these, 
there were no differences between the regimen reported by the woman and that reported by the 
clinician. Two women gave three drug names but omitted a fourth reported by their clinician, three 
women reported ABC or ZDV when the other of the two drugs was reported by their clinician, and 
two women reported regimens with two or more differences – one of whom completed the survey 
five days after delivery, introducing the possibility of postnatal regimen alterations.  
Table 6.5: Knowledge of the names of antiretroviral drugs currently being taken 
 Antenatal Survey 
(n=185) 
Postnatal Survey 
(n=102) 
Complete knowledge 109 (59%) 59 (58%) 
Partial knowledge (i.e. one or two drugs 
reported of cART regimen) 
52 (28%) 25 (25%) 
No knowledge 24 (13%) 18 (18%) 
 
Of the antenatal group with complete knowledge, 14% (15/109) had been taking ZDVm and 86% 
(94/109) cART, 91% (86/94) of whom were on a LPV/r based regimen. Among the 59 women 
completing the Postnatal Survey and with complete knowledge of their regimen, most (80%, 47/59) 
were taking a LPV/r based cART regimen and 15% (9/59) a NVP-based cART regimen. The daily 
pill burden ranged from 2 to 12 pills for 142 antenatal respondents and 2 to 8 for 72 postnatal 
respondents. The median number of pills taken per day was six (taken by 72% (102/142) in the 
Antenatal Survey and 56% (40/72) in the Postnatal Survey).  
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CASE adherence index 
Responses given to the three CASE adherence index questions in Antenatal and Postnatal Surveys 
are summarised in three graphs, Figure 6.8. 
 
 
 
Figure 6.8: Summary of responses to three CASE adherence index questions 
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Of 185 Antenatal Survey respondents and 102 Postnatal Survey respondents currently on ART, 
94% (173/185) and 97% (99/102) respectively answered all three CASE adherence index questions, 
allowing for calculation of a CASE index score. Median CASE scores in both groups were 15 (of a 
possible 16), with slightly wider variance in scores among Antenatal Survey respondents (IQR 13, 
16 and range 6, 16) than among Postnatal Survey respondents (IQR 14, 16 and range 7, 16). Figure 
6.9 shows the distribution of CASE scores in each survey (the seven women with CASE scores in 
both surveys were included only in the postnatal group, making the total number of respondents 
for the Antenatal Survey 166). There was no statistically significant difference in overall scores 
between the two groups (Wilcoxon-Mann-Whitney test, p=0.25).  
 
Figure 6.9: Distribution of CASE adherence index scores in the two surveys 
 
Reasons for missed doses 
Table 6.6 shows the number and proportion of Antenatal and Postnatal Survey respondents 
selecting each of a range of reasons for missing a dose of ART. The most common reasons 
reported for missing doses during pregnancy were being away from home (8%), simply forgetting 
(5%) and feeling sick/ill (5%). In the Postnatal Survey, the most common reasons for missing a 
dose in the preceding four weeks were simply forgetting (15%), sleeping through the dose (9%) and 
being away from home (8%).  
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Table 6.6: Reasons for missed doses of ART in the Antenatal and Postnatal Surveys 
Reason for missed dose Antenatal Survey 
(n=185) 
Postnatal Survey – 
currently on ART 
(n=102) 
I was away from home 14 (8%) 8 (8%) 
I was busy with other things 6 (3%) 7 (7%) 
I simply forgot 10 (5%) 15 (15%) 
I had too many pills to take 3 (2%) 3 (3%) 
I wanted to avoid side effects 1 (1%) 3 (3%) 
I did not want others to notice me taking 
medication 
2 (1%) 2 (2%) 
I had a change in my daily routine 2 (1%) 1 (1%) 
I felt that the drug was toxic / harmful 2 (1%) 4 (4%) 
I fell asleep / slept through the dose 8 (4%) 9 (9%) 
I felt sick or ill 10 (5%) 5 (5%) 
I felt depressed or overwhelmed 1 (1%) 2 (2%) 
I ran out of pills 6 (3%) 3 (3%) 
I couldn’t find my pills 2 (1%) 2 (2%) 
I felt good 1 (1%) 0 
Most common three reasons in bold. 
In all, 25% (26/201) of postnatal respondents gave at least one reason for having missed a dose of 
ART, of whom 19 had answered ‘Never’ to the question ‘When was the last time you missed at least 
one dose of your HIV medications?’  This discrepancy was also found in responses to the questions 
on adherence to ART during pregnancy (12 Antenatal Survey respondents reported never missing a 
dose but went on to give ≥1 reason for having done so), and in responses to questions on 
adherence to neonatal prophylaxis (see section 6.4). When responses to the question on timing of 
last missed dose were taken together with reasons for missing a dose, a total of 35% (61/176) of 
antenatal respondents indicated directly or indirectly that they had missed a dose during pregnancy 
and 31% (31/100) of postnatal respondents indicated that they had missed a dose in the last four 
weeks. 
 
Respondents’ self-assessment of their adherence postnatally compared with during 
pregnancy 
Postnatal respondents were asked to compare their current ART adherence with that during their 
most recent pregnancy. In total, 13% (12/93) reported missing fewer doses when pregnant than 
postnatally, 2% (2/93) that they missed more doses when pregnant than postnatally, 6% (6/93) that 
their adherence was similar antenatally and postnatally, and 78% (73/93) that they had not missed 
any doses in either time period. Of the 12 women who reported that their adherence had been 
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better during pregnancy than postnatally, cited reasons were: concern about MTCT (n=11), more 
frequent clinic appointments during pregnancy (n=3), having more time to take care of oneself 
during pregnancy (n=2), being more concerned about one’s own health (n=1) and being less tired 
of taking pills (n=1) (>1 answer possible). 
6.5 Adherence to neonatal prophylaxis 
Almost all women in the Postnatal Survey reported that their infant had been prescribed neonatal 
prophylaxis (228/230), most (91%, 204/223) for one week (5% (11/223) for four weeks and 4% 
(8/223) could not recall. Women were asked to identify all of the individuals who had been 
involved in administering neonatal prophylaxis to their baby (multiple answers possible). Overall, 
81% (183/225) reported that medical staff had administered at least one dose. Although 59% 
(133/225) indicated administration by medical staff only, 72% (96/133) of these women went on to 
answer questions about their administration of neonatal prophylaxis and 12 gave reasons for missed 
doses, suggesting administration of some doses at home, or confusion over the survey questions. 
Overall, 40% (91/225) of women reported giving their baby neonatal prophylaxis themselves (for 
over half (50/91) the drug administration was shared with medical staff), 6% (13/225) reported that 
the baby’s father had given some HIV medication to their baby, 3% (6/225) that another family 
member had given dose(s) and 1% (2/225) that a friend had been involved with administering the 
medication. 
Self-reported adherence to neonatal prophylaxis was high, probably partly reflecting the 
involvement of medical staff in giving a substantial proportion of doses. Of the 186 women who 
responded to the question ‘How often did you have difficulty giving your baby their medicine on time?’, 
81% (151/186) reported that this was never the case, 17% (31/186) that this was rare, 1% (2/186) 
that they experienced difficulty most of the time and 1% (2/186) that they had difficulty all of the 
time. These proportions were 74% (67/90), 24% (22/90), 0% (0/90) and 1% (1/90) for the 90 
women who reported giving neonatal prophylaxis to their baby themselves and answered this 
adherence question. When asked how many days per week on average their baby missed at least 
one dose of medication, only two women reported that this had ever happened. However, a further 
14 women went on to give reasons for missed doses, and it is possible that this question format was 
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more permissive for reporting of adherence problems. When responses to the two questions 
(average frequency of missed doses and reasons for missed doses) were taken together, 9% 
(16/187) of women reported that ≥1 dose of neonatal prophylaxis had been missed overall (3% 
(3/88) of those who reported having given doses themselves). Of note, women may not have been 
aware of any doses that their infant missed while in hospital and under the care of medical 
personnel. 
Reasons reported for doses of neonatal prophylaxis being missed were: concerns that the drug was 
toxic or harmful (n=6), wanting to avoid side effects (n=6), that the baby was asleep (n=4), that 
supplies of medicine ran out (n=3), not wanting to ask other people caring for the baby to 
administer the medicine (n=2), that there was no one to help (n=1), being away from home (n=1) 
or simply forgetting (n=1) (>1 answer possible). 
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6.6 Validation of CASE adherence index scores 
Table 6.7 shows the number and proportion of women reporting ‘poor’ adherence in the Antenatal 
and Postnatal Surveys according to various CASE score cut-offs. 
Table 6.7: Proportion of women reporting poor adherence antenatally and postnatally, 
according to different CASE score cut-offs 
 Antenatal Survey (n=173) 
n (%, 95% CI) 
Postnatal Survey (n=99) 
n (%, 95% CI) 
CASE score ≤10 15 (9%, 5-14%) 5 (5%, 2-11%) 
CASE score ≤11 25 (14%, 10-21%) 8 (8%, 4-15%) 
CASE score ≤12 33 (19%, 14-26%) 9 (9%, 4-17%) 
CASE score ≤13 45 (26%, 20-33%) 15 (15%, 9-24%) 
 
Validation of CASE scores against viral load measures was not possible for Postnatal Survey 
participants, due to the small number that had enrolled in the Women’s Study by time of the 
analysis and the lack of postpartum virological monitoring in this group (see Figure 6.3, page 199). 
For the Antenatal Survey participants, a subgroup of 36 women had an antenatal viral load measure 
reported in the ECS at least 28 days after initiating ART (see Figure 6.2, page 198); the subsequent 
validation was performed in this subgroup. There was no difference in CASE scores between the 
36 women included in the validation analyses and the remaining 137 women with an antenatal 
CASE score available but no suitable viral load (Wilcoxon-Mann-Whitney test p=0.96); in the 
validation subgroup, the proportions with a CASE score of ≤10, ≤11, ≤12 and ≤13 were 5% 
(2/36), 16% (6/36), 25% (9/36) and 28% (10/36) respectively. 
Fitting statistical models to the data was severely limited by the small number of viral load measures 
available in the validation dataset and the fact that 23 of the 36 were undetectable (<40 copies/ml) 
(20/30 of those with a CASE score of >11 and 3/6 of those with a CASE score of ≤11, viral load 
measures given in Table 6.8). The viral load values used for this work were the last available in 
pregnancy, taken a median of 31 days prior to delivery (IQR 18, 49 days). For women with a low 
CASE score and an undetectable viral load, it is possible that their adherence deteriorated after the 
viral load measure was taken (for 4/6 of women with a CASE score ≤12 and an undetectable viral 
load, the measure was taken more than two weeks prior to delivery). 
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Table 6.8: Viral load measures of 36 women in validation subset, by CASE score 
 CASE score† 
 ≤10 ≤11 ≤12 ≤13 ≥14 
Number of women 
with undetectable 
viral loads (<40 
copies/ml) 
1 3 6 6 17 
Viral load where 
measure detectable 
(copies/ml) 
1608 967 
1507 
1608 
967 
1507 
1608 
114 
967 
1507 
1608 
42 
50 
52 
56 
102 
194 
264 
285 
298 
Total number of 
women 
2 6 9 10 26 
† Categories from CASE score ≤10 to ≤13 are cumulative (i.e. the 1608 copies/ml measure which 
appears in all four categories is from the same woman).  
 
One hypothesis that accounts for this distribution of viral load measures is that the measurements 
come from two latent populations whose identity is not observed. The first population is composed 
of women who have been on a successful regimen for a sufficient duration by the time of the viral 
load measure and have no other factors compromising virological response – a population who 
contribute ‘excess’ undetectable viral load measures. Meanwhile the second population consists of 
women with shorter durations of cART and/or other factors that might affect virologic control, 
whose viral load may or may not be undetectable. A zero-inflated negative binomial model is a 
latent-class model with two parts - an extra-zero part, which models the probability of being in the 
first population (an ‘excess’ undetectable viral load) via a logit link function, and a negative binomial 
part which models the mean level of viral load in a logarithmic scale via a negative binomial 
distribution. The use of the logit and logarithmic links respectively transform the dependent 
variables to allow estimation of predicted values within a given range (i.e. 0 and 1 in the case of the 
probability of being in the extra zero component, and positive values in the case of viral load). The 
equations that follow describe the two parts of the zero-inflated negative binomial model in terms 
of two linear predictors. 
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Equation 1: Extra-zero component     (
  
    
)      
Equation 2: Negative binomial component     ( )      
Where    is the probability of any woman being an ‘excess’ undetectable viral load,   is the mean 
viral load,    and    are vectors of covariates predicting viral load (e.g. cART duration, CASE 
score),   and   are vectors of the regression coefficients (Ridout et al. 2001). 
Different covariates can be considered in each of the two components of the model. Initially, both 
components were adjusted a priori for ART duration and whether cART was PI-based or not. For 
comparison, four models were fitted with CASE score dichotomised at 10, 11, 12 and 13 (these 
four covariates are referred to as CASE 10, CASE 11, CASE 12 and CASE 13). These 
dichotomised CASE scores were included in both the zero-inflated and the negative binomial 
components. Type of cART regimen (i.e. whether PI-based or not) was not significantly associated 
with either being an ‘excess’ undetectable viral load or with level of viral load in any of the four 
models. Its removal resulted in improved model fit as indicated by BIC (Table 6.9, compare step 1 
and step 2). CASE score was not associated with being an ‘excess’ undetectable viral load (i.e. in the 
zero-inflated part of the model, p=1.00 for CASE 10, p=0.46 for CASE 11, p=0.82 for CASE 12 
and p=0.59 for CASE 13 after excluding cART type). Its removal from this component resulted in 
improved fit of all models except the CASE 10 model, which was not preferred over the others at 
any stage (Table 6.9, compare step 2 and step 3). Finally, ART duration was significantly associated 
with the outcome of being an ‘excess’ undetectable viral load, but not with mean level of viral load. 
Its removal from the negative binomial component was associated with a further improvement in 
model fit (Table 6.9, compare step 3 and step 4). The models with the best fit were those which 
included the CASE 11 and CASE 12 covariates, with little difference between them (Table 6.9, 
shaded cells). 
The BIC value for a negative binomial regression model without zero-inflation component and 
including CASE 11 and ART duration was 225.84 (vs. 219.55 for zero-inflated negative binomial 
model, Table 6.9), demonstrating the substantial improvement in goodness-of-fit with a zero-
inflated negative binomial approach.  
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Table 6.9: BIC values for zero-inflated negative binomial regression models with different combinations of covariates 
 Step 1 Step 2 Step 3 Step 4 
CASE 10 covariate 238.31 232.59 225.40 228.35 
CASE 11 covariate 229.66 223.63 220.61 219.55 
CASE 12 covariate 230.14 224.18 220.65 219.57 
CASE 13 covariate 234.07 228.04 224.76 222.21 
Covariates included in logit 
(extra zero) component 
ART duration 
Type of cART 
CASE covariate 
ART duration 
CASE covariate 
ART duration ART duration 
Covariates included in the 
negative binomial component 
ART duration 
Type of cART 
CASE covariate 
ART duration 
CASE covariate 
ART duration 
CASE covariate 
CASE covariate 
The shaded cells indicate the models with the best fit. ART duration was a categorical variable (≥12 weeks vs. 4-11 weeks). 
Type of cART was PI-based vs. not PI-based.  
 
Table 6.10: Coefficients and 95% confidence intervals from two zero-inflated negative binomial regression models of CASE score regressed against viral load. 
 
 Logit coefficients(zero 
inflation)  
(95% CI)  
Predicted probability of 
belonging to the population of 
‘excess’ undetectable viral loads 
Negative binomial 
exponentiated coefficients 
(95% CI) 
BIC 
Model 1    219.55 
CASE score ≤11 vs. >11   12.72 (3.12-51.91) p<0.01   
ART duration  
4-11 weeks 
 
1.00 
 
0.40 
  
≥12 weeks 2.05 (0.47-3.63) p=0.01  0.84   
Model 2    219.57 
CASE score ≤12 vs. >12   12.70 (3.12-51.66) p<0.01  
ART duration     
4-11 weeks 1.00 0.40   
≥12 weeks 2.05 (0.47-3.64) p=0.01 0.84   
 219 
 
Table 6.10 shows coefficients from the two best-fitting zero-inflated negative binomial regression 
models. These models indicate that, of women who were not in the ‘excess’ zero population, those 
with a lower CASE score (≤11 or ≤12) had a viral load around 12-fold greater than those with a 
higher CASE score (>11 or >12). Women who had been on cART for 4-11 weeks by the viral load 
measurement had a probability of 0.40 of being an ‘excess’ undetectable viral load (antilog of 
intercept -0.3935) compared with a probability of 0.84 for those on cART for ≥12 weeks. The lack 
of an association between ART duration and viral load in the negative binomial part of the model is 
probably due to the limitations of the data. These results must be interpreted with caution given the 
small number of data points, but nevertheless indicate support for the CASE score tool and for cut-
offs of 11 and 12 to identify poor adherence of potential clinical relevance. 
In order to explore factors associated with poor adherence, a CASE score cut-off of 11 was chosen 
over a cut-off of 12. This outcome was supported by the BIC value and was more specific than a 
cut-off of 12, thus providing a comparison for the outcome of ‘any reported missed dose’ (the 
outcome providing the most sensitive measure of poor adherence). Overall, 14% of 175 Antenatal 
Survey respondents had a CASE score of ≤11 as did 8% of 99 Postnatal Survey respondents 
currently on ART. The proportions who reported (directly or indirectly) having ever missed a dose 
during pregnancy or in the last four weeks postnatally were 35% (61/176) and 31% (31/100) 
respectively. Factors associated with these two outcomes are explored in the next section. 
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6.7 Factors associated with poor adherence 
ART adherence during pregnancy 
Characteristics of Antenatal Survey respondents by whether they had a CASE adherence index 
score of ≤11 (n=173) and by whether they reported ever missing a dose during pregnancy (n=176) 
are shown in Table 6.11. There was no difference in proportion of women with a CASE score ≤11 
by hospital at which they delivered (Fisher’s exact test p=0.64), but there was a difference between 
hospitals in the proportion reporting ever having missed a dose (43% (30/69) in Kiev, 34% (28/82) 
in Odessa and 12% (3/25) in Simferopol, Fisher’s exact test p=0.01).  
Women living with their extended family more commonly had a CASE score of ≤11 (Table 6.11), 
and this was particularly true for women who had not disclosed their HIV status to a family 
member (40% (8/20) of whom had poor adherence, compared with 14% (5/37) of those living 
with their family who had disclosed their status to a family member, Fisher’s exact test p=0.03). A 
third (18/57) of women living with their extended family also lived with a partner. Overall, women 
living with their family were younger (median age 26.6 years vs. 28.6 years for women living only 
with a partner or alone, Wilcoxon-Mann-Whitney test p=0.02) and more likely to have had an 
unplanned pregnancy (36% (21/58) vs. 23% (27/120) of those living only with a partner or alone, 
2=3.73 p=0.05).  
It was surprising that poor adherence (CASE score of ≤11) was slightly more common among 
women who had disclosed their HIV status to a friend than among those who had not. Women 
disclosing to a friend were more likely to have a history of drug use excluding marijuana (41% 
(7/17) vs. 10% (16/160) of those not disclosing to a friend, Fisher’s exact test p<0.01), and were 
also more likely to have disclosed to another HIV-positive person (53% (9/17) vs. 10% (16/166) of 
those not disclosing to a friend, Fisher’s exact test p<0.01). Drug use and disclosure to an HIV-
positive person were not themselves associated with a CASE score of ≤11 (Table 6.11, Fisher’s 
exact test p=0.40 for disclosure to an HIV-positive person), but these characteristics together may 
indicate social marginalisation among women disclosing to a friend. It is also possible that women 
failing to cope with treatment were more likely to have disclosed to a friend or peer in order to ask 
for support. Finally, women disclosing to a friend may have been better adapted to their HIV status 
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and more likely to report adherence problems accurately, resulting in less inflated self-report 
measures.  
Being a current smoker was associated with ever having missed a dose during pregnancy, but not 
with a CASE score of ≤11 (Table 6.11). Low CASE scores were more common among women 
with a positive depression screening test, reaching statistical significance with the ‘ever having 
missed a dose’ outcome (Table 6.11). Women who received ZDVm during pregnancy rather than 
cART were also more likely to report poor adherence, and this was statistically significant for the 
‘any missed dose’ outcome. As shown in Chapter 3 (Table 3.7 page 104), ZDVm was more 
commonly initiated during pregnancy among women with ≥2 previous live births and those with 
less education. Poor adherence tended towards being more common among multiparous women 
(35% (6/17) of multiparous women reported ever missing a dose vs. 27% (12/44) women with one 
previous live/stillbirth and 21% (6/29) of women no previous births, Fisher’s exact test p=0.54), 
but too few data were available to assess the association between education level and adherence.  
Of the 18 women categorised as having no knowledge of the names of the drugs that they were 
taking, two (11%) had a CASE score of ≤11 compared with 15% (23/155) of those who had partial 
or complete knowledge of their regimen (Fisher’s exact test p=0.50). Among 93 women with 
matched ECS data available, there was also no difference in either adherence outcome measure by 
whether the woman had been diagnosed as HIV-positive prior to or during her most recent 
pregnancy (Fisher’s exact test p=0.38 for CASE score ≤11 and p=0.53 for reporting any missed 
dose). Although women with longer duration of antenatal ART had more opportunity to miss a 
dose during pregnancy, there was also no difference in reporting of a missed dose by timing of 
ART initiation (3/7 (43%) of women starting ART pre-conception reported ever missing a dose vs. 
15/60 (25%) of those starting in the 1st/2nd trimesters and 9/24 (38%) of those starting in the 3rd 
trimester, Fisher’s exact test p=0.39; Fisher’s exact test p=1.00 for outcome of CASE score ≤11). 
There was no significant difference in adherence by severity of HIV disease; 13% (8/64) and 11% 
(2/17) of women with WHO stage 1-2 and 3-4 disease respectively had a CASE score of ≤11 
(Fisher’s exact test p=0.59), and 20% (12/60) and 29% (7/24) respectively reported ever missing a 
dose (Fisher’s exact test p=0.26). Women who reported being somewhat or terribly bothered by 
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side effects were not more likely to have a CASE score of ≤11 (16% (7/43) vs. 14% (18/126) of 
those not bothered or only slightly bothered by side effects, Fisher’s exact test p=0.46; Fisher’s 
exact test p=0.38 for outcome of any missed doses). There was also no association between 
confidence in ability to ask someone for support with taking the medication and either adherence 
measure (Fisher’s exact test p=0.84 for CASE score ≤11 and p=1.00 for any missed dose). 
Median self-efficacy score on the five HIV-ASES questions related to integration of ART-taking 
into daily life was 7 (IQR 2, 8) for women with a CASE score of ≤11 and 5 (IQR 5, 10) for those 
with a CASE score >11 (Wilcoxon-Mann-Whitney test p=0.13). Those with a total score of <5 
over the five questions (i.e. who reported that they ‘could not do’ at least one of the items) were 
more likely to report ever having missed a dose (Table 6.11).  
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Table 6.11: Factors associated with poor ART adherence during pregnancy  
 CASE score 
≤11 points 
(25/173) 
Fisher’s 
exact 
test 
Ever missed a 
dose  
(61/176) 
Fisher’s 
exact    
test 
Age     
<25 years 26% (11/42) p=0.13 52% (23/44) p=0.03 
25-27 years 10% (5/48)   23% (11/48)  
28-30 years 12% (5/41)  29% (12/41)  
≥31 years 10% (4/42)   35% (15/43)  
Marital status     
Married 14% (13/93)  p=0.96 34% (32/95) p=0.83 
Cohabiting 15% (7/48)   33% (16/48)  
Single 16% (5/32)   39% (13/33)  
Pregnancy planned     
Yes 11% (13/120)  p=0.02 30% (36/122) p=0.01 
No 25% (12/48)   49% (24/49)  
Lives with extended family     
No 10% (12/115)  p=0.03 29% (34/117) p=0.02 
Yes 23% (13/57)   46% (26/57)  
Lives with partner     
No 18% (9/49) p=0.25 45% (22/49) p=0.05 
Yes 13% (16/123)  30% (38/125)  
Disclosed status to partner     
No 19% (9/47)  p=0.21 42% (20/48) p=0.16 
Yes 13% (16/125)   32% (41/127)  
Disclosed status to family     
No 18% (13/74)  p=0.22 39% (30/77) p=0.20 
Yes 12% (12/98)   32% (31/98)  
Disclosed status to friend     
No 13% (20/156)  p=0.06 33% (53/159) p=0.15 
Yes 31% (5/16)   50% (8/16)  
Current smoker     
No 14% (18/127)  p=0.58 30% (39/129) p=0.04 
Yes 14% (6/44)   47% (21/45)  
History of marijuana use     
No 13% (20/149)  p=0.37 33% (50/152) p=0.18 
Yes 18% (4/22)   45% (10/22)  
History of other drug use     
No 2% (2/127) p=0.65 35% (52/149) p=0.55 
Yes 14% (3/21)   33% (7/21)  
Is antenatal ART effective 
for PMTCT? 
    
Yes, completely / fairly sure 12% (20/162)  p=0.10 33% (54/165) p=0.15 
Not sure 33% (3/9)   56% (5/9)  
Self-efficacy score     
≥5 (higher self-efficacy) 12% (13/107) p=0.15 28% (30/108) p=0.02 
<5 (lower self-efficacy) 22% (6/27)  50% (14/28)  
Positive depression screen     
No 13% (16/124)  p=0.20 31% (39/125) p=0.05 
Yes 20% (9/46)   46% (22/48)  
Can you ask doctor for 
support? 
    
Certain / fairly certain can do 14% (21/155)  p=0.06 33% (52/156) p=0.19 
Cannot do 36% (4/11)   50% (6/12)  
ART received     
ZDVm 29% (4/14) p=0.13 64% (9/14) p=0.02 
cART 13% (19/141)  31% (44/143  
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Table 6.12 shows PRs adjusted a priori for hospital of delivery, for the eight factors with a p value of 
<0.20 (Fisher’s exact test) in univariable comparisons with CASE score of ≤11. The women with a 
CASE score of ≤11 were younger, more likely to have an unplanned pregnancy and to be living 
with their family, more likely to have disclosed their HIV status to a friend, and more likely to lack 
confidence in their ability to ask their doctor for more information or to share with them concerns 
and worries.  
Table 6.12: Factors associated with poor adherence (CASE score ≤11) during pregnancy 
 
PR adjusted for hospital of delivery 
(95% CI)                             
Age 
 
 
<25 years 1  
25-27 years 0.38 (0.14-0.98)  p=0.05 
28-30 years 0.44 (0.17-1.16)  p=0.10 
≥31 years 0.34 (0.12-1.00)  p=0.05 
Pregnancy planned 
 
 
Yes 1  
No 2.35 (1.16-4.73)  p=0.02 
Living with extended family 
 
 
No 1  
Yes 2.12 (1.01-4.47)  p=0.05 
Disclosed HIV status to friend 
 
 
No 1  
Yes 2.34 (1.01-5.40)  p=0.05 
Opinion on whether ART is effective for 
PMTCT 
 
 
Yes completely/fairly sure 1  
Not sure 2.52 (0.89-7.13)  p=0.08 
Able to ask doctor for support? 
 
 
Confident / fairly confident could do 1  
Could not do 2.65 (1.06-6.66)  p=0.04 
Regimen received during pregnancy 
 
 
cART 1  
ZDVm 2.17 (0.82-5.72)  p=0.12 
Self-efficacy score HIV-ASES – integration of 
HIV treatment into daily living 
 
 
Score of ≥5 (higher self-efficacy) 1  
Score of <5 (lower self-efficacy) 1.76 (0.75-4.15)  p=0.20 
Positive depression screening test   
No 1  
Yes 1.52 (0.72-3.20) p=0.27 
Hospital   
Kiev 1  
Odessa 0.90 (0.42-1.92) p=0.79 
Simferopol 0.49 (0.12-2.05) p=0.33 
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Factors associated with the other outcome of ever having missed a dose during pregnancy after 
adjusting for hospital of delivery included being a current smoker, having received ZDVm (rather 
than cART) during pregnancy and having a lower level of self-efficacy (Table 6.13). Women not 
living with a partner and not disclosing their HIV status to a partner were also more likely to report 
ever having missed a dose (p=0.07 and p=0.09 respectively). Women with low self-efficacy were 
more likely to report having missed a dose, regardless of their depression screening test result 
(Mantel-Haenszel test of homogeneity of ORs p=0.67). 
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Table 6.13: Factors associated with reporting ever having missed a dose during pregnancy 
 
PR adjusted for hospital of 
delivery (95% CI)                             
Age 
 
 
<25 years 1  
25-27 years 0.41 (0.23-0.73)  p<0.01 
28-30 years 0.52 (0.30-0.91)  p=0.02 
≥31 years 0.62 (0.38-1.00)  p=0.05 
Pregnancy planned 
 
 
Yes 1  
No 1.71 (1.16-2.51)  p<0.01 
Living with extended family 
 
 
No 1  
Yes 1.48 (0.99-2.21)  p=0.06 
Living with partner   
No 1  
Yes 0.69 (0.46-1.03)  p=0.07 
Disclosed HIV status to friend 
 
 
No 1  
Yes 1.37 (0.82-2.28)  p=0.23 
Disclosed HIV status to partner   
No 1  
Yes 0.69 (0.45-1.05)  p=0.09 
Current smoker 
 
 
No 1  
Yes 1.67 (1.12-2.51)  p=0.01 
History of marijuana use   
No 1  
Yes 1.25 (0.76-2.06)  p=0.38 
Able to ask doctor for support? 
 
 
Confident / fairly confident could do 1  
Could not do 1.45 (0.75-2.80)  p=0.27 
Is antenatal ART effective for PMTCT?   
Yes, completely / fairly sure 1  
No 1.45 (0.78-2.69) p=0.24 
Regimen received during pregnancy 
 
 
cART 1  
ZDVm 2.46 (1.51-4.00)  p<0.01 
Self-efficacy score  
 
 
≥5 (higher self-efficacy) 1  
<5 (lower self-efficacy) 1.67 (1.06-2.64)  p=0.03 
Positive depression screening test   
No 1  
Yes 1.37 (0.92-2.04) p=0.12 
Hospital   
Kiev 1  
Odessa 0.79 (0.52-1.18) p=0.24 
Simferopol 0.28 (0.09-0.83) p=0.02 
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ART adherence postnatally 
Table 6.14 shows characteristics of the Postnatal Survey respondents currently on ART by whether 
they had a CASE adherence index score of ≤11 (n=99), and by reporting of any missed dose in the 
last four weeks (n=100). The available sample size was limited by the fact that only around a quarter 
of women attending the HIV/AIDS centres postnatally continue on ART, and a substantial 
proportion return infrequently (if at all) for follow-up (see Chapter 5). Numbers enrolled at each of 
the six HIV/AIDS centres were insufficient to make between-centre comparisons, and none of the 
respondents in Kiev, Mykolaiv and Simferopol had a CASE score of ≤11 (out of 7, 10 and 4 
respondents respectively). The proportions with a CASE score of ≤11 at the remaining three 
centres were 4/43 in Odessa, 2/15 in Donetsk and 2/20 in Krivoy Rog. The proportions reporting 
any missed dose in the last four weeks were 3/7 in Kiev, 11/44 in Odessa, 0/10 in Mykolaiv, 7/15 
in Donetsk, 9/20 in Krivoy Rog and 1/4 in Simferopol. 
Although self-efficacy score was the only factor in Table 6.14 associated with a CASE score of ≤11 
to a significance level of p<0.10, this was probably due to the small sample size and lack of 
statistical power for other comparisons. In particular, differences in proportions indicated that 
cohabiting women may have been more likely to have a CASE score of ≤11 than married women, 
and also that current smokers and drinkers may have been less adherent. The more sensitive 
outcome measure of ever missing a dose in the last four weeks was associated with being a current 
smoker, having a history of illicit drug use (excluding marijuana) and with not having used a 
treatment adherence programme. Unmarried and particularly single women were slightly more 
likely to report having ever missed a dose than married women (p=0.08 for comparison of three 
groups), and women not living with a partner were also slightly more likely to report a missed dose 
(p=0.06). Of the subgroup with matched data available, 36% (9/25) of women with WHO stage 1-2 
disease reported having missed a dose in the last four weeks vs. 13% (2/16) of those with WHO 
stage 3-4 disease (Fisher’s exact test p=0.10). Of 35 women with data available from the Women’s 
Study on self-reported affordability of contraception, those reporting a missed ART dose were 
slightly more likely to report that contraception was unaffordable (4/10 vs. 3/25 of those without 
any missed dose of ART, Fisher’s exact test p=0.08).   
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Only 3/86 women on ART postnatally reported being unable to ask their doctor for information 
and to share concerns and worries; none of these three women had ‘poor’ adherence by either 
outcome measure. Of the 23 women who reported not being able to ask someone for support with 
taking their medication, 6 (26%) reported having missed a dose in the last four weeks (vs. 35% 
(22/62) of those fairly confident / certain that they could ask for support, Fisher’s exact test 
p=0.29), and there was also no association between confidence in ability to ask for support and 
having a CASE score of ≤11 (Fisher’s exact test p=0.50). The degree to which a woman reported 
being bothered by side effects was also not associated with the likelihood of either adherence 
outcome (Fisher’s exact p=0.63 for CASE score of ≤11 and p=0.31 for missed dose in the last four 
weeks). Of the 16 women not giving any of the names of the drugs in their regimen, 7 (44%) 
reported missing a dose in the last four weeks (vs. 24 (29%) of those reporting ≥1 drug name, 
Fisher’s exact test p=0.18) and 3 (19%) had a CASE score of ≤11 (vs. 5 (6%) of those reporting ≥1 
drug name, Fisher’s exact test p=0.12). 
Tables 6.15 and 6.16 give unadjusted PRs for factors with a p value of ≤0.20 (Fisher’s exact test) in 
univariable comparisons with the two adherence outcomes (CASE score of ≤11 and any missed 
dose reported over the last four weeks). 
The statistically significant association between a lower level of self-efficacy and a CASE score of 
≤11 must be interpreted with caution, in view of the very small numbers and wide confidence 
interval (Table 6.15), but supports findings from the Antenatal Survey. The measure of self-efficacy 
used here, which focused on various aspects of HIV treatment, was not associated with current 
smoking or drinking (Fisher’s exact p=0.55 and 0.68 respectively), or with report of any missed 
dose over the last four weeks (Table 6.14). 
Women living with a partner were slightly less likely to report a missed dose, indicating the 
potentially important role that a partner may play in supporting adherence behaviours during the 
postpartum period. All types of substance use were associated with an increased likelihood of a 
missed dose (reaching statistical significance for smoking and history of drug use other than 
marijuana). Use of social services was associated with a non-significant increased likelihood of 
reporting a missed dose (p=0.19) - these services are targeted at the most socially vulnerable women 
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(see Chapter 5, page 150). Participation in a treatment adherence programme was associated with a 
reduced likelihood of reporting a missed dose postnatally (Table 6.14). 
Table 6.14: Factors associated with poor postnatal ART adherence 
 CASE score 
≤11 points 
(8/99) 
Fisher’s 
exact 
test 
Ever missed 
a dose 
(31/100) 
Fisher’s 
exact  
test 
Age     
<25 years 9% (2/22)  p=0.95 23% (5/22) p=0.37 
25-27 years 7% (1/15)   19% (3/16)  
28-30 years 5% (1/21)   29% (6/21)  
≥31 years 10% (4/40)   40% (16/40)  
Marital status     
Married 6% (3/54)  p=0.13 22% (12/55) p=0.08 
Cohabiting 19% (4/21)   38% (8/21)  
Single 4% (1/24)   46% (11/24)  
Pregnancy planned     
Yes 7% (5/70)  p=0.35 30% (21/71) p=0.24 
No 12% (3/25)   40% (10/25)  
Lives with partner     
No 10% (2/21)  p=0.55 48% (10/21) p=0.06 
Yes 8% (6/77)   27% (21/78)  
Lives with extended family     
No 8% (6/75)  p=0.60 30% (23/76) p=0.43 
Yes 9% (2/23)   35% (8/23)  
Lives alone     
No 7% (6/86)  p=0.25 30% (26/87) p=0.30 
Yes 17% (2/12)   42% (5/12)  
Disclosed status to partner     
No 10% (2/20)  p=0.52 45% (9/20) p=0.12 
Yes 8% (6/78)   28% (22/79)  
Disclosed status to friend     
No 8% (7/89)  p=0.55 30% (27/90) p=0.30 
Yes 9% (1/9)   44% (4/9)  
Current smoker     
No 6% (4/71)  p=0.13 25% (18/72) p=0.02 
Yes 15% (4/26)   50% (13/26)  
Current drinker     
No 7% (6/91)  p=0.13 29% (27/92) p=0.17 
Yes 25% (2/8)   50% (4/4)  
History of marijuana use     
No 7% (6/84)  p=0.35 28% (24/85) p=0.13 
Yes 13% (2/15)   47% (7/15)  
History of other drug use     
No 8% (6/78)  p=0.44 28% (22/79) p=0.05 
Yes 12% (2/17)   53% (9/17)  
Using treatment adherence 
programme 
    
No 7% (4/60)  p=0.39 38% (23/61) p=0.05 
Yes 10% (4/39)   21% (8/39)  
Using social services     
No 7% (5/71)  p=0.40 28% (20/72) p=0.19 
Yes 11% (3/28)   39% (11/28)  
Self-efficacy score     
≥5 (higher self-efficacy) 5% (3/55) p=0.05 36% (20/55) p=0.21 
<5 (lower self-efficacy) 27% (3/11)  55% (6/11)  
Positive depression screen     
No 7% (5/71)  p=0.39 28% (20/72) p=0.26 
Yes 11% (3/27)   37% (10/27)  
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Table 6.15: Factors associated with having a CASE score ≤11 in the year following delivery 
 
 
 
 
 
 
 
 
Table 6.16: Factors associated with reporting any missed dose over the last four weeks 
postnatally 
 
Crude PR (95% CI)                             
Marital status 
 
 
Married 1  
Cohabiting  1.75 (0.83-3.67)  p=0.14 
Single 2.10 (1.08-4.09)  p=0.03 
Live with partner 
 
 
No 1  
Yes 0.57 (0.32-1.01)  p=0.06 
Disclosed HIV status to partner 
 
 
No 1  
Yes 0.62 (0.34-1.13)  p=0.12 
Current smoker 
 
 
No 1  
Yes 2.00 (1.15-3.49)  p=0.02 
Current drinker   
No 1  
Yes 1.70 (0.79-3.66) p=0.17 
History of marijuana use   
No 1  
Yes 1.65 (0.87-3.14)  p=0.13 
History of other drug use 
 
 
No 1  
Yes 1.90 (1.07-3.38)  p=0.03 
Using treatment adherence programme 
 
 
No 1  
Yes 0.54 (0.27-1.10)  p=0.09 
Using social services  
 
 
No 1  
Yes 1.41 (0.78-2.56) p=0.25 
Reported ≥1 drug name in regimen   
Yes 1  
No 1.53 (0.80-2.94) p=0.20 
WHO Stage (ECS subgroup)   
1-2 1  
3-4 0.35 (0.08-1.43) p=0.14 
 
 
Crude PR (95% CI) 
                             
Marital status 
 
 
Married 1  
Cohabiting 3.43 (0.83-14.14)  p=0.09 
Single 0.75 (0.08-6.92)  p=0.80 
Current smoker 
 
 
No 1  
Yes 2.73 (0.73-10.20)  p=0.14 
Current drinker 
 
 
No 1  
Yes 3.79 (0.90-15.92)  p=0.07 
Reported ≥1 drug name in regimen 
 
 
Yes 1  
No 3.11 (0.82-11.82)  p=0.10 
Self-efficacy score 
 
 
≥5 (higher self-efficacy) 1  
<5 (lower self-efficacy) 5.0 (1.14-21.85)  p=0.03 
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6.8 Limitations 
As self-reported adherence measures are generally inflated, actual levels of adherence are likely to 
be lower than reported here. The recall period for neonatal prophylaxis was particularly long 
(around six months) and this could have resulted in further inflation of measures, although 
responses indicated that a substantial proportion of doses were administered by medical staff 
before hospital discharge. The involvement of physicians in reviewing completed questionnaires to 
identify and refer women with possible adherence problems or depression may have resulted in 
further inflation of self-reported adherence measures due to social desirability bias. Respondents in 
the Antenatal Survey who had received dual therapy for PMTCT may have been miscategorised as 
having only partial knowledge of their ART regimen, but this was likely to apply to one or two 
women at most (dual therapy was received by 20 women enrolled in ECS from 2008-10, see 
Chapter 3, page 84). 
Limited viral load data were available to validate CASE adherence index scores; a quarter of women 
in the Antenatal Survey with ECS data available did not have a viral load measure taken during 
pregnancy, and a further 31% had a viral load measure taken before ART was initiated, or less than 
four weeks later. The date of birth of some women in the Ukraine ECS is reported only to the year, 
which precluded matching with Adherence Survey data and possibly further limited the validation 
sample; among deliveries in 2011, this proportion was 5% (56/1120).  
Despite the bias inherent in self-report measures and the limitations affecting the validation 
analyses, the association found between CASE score and level of viral load points to the utility of a 
short self-report adherence measure in this setting. Validation will need to be reproduced with a 
larger sample, as virological monitoring is further scaled up in Ukraine, and compared with other 
short self-report measures of adherence.  
Power to detect differences in adherence by maternal characteristics and centre of enrolment was 
limited by the study sample size. There were important differences between Antenatal and 
Postnatal Survey groups (particularly with respect to HIV disease stage) which could not be 
adjusted for in analyses due to the limited size of the sample with linked ECS data available, and 
this precluded meaningful comparisons of adherence in the two time periods. Adherence Study 
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participants had higher levels of education than ECS participants overall, and women receiving 
antenatal cART at the time of this study and engaged with HIV care postnatally were non-
representative (explored further in section 3.2.5, page 102 and section 5.2.1, page 146 respectively). 
The high levels of adherence reported in this study may therefore not be generalizable to the wider 
HIV-positive population as cART coverage increases, and as individuals accumulate longer 
durations on ART.  
Limitations affecting the self-efficacy measure included the simplification of the measure from its 
previously validated form (see page 68) and the fact that no measure of a woman’s need for support 
was included in the questionnaire. Previous experiences of needing support and of trying to access 
it (including from healthcare professionals) may have positively or negatively affected a woman’s 
confidence in her ability to seek support in the future. 
  
 233 
 
6.9 Key points 
 Use of the CASE index self-report adherence measure was feasible in this population of 
childbearing women. CASE scores of ≤11 or ≤12 were associated with higher viral load 
measures in a validation subset of 36 women. 
 Overall, 14% of 175 Antenatal Survey respondents reported poor ART adherence during 
pregnancy (CASE score of ≤11) and a third reported having missed a dose of ART during 
pregnancy. 
 Women reporting poor adherence in the Antenatal Survey were younger, more likely to have an 
unplanned pregnancy and to be living with their family (rather than with a partner), more likely 
to lack confidence in their ability to ask their doctor for support, and more likely to have 
disclosed their HIV status to a friend. In addition to these factors, a positive depression 
screening test, lower level of self-efficacy and being a current smoker were associated with 
reporting a missed dose of ART during pregnancy. 
 Of the smaller postnatal sample of women currently on ART (n=99), 8% reported poor 
adherence during the last month (CASE score of ≤11) and a third of respondents reported 
missing a dose of ART during the last four weeks. 
 Factors associated with reporting a missed dose over the preceding four weeks postnatally were 
being unmarried, not living with a partner, not disclosing HIV status to a partner, being a 
current smoker, having a history of drug use and not using a treatment adherence programme. 
Lower levels of self-efficacy were associated with having a CASE score of ≤11. 
 Two of the three most common reported reasons for missing a dose in both the Antenatal and 
Postnatal Surveys were simply forgetting and being away from home. Lack of support from a 
partner was associated with poorer ART adherence in both time periods. 
 Around 1 in 4 women screened positive for depression in both Antenatal and Postnatal Surveys. 
 Levels of anxiety about the safety of ART for the infant were high: 83% of women were anxious 
about the safety of ART for the infant in utero, and two-thirds were worried about the safety of 
neonatal prophylaxis. 
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Chapter 7: Discussion 
7.1: Introduction 
This thesis highlights the diversity of the HIV epidemics affecting childbearing women in Europe, 
the convergence of PMTCT policy and practice in Ukraine with the Western region, and continued 
missed opportunities for PMTCT in both settings. Despite changes over recent years, there remain 
important differences in the characteristics of HIV-positive women living in Ukraine and Western 
Europe, most notably the much greater prevalence of IDU in Ukraine (14% of women enrolling in 
the ECS in 2010, compared with 1% at Western Europe sites) and associated HIV co-infection and 
co-morbidity. Although the proportion of new HIV infections attributable to IDU has declined in 
Ukraine since 2006, this is against a backdrop of an accelerating HIV epidemic, and the decline in 
the absolute number of new infections among IDUs is therefore less marked (Ministry of Health of 
Ukraine 2012). The increase in sexual transmission of HIV from IDUs and other high-risk groups 
to bridging populations and beyond is evidenced by the fact that almost two-thirds of women 
delivering in the Ukraine ECS in 2010 had no reported IDU history or IDU partner, up from 45% 
in 2000. Antenatal HIV screening, coverage of which is >99% (Ministry of Health of Ukraine 
2012), has provided important evidence of the increasing heterosexual transmission of HIV in the 
general population in Ukraine.  
In Western Europe, the predominantly African women enrolling into the ECS in 2010 were slightly 
older than those enrolled in Ukraine (median maternal age was 30 years and 27 years respectively). 
Surveillance data from the UK and Ireland have shown an increasing proportion of repeat 
pregnancies among HIV-positive women, particularly among those from Middle and Western 
Africa (French et al. 2012). Around a third of pregnancies in Western ECS sites since 2006 were 
repeat pregnancies to women previously enrolled in the study. In the Ukraine ECS, this proportion 
was smaller – estimated at 11% in 2010 – probably due to the shorter history of the HIV epidemic 
in Ukraine, poorer access to ART and HIV-related services, and the low birth rate in the general 
population (1.5 births per woman (Lekhan et al. 2010)). Linked to the prevalence of repeat 
pregnancies is the increasing proportion of women diagnosed as HIV-positive prior to conception, 
which reached 80% of enrolments in the Western sites of the ECS in 2010-11 (up from 70% in 
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2000-01), and 44% of enrolments in the Ukraine ECS in 2010 (up from 20% in 2000-01). These 
trends indicate opportunities for optimising the pre-conceptual care of diagnosed HIV-positive 
women, explored in the next section.  
7.2: Pre-conceptual care of HIV-positive women 
The comprehensive care of HIV-positive women requires appropriate management of their HIV 
disease (monitoring of clinical and immunological status and prompt initiation of cART when 
indicated), but also reproductive care and access to family planning. Achieving and maintaining an 
undetectable viral load is the aim of treatment for all individuals on cART; for women who may 
become pregnant this is particularly important, as MTCT risk is lowest when viral load is 
undetectable throughout pregnancy (Tubiana et al. 2010). For maternal health it may also be 
important to maximise immune status prior to pregnancy (Le Moing et al. 2008).  
Many pregnancies among HIV-positive women are unplanned – for example, 31% of pregnancies 
among previously diagnosed women in the Women’s Study were unplanned, and this is an 
underestimate of unplanned conceptions since it excludes pregnancy terminations. Italian 
surveillance data from 2001-06 showed that almost two-thirds of HIV-positive pregnant women 
had not planned their pregnancy (Floridia et al. 2007), while in a European survey in 2003-04 this 
proportion was 50%, with 31% of pregnancies both unplanned and undesired (Fiore et al. 2008). Of 
note, ART initiation was associated with an increased incidence of pregnancy in an African cohort 
study, possibly due to an association between improving health and changes in sexual behaviour or 
fertility desires (Carter et al. 2010). Data from the general population show that the risk of adverse 
neonatal or maternal outcomes is higher when a pregnancy is unintended (Tsui et al. 2010). For 
HIV-positive women, unintended or mistimed pregnancies will be associated with missed 
opportunities to optimise virological control and ART regimen. In a UK study, 31% of 375 women 
conceiving on ART since 1995 were taking an antiretroviral drug not recommended for use during 
pregnancy (Huntington et al. 2011), highlighting the need to consider the possibility of a future 
conception when managing HIV-positive women of reproductive age. Maternal IDU, an 
independent risk factor for lack of antenatal care in Western Europe and Ukraine (Chapter 3), is a 
potential challenge to the delivery of pre-conceptual care. Women with an IDU history accounted 
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for 21% of women diagnosed before conception and 9% diagnosed antenatally in the Ukraine ECS 
in 2008-10; in Western European sites these proportions were 22% and 7% respectively in 2000-09. 
IDUs were more likely to have an unplanned pregnancy than non-IDUs in the Women’s Study, and 
this was reflected in a higher rate of unplanned pregnancies among women diagnosed 
preconception than among those diagnosed during pregnancy. 
7.2.2 Conception on cART and virological failure in pregnancy 
Investigation of the growing subgroup of women who conceive on cART provides a better 
understanding of how well the HIV disease of these women is being managed before pregnancy, 
the implications for virological control during pregnancy for women who conceive on a non-
suppressive regimen, and potential strategies to improve outcomes. In Chapter 4, conception on 
cART at the Western Europe sites of the ECS is investigated, showing a substantial increase over 
the last twelve years; the proportion of women conceiving on cART exceeded 40% in 2010-11 and 
was 54% among those diagnosed prior to conception. Among those conceiving on cART with ≥24 
weeks of treatment, the proportion with a non-suppressed viral load was 34% in 2000-01 declining 
to 3% in 2010-11. This is consistent with improvements over time in virological outcomes reported 
among treated individuals elsewhere (Mocroft et al. 2000; Bannister et al. 2006; Lampe et al. 2006; 
Vo et al. 2008; Raboud et al. 2010).  
Non-boosted PI-based cART has been shown to be associated with poorer virological response 
than NNRTI and boosted PI-based regimens previously in the Western Europe ECS (Patel et al. 
2007) and elsewhere (Walmsley et al. 2002; King et al. 2004; Bannister et al. 2006; Willig et al. 2008) 
and this is supported by findings reported in this thesis (Table 4.2b, page 139). However, the 
secular improvements in virological outcomes (Chapter 4) were independent of the increasing 
potency of first-line regimens (APR 0.80 (95% CI 0.72-0.89) per year after adjusting for cART type 
and other factors), as has been found in other studies (Bannister et al. 2006; Lampe et al. 2006). This 
may be due to general improvements in HIV care and accumulation of clinical expertise, as well as 
reduced toxicity, improved tolerability, and decreased pill burden and dosing frequency of newer 
regimens (Heath et al. 2002; Willig et al. 2008; Atkinson et al. 2009). These advances have helped to 
reduce the substantial impact of ART on health-related quality of life, including the frequency and 
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severity of ART side effects such as diarrhoea and lipodystrophy, thus improving ART adherence 
(Gakhar et al. 2013). Given expanding treatment options, it is also possible that women conceiving 
on cART in later years had already switched away from regimens that they were not tolerating well 
or were responding to sub-optimally. In the Swiss Cohort Study, patients were more likely to switch 
regimen in 2000-05 than in 1995-98, but switches in later years were less likely to be due to 
virological failure and more likely to be due to intolerance (Vo et al. 2008).  
Among women conceiving on cART, those who had been diagnosed with HIV for longer were 
more likely to have a non-suppressed antenatal viral load (APR 1.06 (95% CI 1.01-1.10) per year 
HIV diagnosed prior to conception). Possible reasons include poor adherence due to treatment 
fatigue, and the development of ART resistance (Glass et al. 2006). Women enrolling in more recent 
years tended to have been diagnosed with HIV for longer (a median of 2.8 years for deliveries in 
2010-11, compared with 1.1 years for deliveries in 2000-01), highlighting the increasing importance 
of the management of women with treatment experience. After adjusting for time since diagnosis, 
older women were more likely to achieve virological suppression than younger women. Younger 
age has been shown to be associated with an increased risk of poor ART adherence and/or poor 
virological outcomes in the UK and North America (Porter et al. 2008; Sabin et al. 2008; Sherr et al. 
2010; Ryscavage et al. 2011; Hadland et al. 2012), and now also in Ukraine (Chapter 6). Older age 
was associated with better virological outcomes among women receiving HIV care in a second or 
subsequent pregnancy in the UK (odds of a detectable viral load at delivery were 0.76 (95% CI 
0.63-0.92) for 25-34 years vs. <25 years (French et al. 2013)). Although IDU has been associated 
with poorer ART adherence (discussed in section 7.4.2, page 258), the two-fold increased risk of a 
non-suppressed viral load among IDUs (vs. non-IDUs) conceiving on cART was accounted for by 
their increased probability of enrolment in earlier years. Of note, IDUs may have been under-
represented overall, because barriers to treatment might have made them less likely to meet the 
eligibility criteria for these analyses.  
Women who conceived on cART and had at least two previous pregnancies in the ECS were at a  
three-fold increased risk of treatment failure compared with those who had no previous ECS 
pregnancies (Chapter 4). Most women with a previous ECS pregnancy had a history of antenatal 
cART receipt, and this may or may not have been continued between pregnancies (full treatment 
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histories are not routinely collected in the ECS). In the general HIV-positive population, poorer 
treatment outcomes have been reported when cART was stopped at higher CD4 counts and 
reinitiated at CD4 counts of <250 cells/mm3 than when it was taken continuously (El-Sadr et al. 
2008; Lundgren et al. 2008), but pregnant women are a more immunocompetent group. Studies 
investigating the effect of exposure to short-course PI-based cART in pregnancy have found no 
accumulation of resistance mutations (Gingelmaier et al. 2010), nor increased risk of virological 
failure when cART is received subsequently for PMTCT (Briand et al. 2011; French et al. 2013). 
However, an analysis of UK and Ireland surveillance data showed an increased risk of detectable 
viral load at delivery among women previously receiving short-course NNRTI-based cART for 
PMTCT (French et al. 2013). Other factors including child-care responsibilities may have had a 
negative impact on health-seeking behaviour or adherence among multiparous women; of note, 
such women were at increased risk of multiple missed opportunities for PMTCT in the Ukraine 
ECS (Chapter 3, discussed in section 7.3.2). More research is needed to understand treatment 
response among multiparous women, both with and without a history of HIV care in previous 
pregnancies.   
Virological outcomes among women conceiving on a non-suppressive regimen 
Pregnancy is a time when virological control may improve due to enhanced monitoring and support 
as well as improvements in ART adherence (Nachega et al. 2012). Among women conceiving on 
cART and with a non-suppressed viral load at first antenatal measure, 63% had a suppressed viral 
load (≤200 copies/ml) recorded before delivery and it is reassuring that this proportion increased 
over time (Chapter 4). In a previous ECS analysis which included 127 women conceiving on non-
suppressive cART and enrolled from 1998 to 2006, 103 had a viral load available within four weeks 
of delivery, of whom 39 (38%) had a suppressed viral load at this time (European Collaborative 
Study 2010). Possible reasons for this difference are that a ‘suppressed’ viral load measure was 
defined as below the assay detection limit (<50 copies/ml) in the earlier analysis, and that the earlier 
study analysis was of data before widespread use of boosted PIs. The earlier study also included 
women with a treatment interruption pre-dating their first (non-suppressed) viral load during 
pregnancy, who may have had poorer virological control overall – treatment interruptions during 
pregnancy have become less common over time and are no longer recommended due to their 
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association with increased MTCT risk (Galli et al. 2009; de Ruiter et al. 2012; Panel on Treatment of 
HIV-infected Pregnant Women and Prevention of Perinatal Transmission 2012).  
7.2.3 Management of HIV-positive women in Ukraine 
A substantial proportion of women in the Ukraine ECS had been diagnosed before conception in 
recent years (31% in 2007, increasing to 44% in 2010). However, within this group the proportion 
conceiving on cART was much lower than in Western Europe (2% in 2007 and 12% in 2010, 
Chapter 3). Among those diagnosed but not on cART prior to conception and enrolling in 2010, 
over 40% had indications for treatment for their own health during pregnancy, demonstrating 
substantial unmet need for treatment prior to conception. This figure partly reflects poor cART 
coverage in the general population in Ukraine; although cART scale-up started in 2004, 52% of 
individuals with advanced HIV infection were not receiving it in 2009 (Ministry of Health of 
Ukraine 2010). Disengagement from HIV care was also a contributory factor, evidenced by the fact 
that one in ten women who were diagnosed with HIV but not on cART prior to conception in 
2008-10 did not receive antenatal ART (the corresponding proportion in the Western Europe ECS 
sites in 2000-09 was 5%). Untreated women with indications for cART are not only at increased 
risk of morbidity and mortality, but also of MTCT (European Collaborative Study 2005).  
Of 207 women initiating cART during pregnancy in 2008-10 and with a viral load measure available 
at least three months later, 69% had an undetectable viral load. As the laboratory capacity for 
virological monitoring in Ukraine expands, there will be opportunities to explore virological 
response rates to ART both within and outside the context of pregnancy, including among women 
who have previously received PMTCT interventions. 
7.3. Progress towards the virtual elimination of MTCT 
The virtual elimination of MTCT (a rate of <2%) is a target for the WHO European region by 
2015 (WHO Regional Office for Europe 2011) and has already been achieved for some countries in 
Western Europe (European Collaborative Study 2005; Townsend et al. 2008a; Jasseron et al. 2011). 
From 2000 to 2009, 25 HIV-infected infants were reported in the Western Europe ECS – an 
overall MTCT rate of 1.7%, and 1.1% among women receiving at least 14 days of antenatal ART. 
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The huge successes of PMTCT programmes in Western Europe are increasingly being replicated in 
Ukraine, where scale-up of the most effective interventions has been hindered over the last decade 
by the challenges of resource-limitation and a rapidly accelerating epidemic driven by IDU. As the 
interventions used for PMTCT have become more similar in Ukraine to those used in Western 
Europe, so too have the circumstances surrounding missed opportunities for PMTCT. In both 
regions, missed opportunities are concentrated among marginalised groups with poorer access to 
and uptake of antenatal and HIV care, and with clustering of characteristics indicating potential 
marginalisation including IDU history, lack of a partner and, in Ukraine, multiparity and lower level 
of education.  
7.3.1 Scale-up of cART for PMTCT in Ukraine 
In Chapter 3, the substantial improvements in access to antenatal cART in Ukraine since the 
adoption of an ‘Option B’ policy are described; overall, 22% of women who initiated ART in 
pregnancy and delivered in 2008 received cART, increasing to 67% in 2010. The MTCT rate 
declined from 7% in 2007 (Thorne et al. 2009) to 4.1% in 2008-10, and 1.3% among the 45% of 
women who received antenatal cART in this later time period. This is compared with a 3.1% overall 
MTCT rate reported in St. Petersburg in 2007, a year when coverage with dual or triple antenatal 
ART was around 50% (Kissin et al. 2011). By 2010, 91% of women in the Ukraine ECS with 
treatment indications received cART in pregnancy (up from 56% in 2008), indicating their 
prioritisation for limited cART supplies as per WHO guidelines (WHO 2010a). CD4 count 
measurements are crucial for identification of women with treatment indications during pregnancy 
(Carter et al. 2010; Liu et al. 2011), with important implications for the decision to stop or continue 
ART after delivery. Although substantial advances have been made in the availability of CD4 count 
and viral load monitoring in Ukraine (Table 3.1, page 83) there is still unmet need for 
immunological monitoring, evidenced by the 27% of women delivering in 2010 who lacked an 
antenatal CD4 count; this also suggests that true coverage of women with treatment indications 
may have been lower than 91%.  
In adjusted analyses, there was evidence that women with lower educational status were more likely 
to initiate ZDVm (rather than cART), despite the fact that lower educational status was associated 
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with poorer immunological health among women without treatment indications (Chapter 3). The 
barriers to care experienced by this group as well as by multiparous and unmarried women are 
explored in the next section (‘late HIV diagnosis and/or lack of antenatal ART’). Women 
diagnosed as HIV-positive before conception but not on ART were more likely to start antenatal 
cART than those diagnosed in the first or second trimesters, possibly as they had more opportunity 
to undergo preparatory counselling. Among women who did receive antenatal cART, the potential 
for treatment interruptions around the time of delivery due to a lack of drug supplies at maternity 
hospitals (Personal Communication, Igor Semenenko, PPAI, 2012) has concerning implications for 
their virological control and risk of MTCT. 
Resource limitation is a major barrier to universal access to cART in Ukraine. The cost of one 
year’s treatment with LPV/r, ZDV and 3TC (the combination received by over 90% of women 
receiving cART in the Ukraine ECS from 2008-10) was estimated to be ~$500 in a lower-middle 
income European setting in 2011, according to the WHO (WHO 2012a). Most ($410) of this cost 
was attributed to LPV/r. This regimen is much more expensive than EFV-based alternatives, 
recommended by WHO as first-line treatment for adults outside of the context of pregnancy 
(WHO 2010b) and, as of June 2012, also supported as a first-line option during pregnancy (WHO 
2012d). The 2012 guidance cites the accumulating evidence of the safety of EFV during pregnancy 
(Ford et al. 2011), its superior tolerability and efficacy compared with NVP, and the pressing need 
to simplify and harmonise regimens (‘Treatment 2.0’) in order to reduce cost and maximise the 
public health benefit of treatment programmes (WHO et al. 2011a; WHO 2012d). A once-daily 
fixed dose combination of TDF, 3TC and EFV has the advantage over the currently used LPV/r-
based regimens of reduced pill burden and lower cost – $172 per year in 2011 (WHO 2012a). It 
also meets recommendations for the treatment of HIV-positive individuals co-infected with HBV 
with a regimen which has dual HBV activity (Brook et al. 2010) - important in avoiding the 
development of HBV resistance to 3TC (Pillay et al. 2000; Matthews et al. 2006). Of women 
enrolled in the postnatal Women’s Study, 15% were co-infected with HBV (Chapter 5).  
First-line cART regimens used outside of pregnancy in Ukraine are currently NVP-based (WHO 
2005), Personal Communication, Ruslan Malyuta, PPAI, 2012), which precludes harmonisation 
with antenatal regimens due to the risk of NVP-related hepatotoxicity during pregnancy (Lyons et 
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al. 2006). It is unclear what impact the new WHO recommendations for the use of EFV-based 
regimens will have on national policy.  
7.3.2 Lack of antenatal ART and late HIV diagnosis 
Maternal ART during pregnancy is the most effective intervention for PMTCT (WHO 2010a), and 
most cases of MTCT occur when this has not been received (Mayaux et al. 2003; European 
Collaborative Study 2005; Townsend et al. 2008a). Overall, the proportion of women without 
antenatal or intrapartum ART in the Ukraine ECS in 2008-10 was 5% (vs. 7% in 2007 (Thorne et al. 
2009)), and an additional 5% received sdNVP only. In the Western Europe ECS, 8% of women 
delivering in 2000-03 received no antenatal ART declining to 5% in 2004-09. These groups of 
women without antenatal ART accounted for 42% and 25% of vertical transmissions in Ukraine 
and Western Europe in these time periods respectively. To explore the relative importance of 
overall ART coverage and roll-out of cART for achieving a MTCT rate of <2% in Ukraine, two 
hypothetical scenarios were explored. By applying MTCT rates stratified by ART receipt, the overall 
predicted MTCT rate would have been 2.9% (95% CI 2.3-3.6) if all women on ZDVm had received 
cART, compared with 2.2% (95% CI 1.8-2.8) if cART coverage remained unchanged but the 336 
women without antenatal ART had received ZDVm. These results confirm the importance of 
expanded ART coverage for the virtual elimination of MTCT in Ukraine as well as the prevention 
of residual transmissions in Western Europe. The performance of health systems, both in terms of 
identifying pregnant women with undiagnosed HIV infection and preventing subsequent loss to 
follow-up, are key (Mahy et al. 2010; Barker et al. 2011); postnatal follow-up is also crucial for 
successful implementation of an Option B+ approach (discussed further in section 7.4.1). 
Lack of maternal HIV diagnosis is a major barrier to the elimination of MTCT worldwide (Barker et 
al. 2011). The studies in this thesis include only women with known HIV diagnosis by the time of 
delivery, and this thesis explores the frequency and impact of diagnosis late in pregnancy (i.e. after 
the end of the second trimester). Diagnosis at this time precludes initiation of antenatal ART at or 
soon after 14 weeks gestation (WHO 2010a), and compromises the chances that an undetectable 
viral load will be achieved by delivery (Read et al. 2012). Overall, late diagnoses accounted for 15% 
of enrolments in Western Europe ECS sites in 2004-09 and 11% of enrolments in the Ukraine ECS 
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in 2008-10. In Ukraine, the MTCT rate among women diagnosed late (in the third trimester or 
intrapartum) in 2008-10 was 8.5% (95% CI 5.6-12.2%), compared with 2.6% (95% CI 1.8-3.5%) 
among those diagnosed during the first or second trimester. The proportion of women diagnosed 
late in Western Europe and Ukraine ECS sites has been declining over time, related to the 
increasing proportion of women diagnosed prior to conception (Jasseron et al. 2008; Townsend et 
al. 2008b; Thorne et al. 2009; von Linstow et al. 2010) and the spread of the epidemic to less 
marginalised groups who are more likely to engage promptly with antenatal care. Among women 
undiagnosed at conception, the proportion of late diagnoses has also declined over time in both 
settings, although in Ukraine this stayed constant at around 18% in 2008-10. In the Ukraine ECS in 
2008-10, a fifth of women completely lacking antenatal ART had been diagnosed late but 51% had 
been diagnosed prior to conception, highlighting the importance of retaining diagnosed women in 
care. Similarly in the Western Europe ECS in 2000-09, over a third of women with no or <14 days 
of antenatal ART had been diagnosed late, but around half were diagnosed before pregnancy. 
Barriers to diagnosis and antenatal ART for IDUs 
Women with an IDU history were more likely to be diagnosed late in Ukraine and Western Europe, 
and were also more likely than non-IDUs to lack antenatal ART if diagnosed before conception, 
suggesting that barriers to care exist for diagnosed as well as undiagnosed women. Other studies 
and earlier analyses in the ECS have also shown maternal IDU to be associated with a lack of 
antenatal care among HIV-positive women (European Collaborative Study 2001; Peters et al. 2003; 
Whitmore et al. 2010; Kissin et al. 2011), reflecting the often poorer access to HIV services among 
IDUs compared with non-IDUs in the general population (Lucas et al. 2001; Moore et al. 2004; 
Rodriguez-Arenas et al. 2006; Weber et al. 2009; Spicer et al. 2011). Even where HIV and harm 
reduction services are tailored to IDUs, they frequently do not take into account the needs of 
women, who constitute around 20% of people who use drugs in Eastern Europe and 40% in 
Western Europe (Harm Reduction  International 2012). Female IDUs are at high risk of HIV 
acquisition and HIV-related stigma (El-Bassel et al. 2010), and pregnant IDUs may be particularly 
stigmatised, especially in countries where IDU is criminalised, leading to active avoidance of 
healthcare services (Pinkham et al. 2008; Open Society Institute 2009). Previous findings from the 
Ukraine ECS have shown women with an IDU history to be at increased risk of MTCT, over and 
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above that associated with their lack of PMTCT interventions and increased risk of preterm 
delivery (Thorne et al. 2012), and that IDUs without antenatal care are at particularly high risk of 
abandoning their infant at birth (Bailey et al. 2010). 
Opiate substitution therapy is strongly recommended by WHO guidelines for opioid-dependent 
pregnant women (WHO 2009a), but lack of access is a particular issue for childbearing women in 
Ukraine (Nieburg et al. 2012). This is underscored by the fact that only 14% of current injectors 
enrolled in the postnatal Women’s Study were participating in an opiate substitution programme. 
Methadone and buprenorphine are currently only available at narcology treatment centres, which 
are extremely stigmatising to attend, often a site of police harassment, and rarely accommodate the 
childcare needs of IDU mothers (Mimiaga et al. 2010; Spicer et al. 2011; Nieburg et al. 2012). Daily 
attendance at these centres presents substantial logistical challenges, particularly for pregnant 
women and mothers who have complex health and social needs. 
Other aspects of a comprehensive package of care required for the prevention, treatment and care 
of HIV among IDUs include access to needle and syringe programmes, prevention and treatment 
of STIs, condom provision, and prevention, diagnosis and treatment of viral hepatitis and TB 
(WHO et al. 2012). Female childbearing IDUs require services which are sensitive to gender, and 
address healthcare needs in the context of exposure to intimate partner violence, sex work and 
social adversity. Multidisciplinary, case management approaches which integrate healthcare with 
social and legal services may improve engagement with care, as may psychosocial interventions and 
on-site childcare and parenting support (Pinkham et al. 2012).  
Ecological theory postulates that structural factors are key determinants of individual behaviours, 
and that by altering the environmental conditions in which people live it is possible to influence 
health behaviours (Stokols 1992). The structural barriers that IDUs face to healthcare include not 
only a lack of access to harm reduction and integrated services as outlined above, but also the social 
structural barriers of stigma and discrimination. Stigma can be understood in Parker and Aggleton’s 
conceptual framework as a cultural construct to establish and maintain social order, power 
differentials and social inequalities (Parker et al. 2003). Police harassment of IDUs in Ukraine is 
common: of 200 IDUs who participated in a recent study in Odessa, 35% had been held without 
arrest or charge, 13% had had new syringes taken by the police, 11% had been arrested for carrying 
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syringes, 17% reported not buying syringes due to fear of the police, and 24% had been beaten or 
tortured (Booth et al. 2013). IDUs who reported negative experiences with the police, and especially 
those who had experience of rushing injections due to fear of the police, were more likely to be 
HIV-positive (ibid). Stigma and discrimination are also widespread within healthcare services in 
Ukraine. A quarter of HIV-positive individuals in a recent national survey reported having their 
access to health or social care restricted in the last year as a result of their HIV status, and this 
proportion was 30% among high-risk groups (including IDUs) (Demchenko et al. 2011). 
Involuntary HIV testing exacerbates stigmatisation of testing and diagnosis (WHO et al. 2007) but 
is commonplace in Ukraine, with 22% of 1500 HIV-positive people surveyed in 2010 reporting that 
they had been tested without their knowledge or forcibly, and a third lacking pre- or post-test 
counselling (Demchenko et al. 2011). Such experiences are likely to undermine trust for healthcare 
professionals among IDUs and other high-risk groups with deleterious impact on engagement with 
care, possibly leading to active avoidance of healthcare services (Treloar et al. 2013). Rights-based 
approaches to delivering HIV-related services are needed to tackle structural determinants of 
individual-level risk, and are crucial for improving engagement of IDUs with healthcare services 
(Jurgens et al. 2010). 
Other groups with barriers to HIV care in Ukraine 
Other factors associated with suboptimal HIV care in Ukraine were being unmarried (cohabiting or 
single), having less education and multiparity (Chapter 3). These risk factors were clustered and also 
associated with IDU. Their independent associations with late HIV diagnosis and with lack of ART 
indicate multiple barriers among the most socially disadvantaged groups. Of note, cohabiting status 
is much more common among women enrolled in the Ukraine ECS than among women in the 
general population in Ukraine (40% of ECS enrolments in 2008-10, compared with 5% in the 
Ukraine DHS 2007 (Ukrainian Center for Social Reforms et al. 2008)), and may be a marker of 
social deprivation in this setting. Being unmarried, having less education and multiparity were also 
associated with receipt of ZDVm rather than cART among women initiating ART during 
pregnancy, possibly because clinicians were less likely to initiate cART among women attending 
infrequently for care as reported in other studies (Giordano et al. 2003; McNaghten et al. 2003) or 
because these groups were perceived to be less likely to adhere to cART. Results from the Ukraine 
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Adherence Study confirmed that women not living with a partner were more likely to report poor 
ART adherence during pregnancy (Table 6.11, page 223). In the Western Europe ECS, single 
women were more likely to lack ART than married or cohabiting women among the group 
diagnosed pre-conception. Health literacy (the ability to understand and act on health information) 
has been associated with self-perceived social support (Gordillo et al. 1999). Lack of a partner has 
been associated with late antenatal HIV diagnosis (Whitmore et al. 2010) and, in non-pregnant 
populations, with treatment delay (Samet et al. 1998; Torian et al. 2008).  
Low level of education was associated with financial hardship (proxy: inability to afford 
contraception) in the Ukraine Women’s Study (Chapter 5, page 152), consistent with national data 
on socioeconomic status and education, with 39% of women in the highest wealth quintile having 
some university education and 6% in the lowest quintile (Ukrainian Center for Social Reforms et al. 
2008). Poor socioeconomic status and lower education levels are important factors associated with 
lack of healthcare utilisation in the general population in Ukraine (Balabanova et al. 2004). Although 
HIV care is one of the few areas where out-of-pocket payments are not normally applied (UNAIDS 
2009), the fact that these are otherwise widespread may dissuade women in poor financial 
circumstances from seeking care, as may the other attendant costs (e.g. transport and childcare). 
Less educated patients and those with lower socioeconomic status have also been found to be less 
likely to initiate cART in the resource-rich settings of Switzerland and the US (Junghans et al. 1999; 
Wood et al. 2002).  
Multiparous women had lower socioeconomic status than other women in the postnatal Women’s 
Study, and this reflects demographic patterns in Ukraine’s population overall (the total fertility rate 
is 1.0 in the highest wealth quintile and 1.7 in the lowest (Ukrainian Center for Social Reforms et al. 
2008)). The relationship between economic deprivation and higher parity is likely to be complex, 
and mediated via other socioeconomic factors including employment. Many HIV-positive women 
will have experienced negative attitudes of health-care professionals concerning their reproductive 
potential; in a national survey in Ukraine, 28% of 677 HIV-positive women reported that they had 
been advised by healthcare professionals not to have children, 17% reported being worried that 
they would be forced to terminate a pregnancy if they tested positive and 5% had been coerced to 
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do so (Demchenko et al. 2011). Women who have already encountered stigma related to their child-
bearing may have been less likely to seek care in a subsequent pregnancy.  
Findings on the individual-level characteristics of women with missed opportunities for PMTCT 
can be used to inform the design of specific interventions for these highest-risk groups, but also 
underscore the broader socioeconomic determinants of health in this population. The Health 
Impact Pyramid illustrates the different levels at which public health interventions might act, with 
socioeconomic and contextual factors at the base (requiring the greatest political commitment, but 
also offering the largest impacts on public health outcomes), and targeted clinical and counselling 
interventions at the top (interventions which are easier to implement, but require greater individual 
effort and offer smaller public health gains) (Frieden 2010). Interventions to alter factors at the 
bottom of the pyramid, although more challenging, would have the potential to improve outcomes 
not only among the highest-risk groups identified in this thesis but also for the entire HIV-positive 
childbearing population in Ukraine by shifting the whole population to lower risk, as conceptualised 
in a structural model of health behaviour by Cohen et al. (Cohen et al. 2000). For example, 
interventions which tackled socioeconomic inequalities in health could facilitate earlier antenatal 
HIV diagnosis, longer durations of ART and better virological control among women on ART, by 
reducing barriers to optimal PMTCT interventions for all women. Such a shift could have wider 
ranging benefits for HIV outcomes (e.g. by reducing postnatal disengagement from services), and 
for outcomes in other disease areas (Frieden 2010). 
Lack of HIV knowledge 
A lack of knowledge about HIV and about the availability of effective PMTCT interventions may 
contribute to delays in accessing care, and to a complete lack of antenatal ART for some groups; 
for example, sixteen women delivering in the Ukraine ECS in 2008-10 received only sdNVP despite 
being diagnosed as HIV-positive at least a week prior to delivery. Results from the Ukraine DHS 
2007 showed that in the general antenatal population, only 50% of women knew that risk of MTCT 
of HIV could be reduced by the woman “taking special drugs during pregnancy” (Ukrainian Center 
for Social Reforms et al. 2008), highlighting the importance of post-test counselling in antenatal 
care. Models of health behaviour which focus on motivational factors, such as the Theory of 
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Planned Behaviour, postulate intention as a proximal determinant of action, suggesting that 
education to improve perceptions of HIV care and its benefits could increase an individual’s 
intention to attend and result in better actual engagement with care (Armitage et al. 2000). However, 
although these models take some account of environmental constraints on an individual’s 
behaviour, they are likely to under-estimate the substantial impact of social determinants on missed 
opportunities for PMTCT (indicated by the findings discussed in the previous section). Multi-stage 
models which conceptualise actions as resulting from separate motivational and volitional phases 
(Armitage et al. 2000) may provide a more adequate explanation of uptake of PMTCT services, as 
may a biopsychosocial perspective which more explicitly incorporates predictors such as social 
stressors and support (Suls et al. 2004; Hampanda 2013). The multiple associations between social 
marginalisation and missed opportunities for PMTCT described in this thesis suggest that 
comprehensive education, while necessary, will not be sufficient to ensure adequate uptake of 
PMTCT services among diagnosed women. 
Preterm delivery 
In Western Europe sites of the ECS in 2000-09, delivery at <34 weeks gestation was associated 
with an almost three-fold increased risk of no antenatal ART and over four-fold increased risk of 
receiving only 1-13 days antenatal ART (section 3.3). In the Ukraine ECS in 2008-10, preterm 
delivery at <37 weeks was also associated with a lack of antenatal ART among women diagnosed 
during pregnancy (section 3.2). Missed opportunities for PMTCT among women who deliver 
preterm should be mitigated by the earlier initiation of antenatal ART (from 12 weeks and by 24 
weeks) now recommended by most national guidelines within Europe (Aebi-Popp et al. 2013), 
which reflects the changing risk-benefit around ART use in pregnancy. HIV-positive women with a 
history of or other risk factors for preterm delivery such as IDU or smoking are likely to 
particularly benefit from initiation of antenatal ART earlier than the 24-26 weeks gestation currently 
recommended in Ukrainian guidelines (UNICEF 2012). Preterm delivery is not only a barrier to 
receipt of sufficient antenatal ART but also an independent risk factor for MTCT (European 
Collaborative Study 1999; Kuhn et al. 1999), and further increases MTCT risk by precluding elective 
CS delivery (McDonald et al. 2006), highlighting the importance of achieving virological suppression 
early in pregnancy (National Study of HIV in Pregnancy and Childhood et al. 2007). 
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Other circumstances leading to late diagnosis and/or lack of antenatal ART 
Two other scenarios which may lead to a late antenatal HIV diagnosis and/or lack of antenatal 
ART are refusal of PMTCT interventions and acquisition of maternal HIV infection during the 
course of pregnancy. UK studies have found both positive and negative associations between 
refusal of antenatal screening and infection risk, also linking refusal to religious affiliation, parity 
and previous testing for HIV (Boxall et al. 2004; Conaty et al. 2005). Data on refusal of HIV testing 
or PMTCT interventions are not collected as part of the ECS protocol, but refusals have been 
reported on an ad hoc basis. In the French Perinatal Cohort, the proportion of women without 
antenatal ART who had declined treatment was about a third (Mayaux et al. 2003). In Ukraine, over 
80% of respondents to the Antenatal Adherence Survey reported being worried about the safety 
ART in pregnancy (Chapter 6), highlighting the substantial burden of anxiety even among a group 
accepting antenatal ART as an intervention. Lower levels of worry were reported among women 
who were more confident about the effectiveness of ART for PMTCT. The strengthening of 
counselling about PMTCT for HIV-positive women in Ukraine is therefore a priority.  
In Ukraine, diagnosis during the third trimester may be due to seroconversion during pregnancy, 
since repeat testing during the third trimester is routinely conducted among women testing negative 
earlier in pregnancy. Dates of negative antenatal HIV tests are not currently collected in the ECS, 
and it was therefore not possible to distinguish women seroconverting during pregnancy from 
those who were diagnosed late having not had a previous antenatal test. There is some (although 
inconsistent) evidence from African studies of an increased risk of acquiring HIV sexually during 
pregnancy, possibly due to hormonal changes or to heightened risk behaviours of women or their 
partners (Gray et al. 2005; Morrison et al. 2007; Mugo et al. 2011). Some groups at increased risk of 
being diagnosed late in the ECS (e.g. IDUs) may have poor access to antenatal care but also high 
HIV incidence rates. A study using a recent infection testing algorithm (RITA) among 1313 HIV-
positive people in Odessa found that a quarter had recent HIV infection at the time of their HIV 
diagnosis, and that recent infection was particularly likely among young adults <25 years (Smith et 
al. 2012). Antenatal seroconversions have important implications for MTCT, not only because the 
infection may remain undiagnosed and untreated, but also as acute HIV infection is associated with 
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high plasma viral load (Pilcher et al. 2007) (see also Figure 1.3, page 25) and thus heightened MTCT 
risk, particularly if other STIs are present. 
The contribution of incident HIV infections during pregnancy and breastfeeding to MTCT rates in 
Europe is difficult to quantify, particularly in Western Europe where repeat antenatal testing is not 
carried out unless a women is known to be at risk of HIV acquisition during pregnancy. In 
resource-rich settings, a substantial proportion of perinatal transmissions are now likely to be to 
undiagnosed women, including those with acute HIV infection who had not yet seroconverted at 
the time of their antenatal test (Patterson et al. 2007). In the UK and Ireland, an audit of the 
circumstances surrounding the perinatal infection of 87 HIV-positive infants born between 2002 
and 2005 found that 54 were born to undiagnosed women, with maternal seroconversion occurring 
during pregnancy in at least 20% of these cases (National Study of HIV in Pregnancy and 
Childhood et al. 2007). Among these 54 infants, 17% died within the first two years of life 
(compared with 6% of the 33 infants born to diagnosed women), highlighting the importance of 
timely maternal diagnosis to infant health.  
Over the last few years in Ukraine, between 200 and 400 women annually have tested positive at 
their second antenatal HIV test having tested negative at their first (approximately 3 months 
earlier), which translates to an annual estimated 0.2% incidence rate (UNICEF 2012). Because the 
second antenatal test is conducted around 10-12 weeks before the end of pregnancy, and >95% of 
women in the general population in Ukraine breastfeed for a median duration of 10 months 
(Ukrainian Center for Social Reforms et al. 2008), the number of seroconversions occurring among 
women who remain undiagnosed and at risk of transmitting the infection to their infant is likely to 
be significant. Partner testing of pregnant women is an important strategy to reduce maternal 
seroconversions, since the identification of HIV-negative women in discordant partnerships 
provides motivation for the use of condoms during pregnancy when contraception is not required 
(Saxton et al. 2010), and an opportunity for the use of treatment as prevention (Cohen et al. 2011). 
On a population level, people who are aware of their own HIV-positive status are less likely to 
transmit the infection sexually due to modified risk behaviours and reduced infectiousness 
associated with treatment (Marks et al. 2006). HIV testing for all partners of pregnant women can 
be cost saving, even in a setting with low HIV prevalence where only one or two vertical 
 251 
 
transmissions are averted per 100,000 seronegative early pregnancies (Postma et al. 2000). Women 
with on-going risk of HIV acquisition such as IDUs or sexual partners of IDUs could benefit from 
rapid testing at delivery (currently only conducted in the absence of antenatal screening) and HIV 
testing postnatally, to allow for intrapartum and postpartum PMTCT interventions (Nielsen-Saines 
et al. 2012) in the event of seroconversions. 
7.3.3 Antenatal adherence to ART in Ukraine 
Results from the Antenatal Adherence Survey in Ukraine are presented in Chapter 6 (results from 
the Postnatal Survey are discussed later, page 258). There are no previously published data on ART 
adherence among childbearing women in Eastern Europe and very little information on adherence 
in the non-pregnant population, none of which is specific to Ukraine. Poor adherence as defined by 
a CASE index measure score of ≤11 was associated with poorer virological outcomes in this thesis, 
as found previously (Kerr et al. 2012). Overall, 14% of respondents in the Antenatal Adherence 
Survey had a CASE score of ≤11, and 35% of respondents reported missing at least one dose 
during pregnancy. Comparisons with other studies of adherence among pregnant women are 
difficult to make due to the range of adherence assessment methods and outcome measures used. 
The 72% of women estimated to have adequate (>80%) adherence to ART during pregnancy in a 
recent meta-analysis (Nachega et al. 2012) is similar to the 65% of women here who reported not 
having missed a dose during pregnancy. Two African trials which defined poor adherence as any 
self-reported missed dose or day without medication during pregnancy (and possibly therefore 
provide a better comparison with the Ukraine data) found perfect adherence levels to be 86% (two 
arms: ZDVm or placebo) (Shapiro et al. 2006) and 73% (Kesho Bora, two arms: cART or ZDVm 
plus sdNVP) (de Vincenzi 2011). The care received in the context of these African trials was more 
intensive than standard antenatal care in Ukraine (e.g. follow-up every two weeks in the Kesho 
Bora study (de Vincenzi 2011)), and duration of ART was also shorter (a median of 5 weeks in the 
ZDVm/placebo study (Shapiro et al. 2006)). These and other context-specific factors, as well as the 
potential differences between trial populations and Ukraine Adherence Survey participants, may 
account for the difference in adherence levels reported. 
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The CASE questions were generally well-completed in the Ukraine Survey. However, some women 
who reported never having missed a dose went on to give reasons for missed doses, which suggests 
that the CASE questions may have lacked permissiveness, or that confusion may have arisen over 
the wording of one or other of the questions. This issue was not apparent during the pilot (n=20 
for each of the two surveys). Future work could investigate the reasons for these discrepancies, and 
the sensitivity and specificity of the CASE questions alone and in combination with the ‘reasons for 
missed dose’ question in predicting virological suppression. 
Because a criterion for participation in the Ukraine Survey was receipt of at least four weeks of 
antenatal ART, some groups were under-represented – notably women with lower levels of 
education and those without a partner. Too few data were available to assess the association 
between educational status and antenatal adherence, but poor adherence was more commonly 
reported among women living with their extended family (two-thirds of whom did not live with a 
partner) compared with the remainder who mostly lived with a partner. Lack of financial support 
from a partner and lower levels of education have been associated with poor ART adherence 
among women in South Africa (El-Khatib et al. 2011). The multiple barriers to antenatal HIV care 
experienced by women without a partner and with less education in the Ukraine ECS (Chapter 3) 
have implications for adherence (e.g. access to and uptake of adherence support). The prevalence of 
poor adherence reported in this thesis may therefore be an under-estimate of that seen on a 
population level, particularly as cART is rolled out to more marginalised groups over time. 
Women living with their extended family, and thus probably requiring practical and financial 
support, were more often young (<25 years) and with an unplanned pregnancy. The association 
between youth and increased risk of poor ART adherence, also discussed earlier (page 237), has 
been documented in pregnant and postpartum women in the US (Laine et al. 2000; Turner et al. 
2000) and may be partly due to more chaotic lifestyles in this group; elsewhere, youth has been 
associated with reduced retention in HIV care (Bygrave et al. 2012; Fleishman et al. 2012). Two of 
the most common reasons for missing a dose here were being away from home and simply 
forgetting. The poorer levels of adherence reported by women with unplanned pregnancies is 
particularly concerning as this group are at increased risk of STI co-infections (see Table 5.5a page 
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164 for association with chlamydia), some of which further increase MTCT risk (Drake et al. 2007; 
Thorne et al. 2008).  
Current smokers were more likely to report poor ART adherence both during pregnancy and 
postnatally. Smoking was more common among women unable to afford contraception in the 
postnatal Women’s Study (see Chapter 5, page 153), and thus a marker of economic deprivation. 
Alcohol and tobacco use have been associated with poorer levels of self-reported adherence during 
pregnancy among HIV-positive women in the US (Mellins et al. 2008), where smoking is also 
associated with lower socioeconomic status among women in the general population (Friestad et al. 
2003).  
Perinatal depression 
An important finding of the Adherence Study was the substantial burden of depressive morbidity 
among participants, with a quarter in both Antenatal and Postnatal Surveys screening positive for 
depression (Chapter 6). Screening for depression is not currently part of routine perinatal or HIV 
care in Ukraine, and the depression screening tool used in the Adherence Surveys has not yet been 
validated in Russian. However, this tool has been successfully used elsewhere as part of routine 
perinatal care (Olson et al. 2006; National Collaborating Centre for Mental Health 2007) and had a 
high level of acceptance among Adherence Survey respondents. Because depression is associated 
with lack of self-care (Angelino et al. 2001), the overall prevalence of perinatal depression may be 
higher than the ~25% found in the Adherence Surveys among women accessing services.  
Depressive symptoms during pregnancy were associated with an increased probability of reporting 
a missed dose of ART (Chapter 6); negative affect has also been associated with poorer ART 
adherence among pregnant women in the US (Bardeguez et al. 2008). Other studies using various 
definitions of depressive symptoms have reported very high rates of perinatal and postpartum 
depression of 44% to 74% among HIV-positive women in Thailand, the US and Zimbabwe 
(Chibanda et al. 2010; Ross et al. 2011; Rubin et al. 2011). In Ukraine, it is estimated that 6.6% of 
women in the general population have a major depressive disorder in any one-month period, with 
increased risk among those unmarried or of lower educational or socioeconomic status (Bromet et 
al. 2005) – characteristics disproportionately found among marginalised HIV-positive populations. 
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Of concern to outcomes beyond pregnancy, depression has also been associated with HIV disease 
progression in a number of studies (Ickovics et al. 2001; Antelman 2007; Willig et al. 2008).  
Access to mental health services in Ukraine is poor. In the 2002 World Mental Health Survey, only 
17.4% of women who had ever had a mood disorder had sought help from a medical professional 
(28% among those acknowledging suicidal thoughts), and where professional help had been sought 
this was mostly from general medical physicians with very little expertise in diagnosing and treating 
mental health problems (Bromet et al. 2005). Barriers to psychiatric care may be particularly severe 
for HIV-positive women and include the lack of integration of psychiatric with HIV care, a poorly 
developed outpatient infrastructure for mental health services, out-of-pocket payments for 
psychiatric medication, and severe stigma associated with seeking treatment for mental health 
problems (Bromet et al. 2005; Lekhan et al. 2010). Women screening positive for depression in the 
Adherence Surveys were referred for additional support as per the study protocol, but some women 
were known to have refused. Services which may help to maintain or improve psychological 
wellbeing among HIV-positive women, such as support groups and peer counselling, are provided 
by NGOs on an often ad-hoc basis and are predominantly accessed by women after delivery (see 
Table 6.2, page 203). However, depression is a recurrent condition, and symptoms pre-conception 
are associated with antenatal depression, which is a major risk factor for postnatal depression 
(Leigh et al. 2008; Rubin et al. 2011). The high prevalence of depression during pregnancy among 
women who may be lost to follow-up after delivery provides evidence of the need for on-going 
mental health support for HIV-positive women.  
Lower level of self-efficacy was related to greater prevalence of depressive symptoms as well as to 
poorer ART adherence in the Antenatal Survey, and is a potential area for intervention. Cognitive-
behavioural interventions to increase self-efficacy have been associated with reduced depressive 
symptoms, increases in CD4 count and decreases in viral load among HIV-positive women in the 
US (Ironson et al. 2005; Jones et al. 2010). In South Africa, a ‘mothers2mothers’ peer support 
programme had a beneficial impact on a range of psychosocial outcomes in HIV-positive women 
during pregnancy and postnatally, including improved feelings of agency and reduced hopelessness 
(Baek et al. 2007). Similar peer programmes may also be of relevance to HIV-positive women in 
Ukraine, given resistance to and poor availability of professional mental health support; peer 
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programmes to reduce HIV risk behaviours have been piloted among MSM and commercial sex 
workers with some success (Ministry of Health of Ukraine 2012). 
Adherence to neonatal prophylaxis 
The very high levels of adherence to neonatal prophylaxis reported in this study are partly due to 
the short duration of neonatal prophylaxis (one week) and relatively long postnatal hospital stays 
for HIV-positive women in Ukraine (around 3-5 days, Personal Communication, Igor Semenenko, 
PPAI, 2011). Around half of all neonatal doses were therefore given in hospital, where medical 
personnel could administer them or assist the mother or other family members in doing so. Two-
thirds of women expressed worries about neonatal prophylaxis harming their baby and this anxiety 
was more common among women who were unsure about its effectiveness, suggesting unmet 
needs for counselling and information provision. Poor antenatal ART adherence has been 
associated with poor adherence to neonatal prophylaxis in the US (Demas et al. 2002) and lack of 
attendance for neonatal follow-up (Kingston et al. 2007), but these associations could not be 
assessed in this study due to its cross-sectional nature. Adherence problems during pregnancy may 
persist after delivery; postnatal adherence is discussed in the next section. 
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7.4. Keeping HIV-positive mothers alive in Ukraine 
PMTCT programmes are an important entry point to HIV care for HIV-positive mothers 
(UNAIDS 2011a). Women diagnosed through antenatal screening tend to be healthier than the 
newly HIV-diagnosed population as a whole, which includes individuals diagnosed as a result of 
symptomatic presentation. In the Ukraine ECS, among women diagnosed during pregnancy and 
delivering in 2010, 8% had WHO stage 3-4 disease and 32% had WHO stage 3-4 disease and/or a 
CD4 count ≤350 cells/mm3, while in Ukraine as a whole the proportion of people newly diagnosed 
as HIV-positive with advanced disease or AIDS was 40% (coverage with CD4 count testing not 
stated) (Ministry of Health of Ukraine 2012). 
To preserve the health of HIV-positive childbearing women, access to cART for those with 
treatment indications and CD4 count monitoring for those ineligible for treatment are crucial, but 
both are compromised by resource limitations in Ukraine. HIV care and treatment for mothers is 
also important for preventing poor outcomes in HIV-exposed infants (Newell et al. 2004; Kuhn et 
al. 2005; Marinda et al. 2007), including those associated with orphanhood. However, the PMTCT 
programme in Ukraine does not make specific provision for the needs of HIV-positive women 
following pregnancy and delivery, and there are currently no population-level indicators to assess 
postpartum care and outcomes of these women (UNICEF 2012). 
7.4.1 Continuation of cART postpartum 
Within the current Option B policy in Ukraine, women who do not require treatment for their own 
health stop ART at delivery, while ART-eligible pregnant women are recommended to continue 
cART lifelong (WHO 2010a). Universal coverage of individuals eligible for cART is a target for the 
WHO European Region by 2015 (WHO Regional Office for Europe 2011). Only 53% of women 
requiring treatment for their own health were on ART postnatally at Women’s Study enrolment in 
2008-11 but this doubled from 34% in 2008 to 72% in 2011 (Chapter 5), reflecting scale-up of 
cART more widely for ART-eligible individuals in Ukraine (Ministry of Health of Ukraine 2012). 
These figures will be an overestimate of the true level of coverage of ART-eligible women due to 
unidentified indications for treatment among women without a CD4 count measure during 
pregnancy (27% of women delivering in 2010). Among the 15% of women who were co-infected 
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with HBV, ART discontinuation after delivery is of concern regardless of treatment indication for 
HIV disease, because these women are at risk of HBV viral rebound, hepatic flares, and more rapid 
deterioration of immune function if an antiretroviral drug with anti-HBV activity such as 3TC is 
stopped (Nuesch et al. 2008; Bellini et al. 2009; Dore et al. 2010).  
The importance of postpartum CD4 count monitoring for women stopping ART at delivery is 
highlighted by fact that 25% and 46% of women in the Kesho Bora and MTCT-Plus Initiative 
studies respectively progressed to a CD4 count of <350 cells/mm3 in the two years following 
delivery (from 350-500 cells/mm3 and 400-499 cells/mm3 during pregnancy respectively) (Ekouevi 
et al. 2012; The Kesho Bora Study Group 2012). Benefits of earlier ART initiation at CD4 counts of 
350-500 cells/mm3 in preventing HIV-related clinical events and sexual transmissions have recently 
been demonstrated in the HPTN 052 trial (Cohen et al. 2011), and have implications for risk-benefit 
decisions around continuation of ART after delivery. An Option B+ strategy (in which lifelong 
cART is initiated in all HIV-positive pregnant women) is not yet under consideration for the 
PMTCT programme in Ukraine (UNICEF 2012), but would reduce reliance on CD4 monitoring 
for determining postpartum treatment eligibility and have potential benefits for maternal health 
(WHO 2012b). Option B+ could also reduce onward sexual transmissions, of particular relevance 
given that at least a quarter of women in the Women’s Study were in discordant partnerships and 
use of barrier contraception in this group is poor (Saxton et al. 2010). However, there are major 
obstacles to its implementation, most obviously resource limitation and problems retaining 
diagnosed women in care (evidenced by missed opportunities for PMTCT in this group). Roll-out 
of cART to all eligible individuals (as currently defined) and then more widely would involve the 
monitoring and treatment of vastly increasing numbers of patients and require health-system 
strengthening. The willingness of young women with no symptoms of HIV disease to initiate and 
adhere to lifelong ART, particularly in a setting with a low fertility rate and high levels of HIV-
related stigma, also needs to be investigated. Results from Chapter 4 showed an increased risk of 
virological failure among women who already had at least two children; this may partly reflect 
challenges adhering to ART while caring for a family, and requires further investigation in the 
context of Option B+. Of note, about a quarter of participants in the Adherence Surveys here 
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reported being somewhat or terribly bothered by ART side effects; although these women were not 
more likely to report poor ART adherence, very few had accumulated long periods on ART.  
7.4.2 Postnatal ART adherence 
High levels of adherence are important for the success of current and future treatment 
programmes, particularly given the lack of second-line treatment options currently available in 
Ukraine (Judice et al. 2011). Levels of adherence reported were similar in the Antenatal and 
Postnatal Surveys (Chapter 6), but these surveys were cross-sectional and women with adherence 
problems may have been less likely to continue ART after delivery. When postpartum participants 
were asked to compare their own current adherence with that during pregnancy, a minority (12/93) 
reported that it had declined but only two reported an improvement. It is therefore not possible to 
rule out declining adherence levels postpartum, as have been reported elsewhere (Ickovics et al. 
2002; Vaz et al. 2007; Bardeguez et al. 2008; Cohn et al. 2008; Mellins et al. 2008), when the demands 
of caring for a new baby may compromise health-seeking behaviours (Stein et al. 2000). A 
longitudinal study design is required to directly assess changes in adherence following delivery. 
More advanced HIV disease or health-related symptoms have been associated with poorer ART 
adherence among pregnant and postpartum women (Bardeguez et al. 2008; Mellins et al. 2008), 
including in a predominantly IDU, non-pregnant population in Eastern Europe (Uuskula et al. 
2012). In contrast, there was no association here between WHO stage and adherence during 
pregnancy, while postnatally women with WHO stage 3-4 disease seemed to adhere better than 
those with less severe disease (13% and 36% respectively reported missing at least one dose in the 
last four weeks, p=0.10).  
Other characteristics associated with poor adherence postnatally were similar to those relevant 
during pregnancy, including being unmarried, a current smoker and having low treatment-related 
self-efficacy. Depression was not associated with poorer adherence among women surveyed here at 
a median 6 months postpartum, but elsewhere has been associated with declining adherence over 
time (Byakika-Tusiime et al. 2009). Interestingly, history of drug use was associated with poor ART 
adherence postnatally but not during pregnancy. Women with an IDU history had barriers to 
antenatal care but were not under-represented in the postnatal Women’s Study (21% prevalence 
 259 
 
since 2007, vs. 14-18% per year in the ECS), probably due to care-seeking prompted by their more 
advanced HIV disease stage and symptoms. IDUs accessing care in pregnancy for PMTCT may be 
less marginalised than those coming into contact with HIV care only when symptomatic. There was 
no evidence that current drug use was more common postnatally (as might be the case if 
resumption of drug use after delivery led to a deterioration in adherence), but reporting of current 
drug use may be subject to particularly strong social desirability bias among new mothers. In other 
studies, a history of or current drug use has been associated with poorer adherence among HIV-
positive childbearing women (Laine et al. 2000; Cohn et al. 2008) and in the general population, 
where IDUs have been found to be at higher risk of virological failure and development of 
resistance than non-IDUs (Lampe et al. 2006; Lima et al. 2008a; Mann et al. 2012). There is some 
evidence that harm reduction programmes for IDUs support ART adherence (Weber et al. 2009; 
Uhlmann et al. 2010). 
Only 38% of women accessed treatment adherence programmes postnatally, but these women were 
more likely to report complete adherence in the last four weeks. More work is needed to 
disentangle the impact of the programmes from the characteristics of the women who accessed 
them, and to describe the programmes in operation at different HIV/AIDS centres. Women with 
caring responsibilities for children had lower ART adherence in two US studies (Demas et al. 2002; 
Merenstein et al. 2008), and the multiple barriers to care during pregnancy for multiparous HIV-
positive women indicate that this is as an important area for future investigation. Executive skills 
are important for the management of ART (Waldrop-Valverde et al. 2010), but a number of factors 
which are associated with an increased risk of cognitive impairment such as HCV co-infection, 
substance use and depression (Schouten et al. 2011b) are very common among HIV-positive people 
in Ukraine. Work is needed to ensure that cognitive impairment does not negatively impact on 
adherence and treatment outcomes in this setting.  
The Information-Motivation-Behavioral Skills Model provides a framework within which to 
understand barriers to adherence and design interventions. This model describes determinants of 
adherence as falling into three categories: information (about the regimen, side effects, drug 
interactions, importance of adherence), motivation (in terms of personal attitudes and beliefs about 
the outcomes of adherence, and social perceptions of others’ support and motivation to comply 
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with others’ wishes), and behaviour skills (e.g. for acquiring and administering medication, 
incorporating the regimen into daily life, acquiring adherence support) (Fisher et al. 2008). The 
effects of information and motivation levels on adherence are mediated via behavioural skills and 
other factors (e.g. structural barriers, substance use and psychological illness), with the implication 
that interventions targeting information and motivation will not be effective if behavioural skills are 
inadequate, or other barriers are insurmountable. As an example, poor adherence among women 
with an IDU history may be associated with deficiencies in all three areas, as well as specific IDU-
related structural barriers, all of which will need to be addressed for an intervention to be effective.  
7.4.3 HIV co-infections and associated comorbidities 
Prevalence of a number of HIV co-infections (sexually transmitted and blood-borne) were very 
high among women with test results available in the Women’s Study: 60% of women were positive 
for HSV-2 antibodies, 32% for HCV antibodies, 15% for HBsAg, 24% for chlamydia, 11% for T. 
vaginalis, 2% for syphilis and 0.3% for gonorrhoea (Chapter 5). Against a backdrop of STI 
epidemics in Ukraine following independence (see Introduction, page 23), women in the Ukraine 
ECS were previously found to be at a ten-fold increased risk of being diagnosed with chlamydia, 
syphilis or T. vaginalis during pregnancy compared with women at Western Europe ECS sites (data 
from 1999 to 2005) (Landes et al. 2007). The results in this thesis highlight the continued high 
prevalence of HIV co-infections in Ukraine, in contrast to the much lower prevalence seen recently 
among HIV-positive pregnant women in the UK and Ireland (1.9% for HCV antibodies, 5.8% for 
HBV and 0.5% for chlamydia, Personal Communication, Pat Tookey, NSHPC, 2011) and among 
asymptomatic HIV-positive heterosexuals in the Netherlands (STI prevalence of 1.6%, 
(Heiligenberg et al. 2012)). This partly reflects the IDU-driven nature of the HIV epidemic in 
Ukraine and associated high-risk sexual behaviours (Booth et al. 2007) as well as low condom use 
(Saxton et al. 2010). At an earlier stage in the epidemic in Western Europe, among a cohort of HIV-
positive women with an IDU prevalence of 29%, 15% had an acute STI (chlamydia, gonorrhoea or 
syphilis) (van Benthem et al. 2000b). Given the synergy between other STIs and the acquisition and 
transmission of HIV (Cohen 2006), these results are of substantial concern to the on-going 
heterosexual spread of the HIV epidemic in Ukraine. The prevalence of HIV co-infections on a 
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population level may be even higher than reported here, as the Women’s Study is a clinic-based 
cohort of women engaged with care. 
There was considerable local variation in coverage of testing for HIV co-infections and cervical 
screening as part of HIV care among sites participating in the Women’s Study: coverage of testing 
for HCV antibodies ranged by HIV/AIDS centre from 6% to 94%, and coverage of testing for 
chlamydia ranged from 0% to 91%. Structural-level barriers to testing were particularly notable at 
Mykolaiv and Krivoy Rog HIV/AIDS centres, where testing for chlamydia was almost completely 
unavailable, and where other findings (low self-reported accessibility of family planning and high 
prevalence of pregnancy termination) indicated particularly poor access to reproductive health 
services. 
Importantly, routine data sharing does not take place between HIV/AIDS centres and other 
services which may diagnose and treat HIV co-infections (e.g. contraceptive and sexual health 
services), and so it is possible that women lacking testing or cervical screening as part of HIV care 
were accessing these services elsewhere. However, user fees are often charged for diagnostic 
services in non-HIV specific settings (UNAIDS 2009), and a number of factors indicate that 
utilisation of testing in other settings (with the exception of testing for syphilis and HBsAg as part 
of routine antenatal care) is likely to be low. These include the very high prevalence of chlamydia 
and the fact that only 15% of sexually active women were using modern non-barrier contraceptive 
methods, which are only available through contraceptive clinics. HIV-related stigma may dissuade 
women from seeking sexual and reproductive healthcare from other providers (Demchenko et al. 
2011). Where services are accessed elsewhere, women may conceal their HIV status – of particular 
detriment to the management of cervical abnormalities, as HIV-positive women may benefit from a 
lower threshold for referral to colposcopy and more intensive surveillance than the standard of care 
for HIV-negative women (Fakoya et al. 2008; US Centers for Disease Control and Prevention 
2009). The European Action Plan for HIV/AIDS 2012-15 lays out a target that more than 60% of 
sexual and reproductive health services should have links with or offer HIV-related services in the 
majority of Member States by 2015 (WHO Regional Office for Europe 2011), reflecting the 
importance of service integration for improving the quality of care of vulnerable populations.   
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At centres where testing or screening were offered, the main individual-level barrier to uptake was 
lack of HIV care, indicated by the association between late antenatal HIV diagnosis and lack of a 
chlamydia test or cervical screening test. However, as the Women’s Study is a clinic-based cohort of 
women in HIV care postnatally, opportunities for testing are also likely to have been missed. In 
particular there were some indications that marginalised women were more likely to miss out on 
opportunities for testing: for example, IDUs were more likely than non-IDUs to lack a chlamydia 
test result, despite their 50% increased risk of a positive result where tested. Among women 
diagnosed as HIV-positive prior to their most recent pregnancy, those with less education were less 
likely to have ever had a cervical screening test as part of HIV care, reflecting inequalities seen in 
the general population in Ukraine (where three-yearly cervical screening coverage is 87% and 68% 
in the top and bottom wealth quintiles respectively (Gakidou et al. 2008)).  
Overall, 30% of women had ever received a cervical screening test as part of HIV care at cohort 
enrolment at the three HIV/AIDS centres offering this, and a third of these tests had been done 
more than a year previously. A quarter of those screened had a finding of LSIL or HSIL, which is 
comparable to the 23% prevalence found among 285 HIV-positive women in a study in Brooklyn 
in 1990-93 (Maiman et al. 1998), and 27% prevalence of abnormalities among 1134 HIV-positive 
women at the European sites of a multi-centre cohort study (Kitchener et al. 2007). Higher rates of 
abnormalities (30% and 48%) have been reported among HIV-positive women in Africa (Mbizvo et 
al. 2005; Kitchener et al. 2007), and a lower rate of 15% in the U.S. Women’s Interagency HIV 
Study, possibly because all women in this study participated in six-monthly screening (Massad et al. 
2004). Of note, the prevalence of LSIL and HSIL reported in the Women’s Study may not be 
generalizable to the cohort as a whole, as the women who were screened had a higher prevalence of 
BV than the rest of the cohort, which was an independent risk factor for cervical abnormalities in 
adjusted analyses. 
In adjusted analyses, BV and HSV-2 seropositivity were associated with a three-fold and 80% 
increased risk of a finding of LSIL or HSIL respectively. Selective screening of women at high risk 
for HPV and HSV-2 infection or BV (e.g. women with multiple sexual partners) could account for 
these associations, but further exploration was precluded by a lack of data on HPV infection or 
sexual risk behaviours in the Women’s Study. HSV-2 and BV may increase the risk of cervical 
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cancer by acting as cofactors to HPV or through local inflammatory processes (Castle et al. 2003), 
and a large pooled analysis has found an association between HSV-2 seropositivity and cervical 
cancer independent of HPV infection and sexual risk behaviours (Smith et al. 2002). Although 
evidence of an association between BV and HPV acquisition / persistence or cervical abnormalities 
is less well established (Guijon et al. 1992; Platz-Christensen et al. 1994; Peters et al. 1995; Moscicki 
et al. 2001; Boyle et al. 2003; Verteramo et al. 2009), a recent meta-analysis of twelve studies 
demonstrated a significantly increased risk of cervical HPV infection among women with BV 
(combined OR 1.43, 95% CI 1.11-1.84) (Gillet et al. 2011). Among HIV-positive women, two 
studies have showed an association between BV and cervical HPV infection, independent of sexual 
risk factors (Watts et al. 2005; King et al. 2011). BV is associated with other adverse outcomes 
relevant to HIV-positive childbearing women, including preterm delivery and STI acquisition 
(Leitich et al. 2003; Allsworth et al. 2011), and thus screening and treatment should be a priority. 
As cervical screening is conducted on a predominantly opportunistic basis for the general 
population in Ukraine (Introduction, page 47), an organised screening programme for HIV-positive 
women (whereby they receive written invitations for screening at the HIV/AIDS centre) could 
lessen disparities in screening coverage of these high-risk women. As the majority of women stop 
ART at delivery and therefore do not need to return to the HIV/AIDS centre for ART supplies, a 
regular invitation for cervical screening could also facilitate retention of this group in postpartum 
HIV care. Around 70% of cervical cancer cases in Eastern Europe are attributed to vaccine-
preventable HPV types 16 and 18 (Clifford et al. 2006), but HPV vaccination programmes have not 
yet been introduced in Ukraine (WHO ICO Information Centre on HPV Cervical Cancer 2010). A 
recent meta-analysis found a doubling of HIV acquisition risk among women infected with HPV 
(Houlihan et al. 2012), suggesting that HPV vaccination programmes could potentially reduce the 
incidence of sexually acquired HIV, although many questions remain unanswered regarding the 
potential  impact of this approach (Schim van der Loeff et al. 2012). Issues regarding the 
acceptability of vaccinations in Ukraine (Bazylevych 2011) may impact on the coverage of a future 
HPV vaccination programme. Acceptability issues and out-of-pocket payments in some settings 
have likely contributed to the very low coverage with HBV vaccination of HBsAg negative 
individuals in the Women’s Study (16% among non-IDUs and 5% among IDUs).  
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There was no change over time in the proportion of women reporting that contraception was 
unaffordable (Chapter 5, page 152), but the decline in the proportion reporting that it was 
inaccessible is encouraging, and in line with recommendations for availability of free condoms as 
part of HIV care (UNAIDS 2009). Only 15% of sexually active women were using modern non-
barrier contraceptive methods and these women had higher education levels than other women, 
reflecting the fact that modern contraceptive use is more common among higher socioeconomic 
groups in Ukraine (Ukrainian Center for Social Reforms et al. 2008; Janevic et al. 2012). The finding 
that modern non-barrier contraceptive use was more common among women testing positive for 
chlamydia (25% vs. 16% of those testing negative, p=0.02) highlights the importance of messages 
around dual protection. In Russia, consistent condom use was independently associated with the 
belief that condoms provide reliable protection against unwanted pregnancy, but not with the belief 
that they provide protection against STIs (Bobrova et al. 2005), suggesting that use may be low 
where STI prevention is required without contraception. Provision of comprehensive family 
planning within HIV care (the second component of a comprehensive PMTCT approach, Table 1.2 
page 30) can improve uptake of contraception (Kosgei et al. 2011), and may facilitate discussion of 
prevention of other STIs and superinfection with other HIV strains. 
At 78%, the HCV seroprevalence among women with an IDU history in this cohort is slightly 
higher than the 61-73% reported previously among IDUs in Ukraine (Nelson et al. 2011), as would 
be expected in an HIV-positive cohort. HCV is more transmissible than HIV among IDUs (van 
Beek et al. 1998; Patrick et al. 2001), and so IDUs infected with HIV are likely to have had 
particularly high levels of exposure to HCV, for example because of a long injecting history or 
needle-sharing. Female IDUs also tend to be at higher risk of acquisition of blood-borne infections, 
as they are often injected by their male partners and ‘second on the needle’ (El-Bassel et al. 2010). 
Apart from sentinel surveillance surveys among IDUs, very little is known about HCV 
seroprevalence and transmission in Ukraine. Interestingly, the 20% prevalence of HCV antibodies 
among non-IDUs in the Women’s Study is similar to the 24% HCV seroprevalence reported 
among HIV-positive non-IDU women in St Petersburg in 2008 (Kissin et al. 2011). These figures 
raise questions about the potential under-ascertainment of IDU history, but also invite discussion 
regarding alternative modes of HCV transmission among the HIV-positive population in this 
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region. As biomarkers of current drug use (e.g. urine or hair) were not available, two indirect 
markers of IDU were examined in Chapter 5 – adverse birth outcomes and lack of antenatal care. 
Among non-IDUs, these outcomes were not associated with HCV seropositivity, as might have 
been expected if current IDU had been under-ascertained. Kissin et al similarly found that 
indicators of perinatal transmission among HCV seropositive non-IDUs were more similar to HCV 
seronegative non-IDUs than to IDUs. Although there was no evidence of under-ascertainment of 
current IDU, past IDU is more difficult to rule out, particularly if this was in the form of brief 
experimentation.  
Of 236 HCV seropositive non-IDUs, 13 were diagnosed with HCV at the same time as or prior to 
HIV, suggesting that they may have been identified as being at high risk of blood-borne infections 
before being diagnosed as HIV-positive, and may have accessed outreach testing services for IDUs 
(none of these 13 women reported an IDU partner). HCV seropositive non-IDUs were also more 
likely to have a number of characteristics associated with IDU than their HCV seronegative 
counterparts, including a recent chlamydia diagnosis (at two centres) and a history of pregnancy 
termination, and also tended to have been diagnosed with HIV infection for longer. Importantly, 
these characteristics could also indicate sexual or iatrogenic HCV acquisition risk. One survey of 
HCV seroprevalence in New York among migrants from the former Soviet Union reported HCV 
seroprevalence to be 31% among 29 migrants from Ukraine, 29% among 31 migrants from 
Uzbekistan and 11% among 18 migrants from Russia, whilst overall prevalence of drug use history 
was only 2%, and concluded that inadequately sterilised medical equipment and blood transfusions 
were the most likely sources of most of these infections (Batash et al. 2008). An HCV 
seroprevalence of 8% has also been found among the antenatal population in Kiev, where HCV 
testing is now conducted routinely for all pregnant women (Personal Communication, Bila Zerkva, 
Kiev Antenatal Clinic, 2012). 
In order to better understand modes of HCV acquisition among HIV-positive women in Ukraine, 
longitudinal data are needed on HCV serostatus and on possible sources of infection, including 
IDU, sexual and iatrogenic risk factors, non-injection drug use and exposure to infected household 
contacts. HCV antibody avidity assays allow for identification of recent HCV infection (Gaudy-
Graffin et al. 2010), which may be helpful in establishing HCV incidence as well as the relative 
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timing of HCV and HIV acquisition. The results presented in Chapter 5 suggest that HCV 
seroprevalence may not be an appropriate proxy for HIV injecting risk behaviour in Ukraine, unlike 
in the European Union (Wiessing et al. 2006). In centres other than Kiev, where HCV testing is 
currently only repeated annually for HIV-positive individuals with known risk behaviours (e.g. 
IDUs), it may be appropriate to extend screening to include those with high-risk sexual partners, or 
to all HIV-positive individuals; almost half of the HCV seropositive women in this study had no 
reported history of IDU. 
HCV RNA PCR testing is not routinely carried out in Ukraine due to its relative expense, and so it 
was not possible to distinguish individuals with active infection from those who had spontaneously 
cleared it. Spontaneous clearance rates are lower among HIV-positive than HIV-negative 
individuals (Thomas et al. 2000); in a large European cohort of HIV-positive individuals, the 
spontaneous clearance rate was 23% (Soriano et al. 2008). It was also not possible to exclude HCV 
exposure among HCV seronegative individuals, as some individuals may have lost antibodies 
following spontaneous clearance (Heintges et al. 1997). Severely immunosuppressed individuals may 
also not mount a detectable HCV antibody response, although only 8% of HCV seronegative 
individuals in the Women’s Study had a CD4 count ≤200 cells/mm3 (Table 5.6b, page 172). These 
scenarios might explain the fact that 22% of IDUs were HCV seronegative – a group at high risk of 
infection or re-infection, and an important focus for prevention activities.  
Among this young population of HIV/HCV co-infected women who were almost entirely 
untreated for HCV and at an early stage of HIV disease, non-invasive markers of liver fibrosis 
indicated that the proportion with advanced/significant liver fibrosis was low: 1% according to 
FIB-4 scores and 8% according to the possibly less specific APRI scores. However, differences in 
FIB-4 and APRI scores were already detectable by HCV serostatus and by IDU status, with HCV-
seropositive IDUs tending to have higher scores than HCV-seropositive non-IDUs. The field of 
HCV treatment is undergoing rapid expansion with the development of numerous directly acting 
antivirals which have the potential to make regimens less toxic, more potent and of shorter 
duration than the standard of care of PegIFN/RBV (Soriano et al. 2011) (anti-HCV therapy is not 
currently publicly funded in Ukraine). Telaprevir and boceprevir, two protease inhibitors licensed 
for the treatment of HCV genotype 1 infection in Europe and North America in 2011, improve the 
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rate of sustained virological response when used in combination with PegIFN/RBV in HIV-
negative and HIV-positive individuals (Cooper et al. 2012). However, uptake of these new therapies 
is limited by cost and, among HIV/HCV co-infected individuals, by high prevalence of 
contraindications and drug interactions with ART (Klein et al. 2012). Most antivirals in 
development for HCV are active mainly or only against HCV genotype 1 (Soriano et al. 2011), a 
“hard to treat” genotype (Kalinina et al. 2001). The HCV genotypes circulating in Ukraine are 
unknown, but the 3a subtype predominates among IDUs in Western Europe and the US 
(Hnatyszyn 2005), and was also the most common subtype among both IDUs and non-IDUs in a 
study in St. Petersburg (Kalinina et al. 2001). A better understanding of the modes of HCV 
transmission in Ukraine and improved coverage of harm reduction measures are of utmost 
importance, not only for primary prevention but also for preventing the re-infection of treated 
individuals should treatment become available.    
7.5 Strengths and weaknesses 
This thesis uses data from a variety of sources: an established multi-centre prospective cohort study 
of HIV-infected women and their infants, a nested postnatal cohort in Ukraine, and a survey on 
adherence. Limitations specific to each analysis are discussed in the corresponding chapters; this 
section describes the general strengths and weaknesses of the studies.  
As pregnancy/delivery-based observational cohorts, major strengths of the ECS and Women’s 
Study lie in their ability to capture information on ‘real world’ implementation of policies affecting 
the health and MTCT risk of HIV-positive women in Europe. Data collected in these studies allow 
for coverage with testing and interventions to be investigated, as well as the divergence of clinical 
practice from policy and variation in practice in areas where policy is poorly defined. These cohorts 
also capture information on women who are more often asymptomatic and in better health than 
clinic-based cohorts of predominantly ART-eligible individuals. The ECS enrols highly marginalised 
women, some of whom engage with healthcare services only when in labour and are unlikely to be 
included in other clinic-based cohorts (as indicated by their under-representation in the Women’s 
Study). Information about these high-risk groups is important for the development of strategies to 
eliminate MTCT in Ukraine and to prevent residual transmissions in Western Europe, as well as for 
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the design of outreach services. Of note, even among women receiving a rapid test in labour, 
marginalised groups may be less likely to receive a diagnosis before delivery (as shown among IDUs 
in Russia (Kissin et al. 2008)) and thus be ineligible for ECS enrolment. Women terminating their 
pregnancies are not included in the ECS, and groups who are least likely to complete their 
pregnancy will therefore have been under-represented. 
The clinical centres which participate in the ECS are regional referral centres for HIV-positive 
pregnant women. Although participation rates among eligible women at these centres are very high 
(>95% at Western Europe sites (Patel 2007)), their characteristics may differ from women receiving 
care at non-participating centres, as may the treatment and care they receive. This is particularly the 
case in Ukraine where there is substantial regional variation in access to cART and to CD4 count 
and viral load monitoring (Chapter 3), and where ECS and Women’s Study sites are situated in 
some of the worst affected regions of the country, where staff may be more experienced in the 
management of HIV in pregnancy but may also be operating within greater resource constraints. 
Analyses using data from the Western Europe ECS were adjusted for by country (to reflect national 
policy differences) rather than by centre, because of the large number of participating centres and 
sometimes small number of women enrolled at each. Unmeasured confounding between centres 
could therefore not be accounted for. In Ukraine ECS analyses, adjustment by centre was possible, 
but differences between the centres (and between countries in Western Europe) may limit the 
generalizability of results to specific sites.  Changes over time in the characteristics of women 
participating at a particular site (and in centres participating in the study) will have had some impact 
on overall trends, an example being the impact of the changing demographics of women enrolling 
in Mykolaiv on overall MTCT rates reported in the Ukraine ECS in 2008 to 2010 (section 3.2.6). 
However, the good nationwide coverage of the Ukraine ECS, which enrolled around a third of 
HIV-positive women delivering in the country in 2009, makes findings broadly generalizable. 
Of women enrolled in the ECS at each site, participation rates in the Women’s Study varied from 
24% in Donetsk to 87% in Kiev, probably because some centres more systematically invited or 
supported women to enrol rather than because of large variation in refusal rates. Participation rates 
were highest at the best resourced centres (e.g. Kiev), possibly reflecting the fact that staff had more 
time to counsel women about the study and complete the study forms. Participation rates in the 
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Adherence Study, estimated to be between 39% and 49% of eligible women for the antenatal 
survey and 35% of women attending HIV care after delivery in the postnatal survey (75% among 
women on ART) also varied by centre (section 6.3). In both the Women’s Study and the Adherence 
Study, women with the poorest access to and uptake of care were under-represented, because 
eligibility was limited to women who had received ART for at least the last four weeks of pregnancy 
(for the antenatal adherence survey) or those attending HIV care postnatally (for the Women’s 
Study and postnatal adherence survey); representativeness of the study samples is explored in 
section 5.2 and section 6.3. Taken together, these data have important implications for 
interpretation of the results. Specifically, prevalence of outcomes positively associated with health 
behaviours and access to care (e.g. receipt of a cervical screening test) are likely to have been over-
estimated and those linked to poor access to or uptake of care (e.g. a recent chlamydia diagnosis) 
under-estimated when compared with these outcomes among HIV-positive childbearing women in 
Ukraine overall. The substantial unmet need for care and support among women participating in 
the Women’s Study and Adherence Study – groups of women who were comparatively well-served 
– underscores the inadequacies of service provision on a population basis. 
The Adherence Study had a number of specific limitations related to its cross-sectional design. A 
cross-sectional design was chosen because a longitudinal design would have required an unfeasibly 
large number of participants in the antenatal survey to allow for a sufficient number to be followed 
up postnatally (a time when many women stop ART and/or are lost to follow-up), and a longer 
study duration. The cross-sectional design allowed for adherence levels at the two time points to be 
broadly described, but precluded a more detailed analysis of changes in ART adherence and 
perinatal depression following delivery. Future studies could consider active follow-up of women 
postnatally to facilitate longitudinal data collection, but the acceptability of this approach would 
need to be investigated given that researchers would require access to identifying information 
including name and address/phone number. The paper-based format of the Adherence Study 
surveys may have dissuaded less literate women from taking part. Audio computer-assisted self-
interview techniques, which may result in more accurate self-report of sensitive information than 
face-to-face interviews (Gorbach et al. 2013), could be considered for use in future surveys to 
increase accessibility and reduce bias. 
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Missing data limited the interpretation of some findings in this thesis. In Ukraine, availability of 
data on some variables, particularly CD4 count, viral load and diagnosis of co-infections, depended 
on local budgets and other factors with substantial variation between centres. Individual-level 
engagement with HIV services also played an important role in determining availability of test 
results (Chapter 5) and data on other variables; for example, women without antenatal ART were 
more likely to be missing information on marital status and timing of HIV diagnosis (Chapter 3). 
As data were systematically missing for some groups, imputation of missing data was not 
considered appropriate and a complete case approach was taken throughout. The possible effects 
of the resulting selection bias include under- or over-estimation of size of association between 
explanatory and outcome variables (respective examples are between IDU and insufficient ART, 
Chapter 3 and between BV and cervical abnormalities, Chapter 5) and under- and over-estimation 
of the prevalence of an outcome (respective examples are the MTCT rate in 2010, Chapter 3, and 
possible over-estimation of cervical abnormality prevalence, Chapter 5).  
Maternal characteristics associated with poor access to or uptake of services were explored 
throughout this thesis, and although some markers of marginalisation were available (such as IDU), 
the lack of direct measures of socioeconomic status limited characterisation of marginalised groups. 
Information on sexual risk behaviours was not available in the Women’s Study, precluding more 
detailed exploration of factors associated with a recent chlamydia diagnosis, HCV seropositivity 
among non-IDUs, and of the relationship between BV or HSV-2 and cervical abnormalities. Self-
reported IDU history was likely to have been subject to social desirability bias and in the absence of 
objective measures of drug use, IDU may have been under-ascertained (explored in section 5.3.2). 
The lack of data sharing between HIV/AIDS centres and other healthcare providers in Ukraine 
limited conclusions in some areas. Access to other sources of sexual and reproductive health care, 
although suspected to be low, could not be verified. These barriers to data collection reflect barriers 
to the delivery of integrated clinical care, as described in Chapter 1, and to decision-making by HIV 
physicians, and thus highlight important weaknesses of the health system in caring for HIV-positive 
childbearing women. 
The Adherence Study was designed to collect detailed data on a range of psychosocial factors 
possibly important in understanding the adherence behaviours of HIV-positive women in Ukraine. 
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These factors had not been previously measured in this population and the measures used in the 
Adherence Study, although previously validated in English and some other languages, had not 
previously been validated in Russian. Linkage of Adherence Study data with data from the ECS 
allowed for some validation of CASE adherence index scores against viral load; despite the 
sparseness of viral load data available, the results of the validation analyses lent weight to the use of 
the CASE self-report adherence measure. Depression screening test results using the PHQ-2 
screening tool could not be validated, both due to lack of access to mental health services at some 
centres and lack of data sharing with these services if they did exist. As characterisation of 
depression is influenced by culture and language (Oates et al. 2004), it is possible that the PHQ-2 
tool performed differently in this Ukrainian population than in previous validation analyses in the 
UK (Arroll et al. 2005). Measurement of HIV-related self-efficacy in the Adherence Study was 
limited by the use of an abbreviated version of the HIV-ASES tool, after pilot study results 
indicated that use of the full tool was not feasible. It was therefore not possible to compare the 
results on self-efficacy with those from other studies; however, the responses to these questions 
and their associations with depression and ART adherence highlight some potentially useful areas 
for intervention.  
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7.6 Conclusions and future work 
This thesis explores a number of issues pertinent to the contemporary management of HIV-
positive childbearing women in Europe and particularly to the substantial and growing proportion 
living in the resource-limited setting of Ukraine. Missed opportunities for PMTCT persist and are 
concentrated in the East, where the MTCT rate was 4.1% in Ukraine in 2008-10 compared with 
1.7% in Western European sites of the ECS in 2000-09. Findings in Chapter 3 indicate social 
marginalisation to be a key factor impeding access to antenatal ART in both settings, and suggest 
that strategies to engage marginalised groups are essential for achieving an overall MTCT rate of 
<2% in Ukraine, as elsewhere (Mahy et al. 2010; Barker et al. 2011; Ciaranello et al. 2012). Findings 
in this thesis focus on individual-level characteristics of women lacking care, important for the 
design of interventions for specific high-risk groups (see section 7.7, Recommendations). However, 
further work exploring the context of these women’s behaviour is also needed because 
interventions which address social and structural determinants of health, while more challenging to 
implement, are likely to have larger and wider-ranging benefits, not only for HIV-positive women 
but for all childbearing women in Ukraine (Frieden 2010). Of note, IDUs and other marginalised 
groups constitute a declining proportion of HIV-positive childbearing women, and so overall 
declines in MTCT rates may not reflect improvements in their access to care. MTCT rates specific 
to these groups need to be monitored to evaluate the success of outreach strategies, not only in 
terms of reducing transmissions but also in improving other treatment and care outcomes.  
An increasing proportion of HIV-positive women are having multiple pregnancies following their 
HIV diagnosis and this thesis highlights some important challenges regarding the management of 
multiparous HIV-positive women. The increased risk of virological failure among women 
conceiving on cART with prior exposure to HIV care in ≥2 pregnancies, or with longer duration of 
diagnosed HIV infection, has potential implications for the risk-benefit of an Option B+ strategy. 
More work is needed to understand the mechanisms underlying these findings and to clarify the 
support that treatment-experienced women may require prior to and during pregnancy to achieve 
optimal outcomes. In Ukraine, HIV-positive women with two or more children had pervasive 
barriers to antenatal and HIV care. Qualitative work with this group, who were also more likely to 
have indicators of social deprivation, could inform the design of services sensitive to their needs. 
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The virological response to treatment of women with prior exposure to pregnancy-related HIV care 
in Ukraine requires specific exploration, because sdNVP has been used more widely and more 
recently here than in Western Europe (Chapter 3), and without the recommended NRTI ‘tail’ to 
prevent the development of NNRTI resistance (Lockman et al. 2010; WHO 2010a). NNRTI 
resistance will be of particular relevance to women starting cART outside of the context of 
pregnancy, where first-line regimens are currently NVP-based. Further work is needed to explore 
the equitability and sustainability of cART provision in Ukraine, particularly with regard to possible 
future policy changes around the use of Option B+ and harmonisation of treatment programmes.  
Findings from the postnatal Women’s Study in Ukraine (Chapter 5) provide evidence that barriers 
to antenatal care persisted postpartum and that, even among women engaged with HIV services, 
there was a substantial unmet need for sexual and reproductive healthcare. These results highlight a 
lack of preventative healthcare for HIV co-infections and integrated diagnostic and treatment 
services, placing HIV-positive women at risk of preventable co-morbidity. The lack of functional 
linkages between HIV/AIDS centres and other primary care providers poses barriers to both 
healthcare and research. Future work to link data from multiple primary care sources could help 
advance understanding in areas related to the detection and management of HIV co-infections (for 
example, the sensitivity and specificity of cytologic screening). Many questions remain regarding the 
transmission and impact of HIV/HCV co-infection in this population and further work is needed 
to ascertain non-IDU modes of HCV acquisition, circulating genotypes and impact on liver 
function.    
The Ukraine Adherence Study (Chapter 6) is the first study to investigate ART adherence among 
HIV-positive childbearing women in Ukraine. The utility of the self-report CASE adherence index 
used in this study is an important finding and further validation against virological outcomes in this 
population is required, as is comparison with other short self-report measures. Future work is 
needed to assess adherence among groups who were under-represented in the Ukraine Adherence 
Study, such as women with low levels of education, as well as among individuals with longer 
treatment durations. Further investigations into depressive symptoms and anxiety about the safety 
of ART reported in the Adherence Study were beyond the scope of this thesis but are important 
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areas of enquiry. Interventions which could improve adherence as well as outcomes in other areas 
such as mental health and drug use (e.g. those raising self-efficacy) require evaluation.  
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7.7 Recommendations 
The practical implications of results from this thesis for the treatment and care of HIV-positive 
childbearing women in Europe are summarised below. 
Western Europe 
Results from Chapter 3 highlight the need for supportive outreach for IDUs and other women at 
risk of disengaging from on-going HIV care, in order to optimise their own health (with prompt 
initiation of ART when this is indicated) and to avoid missed opportunities for PMTCT in future 
pregnancies. Provision of low-barrier antenatal services, and support for marginalised groups to 
access these, could reduce the number of HIV diagnoses late in pregnancy. The shift in national 
and international guidelines to recommend earlier initiation of antenatal ART for PMTCT from 14 
weeks gestation will be particularly beneficial for women with risk factors for preterm delivery; 
implementation of these policies should be monitored. Women diagnosed as HIV-positive may 
benefit from education about the benefits of accessing HIV care as soon as they become pregnant 
(and ideally before conception, if the pregnancy is planned) so that MTCT risk can be minimised. 
For those already on ART at conception, results highlight the need for careful monitoring of 
women with long durations of treatment, including those who have received ART in previous 
pregnancies. Adherence support tailored to the needs of young and multiparous women is 
particularly important, as these groups are at potentially increased risk of virological failure.  
Ukraine 
Findings show that pregnant women with characteristics indicating potential marginalisation or 
social or economic disadvantage are at risk of multiple missed opportunities for PMTCT. 
Healthcare services are needed which prioritise the needs of these pregnant women (including 
IDUs and women without a partner). These services would ideally be locally accessible, have an 
outreach component, provide practical and emotional support, and integrate antenatal and HIV 
care with sexual health and other services (e.g. harm reduction), as these women are likely to 
experience challenges accessing a wide range of services. Results highlight the importance of 
expansion of opioid substitution therapy programmes, including programmes which cater for the 
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needs of female IDUs in general and for those who are pregnant or have childcare responsibilities 
in particular. For all HIV-positive women, stronger links between HIV care and other healthcare 
services are needed, particularly links with services which diagnose and treat HIV co-infections and 
associated morbidity. Improvements in preventative healthcare (e.g. HBV vaccination and cervical 
screening) should be a priority.  
The scale-up of antenatal cART since the adoption of an Option B policy has been encouraging, 
but further expansion is required along with strategies to improve equity of access. Programmes for 
postnatal follow-up of HIV-positive women should be expanded and evaluated and should include 
improved cART coverage of women with treatment indications and supportive outreach for 
women at high risk of loss to follow-up (e.g. those with poor uptake of antenatal services). Regular 
assessment of ART adherence and depressive symptoms during pregnancy and postnatally using 
validated tools could help to identify women in need of additional support; improved access to high 
quality mental health care is urgently required. Improvements in information provision and peer 
support for pregnant women could help to alleviate their high levels of anxiety about the safety of 
ART for PMTCT, and could also improve health behaviours such as prompt attendance for 
postnatal follow-up.  
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For clinician to complete 
Maternity hospital name___________________ Study number__________________ 
 
Today’s Date:  ___/___/2011  Your date of birth: ____/____/_______ 
Date that your baby was born:  ___/____/___ Is your baby… a boy?  □ a girl?  □ 
1. Are you..  
Single □ Married □ Divorced, separated or widowed  □ Cohabiting □ 
2. Was this pregnancy planned? 
Yes  □ No □  
3. Who do you currently live with (excluding your children)? (Tick all that apply) 
Husband / partner / boyfriend    □ 
Extended family (e.g. your parents, aunt, grandparents) □ 
On my own       □ 
  
4. Which of the following people have you told that you are HIV-infected? (Tick all that 
apply) 
Husband / current partner / boyfriend   □ 
Mother and/or father      □  
Other close family member (e.g. sister, brother, aunt) □ 
Friend(s)       □ 
Other HIV positive people      □ 
I haven’t told anyone     □ 
 
5. Do you currently smoke? 
Yes □ No □ 
If yes, how many cigarettes do you smoke a day? _____________________ 
 
6. Did you use alcohol during your pregnancy?  
Yes □ No □ 
If yes, in average how many days during a week you have used alcohol? ____________ 
 
7. Have you ever used marijuana (hashish)? 
Yes – currently using  □ 
Yes – in the past  □ 
No    □ 
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8. Have you ever used any non-prescribed (illicit) drugs apart from marijuana? ( e.g. 
heroin, shirka, cocaine, stimulants such as vint, jeff, mul’ka, hypnotics or 
benzodiazepines etc.) 
Yes – currently using  □ 
Yes – in the past  □ 
No    □ 
If yes: 
 
 Are you currently in contact with any harm reduction programme or organisation? 
Yes □ No □ 
 
 Are you participating in a substitution treatment programme (methadone, 
buprenorphine)? 
Yes □ No □ 
 
9. How sure do you feel that taking HIV medications during pregnancy can help prevent 
HIV from being passed on to the baby?  
Completely sure   □  Fairly sure □ Not sure at all  □ 
 
10. Were you worried that taking HIV medication during pregnancy might harm your 
baby? 
Yes I was worried □ A little     □ No I wasn’t worried   □ 
 
Many people find it difficult to take HIV medication exactly as prescribed. We would like to find 
out how you took your medication during pregnancy and about any problems that you had, so 
that we can find ways of helping people to take their medicines in the future. 
 
11. Do you know the name(s) of the HIV medication you have been taking? If so, 
please write below 
 
 
How many pills do you take a day? ____________________ pills 
 
12. During your pregnancy, how often did you have difficulty taking your HIV 
medications on time? (no more than two hours before or after the time your doctor 
told you to take it) 
Never    □   Most of the time  □ 
Rarely    □   All of the time  □ 
 
13. On average, how many days per week when taking ARVs during pregnancy would 
you say that you missed at least one dose of your HIV medications? 
Everyday   □   Once a week   □ 
4-6 days/week  □   Less than once a week □ 
2-3 days/week  □   Never    □ 
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14. When was the last time before the birth of your baby that you missed at least one 
dose of your HIV medications? 
In the week before birth □ Between 1 and 3 months before birth □ 
1-2 weeks before birth □ More than 3 months before birth  □ 
3-4 weeks before birth □ Never      □ 
 
15.  How bothered were you by side effects to your medication (e.g. nausea, vomiting, 
diarrhoea, headache) during pregnancy? 
Not at all bothered  □   Somewhat bothered  □ 
Slightly bothered  □   Terribly bothered  □ 
 
16.  Do you currently use any of the following services? 
Support group   □ Social services   □ 
Peer counsellors   □ Treatment adherence programme □ 
Other________________________□ 
 
17.  Below is a list of common reasons why people miss doses of their HIV medications. 
If you missed any doses of medication during your pregnancy, please read the list 
and tick any reasons that were true for you. If you didn’t miss any doses, move on 
to question 18. 
 I missed a dose of HIV medication because… Tick all that apply 
1 I was away from home  
2 I was busy with other things   
3 I simply forgot  
4 I had too many pills to take  
5 I wanted to avoid side effects  
6 I did not want others to notice me taking medication  
7 I had a change in my daily routine  
8 I felt that the drug was toxic / harmful (to me or my baby)  
9 I fell asleep / slept through dose  
10 I felt sick or ill (including “morning sickness”)  
11 I felt depressed or overwhelmed  
12 I ran out of pills  
13 I couldn’t find my pills  
14 I felt good  
 
18.  During the last month of your pregnancy, were you often bothered by feeling down, 
depressed or hopeless? 
Yes □ No □ 
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19. During the last month of your pregnancy, were you often bothered by little interest 
or pleasure in doing things?  
Yes  □ No □ 
20.  If you answered “Yes” to question 18 OR question 19, is this something you feel 
you need or want help with? 
Yes □ Yes, but not today □ No □ 
21. Do you have someone you feel you can rely on to help you care for your baby? 
Yes  □ No □ 
22.  In the 4 weeks before birth, how confident did you feel that you could.. 
 
a.  Keep taking your medication even if side effects began to interfere with daily 
activities? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
b.  Keep taking your medication even if you needed to take it in front of people 
who didn’t know you were HIV-infected?   
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
c.  Keep taking your medication when your daily routine was disrupted (e.g. at 
weekends, staying away from home)? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
d.  Keep taking your medication when you weren’t feeling well? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
e. Keep attending your appointments at the AIDS centre even if they interfere 
with your daily activities? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
 
f.  Ask your clinician for more information if you needed to, and tell them about 
your concerns or worries? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
g.  Ask someone for support with taking your medication, if you needed it? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
Thank you very much for taking part in this study. 
Please return this questionnaire to your obstetrician or clinician. 
 
For clinician’s use only Was a referral made? Yes □  No □ 
If yes, please make a note of the reason for the referral and the service the woman was referred 
to:
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For Clinician to complete 
 
AIDS Centre name________________ ECS / study number_______________ 
 
Today’s Date:  ___/___/2011  Your date of birth: ____/____/_______ 
 
Date that your youngest baby was born:  ___/____/20__    
Is your baby..a boy?  □ a girl?  □ 
 
1. Are you..  
Single □ Married □ Divorced, separated or widowed  □ Cohabiting □ 
 
2. Did you plan your most recent pregnancy? 
Yes  □ No □ 
3. Who do you currently live with (excluding your children)? (Tick all that apply) 
Husband / partner / boyfriend    □ 
Extended family (e.g. your parents, aunt, grandparents) □ 
On my own       □ 
  
4. Which of the following people have you told that you are HIV-infected? (Tick all that 
apply) 
Husband / current partner / boyfriend   □ 
Mother and/or father      □  
Other close family member (e.g. sister, brother, aunt) □ 
Friend(s)       □ 
Other HIV positive people     □ 
I haven’t told anyone     □ 
 
5. Do you currently smoke? 
Yes □ No □ 
If yes, how many cigarettes do you smoke a day? _____________________ 
6. Do you currently drink alcohol? 
Yes □ No □ 
If yes, how many days a week on average do you drink alcohol? ____________ 
 
7. Have you ever used marijuana (hashish)? 
Yes – currently using  □ 
Yes – in the past  □ 
No    □ 
Postnatal adherence survey 
338 
 
8. Have you ever used any non-prescribed (illicit) drugs apart from marijuana? (e.g. 
heroin, shirka, cocaine, hashish/cannabis, stimulants such as vint, jeff, mul’ka etc.) 
Yes – currently using  □ 
Yes – in the past  □ 
No    □ 
  If yes: 
 
 Are you currently in contact with any harm reduction programme or organisation? 
Yes □ No □ 
 
 Are you participating in a substitution treatment programme (methadone, 
buprenorphine)? 
Yes  □ No □ 
 
Babies born to women with HIV are usually prescribed some HIV medicine in the first week(s) of 
life.  We are interested in your thoughts about this. 
 
9. In your opinion, can HIV medication for your baby help to prevent HIV from being 
passed to them? 
Yes    □  Not sure / don’t know □  No  □ 
 
10. Have you been worried (either now or in the past) that giving HIV medication to 
your baby might harm them? 
Yes □  A little worried  □  No □ 
 
 
11. Was your baby prescribed HIV medicine after birth? 
Yes □ for how long?  1 week □ 4 weeks □ Not sure □ continue to 
question 12 
No □ go to question 16 
 
12.  Who gave the HIV medicine to your baby? (tick all that apply) 
Me        □ 
The baby’s father      □ 
Family member(s) (including baby’s grandparents) □ 
Friend(s)       □ 
Other carer(s) (e.g. babysitter, child minder)  □ 
Medical staff       □ 
Nobody – we didn’t give any medicine to the baby  □ 
 
Postnatal adherence survey 
339 
 
When caring for a newborn baby, it can be difficult to give them all of the doses of HIV medicine. 
We would like to find out about any problems that you had with this, so that we can find ways of 
helping new mothers in the future. 
 
13.  How often did you have difficulty giving your baby their medicine on time?  
(By ‘on time’ we mean no more than two hours before or two hours after the time your 
doctor told you to give it.) 
Never    □  Most of the time  □ 
Rarely    □  All of the time  □ 
14.  On average, how many days per week would you say that your baby missed at least 
one dose of their HIV medication? 
Every day   □  Less than once a week □ 
More than once a week □  Never    □ 
   
15. Below is a list of common reasons why people may find it difficult to give their baby 
the HIV medicines prescribed by the doctor. If your baby missed any doses of 
medication, please read the list and tick any reasons that apply. If your baby didn’t 
miss any doses, please go to question 16. 
 My baby missed a dose of medication because.. Tick all that apply 
1 I was away from home  
2 I was busy with other things  
3 I simply forgot  
4 I was worried that my baby would have side effects  
5 I didn’t want others to notice my baby being given medication  
6 I didn’t want to ask other people caring for my baby to give 
him/her the medicine 
 
7 I didn’t have anyone to help  
8 I had a change in daily routine  
9 I felt like the drug was toxic / harmful to my baby  
10 The baby fell asleep / slept through dose  
11 The baby seemed unwell  
12 I felt depressed or overwhelmed  
13 I ran out of medicine to give the baby  
14 I couldn’t find the medicine to give the baby  
15 The baby seemed healthy  
 
16. During the past month, have you often been bothered by feeling down, depressed 
or hopeless? 
Yes □ No □ 
 
17. During the past month, have you often been bothered by little interest or pleasure 
in doing things?  
Yes  □ No □ 
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18. If you answered “Yes” to question 16 OR question 17, is this something you feel 
you need or want help with? 
Yes □ Yes, but not today □ No □ 
 
19.  Do you currently use any of the following services? 
Support group   □  Social services   □ 
Peer counsellors   □  Treatment adherence programme □ 
Other_______________________ □ 
 
 
20. Do you have someone you feel you can rely on to help you care for your baby? 
Yes  □ No □ 
 
21.  Are you currently taking HIV medication? 
Yes □ Continue to question 22.  
No □ Stop here. Thank you very much for taking part in this study 
The following questions are for women who are currently taking HIV medication 
 
22.  Do you know the names of your HIV medications? If so, please write below 
_________________________________________________________ 
How many pills do you take a day? ___________________ pills 
 
23. How often do you feel that you have difficulty taking your HIV medications on time? 
(By ‘on time’ we mean no more than two hours before or two hours after the time your doctor 
told you to take it.) 
Never    □ Most of the time  □ 
Rarely    □ All of the time  □ 
 
24. On average, how many days per week would you say that you missed at least one 
dose of your HIV medications? 
Every day   □  Once a week   □ 
4-6 days/week  □  Less than once a week □ 
2-3 days/week  □  Never    □ 
 
25. When was the last time you missed at least one dose of your HIV medications? 
Within the past week  □ Between 1 and 3 months ago □ 
1-2 weeks ago  □ More than 3 months ago  □ 
3-4 weeks ago  □ Never     □ 
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26. How bothered have you been by side effects (nausea, vomiting, diarrhea, headache 
etc.) to your HIV medication over the past 4 weeks? 
Not at all bothered  □ Somewhat bothered  □ 
Slightly bothered  □ Terribly bothered  □ 
27. Thinking about taking your medicines when you were pregnant and taking them 
now (since the baby was born), which of the following do you agree with? 
 I missed fewer doses when I was pregnant than I do now       □ Go to Q 28 
I miss fewer doses now than I used to when I was pregnant      □ Go to Q 29 
I miss about the same number of doses now as when I was pregnant □ Go to Q 29 
I haven’t missed any doses at all          □ Go to Q 29 
28. Why do you think you took your medicine better when you were pregnant than you 
do now? (tick all that apply) 
I was worried about the risk of passing on HIV to my baby  □ 
I was more concerned about my own health    □ 
I was going to the doctor more      □ 
I had more encouragement / support from friends and family □ 
I had more time to take care of myself     □ 
I was less tired of taking pills      □ 
I felt more positive about the benefits of treatment   □ 
Other__________________________________________________□ 
 
29. Below is a list of common reasons why people miss doses of their HIV medication. 
If you have missed any doses over the last 4 weeks, please read the list and tick any 
reasons that were true for you. If you didn’t miss any doses, please continue to 
question 30. 
 
  Tick all that apply 
1 I was away from home  
2 I was busy with other things  
3 I simply forgot  
4 I had too many pills to take  
5 I wanted to avoid side effects  
6 I did not want others to notice me taking medication  
7 I had a change in daily routine  
8 I felt like the drug was toxic / harmful  
9 I fell asleep / slept through dose  
10 I felt sick or ill  
11 I felt depressed or overwhelmed  
12 I ran out of pills  
13 I couldn’t find my pills  
14 I felt good  
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30. In the past 4 weeks, how confident have you been that you could.. 
 
a.  Keep taking your medication even if side effects began to interfere with daily 
activities? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
b.  Keep taking your medication even if you needed to take it in front of people 
who didn’t know you were HIV-infected?   
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
c.  Keep taking your medication when your daily routine was disrupted (e.g. at 
weekends, staying away from home)? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
d.  Keep taking your medication when you weren’t feeling well? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
e.  Keep attending your appointments at the AIDS centre even if they interfere 
with your daily activities? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
f.  Ask your clinician for more information if you needed to, and tell them about 
your concerns or worries? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
g.  Ask someone for support with taking your medication, if you needed it? 
Confident I could do □ Fairly confident I could do □ Could not do □ 
 
Thank you very much for taking part in this study. 
Please return this questionnaire to your obstetrician or clinician. 
 
For clinician’s use only  Was a referral made? Yes □  No □ 
If yes, please make a note of the reason for the referral and the service the woman was referred 
to:
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Infant deaths at <6 months of age in Ukraine ECS by year and HIV status 
Where infants died with an indeterminate HIV status, their deaths were categorised as probable HIV-related, probable non HIV-related and indeterminate with relation to 
HIV infection according to guidelines: Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues Ghent (Belgium), 17-20 February 1992. 
Probable HIV-related deaths were those in infants with AIDS or dying from severe infection (pneumonia or septicaemia) beyond 4 weeks of age; probable non-HIV-
related deaths were those in infants with no AIDS and dying from non-infectious cause (accident, sudden infant death syndrome, severe asphyxia, respiratory distress 
syndrome, congenital heart malformation, prematurity, intracranial haemorrhage), deaths indeterminate with relation to HIV status were those in infants dying from severe 
infection (pneumonia or septicaemia) within the first four 4 weeks of life, and those with no cause of death reported.
 2003 2004 2005 2006 2007 2008 2009 2010 
Number of deaths at <6  
months of age 
7 5 3 8 20 11 11 3 
HIV status at death         
  Infected 2 0 3 0 3 3 1 1 
  Uninfected 0 2 0 1 2 2 2 0 
  Indeterminate 5 3 0 7 15 6 8 2 
Of indeterminate infants         
  Probable HIV-related death 1 1 0 1 8 2 2 0 
  Probable non HIV-related 3 1 0 2 3 3 3 0 
  Death indeterminate with relation to HIV 
infection 
1 1 0 4 4 1 3 2 
MTCT rate, omitting all indeterminate  
infants (as in Figure) (95% CI) 
14.6% 
(10.7-19.3) 
10.3% 
(7.6-13.6) 
4.7% 
(2.9-7.1) 
6.2% 
(4.4-8.4) 
7.7% 
(6.2-9.3) 
4.7% 
(3.5-6.1) 
2.1% 
(1.3-3.1) 
6.2% 
(4.5-8.3) 
MTCT with probable HIV-related and non-HIV 
related deaths assigned as infected and uninfected 
respectively (95% CI) 
14.8% 
(10.9-19.5) 
10.5% 
(7.7-13.8) 
4.7% 
(2.9-7.1) 
6.3% 
(4.5-8.5) 
8.3% 
(6.8-9.9) 
4.9% 
(3.7-6.3) 
 
2.3% 
(1.5-3.4) 
6.2% 
(4.5-8.3) 
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